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Abstract 
ABSTRACT 
Background: There is growing evidence that atherosclerosis begins at an early age and 
progresses silently throughout the life span before clinical complications such as myocardial 
infarction and stroke present. Adverse blood lipid levels (dyslipidemia) are an important 
contributor to the disease and have been the target of consensus statements for paediatric 
screening and treatment issued by the American Academy of Pediatrics and the US National 
Cholesterol Education Program since 1992; the most recent update being July 2008. The 
basis of these documents is that treatment of lipid disorders beginning in childhood or 
adolescence may reduce the lifetime risk of atherosclerotic cardiovascular disease. 
Aims: This study examined: tracking of blood lipid levels from childhood to adulthood; the 
utility of two paediatric dyslipidemia classifications that define normal-, borderline-, and 
high-risk lipid blood levels to predict dyslipidemia and a measure of preclinical 
atherosclerosis (arterial wall thickness) in adulthood; factors that both reduce and improve 
prediction of those with dyslipidemia or arterial wall thickening in adulthood; whether 
changes in blood lipid levels between adolescence and adulthood had an effect on the level of 
arterial thickening measured in adulthood. 
Methods: This study utilised data from three population-based prospective cohort studies 
from Australia (Childhood Determinants of Adult Health Study), Finland (Cardiovascular 
Risk in Young Finns Study), and the United States (Bogalusa Heart Study). Baseline data 
were collected on children and adolescents aged 9-18 years in 1980-1986. Between 2001 and 
2006 participants from the original cohorts, now young adults aged 28-39 years, were re-
examined (follow-up). Participants from each cohort had risk factor data (including fasting 
blood lipids) measured at both time-points. At follow-up, each cohort used carotid artery 
ultrasound to determine arterial wall thickness. 
Results: The findings showed that paediatric dyslipidemia classifications predicts 
dyslipidemia and arterial thickening in young adulthood; that the classifications examined 
differ marginally in how strongly they predict adult dyslipidemia but perform with equal 
success in the prediction of arterial thickening in adulthood; that universal (population-wide) 
Abstract 
or selective screening approaches that use paediatric dyslipidemia classifications would be 
limited by either high rates of false positives or high rates of false negatives; that adolescent 
lipid levels are more strongly associated with arterial thickening in adulthood than change in 
lipid levels; that dyslipidemia in the presence of overweight or obesity places affected 
adolescents at substantially higher risk of increased arterial thickening as adults; and that 
participants identified as high-risk in childhood but who adopted positive changes in lifestyle 
habits in the intervening years were less likely to have dyslipidemia as adults. 
Conclusions: These findings suggest that paediatric dyslipidemia classifications are useful in 
predicting adolescents who are at increased risk of having dyslipidemia or preclinical 
atherosclerosis in young adulthood. While these findings suggest there would be limitations 
in screening the general paediatric population for dyslipidemia, they underscore the 
importance of both population-wide and individualised prevention programs to reduce the 
early development of atherosclerosis associated with paediatric dyslipidemia. 
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FELIC = Fate of Early Lesions in Children 
FH = familial hypercholesterolemia 
FMD = flow mediated dilatation 
HC = hormonal contraception 
HDL = high-density lipoprotein 
HR = hazard ratio 
ICA = internal carotid artery 
IMT = intima-media thickness 
LDL = low-density lipoprotein 
LRC = Lipid Research Clinics 
Abbreviations 
MI = myocardial infarction 
MONICA = MONItoring of trends and determinants in CArdiovascular disease 
NCEP = National Cholesterol Education Program 
NHANES = National Health and Nutrition Examination Survey 
NHLBI = National Heart, Lung and Blood Institute 
NPV = negative predictive value 
OR = odds ratio 
PDAY = Pathobiological Determinants of Atherosclerosis in Youth 
PPV = positive predictive value 
RR = relative risk 
SD = standard deviation 
SEP = socioeconomic position 
STRIP = Special Turku Coronary Risk Factor Intervention Project for Children 
TCH = total cholesterol 
TG = triglycerides 
US = United States 
VLDL = very-low-density lipoprotein 
WHO = World Health Organization 
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1. INTRODUCTION 
"Give me a child until he is seven and I will give you the man" 
St. Francis Xavier (1506— 1552) 
Although death from cardiovascular disease (CVD) has been dramatically reduced since it 
peaked in industrialised countries in the 1950s, it remains the single biggest killer worldwide. 
While favourable changes in risk factor distribution and improved treatment have been the 
major explanations for this decline, most of these efforts have focused on adults. Data have 
existed since the 1950s that demonstrated the presence of the early stages of CVD in young 
men and adolescent boys. If the origin of CVD is in early life, are children with one or more 
of the major established CVD risk factors at an increased risk of developing clinically 
significant disease later in life? What effect will the control of these CVD risk factors in early 
life have on the incidence of clinical disease later in life? Currently, there are no available 
data to answer these questions, but a growing level of evidence has been compiling since the 
1970s to suggest that risk factor control, if implemented in early life, would indeed further 
reduce mortality due to CVDs. This thesis and the aims studied herein attempt to build on, 
and add evidence to, a component of this premise. This chapter provides an overview of the 
epidemiology of CVD, the pathogenesis of atherosclerosis, evidence of the childhood origin 
of atherosclerosis, and details essential literature that paves the way for the aims examined as 
part of this thesis. 
1.1. EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
1.1.1 THE GLOBAL BURDEN OF CARDIOVASCULAR DISEASES 
Cardiovascular diseases are the major cause of death in high- and middle-income countries 
and are becoming an increased burden to low-income countries." 2 In 2004 the two leading 
causes, coronary heart disease and stroke, were responsible for 7.2 million and 5.7 million 
deaths respectively, accounting for 22% of total deaths (Figure 1). 1 By 2030, the World 
Health Organization (WHO) estimates that CVDs will remain the leading cause of death in 
high- and middle-income countries, and will replace respiratory infections and perinatal 
conditions (prematurity, low birth weight, birth asphyxia, birth trauma, and neonatal 
infections) as the leading cause of death in low-income countries.' 
Stroke and other 
ce re b rovascular 
diseases, 10% 
Lower respiratory 
infections, 7% 
Perinatal 
conditions, 5% 
Chronic obstructive 
Diarrhoeal pulmonary disease, 
diseases, 40/0 5% 
Road traffic 
accidents, 2% 
HIV/AID 5,4% 
Trachea, bronchus, 
lung cancers, 2% 	 Tuberculosis, 3% 
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Figure 1. The 10 leading causes of death worldwide in 2004. Figure reproduced from data reported by 
the WHO' 
1.1.2 SECULAR TRENDS IN CARDIOVASCULAR DISEASE 
Since a peak in 1950, death rates from CVDs have declined by approximately 70% in the 
United States (Figure 2); 3 a trend that has been observed in most economically-developed 
countries. 4 The WHO's MONICA (MONItoring of trends and determinants in 
CArdiovascular disease) project, using standardised protocols, procedures, and quality-
assurance methods, confirmed a decline in CVD mortality rates from 37 populations in 21 
countries over a 10-year period. 5 Data from MONICA suggested that favourable changes in 
risk factors accounted for approximately 15% of the decline in CVD-event rates for females 
and 40% for males. 6 In the Framingham Heart Study, favourable changes  in risk factors 
accounted for approximately half of the decline, whereas improved treatment accounted for 
the other half. 7 The extent and severity of atherosclerosis, a slowly progressive systemic 
disease that causes narrowing and hardening of large- and medium-sized arteries, also 
declined during this period. 8 ' 9 
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Figure 2. Age-adjusted death rates (per 100,000 population, standardised to 1940 US population) for 
total cardiovascular disease, diseases of the heart, coronary heart disease and stroke by year in the 
United States 1900 to 1996. From US Department of Health and Human Services, National Institutes 
of Health.5' 
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1.2. PATHOGENESIS OF ATHEROSCLEROSIS 
The major clinical complications of atherosclerosis such as myocardial infarction, stroke, and 
peripheral artery disease account for approximately 50% of all deaths in economically-
developed countries." Atherosclerosis is characterised by the process in which deposits of 
fatty substances, cholesterol, cellular waste products, white blood cells, calcium and other 
substances build-up in the inner most layer (the intima) of an artery to form atheromas or 
plaques that protrude into and alter the blood flow through an artery, weaken the structural 
integrity of the vessel, and cause an increase in the stiffness of the vessel. I2 The coronary 
arteries, aorta, and cerebral arteries are the vessels most often affected. The mechanisms that 
lead to the initiation of atherosclerosis have not been unequivocally established. Several 
hypotheses have been postulated however. Of these, models placing inflammation, 
endothelial alterations, retained lipoproteins, and oxidation as the initiating and/or central 
process have received most support. I3-15 Most hypotheses share the common elements of 
some damage to the endothelial cells that line the arteries as well as low-density lipoprotein 
(LDL) cholesterol uptake and inflammation at the site, and free radical production. The 
causes of endothelial cell damage include elevated serum cholesterol levels (hyperlipidemia 
or hypercholesterolemia), free radicals caused by smoking, high blood pressure 
(hypertension), infection, heavy metal exposure, genetic alterations, and combinations of 
these and other factors. 12 
The American Heart Association (AHA) has defined six types of atherosclerotic 
lesions (Figure 3, Figure 4), I6 ' 17 The initial (type I) lesion contains sufficient levels of 
atherogenic lipoprotein to elicit an increase in the numbers of macrophages and cholesterol-
containing macrophages (foam cells) invading the intima, resulting in adaptive thickening. 
Type II lesions (fatty streaks) denote the first visible sign of an arterial lesion forming. It is 
characterised by layers of macrophage foam cells and lipid droplets within intimal smooth 
muscle cells, and some evidence of droplets of extracellular fluid. Type I and type II lesions 
are often referred to as "early lesions" because they can be present in the arteries of children 
and adolescents and because they precede "later" or advanced lesions. Type III (intermediate) 
lesions, typically observed in the third decade of life, are characterised by pools of 
extracellular lipid in addition to all components of type II lesions. Type IV lesions 
(atheromas) are characterised by a dense accumulation of extracellular lipid in an extensive 
but well-defined region of the intima and is the first lesion considered as advanced in the 
Al-IA classification. This dense accumulation of lipid, also called the lipid core, causes severe 
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intimal disorganisation. During the fourth decade of life, connective tissue that forms in and 
around the intima as a result of a type IV lesion may lead to the formation of a thick fibrous 
cap that overlies either a core of lipid, calcific, or fibrotic tissue. The presence of this fibrous 
cap (principally comprised of smooth muscle cells and collagen) characterises the type V 
lesion (fibroatheroma). Type VI (complicated) lesions, the most symptomatic, are type IV or 
type V lesions that have become increasingly complex due to rupture (tears, fissures or 
ulcerations) of the surface of the lesion (fibrotic cap), hematoma or haemorrhage, thrombotic 
deposits, or a combination of these that results in additional damage, de-stabilisation, and 
thickening of the lesion accelerating the conversion from clinically silent to overt disease. 
The formation of a thrombus or blood clot causing acute occlusion of the artery is responsible 
for the most important clinical complications of atherosclerosis, myocardial infarction and 
stroke, which occur largely as a result of type VI lesions. 
-Media 
lype III (preettherama) 	Type (atheroma) 
Coronary artery 
loSion -wale location 
Introduction 	 29 
1\47peTL ifibroatherantA 'Npelta (complio.ted ledien) 
Figure 3. American Heart Association classification of atherosclerotic lesion types. The morphology 
of the intima ranges from adaptive intimal thickening (top left-hand corner) to a type VI lesion in 
advanced atherosclerotic disease (bottom right-hand corner). From Stary et al. I6 ' 17 
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Figure 4. Major characteristics, possible sequence of progression, and likely onset of lesions that 
comprise the AHA classification. From Stary et al. 16. 17 
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1.3. ORIGIN OF ATHEROSCLEROSIS 
Although the major clinical complications of atherosclerosis do not typically present until 
middle or older age, the atherogenic process has been shown to begin in early life and 
progresses from an asymptomatic phase to a clinically manifest disease over decades. 
Autopsy studies on causalities of the Korean war by Enos et a1, 18-2° later confirmed in the 
Vietnam conflict by McNamara and colleagues, 21 provided the first clinical evidence of 
advanced atherosclerotic lesions (grossly visible lesions that varied from mild fibrous lesions 
to complete coronary artery occlusion) already being-present in the coronary arteries among 
75% of 300 young male United States (US) soldiers (mean age of 22 years); while 
approximately 10% had advanced lesions that obstructed the lumen of a major vessel by 70% 
or more. The first evidence of atherosclerotic disease beginning in childhood was provided 
by Strong, McGill and colleagues 22-24 who demonstrated not only the presence of fatty streaks 
in the aortas of children as young as three years, but that these fatty streaks progressed to 
clinically significant lesions (fibrous plaques) by young adulthood (Figure 5). An extension 
of this work that compared pathologic findings from different geographic areas showed that 
fatty streaks were found uniformly at young ages, but major differences were evident in the 
progression to fibrous plaques between populations. 25 This difference appeared to coincide 
with the incidence of clinical manifestations of atherosclerosis in each geographical region. 
For example the rate of progression from fatty lesions to fibrous plaques occurred more 
rapidly in a region (New Orleans, USA) where the incidence of clinical complications was 
high, compared with slower progression rates in regions where incidences were lower 
(Guatemala and Costa Rica). 
Around this time, a number of groups initiated large prospective observational studies 
in adults to examine the cardiovascular risk factor concept. 26-29 The cardiovascular risk factor 
concept proposed that there were multiple causes of atherosclerosis that, if identified, could 
be modified to reduce the risk of CVDs. As the effects of risk factors on adult CVD were 
demonstrated by studies such as the Framingham Heart Study, the Evans County study, and 
the Seven Countries' Study, 30-32 a number of large prospective observational studies were 
initiated to examine the importance of childhood cardiovascular risk factors and lifestyle to 
the development of atherosclerosis (Table 1). 
Abdominal 
Thoracic 
d Ring 
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Figure 5. Atherosclerosis in the aorta of young men from the New Orleans area. From Berenson et 
al.33 
Table 1. Key studies and findings with vascular (pathological or imaging) outcomes that have examined the paediatric origin of cardiovascular risk and 
atherosclerosis, sorted by year of commencement 
Study Country Year 
commenced 
Design Population at 
baseline 
Vascular outcomes Key 
publications 
Muscatine Study 
Bogalusa Heart Study 
The Amsterdam Growth and 
Health Longitudinal Study 
Cardiovascular Risk in 
Young Finns Study 
Childhood Determinants of 
Adult Health (CDAH) Study 
Pathobiological 
Determinants of 
Atherosclerosis in Youth 
(PDAY) Study 
Northern Ireland Young 
Hearts Project 
Special Turku Coronary 
Risk Factor Intervention 
Project for Children 
(STRIP) 
USA 
USA 
The 
Netherlands 
Finland 
Australia 
USA 
Northern 
Ireland 
Finland 
1971 
1973 
1977 
1980 
1985 
1987 
1989 
1990 
Longitudinal 
Longitudinal 
Longitudinal 
Longitudinal 
Longitudinal 
Pathological 
Longitudinal 
Intervention 
N=4829, aged 8-18 y 
N=3525, aged 5-14 y 
at first cross- 
sectional 
examination 
N>600, aged 13 y 
N=3596, aged 3-18 y 
N=8498, aged 7-15 y 
N=2876, aged 15-34 
N=1015, aged 12-22 
N=1062, aged 7 
months 
Carotid calcification, carotid 
IMT 
Autopsy (specimens 
included coronary arteries 
and aorta), arterial elasticity, 
carotid IMT 
Carotid IMT, arterial 
stiffiiess 
Carotid IMT, arterial 
elasticity, brachial FMD 
Carotid IMT, arterial 
elasticity, brachial FMD 
Autopsy (specimens 
included coronary arteries 
and aorta) 
Arterial stiffness 
Carotid & aortic IMT, 
brachial FMD 
34, 35 
36,37 
38-40 
41-43 
44 
45-47 
48,49 
50-52 
Abbreviations: IMT = intima -media thickness; FMD = flow-mediated dilatation 
U
0p
an
p
0.
11
111
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Autopsy data from the Bogalusa Heart Study 36' 53-56 and the Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) Study extended the work by Strong et al. 
by demonstrating that CVD risk factors measured antemortem (in the case of the Bogalusa 
Heart Study), and postmortem (in the case of PDAY) were associated with the presence and 
extent of atherosclerosis in the aortic and coronary arteries of young persons (ranging in age 
from 2-39 years), and provided the first evidence that risk factor control beginning in young 
persons may delay the development of atherosclerosis. The advancement in novel non-
invasive techniques throughout the 1990s allowed functional and structural markers of early 
(pre-clinical) atherosclerosis to be measured in young, apparently healthy populations. 57-59 
Such measures included the ultrasonic assessment of carotid artery intima and media 
thickness (IMT), arterial endothelial function using flow-mediated dilatation (FMD), and 
arterial elastic properties, as well as computed tomography to measure coronary artery 
calcification (see Table 1 for a summary of these methods and Appendix 1 for a more 
detailed overview of each technique). Once the reproducibility and prognostic value of these 
measures was established, they provided an intermediate end-point that could be used to 
assess the effects of risk factors and risk-factor interventions long before clinical 
manifestations of CVD would present. Utilising non-invasive imaging technologies, 
longitudinal studies were able to provide data directly linking childhood risk factors with 
preclinical measures of atherosclerosis in young adulthood. 34' 35 ' 37' 41 ' 43 Landmark papers 
from the Muscatine Study (1996, 2000, 34' 35 Bogalusa Heart Study (2003),37 and 
Cardiovascular Risk in Young Finns Study (2003, 2004, 2005) 41-43 together have accumulated 
over 900 citations in the scientific literature since they were first published, clearly 
demonstrating the importance of these data. 
Two other extremely important observations from both pathological and imaging 
studies of atherosclerosis have been that the extent of lesions or indicators of atherosclerosis 
increases as the number of childhood risk factors increases, suggesting that risk factors 
measured in childhood appear to be stronger predictors of future atherosclerosis than 
contemporous measurements obtained at the time autopsy or imaging was performed. 
Together, these findings provide a strong rationale for both the identification of children at 
high-risk and for efforts to prevent the development of CVD risk factors in early life. The 
following section provides an overview of the major paediatric CVD risk factors that have 
been linked with atherosclerosis, before focusing on the importance of blood lipid and 
lipoprotein levels in childhood and adolescence in the development of atherosclerosis. 
Table 2. Most common non-invasive imaging techniques used to assess preclinical atherosclerosis in studies of children, adolescents and young adults 
Arterial Phenotype 
Intima-media thickness 
(structural)60 '  
Flow-mediated dilatation (functional) 62 : 
63 
Arterial stiffness (mechanical) 64 ' Calcification (structural) 
Premise -Diffuse intimal 
thickening occurs early in 
atherosclerosis, prior to 
lesion development. 
-The endothelium regulates vascular 
homeostasis and has antithrombotic and 
antiproliferative properties. Nitric oxide 
in the endothelium plays a major role in 
both actions. 
-Alteration in endothelial function 
precedes structural atherosclerotic 
changes. 
-Proximal large arteries have high elastic 
properties that are a result of the high elastin to 
collagen ratio in their walls. The gradual loss 
of elastic properties of these variables with 
aging is a result of progressive elastic fibre 
degeneration. 
-Decreased elasticity is thought to represent an 
early risk marker for CVD. 
-Coronary artery calcification 
is part of the pathogenesis of 
atherosclerosis. 
-It occurs almost exclusively in 
atherosclerotic arteries. 
-Is absent in the normal vessel 
wall. 
Technology B-mode ultrasound B-mode ultrasound B-mode ultrasound, Doppler Computed tomography (CT) 
Limitations -Not able to differentiate 
between intima and 
media, so both are 
measured. 
-Non-standardised 
protocols. 
-Imperfect correlation 
with coronary 
atherosclerosis. 
-Requires highly-skilled technicians. 
-High normal physiological variability. 
-Degree of dilatation can be effected 
by: recent smoking, recent 
food/beverage intake; recent exercise, 
circadian pattern; viral illness; and 
phase of the menstrual cycle for 
females. 
-Imperfect correlation to coronary 
circulation. 
-Vasodilatory response is related to 
vessel size. 
-Large number of different protocols and 
equipment used, each with strengths and 
limitations: 
Pulse Wave Velocity  
-Does not provide information on arterial 
geometry. 
-Inaccuracy of distance measurement. 
Central pulse-waves  
-Indirect measure of arterial stiffness. 
Change in vessel diameter to distending 
pressure 
-Requires skilled technician 
-Requires measurement of central pulse 
pressure. 
-Radiation exposure 
-High rates of zero scores 
before 56 decade. 
-`Noise' can be mistaken for 
calcium on CT images leading 
to higher scores. 
-Cost 
-More recent technologies 
have high reproducibility, but 
earlier technologies had poor 
short-term reproducibility. 66 
-Vulnerable plaque may not 
exhibit significant 
calcification. 
Predictive value' -H- -H—f- 
Simplicity' ++/+++/+ + 
Reproducibility* -H—F ++ 
Safety" -H--1- -F++ +++/+++/+++ + (radiation) 
Low cost* ++ +-I- +++/+++/-F-F 
* Ratings based on review articles of these measures. 60 63-67 + = fair, ++ = good, ++F = excellent. 
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1.4. RISK FACTORS FOR ATHEROSCLEROSIS IN CHILDREN AND 
YOUNG ADULTS 
The value of a number of non-modifiable and modifiable risk factors for CVD risk prediction 
(including increasing age, male sex, race, heredity, high-risk blood lipid levels, high blood 
pressure, smoking, overweight and obesity, diabetes and physical inactivity) in adult studies 
have also been shown to be important in the development and progression of preclinical 
atherosclerosis in young persons. 
1.4.1 NON-MODIFIABLE RISK FACTORS 
1.4.1.1 Increasing age 
In the PDAY study, increasing age was found to be significantly associated with the extent of 
fatty streaks and raised lesions, and a two to three fold increase in the prevalence of AHA 
type IV and V lesions in the coronary arteries of deceased persons. 45 ' 46 Data from Holman et 
al.22 presented in Figure 5 demonstrated that the extent of fatty streaks in the aorta of young 
men increased with age. In a cross-sectional study by Ishizu et al." increasing age was 
shown to be directly associated with mean and maximum IMT in children aged 5 to 14 years 
(mean IMT, 3 = 0.009 mm/year; max IMT 1 = 0.010 mm/year). Age was related with 
significant increases in composite (multiple sites of measurement) IMT in Caucasian males 
(0.012 mm/year), Caucasian females (0.005 mm/year), and African-American females (0.008 
mm/year) in the Bogalusa Heart Study. 69 Data from the Cardiovascular Risk in Young Finns 
study showed that age was directly associated with carotid IMT (0.06 mm/year) and inversely 
associated with carotid artery compliance (-0.04 %/10 mmHg/year) even after adjustment for 
other risk factors." While data from the Coronary Artery Risk Development in Young Adults 
(CARDIA) study observed a greater prevalence of coronary artery calcification in older 
participants compared with younger participants (13.3 vs. 5.5%). 7I 
1.4.1.2 Male sex 
Using a very high-resolution ultrasound technique that could differentiate intima and media, 
Osika et al recently demonstrated that male students from two schools in Gothenburg had 
significantly larger intima (0.057 vs. 0.054 mm), media (0.176 vs. 0.153 mm), and 1MT 
measurements (0.232 vs. 0.207 mm) in the radial artery and significantly larger media (0.160 
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vs. 0.149 mm), and IMT measurements (0.222 vs. 0.209 mm) in the dorsal pedal arteries 
compared with female students." In the PDAY study, females had approximately half the 
extent of raised lesions in the right coronary artery and approximately half the prevalence of 
advanced lesions in the left anterior descending coronary artery compared with their age-
matched male counterparts."' 73 The CARDIA study found young adult males to have a 
greater prevalence of coronary calcium than females (15.0 vs. 5.1%). 71 Data from the 
Bogalusa Heart Study also suggested that lesion development was delayed in females 
compared with males, 54 while males had increased carotid IMT (0.757 vs. 0.719 mm) 37 and 
greater age-related changes in IMT compared with females. 69 These studies however, did not 
examine if these differences remained after adjustment for risk factors. In the Cardiovascular 
Risk in Young Finns study, male sex was associated with significantly increased carotid IMT 
(0.59 vs. 0.57 mm), decreased carotid compliance (2.00 vs. 2.31 %/I0 mmHg), and decreased 
FMD (6.95 vs. 8.83 %)•" These differences became non-significant after adjustment for risk 
factor levels in the case of IMT and carotid compliance, and reversed after adjustment for 
baseline brachial diameter in the case of FMD; suggesting that sex differences in markers of 
atherosclerosis were mostly explained by differences in risk factors and vessel size." 
1.4.1.3 Race 
Studies in the United States have shown that while African-Americans have higher levels of 
CVD risk factors, 74 it is Caucasians that have the highest incidence of CVD." Pathological 
studies in youth and young adults have found more extensive fatty lesions in the arteries of 
African-Americans compared with Caucasians, seemingly reflecting increased risk factor 
load, but similar amounts of raised lesions have been observed. In the PDAY study, minor 
differences were observed between Caucasian and African-Americans in extent and qualities 
of lesions." In the Bogalusa Heart Study, African-Americans had a greater extent of fatty 
lesions in the aorta and Caucasian males a greater prevalence of fibrous plaques in the 
coronary artery," Although autopsied decedents may not be representative of the living 
population, this race difference has been shown in young adults in the Bogalusa study. For 
example, African-American males and females had greater levels of carotid IMT compared 
with Caucasian males (0.770 vs. 0.751 mm) and females (0.753 vs. 0.705 mm). 37 In the 
CARDIA study no significant race differences were reported initially, 74 but more recently, 
Caucasian males had a greater prevalence of coronary artery calcium than African-American 
males (17.6 vs. 11.3%). 7i In the Bogalusa Heart Study, Caucasian males had greater age- 
Introduction 
	
38 
related IMT changes over a five year period than African-American males (0.009 vs. -0.001 
mm/year). 69  While studies are continuing to examine racial differences in atherosclerosis, it is 
possible that Caucasians experience more rapid progression to advanced lesions than do 
African-Americans, possibly in early to middle adulthood. 
1.4.1.4 Heredity 
Children who are first-degree relatives of persons with premature CVD have been shown to 
have reduced endothelial function and increased IMT. Gaeta et al." found that 40 healthy 
adolescent offspring of parents who had premature myocardial infarction had lower brachial 
FMD (5.7 vs. 10.2%) and increased carotid IMT (0.49 vs. 0.44 mm) compared with 40 age-
and sex-matched controls. These differences between groups remained significant after 
adjustment for risk factors," suggesting that vascular changes associated with positive family 
history are independent of risk factor levels. Cuomo et al. also showed that children, 
adolescents, and young adults with a history of premature parental myocardial infarction had 
increased carotid IMT compared with age- and sex-matched controls (age 5-18 years: 0.45 
vs. 0.40 mm; age 19-30 years: 0.48 vs. 0.45 mm). 78 As in the Gaeta study, differences in 
carotid IMT between the two groups remained after adjustment for other risk factors. 78 A 
study by Magadle et al. found that young adults with family history of premature myocardial 
infarction had increased carotid IMT (0.48 vs. 0.43 mm) compared with age-, sex-, and risk 
factor-matched controls. 79 Sabri et al.8° demonstrated that child offspring of those with 
premature myocardial infarction had significantly increased carotid IMT (0.29 vs. 0.22 mm) 
and left ventricular mass (37.8 vs. 36.2 g/m 2.7) compared with age- and sex-matched controls 
who did not have positive family history. While the evidence for increased atherosclerosis in 
the offspring of persons who suffered premature myocardial infarction appears compelling, 
data on the vasculature of offspring of parents who suffered premature stroke is sparse. To 
the best of the author's knowledge, the only study by Varda et al." to examine this issue 
found that carotid IMT at multiple sites was not significantly different in children of parents 
with or without premature stroke. In both the Bogalusa Heart Study 82 and the Cardiovascular 
Risk in Young Finns Study, 83 the adverse effects of metabolic risk factors were amplified in 
those with positive family history of CVD. While the Bogalusa Heart Study showed that 
family history of CVD (parental, any age) predicted five-year carotid IMT progression in 
young men (3 = 0.014 mm).' 
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1.4.2 MODIFIABLE RISK FACTORS 
1.4.2.1 Hypertension 
A number of cross-sectional and case-control studies have shown that children and 
adolescents with primary (essential) hypertension have significantly greater values of carotid 
and femoral IMT and reduced arterial elasticity compared with those without hypertension. 85 " 
88 In the PDAY study, hypertensive (defined as mean arterial pressure >110 mm/Hg) males 
had approximately twice the prevalence of raised lesions in the right coronary artery 
compared with their normotensive peers. 89 Hypertension was also associated with larger 
diameters of the right coronary and left anterior-descending arteries and with the prevalence 
of AHA grade IV and V lesions. 9° These associations remained after adjustment for other 
CVD risk factors including body mass index (BMI), smoking, and lipoprotein levels."' 90 In 
the Bogalusa Heart Study,36 systolic blood pressure was positively correlated with the extent 
of fatty streaks in the aorta (r = 0.31) and with fatty streaks and fibrous plaques in the 
coronary arteries (r = 0.47, and r = 0.41 respectively). 
In living participants, systolic blood pressure was a significant independent predictor 
of five-year internal carotid IMT progression in young men of the Bogalusa Heart Study (0 = 
0.001 mm per 1 mm/Hg increase)," while childhood and cumulative (measures collected at 
multiple time-points) systolic blood pressure was directly associated with carotid IMT (r = 
0.103, and r = 0.165 respectively) 37 and arterial stiffness (r = 0.11, and r = 0.32 
respectively).9t A direct and significant relationship between a single measure of systolic 
blood pressure taken in adolescence and arterial stiffness in young adulthood was however, 
not found in the Atherosclerosis Risk in Young Adults (ARYA) study. But measurement 
error in the use of a single baseline measurement of blood pressure may have partly explained 
the lack of association. 92 In the Muscatine study, systolic and diastolic blood pressures 
measured in early adult life but not childhood were associated with increased odds (ranging 
from 3.2 to 6.4) of coronary artery calcium as measured by electron-beam computed 
tomography." Systolic and diastolic blood pressures in childhood were directly associated 
with carotid IMT in Muscatine women, but these associations were attenuated after 
adjustment for current risk factors. 35 In the Cardiovascular Risk in Young Finns study, 
childhood systolic blood pressure was positively associated with adult carotid IMT 4I (p = 
0.013 mm per 1 standard deviation [SD] increase) and inversely associated with adult 
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measures of carotid elasticity43 (13 = -0.107 %/10 mmHg per 1SD increase) and brachial FMD 
in male adults (p = -0.049% per 1SD increase). 93 Importantly, the prospective association 
observed between blood pressure and carotid IMT and brachial endothelial function was 
stronger than the cross-sectional association. 41 ' 93 In the 10-year follow-up of the CARDIA 
study, baseline and current systolic blood pressure levels were associated with increased_odds 
ratios (OR = 1.3, and OR = 1.3 per 10 mm/Hg increase respectively) of presence of coronary 
calcium, but both associations were attenuated and no longer statistically significant after 
adjustment for other CVD risk factors. 74 At the 15-year follow-up, baseline, year 15, and 
average (from years 0, 2, 5, 7, 10, and 15) systolic blood pressure levels were significantly 
associated with increased odds of coronary calcium (baseline OR = 1.3, 15-year OR = 1.3, 
average years 0 to 15 OR = 1.6 per 10 mm/Hg increase) after adjustment for other risk factors 
(LDL cholesterol, high-density lipoprotein [HDL] cholesterol, cigarette smoking, BMI, and 
glucose). 71 Also in this study, systolic blood pressure was the only risk factor examined 
where 15-year change in levels predicted coronary calcium levels more strongly than the 
baseline level (change OR= 1.20 vs. baseline OR = 1.16 per 10 mm/Hg). 71 
1.4.2.2 Smoking 
Autopsy studies in the young demonstrate robust associations between exposure to cigarette 
smoking and extent of atherosclerotic lesions. In the PDAY‘ study, smoking (defined as 
having a serum thiocyanate level of >90 gmol/L) was associated with more extensive fatty 
streaks and raised lesions in the abdominal aorta 94 even in those with favourable lipoprotein 
profiles,73 and a higher microscopic grade of atherosclerosis in the left anterior descending 
coronary artery,95 but not the right coronary artery. 73 In autopsy studies from the Bogalusa 
Heart Study, 36 the percentage of the intimal surface involved with fatty streaks in the 
coronary arteries was significantly higher in smokers compared with non-smokers (8.27 vs. 
2.89 %), as was the percentage of fibrous plaque in the aorta (1.22 vs. 0.12 %). The 
prevalence of fatty streaks and fibrous plaques in the aorta and coronary arteries were also 
increased in smokers compared with non-smokers but the association was non-significant, 
probably owing to low statistical power. 36 
In a series of case-control studies, Celermajer and colleagues in the early 1990s were 
the first to provide landmark evidence linking exposure to cigarette smoking and exposure to 
environmental tobacco smoke (including side-stream smoke from a burning cigarette and 
exhaled smoke) in living young persons to early signs of atherosclerosis. 96-98 Never smokers 
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had significantly higher endothelium-dependent FMD compared with current smokers (10.0 
vs. 4.0 %) in multivariable analyses adjusted for age, sex, cholesterol and vessel size, while 
lifetime dose smoked (pack years) was inversely associated with FMD (r = -0.33). 
Endothelium-dependent FMD was also higher in former-smokers compared with current 
smokers (5.1 vs. 4.0%) in multivariable analyses. 97 A second study from the group showed 
that endothelium-dependent FMD was reduced not only in smokers but also in those exposed 
regularly to environmental (passive) tobacco smoke (controls, FMD = 8.2%; smokers, FMD 
= 4.4%, passive smokers, FMD = 3.1%).98 In passive smokers, the intensity of exposure to 
environmental tobacco smoke was inversely related with FMD (r = -0.67). These data 
showed that cigarette smoking and passive smoking was associated in a dose-dependent, but 
potentially reversible, impairment in endothelial function. 
Cross-sectional data from the Atherosclerosis Risk-Factors in Male Youngsters 
(ARMY) study showed that adolescent smoking was significantly associated with prevalence 
of high IMT in a linear fashion (non-smokers, OR = 1.0; 1 to 9 cigarettes per day, OR = 2.7; 
10-19 cigarettes per day, OR = 3.6; ?20 cigarettes per day, OR = 5.0)• 99 A sub-analysis of the 
Special Turku Coronary Risk Factor Intervention Project (STRIP) demonstrated that the 
association between tobacco smoke exposure and decreased endothelium-dependent flow-
mediated dilation was dose dependent (FMD for the noncotinine group = 9.1%, the low-
cotinine group = 8.6%, and the top-decile cotinine group = 7.7%), suggesting that even 
modest exposure to tobacco smoke in childhood may be hazardous. 1® The Cardiovascular 
Risk in Young Finns study showed that carotid IMT was significantly associated both with 
childhood smoking4I and with various definitions of young adult smoking (ever, current, 
cigarettes per day, pack-years of smoking). 42 In the CARDIA study, baseline cigarettes per 
day were associated with increased odds (OR = 1.4 per 10 cigarettes/day) of coronary 
calcium at year 15 but not change in cigarettes smoked per day between baseline and year 
15. 71 In the Bogalusa Heart study, current smoking was the most consistent predictor of 
composite IMT progression in males (p = 0.017 mm, compared with current non-smokers) 
and females (f3= 0.011 mm, compared with current non-smokers)." 
1.4.2.3 Overweight and obesity 
The role of excess adiposity (overweight and obesity) in youth is one of few risk factors that 
have been linked with incident cardiovascular events in adulthood. Findings to date however 
have been equivocal. For example, data from 11,000 persons born in Aberdeen, Scotland, 
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found that BMI measured at age 5 years was not associated with future risk of coronary heart 
disease.' ° ' Another study that combined data on more than 23,000 participants from three 
historical cohorts (Boyd Orr, Christ's Hospital, and Glasgow Alumni cohort) that collected 
height and weight measures in childhood and adolescence found that overweight and obese 
children were not at significantly increased risk of ischemic heart disease (hazard ratio, HR = 
1.34, 95% confidence interval, Cl = 0.95 to 1.91) or stroke (HR = 0.94, 95%CI = 0.82 to 
1.08). 102 Both these studies were likely underpowered given there were only few children at 
the extreme (overweight or obese) end of the distribution, which is in contrast to 
contemporary children. The best evidence to date on the effect of childhood adiposity on 
coronary heart disease risk in adulthood was provided in a landmark study by Baker et al. 1°3 
Using data from almost 300,000 participants, the authors were able to demonstrate that the 
risk of any coronary event in adulthood was positively associated with BMI in boys (9-20% 
increase per 1-unit increase in BMI z-score) and girls (4-15% increase per 1-unit increase in 
BMI z-score). The data showed a strikingly linear trend for increased risk across the entire 
BMI distribution (Figure 6), suggesting that even a small increase in childhood adiposity may 
increase risk in adulthood. 
Figure 6. BMI in childhood and risk of any coronary heart disease event in adulthood. From Baker et 
al)" 
Evidence from pathological and imaging studies has shown much more consistent 
trends regarding childhood adiposity and atherosclerosis. In age- and/or sex-matched case-
control studies, excess BMI in youth was shown to be associated with endothelial 
dysfunction, 104-107 increased carotid IMT, 105, 106, 108 and increased arterial stiffness. 104, 107, 108 
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The study by Aggoun and colleagues demonstrated that impaired endothelial and smooth 
— 
muscle function as well as arterial stiffness develops before puberty in obese children. In the 
Bogalusa and PDAY studies, BMI 36 and a thick panniculus adiposus 46 ' 109 (a marker of 
visceral fat) were strong independent (of other risk factors) predictors of the extent of 
atherosclerosis in deceased young persons. 
In longitudinal analyses, childhood adiposity has also been shown to be a significant 
predictor of adult vascular measures. In the Amsterdam Growth and Health Longitudinal 
Study, childhood BMI and sum of skin folds were significantly associated with carotid IMT 
(BMI, r = 0.19; sum of skin folds, r = 0.25) independent of current risk factors (pulse 
pressure, blood lipids, glycated haemoglobin, resting heart rate and cardiorespiratory fitness), 
but the authors did not examine whether the effect of childhood adiposity was independent of 
adult adiposity.° Also, adolescent truncal subcutaneous fat was inversely associated with 
carotid artery compliance (r = -0.18) after adjustment for current risk factors (as above). In 
the Cardiovascular Risk in Young Finns Study, adolescent BMI was a significant predictor of 
adult carotid IMT (p = 0.01 mm for a 1 standard deviation change) in a multivariable model 
that also contained adolescent measures of LDL cholesterol, systolic blood pressure and 
smoking.'" Additional analyses of these data showed that adult IMT values were comparable 
in subjects who had been overweight or obese in both childhood and adulthood and in 
subjects who became obese in adulthood, 0.642 mm versus 0.634 mm; whereas IMT values 
were lower and comparable in subjects who were not overweight or obese at both time-points 
and those who had been overweight or obese in youth but were not in adulthood, 0.610 mm 
versus 0.627 mm. n° The authors concluded that while childhood adiposity predicts adult 
IMT, the effect is explained by significant tracking of adiposity from childhood to adulthood 
and is not independent of adult adiposity. Data from the ARYA study also found that while 
adolescent levels of BMI were significantly associated with carotid IMT (0 = 0.002 mm per 
standard deviation increase in adolescent BMI), the association was attenuated after 
adjustment for adult BMI (p = 0.001 These findings however were in contrast to 
those from the Bogalusa Heart Study. For example, Li et al. found that childhood but not 
adulthood BMI significantly increased the odds for high carotid IMT (child OR = 1.25, adult 
OR = 1.09), 37 while Freedman et al. showed that the association between childhood BMI and 
adult IMT persisted but was reduced after adjusting for adult BMI, I12 suggesting an 
independent effect of childhood BMI on adult IMT. In the Muscatine study, children in the 
upper decile of weight were at a three-fold increase in odds of having calcium in the coronary 
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arteries compared with children in the lower nine deciles. 34 In the CARDIA study, young 
adulthood BMI >25 kg/m 2 but not change in BMI between baseline and follow-up was 
associated with 50% increased odds of having coronary calcium at year 15 in a multivariable 
model that included age, race, sex, blood lipids, blood pressure, glucose, and smoking. 71 
1.4.2.4 Diabetes and associated abnormalities 
There is evidence that diabetes mellitus and metabolic-related risk factors in youth are 
associated with atherosclerosis. For example, publications from Jarvisalo, 113-115 Singh 116 
Krantz," 7 Atabek, 118 DaIla Pozza, H9 and Schwab, 12° have found that children and adolescents 
with type 1 diabetes had impaired endothelial function, 115 ' 116 increased arterial stiffness, 118 
and increased arterial IMT 113, 114, 117-120 compared with matched non-diabetic control children 
and adolescents. In these studies, the degree of endothelial impairment and increased IMT in 
those with type I diabetes appeared to be a result of duration of diabetes, presence of diabetes 
complications, blood pressure (systolic and diastolic) or LDL cholesterol levels. 113, 116, 117, 120 
119 Currently, there are no published data available that examine preclinical atherosclerosis in 
those children with type 2 diabetes. In the PDAY study, autopsied youth with 
hyperglycaemia (measured using level of glycohemoglobin in the blood) had increased odds 
of lesions in the coronary arteries (OR = 2.6) and the abdominal aorta (OR = 2.3). 47 Insulin 
resistance in adolescents has been cross-sectionally linked with brachial distensibility; 121 
while data from the Cardiovascular Risk in Young Finns Study suggested a longitudinal 
inverse association of childhood insulin levels with carotid arterial elasticity in adulthood (r = 
-0.17), but did not remain a significant predictor in the final multivariable model that 
included sum of skin folds. 43 
Presence of the metabolic syndrome, a cluster of cardiometabolic risk factors 
including obesity, hypertension, dyslipidemia, and impaired glucose tolerance, I22 is 
associated with increased risk of developing type 2 diabetes 123 and CVD124-126 in adults. 
Currently, there is no consensus definition for what constitutes metabolic syndrome in 
children and adolescents, I27 although a number have been proposed. 128-132 Moreover, no 
published data have examined the ability of these different paediatric definitions to predict 
markers of atherosclerosis in adulthood. A recent cross-sectional study on 264 overweight or 
obese adolescents found that the metabolic syndrome definition indicated by Weiss and Viner 
significantly predicted carotid IMT, but other definitions were not associated with carotid 
IMT. 133 A report by Iannuzzi et al. 134 found obese children with metabolic syndrome to have 
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increased carotid artery stiffness compared with obese children who did not have metabolic 
syndrome, which persisted after adjustment for age, sex, and C-reactive protein. There has 
been a recent attempt by Morrison and colleagues to examine in the Princeton Lipid Research 
Clinics Follow-up Study the relation between metabolic syndrome in children and 
adolescents aged 5 to 19 years with CVD 25 years later. 135 In the 771 participants followed 
into adulthood, there were only 17 cases of participant-reported CVD at the follow-up 
examination. Using a definition that had been previously used in National Health and 
Nutrition Examination Survey (NHANES) data, the authors found that those with paediatric 
metabolic syndrome had 15 times the odds (95% CI = 5-45) of having CVD in adulthood 
compared with those children who were not classified as having metabolic syndrome. 135 
Clear limitations of this study were the low case numbers and the non-use of hospital records 
to ascertain case information. Although it is clear the current available evidence on the 
association between diabetes and related metabolic abnormalities in childhood with 
atherosclerosis is at an early stage, the available data do suggest that diabetes and the 
metabolic syndrome in childhood may indeed be risk factors for atherogenesis. Given the 
close relationship between obesity, insulin resistance, metabolic syndrome, and type 2 
diabetes and childhood trends of increasing prevalence for each of these factors since the 
1980s, more robust data linking them with atherosclerosis is likely forthcoming. 
1.4.2.5 Physical inactivity 
There is good epidemiological and clinical evidence in adults that suggest physical inactivity 
and poor cardiorespiratory fitness are major risk factors for atherosclerosis, with the 
increased risk similar to that seen for conventional CVD risk factors of hypercholesterolemia, 
hypertension, and blood pressure." 6 Data from prospective cohort studies in older adults have 
demonstrated that low cardiorespiratory fitness, and low physical activity 137 as well as 
declining cardiorespiratory fitness 138 and declining physical activity 139 have been associated 
with increased risk for clinical CVD events; while clinical trials have provided data on the 
antiatherogenic effect of improving cardiorespiratory fitness and regular physical activity. 140 
Despite comprehensive evidence in adulthood, comparatively limited data exist that have 
examined childhood exposure to physical inactivity or low fitness with atherosclerosis (even 
when compared to the available data on other childhood risk factors). The Bogalusa and 
PDAY studies did not collect physical activity or fitness data, therefore no data from these 
studies were available to link with atherosclerotic lesions. The Muscatine and Young Finns 
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studies have collected childhood measures of fitness and physical activity but to date, no 
publications have reported their association with preclinical markers of atherosclerosis. In the 
available literature, the evidence does suggest that physical inactivity and low 
cardiorespiratory fitness in childhood and adolescence are associated with markers of 
atherosclerosis. 
Short-term clinical trials in overweight and obese youth have shown that aerobic 
exercise interventions improved cardiorespiratory fitness, 141, 142 increased endothelial 
function 142-146 and regressed carotid intima-media thickness.'" The study by Kelly et al. 142 
showed that improvements in endothelial function after 8 weeks of aerobic exercise training 
in overweight youth occurred without a loss of body weight or adiposity, suggesting a direct 
benefit of exercise on arterial function. Only two studies have examined the cross-sectional 
association between habitual physical activity and endothelial function. A study by Abbot 
and colleagues found that increasing habitual physical activity levels was the strongest 
multivariable determinant of brachial artery FMD (r = 0.39) in 47 children. I47 A recent 
publication from the STRIP cohort by Pahlcala et al. 52 showed that leisure-time physical 
activity was directly associated with brachial FMD in 13 year old boys (13 = 0.026% per MET 
h/wk) but not 13 year old girls. The association in boys remained significant after further 
adjustments for BMI, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood 
pressure, and C-reactive protein (13 = 0.028% per MET h/wk). 52 No studies have examined 
the cross-sectional association of cardiorespiratory fitness and markers of atherosclerosis in 
childhood or adolescence. Cross-sectional data from the Northern Ireland Young Hearts 
Project found cardiorespiratory fitness and sports-related physical activity (but not leisure- or 
work-related physical activity) to be inversely associated with arterial stiffness in 405 young 
adults aged 20 to 25 years independent of age, sex, height, weight, mean arterial pressure, 
smoking behaviour, alcohol consumption, fat intake, and sum of four skin folds. 48 
Longitudinal evidence linking childhood physical activity or fitness to adult markers 
of atherosclerosis is also limited. In the Amsterdam Growth and Health Longitudinal Study, 
VO2max measured in adolescence (13-16 years) was independently (model adjusted for 
height, weight, sum of four skin folds, systolic and diastolic blood pressures, total and HDL 
cholesterol, resting heart rate and smoking status) associated with lower carotid IMT in males 
at age 36 years. 38 VO2max was not associated with carotid IMT in females nor carotid 
stiffness in both sexes. 38 A second publication by this group found that changes in VO2max 
levels between childhood and adulthood was inversely associated with arterial stiffness in the 
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carotid and femoral arteries but was not associated with carotid IMT. 39 Currently, no data are 
available that examine the association between childhood physical activity and adult markers 
of atherosclerosis. Given the extent of physical activity and fitness data available at baseline 
examination 148' 149 and the collection of imaging data at follow-up ,44, 150 it is likely the 
Childhood Determinants of Adult Health Study will be the first to comprehensively examine 
these associations. The limited evidence that exists however suggests that physical activity 
and fitness levels in youth may have a direct impact (independent of adiposity) on the 
development of atherosclerosis. 
1.4.2.6 Multiple risk factors 
Evidence from epidemiological studies shows that multiple risk factors increase the 
probability of cardiovascular events, since CVD risk factors tend to reinforce each other in 
their influence on morbidity and mortality. m The importance of multiple risk factors in youth 
has been documented in several studies. The Bogalusa Heart Study demonstrated that the 
degree of fatty streaks and fibrous plaques accelerate in the aorta and coronary arteries of 
autopsied individuals with increasing number of risk factors (including BMI, systolic blood 
pressure, triglycerides, and LDL cholesterol, Figure 7). 36 Longitudinal analyses of free-living 
participants demonstrated a similar association with the outcomes of carotid IMT I52-154 and 
decreased carotid artery elasticity 155 across sex- and race-strata. Data from the Cardiovascular 
Risk in Young Finns Study demonstrated that in every category of adults with 0, 1, or 2 or 
more current risk factors, there was a significant increasing trend in carotid IMT values 
according to the number of childhood risk factors (Figure 8). 41 Additional data from this 
group showed that the number of risk factors was correlated with IMT in subjects with 
impaired and intermediate endothelial function, whereas there was no significant correlation 
between the number of risk factors and IMT in subjects with enhanced endothelial function. 42 
These data suggest that endothelial function in adulthood may offer some protection for 
arteries against the development of atherosclerosis in response to early-life exposure to risk 
factors. Another study from the Young Finns cohort showed that carotid artery elasticity 
decreased as more childhood risk factors were present.43 
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Risk prediction estimates that combine multiple risk factors (age, sex, total 
cholesterol, smoking, HDL cholesterol, and systolic blood pressure) using the Framingham 
Risk Score have also been shown to predict carotid IMT in the Bogalusa sample. I56 Similar in 
concept to the Framingham Risk Score, the PDAY study group provided a risk assessment 
tool combining multiple risk factors (age, sex, non-HDL cholesterol, HDL cholesterol, 
smoking, blood pressure, obesity, hyperglycaemia) to predict advanced atherosclerosis in the 
coronary arteries and abdominal aorta of adolescents and young adults. 47. 157 The utility of this 
risk score was demonstrated in unique datasets. In the CARDIA study, risk factors measured 
at 18 to 30 years of age predicted coronary artery calcium in 33 to 45 year olds (for a one-
point increase in risk score the odds for presence of any amount of calcium in the coronary 
artery increased by 10-15%), and the change in risk score between the baseline and 15-year 
follow-up also predicted coronary artery calcium (i.e. those who had an increase in their risk 
score between baseline and follow-up had higher odds of coronary calcium compared with 
those who remained the same or decreased their risk score). 158 In the Young Finns Study, the 
baseline PDAY risk score and change in the PDAY risk score between measurement time-
points both independently predicted adult carotid IMT (odds of IMT >90 th percentile or 
plaque were 1.12 for a one-point increase in baseline risk score and 1.04 per one-unit change 
in risk score between baseline and follow-up)." 9 Taken together these data provide evidence 
that the extent of atherosclerosis increases considerably when multiple risk factors are 
present. These findings support the concept that multiple childhood risk factors have a 
synergistic effect on atherosclerosis later in life, as has been demonstrated by epidemiological 
studies linking multiple risk factors in middle and older age with CVD morbidity and 
mortality. Moreover, these data underscore the importance of prevention strategies to focus 
on multiple risk factors, rather than a specific risk factor. 
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1.5. IMPORTANCE OF BLOOD LIPID LEVELS IN CHILDREN AND 
ADOLESCENTS 
As with findings in adult populations, studies involving children have provided compelling 
evidence that blood lipid and lipoprotein levels measured early in life play an important role 
in atherogenesis. For example, abnormal lipoprotein levels in children and adolescents have 
been associated with atherosclerosis in pathological studies; 36' 73 ' 113 prospective cohort studies 
have shown that lipoprotein levels not only track strongly from childhood and adolescence to 
adulthood, 160-162 but that adverse lipoprotein levels in early life may induce arterial changes 
that contribute to adult atherosclerosis. 34' 35 ' 37' 41 Given these data and findings that have 
demonstrated lifestyle and pharmacological intervention in children and adolescents to be 
effective in modifying lipoprotein levels 163-166  and improving markers of atherosclerosis,"' 166 
there is justification for identifying those at high-risk, and those who may benefit most from 
intervention. The following sections detail each of these areas. 
1.5.1 BLOOD LIPID AND LIPOPROTEIN LEVELS IN CHILDHOOD, 
ADOLESCENCE AND YOUNG ADULTHOOD AND ARTERIAL LESIONS: 
PATHOLOGICAL EVIDENCE 
Autopsy studies in youth and young adults have shown that high levels of total, LDL, very-
low-density lipoprotein (VLDL) cholesterols, and triglycerides, and low levels of HDL 
cholesterol are associated with increased atherosclerosis in the aorta and coronary arteries. In 
their first analyses of autopsy data from 35 deceased participants, investigators from the 
Bogalusa Heart Study found that aortic fatty streaks were directly related to total and LDL 
cholesterol concentrations (r = 0.67 for both) and inversely associated with the ratio of HDL 
cholesterol to LDL plus VLDL cholesterol (r = -0.35), and that coronary artery fatty streaks 
were directly related to VLDL cholesterol concentrations (r = 0.4l). A later analysis that 
included autopsy specimens from 93 participants that had antemortem risk factors available 
confirmed the previous findings but also demonstrated a direct association between 
triglyceride levels and the extent of fatty streaks in the coronary arteries (r = 0.26) and fibrous 
plaques in the abdominal aorta (r = 0.32) and coronary arteries (r = 0.37), as well as a direct 
association of LDL cholesterol with the extent of fibrous plaques in the coronary arteries (r = 
0.32).36 
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In the PDAY study, autopsy data from 1506 males and females showed that the 
extent of fatty streaks and raised lesions in the abdominal aorta and right coronary artery 
were directly associated with levels of non-HDL cholesterol (total cholesterol minus HDL 
cholesterol) and inversely associated with increasing levels of HDL cholestero1. 73 The effects 
were essentially similar across race and sex with the exception that a greater increase in the 
extent of fatty streaks in the abdominal aorta was attributable to non-HDL cholesterol levels 
in males compared with females. In another study by the PDAY group that examined risk 
factor associations with AHA lesion grade in the left anterior descending coronary artery, 
high non-HDL cholesterol (>4.14 mmol/L, >160 mg/dL) concentrations were associated with 
increased odds of grade II or III lesions (OR = 2.0), grade IV or V lesions (OR = 2.6), and 
_>_40% stenosis (OR = 3.0). Low HDL cholesterol (<0.91 mmol/L, <35 mg/dL) concentrations 
were associated with increased odds of grade II or HI lesions (OR = 1.6). 46 In multivariable 
analyses presented in a subsequent paper, high non-HDL cholesterol was significantly 
associated with increased odds of atherosclerotic lesions in the coronary arteries (OR = 1.41) 
and abdominal aorta (OR = 1.23) whereas low HDL cholesterol was no longer significant in a 
model that included age, sex, smoking, hypertension, obesity and hyperglycaemia.'" 
A series of publications by Napoli et al. 167-169 has demonstrated the potential of the 
foetal environment to affect future CVD risk. Postmortem examination of foetal aortas 
delivered from hypercholesterolemic (total cholesterols levels >4.65 mmol/L, >185 mg/dL) 
mothers contained significantly more and larger fatty streaks than aortas from 
normocholesterolemic mothers. I67' 168 These observations were extended in the FELIC (Fate 
of Early Lesions in Children) Study with data confirming that deceased children who had 
been exposed to maternal hypercholesterolemia during pregnancy had a more rapid rate of 
fatty streak formation in the aortic arch and abdominal aortas compared with children who 
had normocholesterolemic mothers, despite normal lipid levels at the time of autopsy. I69 
Collectively, these pathological data provide evidence that lipid and lipoprotein 
abnormalities in early life whether passive (in utero exposure to a hyperlipidemic 
environment) or direct (exposure to a hyperlipidemic environment in childhood or 
adolescence) are associated with accelerated atherosclerosis alreaily by the first and second 
decade of life. 
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1.5.2 BLOOD LIPID AND LIPOPROTEIN LEVELS IN CHILDHOOD, 
ADOLESCENCE AND YOUNG ADULTHOOD AND PRECLINICAL 
ATHEROSCLEROSIS: EVIDENCE FROM IMAGING STUDIES 
In more recent years, data has become available that link early life blood lipid and lipoprotein 
levels to non-invasive measures of atherosclerosis such as those outlined in Table 2. Leeson 
and colleagues found that total and LDL cholesterol were associated with brachial artery 
stiffness indices,'" in over 300 British school children aged 9 to 11 years, suggesting that 
more adverse blood lipid and lipoprotein levels in the first decade of life may already be 
having an impact on the early stages of atherosclerosis. Another cross-sectional study by the 
same group, this time in children aged 13 to 15 years (some of whom had previously been 
studied at ages 9-11 years), found again that increasing levels of total and LDL cholesterols 
were significantly associated with indices of increased stiffness with the strength of effect 
similar to what was observed in the earlier study. 121 Total cholesterol remained significant in 
analyses that included all adiposity measures (BMI, percent body fat, sum of four skin folds, 
and waist circumference) in the model (analyses examining LDL cholesterol were not 
detailed). 121 In multivariable analyses of 141 Austrian 17 to 18-year old males in the ARMY 
study, increased HDL cholesterol levels were associated with significantly reduced odds of 
high IMT (OR = 0.56 for a one standard deviation increase in HDL cholesterol levels). 99 In a 
case-control study by Jarvisalo and colleagues, children with hypercholesterolemia (defined 
as total cholesterol level >6.0 mmol/L or LDL cholesterol level >4.5 mmol/L) had increased 
carotid (0.53 vs. 0.44 mm) and aortic (0.46 vs. 0.42 mm) IMTs compared with age-, sex-, and 
body-size-matched controls.' 13 Another study by this group found that total cholesterol levels 
were inversely associated with brachial FMD (multivariable 13 = -1.13 % per 1 SD increase in 
cholesterol levels) in a convenience sample of children aged 9 to 16 years. 171 
Not only are blood lipid and lipoprotein levels associated with concomitant markers 
of atherosclerosis, data from the Muscatine, Bogalusa Heart, and Young Finns studies have 
shown that elevated levels in childhood predict increased levels of preclinical atherosclerosis 
in adulthood. Using data from the Muscatine study, Davis et al. were the first to demonstrate 
this longitudinal relationship." Total cholesterol levels measured at 8 to 18 years of age in 
346 males and 379 females were significant independent predictors of high IMT (defined as 
the upper quarter of the IMT distribution) measured in adulthood 25 years later (male, OR = 
1.53 for a one standard deviation increase; female, OR = 1.43). 35 Data on lipoproteins were 
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not collected at the baseline examinations but were at subsequent follow-ups. LDL 
cholesterol levels measured in young adulthood (measured 2 to 15 years before IMT 
measurement) were associated with significantly increased odds of high IMT in both sexes 
(males, OR = 1.39; females, OR = 1.54), while HDL cholesterol was significant only in 
males (OR = 0.70). earlier study of the Muscatine cohort showed a non-significant 
increased risk of having calcium in the coronary artery in adulthood for a one standard 
deviation increase in childhood total cholesterol levels for both males (OR = 2.3) and females 
(OR = 2.1), however it is likely these analyses were limited by low statistical power. 34 
Analyses of 486 participants from the Bogalusa Heart study who had at least three 
measurements of risk factors between childhood and adulthood showed that LDL cholesterol 
in childhood (OR = 1.42), cumulative burden of LDL (OR = 1.58) and HDL cholesterol (OR 
= 0.75) since childhood were independent predictors for having increased carotid IMT (top 
vs. lower three quartiles of carotid IMT) in young adulthood. 37 Among the risk factors 
examined, LDL cholesterol was shown to be the most consistent and strongest predictor of 
carotid IMT. A more recent analysis compared the usefulness of several childhood 
lipoprotein measures in predicting adult carotid IMT. I72 In separate multivariable analyses 
(adjusting for childhood BMI, systolic blood pressure, and length of follow-up) that 
examined each childhood lipoprotein measure as a predictor variable, non-HDL cholesterol 
(OR = 2.6), LDL cholesterol (OR = 3.0), total cholesterol/HDL cholesterol ratio (OR = 1. 8), 
apolipoprotein (apo) B (OR = 1.4), and apoB/apoA-I ratio (OR = 1.7) were significant 
predictors of adult carotid IMT. The ability to predict adult IMT from non-lipid risk factors in 
addition to any one of the different lipoprotein measures was not different in magnitude. 
A study by Li et al. 173 found that the relationship between childhood risk factors and 
adult IMT varied by sex and race in the Bogalusa cohort, suggesting that targeting certain 
risk factors in different population groups may improve prevention programs. In 
multivariable analyses stratified by race and sex, significant lipid and lipoprotein predictors 
of carotid IMT were triglycerides and LDL cholesterol in Caucasian males; LDL cholesterol 
in Caucasian females; and LDL cholesterol in African-American females.' 73 Although arterial 
stiffness, I55 common carotid lumen diameter, 174 and femoral artery IMT I75 measurements 
have been collected and related to adult CVD risk factors in the Bogalusa Heart Study, no 
studies to date have been published linking childhood risk factors to these measures; it is 
possible that childhood risk factors were not found to be associated with these measures. 
Although there are currently no longitudinal data that examine predictors of atherosclerosis 
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progression between childhood and adulthood, data on carotid IMT progression over six 
years in young adults from the Bogalusa Heart Study did not suggest that blood lipid and 
lipoprotein changes during this period were important." 
In the Cardiovascular Risk in Young Finns Study, univariable analyses of baseline 
(measured in 1980) and cumulative (average of levels measured at 1980, 1983, and 1986) 
total cholesterol, LDL cholesterol, the LDL cholesterol to HDL cholesterol ratio, and 
triglycerides were all shown to be directly associated with carotid IMT measured at the 2001 
follow-up, but the effects were only significant in males. 4 ' In a multivariable model that 
included sex, and childhood measures of age, BMI, systolic blood pressure and smoking, 
baseline LDL cholesterol was a significant predictor of adult IMT = 0.01 mm for a 1-SD 
increase in levels). The effects of childhood LDL cholesterol remained independently 
associated with carotid IMT when the model was further adjusted for current risk factors 
(beta coefficient was not shown). In a separate model examining the association of current 
risk variables and carotid IMT, LDL cholesterol was borderline significant (f3 = 0.004 mm for 
a 1-SD increase in levels, P = 0.06), suggesting that childhood levels were a stronger 
predictor of adult IMT than those collected at the time of imaging. In two separate reports, 
current but not baseline LDL cholesterol and HDL cholesterol levels were found to be 
significant multivariate predictors of stiffness indices of the carotid artery43 and brachial 
artery endothelial function respectively. 42 
Another paper from the Young Finns Study reported the effects of dyslipidemias 
from childhood to adulthood on adult markers of preclinical atherosclerosis." 6 Subjects with 
type lib dyslipidemia (those with mean cumulative z-scores over the 90 th percentile for LDL 
cholesterol and triglyceride levels in the 1980, 1983, 1986, and 2001 examinations) had 
increased carotid IMT compared with subjects without any dyslipidemias (type Ilb = 0.621 
mm vs. controls, 0.578 mm) and remained after adjustment for other risk factors (sex, age, 
carotid diameter, blood pressure, BMI, C-reactive protein, homocystine, insulin, glucose, 
family history of CVD, and smoking; adjusted IMTs were 0.607 vs. 0.579 mm). Additional 
analyses showed that the association between IMT with increasing number of non-lipid risk 
factors or presence of the metabolic syndrome was stronger in those with type lib 
dyslipidemia than in controls, suggesting that the increased IMT in those with type lib 
dyslipidemia was partly explained by their increased vulnerability to the effects of non-lipid 
risk factors and the metabolic syndrome. 176 The association between apoB and apoA-I, the 
major constituent proteins of LDL cholesterol and HDL cholesterol respectively, in 
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childhood with preclinical markers of atherosclerosis were recently examined in the Young 
Finns cohort: 77 Childhood levels of apoB and apoB/apoA-I ratio were directly associated and 
apoA-I inversely associated with adult carotid IMT. In analyses using brachial artery 
endothelial function as the outcome measure, apoB and apoB/apoA-I ratio were inversely 
associated and apoA-I directly associated with adult FMD. In a multivariable model that 
included non-lipid risk factors and adulthood apolipoproteins, both apoB and apoA-I were 
significant independent predictors of adult carotid IMT (apoB, (3 0.017 mm for a 1-SD 
increase; apoA-I, -0.011 mm) and brachial FMD (apoB, 0 -0.38 % for a 1-SD increase; apoA-
1, 0.47 %). Interestingly, a multivariable model that contained the childhood apoB/apoA-I 
ratio in addition to blood pressure and smoking significantly increased the prediction of high 
carotid IMT in adulthood compared with a model that included LDL/HDL cholesterol ratio in 
addition to blood pressure and smoking. These data suggest that measurement of apoB and 
apoA-I in childhood may be more useful in paediatric CVD risk assessment than serum 
concentrations of LDL and HDL cholesterols. Publications linking childhood risk factors to 
6-year IMT progression in young adulthood in this cohort are currently pending. 
In the CARDIA study, multivariable models showed that for each 30mg/dL increase 
in LDL cholesterol levels measured at 18 to 30 years the odds of calcium being present in the 
coronary arteries after 10-years (OR = 1.71) 74 and 15-years of follow-up (OR = 1.41)71 
significantly increased. Of interest, was that baseline LDL cholesterol levels were stronger 
predictors of 10-year and 15-year coronary calcification than contemporary risk factors 
measured at the time of scanning. In the I5-year follow-up, baseline LDL cholesterol levels 
predicted coronary calcium regardless of 15-year change in levels, and 15-year change in 
LDL cholesterol levels were not related to calcification independently of baseline levels 
(baseline, OR = 1.42; 15-year change, OR = 1.09). These data from the CARDIA study 
demonstrated that LDL cholesterol levels measured in young adulthood predicted the 
presence of calcified plaque better than concurrent levels, and regardless of the change in 
levels that had occurred in the 15-year interval. 
Taken together the above evidence highlights that while childhood and young 
adulthood levels of blood lipid and lipoprotein levels may be relatively low, they are, and in 
some cases more, important in the prediction of markers of atherosclerosis in young to 
middle adulthood suggesting that earlier risk assessment and preventive efforts targeted at the 
young may prove beneficial in reducing CVD burden. 
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1.5.3 FAMILIAL AGGREGATION OF ELEVATED LIPID AND 
LIPOPROTEIN LEVELS AND THEIR RELATIONSHIP TO 
ATHEROSCLEROSIS 
Children of families in which adult members have hypercholesterolemia tend to have more 
adverse lipid and lipoprotein profiles compared to their peers. 178 The aggregation of more 
adverse lipid profiles in these children is a result of both shared genetic (inherited) factors 
and shared environmental (lifestyle) factors. Inherited forms of lipid disorders that present in 
youth include familial hypercholesterolemia (FH), and familial combined hyperlipidemia 
(FCH); 179 both occur as a result of genetic defects in lipid metabolism pathways. For 
example, FH results from a single gene defect that affects LDL cholesterol receptors on the 
surface of hepatocytes impairing the clearance of circulating LDL cholestero1 18° that leads to 
severely elevated LDL cholesterol levels from birth onwards. 181 Familial combined 
hyperlipidemia results from hepatic overproduction of VLDL cholesterol due to what is 
thought to be the influence of multiple genetic factors. 182 The phenotype expression of FCH 
may include elevated LDL cholesterol alone (type ha) or in combination with 
hypertriglyceridemia (type Ilb), or acceptable LDL cholesterol with hypertriglyceridemia 
- (type IV). 18° Both FH and FCH have been attributed to premature CVD, 183185  in some cases 
before the age of 20. 186 Multiple studies have also compared non-invasive measures of 
atherosclerosis in youth with and without these lipid disorders. A study by Gidding et al. 187 
found that youth with FH had detectable coronary calcium in the second decade of life, long 
before it would typically present. Children and adolescents with the heterozygous form of FH 
189 show impaired endothelial-dependent FMD 188, 	and increased carotid IMT 19° compared 
with matched controls. In case-control studies, youth with FCH have also been shown to have 
impaired brachial FMD, 191 ' 192 and to have abnormalities in coronary flow regulation. 193 Data 
on carotid IMT in youth with FCH are not currently available, however, a recent publication 
from the Young Finns study showed that youth with type lib FCH had increased carotid IMT 
(0.62 vs. 0.58 mm) but not impaired brachial FMD or carotid compliance in adulthood 
compared with those who did not have any form of FCH. 176 It should be noted that while 
children and adolescents with FH and FCH are at high risk for CVD, not all of these youth 
195 have accelerated atherosclerosis or reduced life expectancy. 194  ' 	Moreover, while FH and 
FCH are the most common inherited lipid disorders, they do not account for all children and 
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adolescents with elevated blood lipid and lipoprotein levels nor do they explain the majority 
of premature CVD. I96 
Studies that collect phenotypic information from families with different degrees of 
genetic similarity (low similarity in the case of spouses or adoptees to high similarity in the 
case of monozygotic twin-pairs) have demonstrated that both shared genetic backgrounds and 
shared environments help explain the variance in blood lipid and lipoprotein values. These 
studies show heritability (i.e. the percentage of total variance attributed to shared genetics) to 
be in the order of 40 to 60%, 197 with shared environment tending to explain less variance in 
total and LDL cholesterol compared to HDL cholesterol and triglyceride, I98 suggesting a 
greater role for family environment and lifestyle factors in the modification of HDL 
cholesterol and triglyceride levels. These findings are not surprising given the concomitant 
increase in the prevalence of youth with low HDL cholesterol and high triglycerides in recent 
history due to the obesity epidemic. It is evident therefore, that children of families in which 
premature CVD or hypercholesterolemia occurs are at an elevated risk of adverse blood lipid 
and lipoprotein levels — promoted through the aggregation of both shared genes and shared 
environment. 
The evidence outlined in the previous sections suggests that child and adolescent 
lipid and lipoprotein levels are strong, and in most cases, independent predictors of current 
and future atherosclerosis burden and that raised blood lipid and lipoprotein levels tend to 
aggregate within families. The following section details evidence of the effect of lipid and 
lipoprotein modification in children and adolescents on markers of atherosclerosis. 
1.5.4 DOES THE MODIFICATION OF BLOOD LIPID AND LIPOPROTEIN 
LEVELS IN CHILDREN AND ADOLESCENTS HAVE AN EFFECT ON 
ATHEROSCLEROSIS? 
A recent systematic review by the US Preventive Service Task Force provided an elegant 
summary of the effectiveness of drug, diet, exercise, and combination therapies for treating 
dyslipidemia in children and adolescents.' 99 The available evidence summarised by this 
group 199 and others200, 201  suggests a benefit of statin drugs among children with FH in 
reducing total cholesterol, LDL cholesterol, and apoB levels whereas HDL cholesterol and 
apoA-1 levels increase; diet treatments in those children and adolescents with or without FH 
appear to reduce total and LDL cholesterol; and a benefit of exercise treatment for increasing 
Introduction 	 58 
HDL cholesterol in children and adolescents without FH. While these studies provide 
evidence of improved lipid levels, they do not demonstrate effectiveness of such treatments 
in reducing the optimal outcome of CVD morbidity and mortality. In the absence of such 
data, preclinical markers of vascular function and structure (as outlined in Table 2) that are 
directly related to the atherosclerotic process are increasingly being used as intermediary 
outcomes. 
In children with FH, pharmacological intervention with statin drugs (simvastatin and 
pravastatin) reduced total and LDL cholesterol levels, improved endothelial function, 188, 202 
and regressed carotid IMT 166 compared with matched placebo groups. The study by de Jongh 
et al. 188 showed that changes in total and LDL cholesterol after 28 weeks of therapy were 
responsible for part of the observed increase in endothelial function (correlation between 
change in total cholesterol and LDL cholesterol with change in FMD were r = -0.31, and r = - 
0.31 respectively). Interestingly, Rodenburg et al. 203 demonstrated that earlier initiation of 
statin therapy in childhood delayed the progression of carotid IMT into adolescence and 
young adulthood. 
The STRIP study, a clinical trial of dietary counselling in infancy aimed at reducing 
saturated fat intake,204 has shown the intervention group to have more favourable total and 
LDL cholesterol values during the first 3 years, and again at age 5, 7, and 14 years, 51, 164, 205, 
206 but does not harmfully influence children's growth. 207, 208 The effect on endothelial 
function was also demonstrated with boys in the intervention group at the age of 11 years 
shown to have significantly higher endothelium-dependent FMD compared with control boys 
(9.6 vs. 8.4%)." This difference remained significant after adjustment for current total or 
LDL cholesterol levels but became non-significant after adjusting for mean total cholesterol 
levels measured during the first 3 years, suggesting that the difference between the 
intervention and control groups was explained in part by the diet-induced reduction in 
cholesterol levels." These studies provide evidence that the modification of lipid and 
lipoprotein levels in children and adolescents does appear to impact on surrogate markers of 
atherosclerosis. While preliminary, these data suggest that there may be a benefit of 
beginning preventive and intervention efforts in childhood and adolescence as a means of 
reducing CVD later in life. 
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1.5.5 LEVELS AND PATTERNS OF LIPIDS AND LIPOPROTEINS IN 
CHILDREN AND ADOLESCENTS 
Research has identified two periods in childhood and adolescence when lipoprotein profiles 
undergo a substantial shift: during the first two years of life, and during sexual maturation. 
Observations on infants, pre-school children and school-aged children from the Bogalusa 
Heart Study209 and Lipid Research Clinics (LRC) Prevalence Study2I° indicate that the most 
dramatic shift in lipid and lipoprotein levels occurs during the first two years of life when 
concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides 
increase to approach young adult levels. This shift parallels the sudden growth spurt that 
occurs during this period. After this time, blood lipid and lipoprotein levels remain relatively 
stable until the onset of puberty. Rapid alterations in growth and sexual maturation during 
puberty bring dynamic sex- and race-related changes in lipid and lipoprotein levels. Data 
from the Bogalusa Heart study showed that total cholesterol levels decline at the onset of 
puberty in Caucasian and African-American males and females. This decline in Caucasian 
males reflects a drop in HDL cholesterol levels, whereas a drop in LDL cholesterol levels in 
Caucasian females and African-American males and females is responsible for the decline in 
total cholesterol levels. At maturation, LDL cholesterol levels begin to rise but HDL 
cholesterol continues to fall in Caucasian males. Triglyceride levels tend to rise during 
puberty and level-off at maturation in females, whereas levels continue to rise in males. A 
review of blood lipid and lipoprotein distributions in childhood and adulthood using data on 
60,494 observations from 26 countries showed similar trends to those reported in the 
Bogalusa Heart Study with changes occurring from 10 to 13 years of age. 
A number of population-based studies have provided data on the distribution of lipid 
and lipoprotein levels in youth. An elegant study by Knuiman et al.211 averted difficulties of 
comparing distributions and levels across different populations by using standardised 
methodology to assess total cholesterol and HDL cholesterol in boys aged 8 to 16 years from 
16 countries. The results showed that every population (even within countries) has its own 
unique cholesterol distribution, and that this distribution tends to reflect the adult CVD 
mortality in the region, with the highest total cholesterol concentrations observed in 
populations from the US and Northern Europe and the lowest observed in populations from 
Western Africa. A study by Dwyer et al. 212 that compared HDL cholesterol levels in children 
from Australia, the US, and Japan found that Japanese children had significantly higher HDL 
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cholesterol levels compared with their Australian and US contemporaries. Moreover, the 
decline in HDL cholesterol observed in males at the onset of puberty was much more 
pronounced in Australian (-15%) and US boys (-9%) than Japanese boys (-4%). They 
concluded that the differences observed may help to explain why CVD mortality in Japan is 
low compared with that in other developed countries. Differences observed across 
geographical regions are likely both genetic and environment-based. Evidence for genetic-
based differences are provided by US data from the NHANES, 213 the Bogalusa Heart 
Study,209 and the Cardiovascular Health in Children Study214 that have demonstrated 
differences in blood lipid and lipoprotein levels by ethnicity with African-American children 
tending to have higher total and HDL cholesterol levels compared with Caucasian. While 
data from the aforementioned Knuiman 211 ' 215 and Dwyer212 studies provided evidence for 
possible environmental differences between populations in their studies. For example, 
Knuiman found that the percent of energy intake from saturated fat was substantially higher 
in boys from countries where total cholesterol levels were higher. 215 In the Dwyer paper, 
Japanese children participated in more physical activity per week compared with Australian 
children.212 Collectively, these data suggest that lipid and lipoprotein distributions differ 
considerably by geographical region and by age, sex, race, and pubertal-status. 
Routine observations of lipid and lipoprotein levels in children and adolescents at 
different periods using standardised methodology allows secular trends to be observed. 
Reporting risk factor trends between 1966-1970 and 1988-1994, Hickman et al. 213 reported a 
secular decline of 0.18 mmol/L (7 mg/dL) in mean total cholesterol levels in 12 to 17 year 
old adolescents using NHANES data. The separate contribution of LDL and HDL cholesterol 
could not be deduced from these data, since lipoprotein measures were not collected from the 
earlier survey. A more recent update by Ford et al. 216 examined temporal trends between 
1988-1994 and 1999-2000 in the NHANES data. A significant decline in triglyceride levels (- 
0.24 mmol/L; -8.8 mg/dL) was observed over this time but total cholesterol, LDL cholesterol, 
and HDL cholesterol levels remained largely unchanged. Data from the Young Finns Study 
found evidence for declines in total cholesterol (-0.41 mmol/L; -16 mg/dL), LDL cholesterol 
(-0.21 mmol/L; -9 mg/dL) and HDL cholesterol (-0.28 mmol/L; -11 mg/dL) levels, and an 
increase in triglyceride levels (0.13 mmol/L; 12 mg/dL) in 15 and 18 year olds between 1980 
and 1992. 217 Significant declines in total cholesterol and HDL cholesterol and an increase in 
triglyceride levels were also confirmed in 24 year olds from this cohort between the 1986 and 
2001 surveys. 218 Data on children from the Bogalusa Heart Study were consistent with those 
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from adolescents in the Young Finns Study. For example, Gidding et al. 219 showed that HDL 
cholesterol levels had decreased (-0.16 to 0.34 mmol/L; -6 to 13 mg/di) and triglyceride 
levels had increased (0.09 to 0.41 mmol/L; 8 to 36 mg/di) in 7 to 9 year olds between 1973 
and 1992. While the reasons for these changes are not completely understood, 22° the observed 
reductions in total cholesterol and LDL cholesterol may be explained by reductions in 
cigarette smoking and saturated fat intake. 221-225 Whereas the reduction in HDL cholesterol 
levels and increase in triglyceride levels may be attributed to the well-documented increase in 
prevalence of child and adolescent overweight and obesity, particularly since the 1980s. 226-230 
The available data from a number of cohort studies have shown that the most consistent 
predictor of changes in lipid and lipoprotein levels is changes in adiposity; with increased 
adiposity associated with a subsequent decrease in HDL cholesterol levels and an increase in 
triglyceride levels. 161, 219, 223, 231 Obesity-associated dyslipidemia is a major concern facing 
contemporary youth. Not only is it associated with a more atherogenic lipid profile, the 
constellation of obesity-associated dyslipidemia with other indicators of the metabolic 
syndrome have been linked with markedly increased risk of type II diabetes and CVD 
mortality. 
1.5.6 TRACKING OF BLOOD LIPID AND LIPOPROTEIN LEVELS FROM 
CHILDHOOD OR ADOLESCENCE INTO ADULTHOOD 
Are blood lipid and lipoprotein levels measured in childhood or adolescence good indicators 
of levels in adulthood? This question has been examined in a number of prospective cohort 
studies conducted over the past three decades 160-162, 223, 224, 231-245 . 	 The term tracking has been 
used to describe analyses of this type. Essentially, tracking denotes the degree of consistency 
over time of an attribute, and is used to determine the ability to predict future values from 
measurements taken early in life. 246 For diseases that have a long latency before clinical 
manifestation and have established risk factors (such , as atherosclerosis), studies of 
modifiable risk factor tracking provide an insight as to whether identifying high-risk 
individuals at one time point may be useful in identifying those at highest risk of developing 
the disease at a later time point. There are important public health implications if risk factors 
are found to track. For example, prevention or treatment programs could begin earlier and 
targeted to the populations or individuals at highest risk of the disease. 
Introduction 
	
62 
The studies that have examined tracking of blood lipid and lipoprotein levels between 
160-162, 223, 224, 231-245 childhood or adolescence and adulthood 	 are extensively covered in Chapter 
3 of this thesis but a summary is provided here. These studies suggest moderate to strong 
tracking of total cholesterol (correlation coefficients, r, ranging from 0.33-0.73), LDL 
cholesterol (range r = 0.40-0.72), and HDL cholesterol levels (range r = 0.20-0.71), and low 
to moderate tracking of triglyceride levels (range r = 0.11-0.57) between childhood or 
adolescence and adulthood. While these studies suggest that children with high lipid and 
lipoprotein levels have a greater risk of having elevated adult levels than their peers with 
lower levels, they show that a substantial proportion of these children do not have adult levels 
that meet cut-points for intervention. 
Key limitations of the tracking literature includes use of only one measurement to 
assign risk status at both baseline and follow-up in most studies, non-standardised definitions 
of the at-risk group, and the paucity of data examining both tracking of fasting LDL 
cholesterol, HDL cholesterol and triglycerides levels from large population-based samples, 
and lifestyle factors that may have contributed to individuals changing their risk status 
between childhood or adolescence and adulthood. 
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1.6. PRIOR AND CURRENT GUIDELINES FOR SCREENING AND 
MANAGEMENT OF LIPID DISORDERS IN CHILDREN AND 
ADOLESCENTS 
The US National Cholesterol Education Program (NCEP) expert panel published consensus 
guidelines in 1992 for the detection and treatment of dyslipidemia in children and adolescents 
aged 2 to 19 years. This was in response to accumulating laboratory, clinical, pathological, 
and epidemiological evidence available at the time, that demonstrated elevated levels of total 
and LDL cholesterol in adults to be associated with cardiovascular outcomes, pathological 
data suggesting the presence of dyslipidemia in youth to be associated with early 
atherosclerotic lesion development, the tracking of lipid and lipoprotein levels from 
childhood to adulthood, and family history of premature CVD to be useful in identifying 
youth with elevated LDL cholesterol levels. I96 The panel recommended that a combined 
strategy consisting of both a population and an individualised approach be adopted in the aim 
of lowering total and LDL cholesterols. The purpose of the population approach was to lower 
the average blood lipid levels of all youth through providing population-wide dietary 
recommendations; while the purpose of the individualised approach was to identify children 
at highest risk of CVD by selective screening blood lipid and lipoprotein levels in those with 
family history of premature CVD and/or parental hypercholesterolemia. The selection, 
screening, and therapeutic recommendations were determined by a series of algorithms 
(Figure 9, and Figure 10). 
For children and adolescents with a parental or grandparental history of premature 
(<55 years) CVD (coronary atherosclerosis, coronary procedure [balloon angioplasty or 
bypass surgery], myocardial infarction, angina pectoris, peripheral vascular disease, 
cerebrovascular disease, or sudden death), the panel recommended a fasting lipoprotein 
analysis. For children and adolescents with parental hypercholesterolemia (total cholesterol 
level >6.20 mmol/L; 240 mg/dL), the panel recommended screening for total cholesterol 
levels in the first instance (Figure 9). Three levels for classification of total cholesterol levels 
were provided. Total cholesterol levels <4.40 mmol/L (<170 mg/dL) were classified as 
acceptable, levels from 4.40 mmol/L to 5.17 mmol/L (170-200 mg/dL) were considered 
borderline-high, and values that exceeded 5.20 mmol/L (200 mg/dL) were considered as 
high. In those with borderline-high levels, a repeat measurement was emphasised. If the 
average of both measurements was <4.40 mmol/L (<170 mg/dL) or the initial measurement 
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was acceptable, repeat measurements were recommended within five years. For those that 
remained in the borderline-high category after repeat analysis, no recommendation was 
provided. If the average of the two measurements exceeded 5.20 mmol/L (200 mg/dL), or for 
those classified as having high total cholesterol levels at the initial measurement, analysis of 
fasting lipoprotein levels were to be obtained. 
For those where fasting lipoprotein analysis was emphasised, further evaluation and 
treatment recommendations were then based on LDL cholesterol levels (Figure 10). 
Classification was based on the average of two measurements to account for within-person 
variability. Those with LDL cholesterol levels <2.85 mmol/L (<110 mg/dL) were defined as 
acceptable and required lipoprotein analysis again within five years. Those with values from 
2.85 to 3.35 mmol/L (110-130 mg/dL) were defined as borderline-high, advised to follow the 
dietary guidelines set out for the population-based approach and to have their lipoprotein 
status re-evaluated in one year. Those with levels above 3.35 mmol/L (1.30 mg/dL) were 
considered as high, and advised to progress from the 'step-one' diet, which was consistent 
with the dietary guidelines for the general population, followed by the 'step-two' diet which 
placed further restrictions on saturated fat and cholesterol intake. The panel recommended 
the consideration of pharmacological therapy in youth aged 10 years and older if, after an 
adequate trial (6 months to 1 year) of diet therapy (step-one progressing to step-two), LDL 
cholesterol levels were above 4.90 mmol/L (190 mg/dL) or were above 4.10 mmol/L 
(160mg/dL) together with either a positive family history of premature CVD or two or more 
other current CVD risk factors (cigarette smoking, elevated blood pressure, low HDL 
cholesterol levels, severe obesity, diabetes mellitus, or physical inactivity). 
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Figure 9. Individualised approach of risk assessment of paediatric blood cholesterol levels according 
to the NCEP guidelines.'" 
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Figure 10. Classification and treatment recommendations based on paediatric LDL cholestero levels 
from the NCEP using the individualised approach.196 
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Universal (or population-wide) screening of blood lipid levels in all children and 
adolescents was not recommended due to reservations from the panel with regard to (1) 
predictiveness (not all youth with high-risk levels become adults with high-risk levels); (2) 
psycho-social aspects of labelling youth with lipid disorders as having a 'disease'; (3) there 
being sufficient time to begin lipid-lowering therapies in adulthood, and (4) insufficient 
evidence concerning the long-term safety and efficacy of pharmacological therapy in youth. 
In 1998, the American Academy of Pediatrics (AAP) Committee on Nutrition issued 
a statement on cholesterol in childhood that adopted all of the attributes of the original NCEP 
guidelines, but made some minor modifications to nutrient recommendations. 247 In 2003, the 
AHA issued guidelines for the primary prevention of CVD beginning in childhood. 248 Again, 
these essentially followed the recommendations set forth by the 1992 NCEP consensus. The 
AHA guidelines further added that pharmacologic intervention for dyslipidemia be 
accomplished in collaboration with a physician experienced in the treatment of cholesterol 
disorders in youth. This report also recommended therapeutic lifestyle changes (weight 
management with appropriate diet and increased physical activity, decreased intake of simple 
sugars) in those with elevated triglyceride levels (>1.50 mmol/L; 150mg/dL) and/or low HDL 
cholesterol levels (<0.90 mmol/L; 35 mg/dL). No pharmacologic intervention was 
recommended for those children with elevated triglyceride or low HDL cholesterol levels. In 
addition, the report suggested that the average of three fasting lipid profiles be used before 
risk was classified, and emphasised weight management and increased physical activity in 
those with high total or LDL cholesterol levels. 
In the time since the commencement of this dissertation, new guidelines for testing 
and treating lipid disorders have been published. In 2007, the AHA updated 
recommendations for pharmacologic therapy in children and adolescents with high-risk lipid 
abnormalities, 249 and in mid 2008, the AAP issued a revised set of guidelines on cholesterol 
in childhood that superseded those issued in 1998. 220 The updated guidelines continued to 
emphasise both the population-based approach and the individualised approach, but provided 
recommendations for more comprehensive screening (extending lipid and lipoprotein 
analysis to youth with other CVD risk factors — particularly overweight and obesity, but also 
hypertension, cigarette smoking or diabetes), age- and sex-specific decision cut-points, the 
inclusion of routine HDL cholesterol and triglyceride analysis in addition to LDL cholesterol, 
improved quality of fat in the diet rather than reducing total fat consumption, a lowering of 
the age at which pharmacologic intervention may be considered (from 10 to 8 years), and the 
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inclusion of statins as potential first-line pharmacologic agents, with the target LDL 
cholesterol level reduced from <4.1 mmol/L (160 mg/dL) to 'minimum' <3.3 mmol/L (<130 • 
mg/dL) and 'ideal' <2.85 mmol/L (110 mg/dL) levels. A comparison of the recommendations 
on blood lipid screening and management in paediatrics issued by NCEP in 1992 and revised 
by the AAP in 1998 with recommendations set-forth in the 2008 revision from the AAP are 
presented in Table 3. The revised guidelines from both groups were issued in concert with a 
systematic review from the US Preventive Services Task Force 25° and in reply to recent calls 
from this group, the American Heart Association, 249 and others 220, 251-253 that outlined 
challenges with the existing guidelines and had called for revision based on data that had 
become available since the guidelines were first published. I96 It should also be noted that the 
National Heart Lung and Blood Institute (NHLBI) will soon release recommendations from 
the Pediatric Cardiovascular Risk Reduction Initiative that aims to address overall CVD risk 
factor identification and risk reduction in children 
(http://www.nhIbi.nih.gov/guidelines/cvd_ped/index.htm).  
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Table 3. Comparison of paediatric guidelines on lipid screening and treatment from 1992 to 2008 
Recommendation 	 NCEP, 1992 1 ' 6 :Ind AAP, 1993 2' 7. 
	
AAP, 21108' 2" 
Screening Population approach 
No screening recommended 
Individual approach 
Measure non-fasting TCH or fasting lipids if: 
I. 	family history (parent or grandparent) of premature 
CVD 555 years, or 
2. at least one parent with known high cholesterol levels 
26.20 nunol/L (2240 mg/dL), or 
3. optional with unknown/unobtainable family history, or 
4. optional given personal risk factors (cigarette smoking, 
high blood pressure, consumption of excessive 
saturated fat, overweight, those with medical 
conditions such as diabetes). 
Start age: 22 years. 
Screening interval: at least every 5 years 
No specific recommendations for high TO levels or low 
HDL-C levels. 
Population approach 
No screening recommended 
Individual approach 
Measure fasting lipid profile if 
I. 	family history (parent and/or grandparent not- 
specified) of premature CVD 555 years for males 
and 565 years for females, or 
2. family history (parent and/or grandparent not-
specified) of dyslipidernia (values not specified), or 
3. recommended with unknown family history, or 
4. Recommended given personal risk factors 
(overweight or obese, BMI 285 6 percentile; 
hypertension, blood pressure 295' percentile; 
cigarette smoking, diabetes mellitus). 
Start age: 22 years, no later -than 10 years 
Screening interval: every 3-5 years 
HDL-C and TG considered in recommendations for those 
who are overweight or obese. 
Age- and sex-specific values corresponding to nomism 
(>95 th percentile for TCH, LDL-C and TG, <5 th percentile 
for HDL-C). 
Cut-points 	Single set of cut-points (for all ages and both sexes) for total 
cholesterol and LDL cholesterol. 
Diet Population approach 
NCEP Step-One Diet (total fat <30% of total calories; 
saturated fat <10% of total calories; dietary cholesterol <300 
mg/day). The AAP later added that total fat should be no less 
than 20% of total calories?'" 
Individual approach 
Nutritional therapy: begin at 2 years of age 
I. 	NCEP Step-One Diet (outlined above) 
2. 	If Step-One Diet not effective after 3-mo, progress to 
Step-Two Diet (saturated fat <7% of total calories; 
dietary cholesterol <200 mg/day) 
Population approach 
Follow Dietary Guidelines for Americans (saturated fat 
<7%, trans fat <1% of total calories; dietary cholesterol 
<200 mg/dL; fibre intake equal to child's age plus 5 g/day 
up to 20 g/day at age 15). 
Individual approach 
Nutritional therapy: 
I. 	Reduced-fat milk to begin at 1 year for children at 
risk of overweight or obesity or who have family 
history of obesity, dyslipidemia, or CVD. 
2. 	Follow Dietary Guidelines for Americans when 22 
years of age. 254 '  
Physical activity 	No specific guidelines, but regular exercise encouraged. 	No specific guidelines, but increased physical activity 
encouraged for treatment of high TO levels and low HDL-
C levels in overweight or obese. 
Pharmacology 	Individual approach 
Consider drug therapy if children 210 years of age, after an 
adequate trial of diet therapy (6 mo to 1 year) and either: 
I. 	LDL-C remains 24.90 nunol/L (2190 mg/dL), or 
2. 	LDL-C remains >4.10 rnmol/L (>160 mg/dL) and 
a. family history of premature CVD, or 
b. 22 CVD risk factors 
Use bile acid-binding resins as first-line treatment, Niacin 
(nicotinic acid) under supervision of lipid specialist. 
Individual approach 
Consider pharmacologic intervention if children <8 years 
of age and LDL-C >12.90 nunol/L (>500 mg/dL), or 28 
years of age and either: 
I. 	LDL-C 24.90 mmol/L (2190 rns/dL), or 
2. 	LDL-C >4.10 mmol/L (>160 mg/dL) and 
a. family history of premature CVD, or 
b. 22 CVD risk factors, or 
c. 23.35 mmoVL (2130 ing/dL) if diabetes 
mellitus is present 
Statins, bile acid-binding resins, cholesterol-absorption 
inhibitors as potential first-line agents, fibrates under 
supervision of paediatric lipid specialist. 
NCEP = National Cholesterol Education Program; AAP = American Academy of Pediatrics; CVD = 
cardiovascular disease; TCH = total cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C 
= high-density lipoprotein cholesterol; TG = triglycerides; BMI = body mass index 
*Guidelines issued by the AAP were consistent with the NCEP guidelines with exceptions noted in the 
table. 
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1.6.1 CHALLENGES WITH THESE GUIDELINES 
Reports from the AHA 249 and the US Preventive Services Task Force' 99 have provided recent 
and thorough reviews examining the application of the NCEP and AAP guidelines in view of 
newer evidence that has become available since they were first issued. The areas outlined for 
revision can be loosely categorised as follows: screening, guideline compliance, and 
management (efficacy, effectiveness, and type of therapeutic intervention). In the following 
section, issues concerning screening will be summarised as they are key to the aims of this 
thesis. 
1.6.2 SCREENING 
How many children and adolescents would be screened? 
Using data from the LRC Prevalence Study, the NCEP panel estimated that 25.1% of youth 
aged 2 to 19 years would be screened according to the individualised approach using a 
combination of positive family history of premature CVD (5.6%) and parental 
hypercholesterolemia (19.5%). However, a number of population-based studies with medium 
to large sample sizes have suggested that the number of youth requiring lipid screening to be 
in the order of 25 to 55%. 256-265 In the largest study of these, Dennison et al., found that 38% 
of 10,457 youth aged 2 to 19 years would meet screening criteria, 27% due to family history 
of premature CVD and 11% due to parental hypercholesterolemia. Griffin et al. reported 35% 
of pre-pubertal, predominantly Caucasian children aged 2 to 13 years would meet the 
screening criteria. A report from O'Loughlin et al. on data from the Quebec Child and 
Adolescent Health and Social Survey suggested that targeted screening would be evident for 
26% of 3665 predominantly French-Canadian youth aged 9, 13, and 16 years. Because only 
parental history of premature CVD was collected, this was likely an underestimate of the 
actual amount that would have met the NCEP/AAP criteria. A study of 1140 fifth-grade 
students in a school-affiliated, health-education program in Arizona found that 54% had a 
family history of hypercholesterolemia or MI. While the wide discrepancy in the proportions 
of youth that would be subject to lipid screening is likely a function of discordant definitions 
of family history of premature CVD, the threshold used to denote hypercholesterolemia, 
population differences, or a combination of these, it is evident from these data that a higher 
proportion of children and adolescents would be screened than was first estimated.I99'22° 
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What is the diagnostic accuracy of the selective screening approach? 
A perfect, cost effective, screening tool would be able to identify all of those children with 
high-risk blood lipid and lipoprotein levels, while at the same time not unduly subject those 
children that do not have high blood lipid or lipoprotein levels to blood draws. Diagnostic 
tests are often examined in terms of sensitivity, the proportion of diseased persons that are 
correctly identified as positive by the screening test; and specificity,  the proportion of healthy 
(non-diseased) persons that are correctly identified as negative by the screening test. Ideally, 
a screening test should have both high sensitivity and high specificity, or a reasonable trade- 
off between the two values that is considered 'acceptable'. In the case of testing for blood 
cholesterol levels in youth, the 'disease' is high blood lipid or lipoprotein levels, which is 
only a surrogate marker for the risk of the true disease outcome, atherosclerosis and CVD. 22° 
A number of studies have examined the diagnostic utility of the individualised 
screening approach based on family history256, 257, 259, 261, 262, 264-275 recommended in the 
previous, I96 ' 247 and adopted with other triggers for screening in the updated AAP 
guidelines. 220 The recent systematic review from the US Preventive Services Task Force of 
these studies reported that a substantial proportion of youth with elevated lipid and 
lipoprotein level were missed using the selective screening approach based on family 
history. I99 Sensitivity estimates in these studies ranged from 10 to 83% with most studies 
suggesting that 30 to 60% of youth with high-risk levels would not be identified. Specificities 
also varied substantially from 24 to 79%; the lowest reported in a sample of predominantly 
Caucasian fifth-grade students, 259 and the highest reported in a sample of mostly Hispanic 
senior high-school students. 274 It should be noted that these studies used varied definitions of 
what constituted positive family history (first- or second-degree relatives, age definition of 
'premature', total cholesterol level used to denote the presence of family history for 
hypercholesterolemia). Findings from Friedman et 31.276 reporting on data from the Princeton 
LRC Prevalence Follow-up Study deserve special mention. This study measured 900 
participants aged 5 to 19 years at baseline and again when they were aged 28 to 48 years to 
examine the diagnostic utility of the selective screening approach in identifying children who 
would have high total cholesterol or LDL cholesterol levels in adulthood. They found 
sensitivities of 46% for both total and LDL cholesterol and specificities of 84% and 82% 
respectively for the selective screening approach endorsed by NCEP and the AAP. 
Interestingly, they showed that a universal (population-wide) approach to screening to 
provide comparable prediction of adult values when compared with the more-focused 
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screening of youth with positive family history, illustrating limited benefits of targeted 
screening for this purpose. 
Limitations in accurately obtaining full family history of premature CVD and 
hypercholesterolemia have also been highlighted,I99, 220, 249 which  may also have affected 
diagnostic utility of this screening approach. For example, family history may not be known 
by the parents, both parents may not be available, the parents may not have had their 
cholesterol levels checked themselves, or those parents that have had their cholesterol level 
measured may not know their results. 260. 277 Another concern is how well total cholesterol 
levels sampled from those youth with family history of hypercholesterolemia identify high-
risk LDL cholesterol levels, which are used as the basis for treatment decisions in the NCEP 
guidelines. The available evidence suggests that total cholesterol levels are insufficient in 
identifying youth with elevated LDL cholesterol levels with sensitivities in the order of 50% 
when a total cholesterol level above 5.2 mmol/L (200 mg/dL) is applied as per the NCEP 
guidelines.271,278,279 
In the most recent guidelines from the AAP, 22° additional triggers for lipid and 
lipoprotein screening are recommended, particularly for overweight or obese youth. This 
modification is in reply to the rapid increase in the prevalence of overweight and obesity in 
the US and other industrialised nations since the 19805 ,227-229, 280 and the associated evidence 
for the consequences of the childhood obesity epidemic that have accumulated in this time. 
As outlined earlier, lipid and lipoprotein abnormalities have been shown to be common in 
overweight and obese children ,28I-284 with low HDL cholesterol and high triglyceride levels 
particularly prevalent. The clustering of metabolic abnormalities such as insulin resistance 
and other factors associated with the metabolic syndrome in overweight and obese 
adolescents is also cause for concern. For example, Sinaiko et al. 285 found evidence of a 
significant interaction between obesity and insulin resistance and their effect on CVD risk 
factors, including HDL cholesterol and triglycerides but not LDL cholesterol, in a cross-
sectional sample of adolescents. Therefore, the obesity-associated dyslipidemia is distinctly 
different to the more traditional elevation of total or LDL cholesterol levels associated with 
family history of premature CVD or hypercholesteremia. A number of cross-sectional studies 
have consistently shown increased adiposity to be the most effective predictor of 
dyslipidemia compared with other factors assessed, including family history of premature 
CVD and hypercholesterolemia. 149, 282, 286-299 Adding further credence to these data, 
longitudinal findings from the Cardiovascular Risk in Young Finns and Bogalusa Heart 
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Study have also shown adiposity at baseline, as well as change in adiposity, to be the best 
predictors of follow-up blood lipid and lipoprotein levels outside of the baseline lipid 
measurement. 161 ' 231 Combining these findings with those covered in section 1.5.4 that 
demonstrated the efficacy of weight reduction in improving lipid and lipoprotein levels in 
youth, it becomes evident why the revised guidelines included overweight or obese youth for 
lipid screening. Nevertheless, the diagnostic utility of screening overweight or obese youth 
for the identification of either concurrent or future lipid abnormalities have not been formerly 
assessed.'" An equally important consideration in the diagnostic utility of blood lipid and 
lipoprotein screening in youth is the cut-points used to stratify risk. 
1.6.3 CUT-POINTS 
Dichotomous cut-points for risk stratification aim to define those who are at an increased risk 
of developing clinically significant CVD, and in whom risk modification will reduce the 
likelihood of subsequent complications. The initial NCEP report published a single set of 
fixed cut-points that defined borderline-, and high-risk cut-points for total cholesterol, LDL 
cholesterol, HDL cholesterol, and triglycerides at values coinciding with the 75 th , and 95 °1 
percentiles (25 th , and 5 th for HDL cholesterol) of the entire population distribution from the 
LRC Prevalence Study. 196 ' 21° The LRC Prevalence Study was a multi-stage NHLBI survey of 
lipid and lipoprotein levels and other CVD risk factors in nine US and one Canadian 
community conducted between 1972 and 1976. 21° The NCEP cut-points apply to all children 
and adolescents aged 2 to 19 years, hence do not account for changes in distributions that 
occur with growth and maturation, or by sex or race 300-302 — as was outlined in section 1.5.5. 
These cut-points were later adopted in primary prevention guidelines from the AHA 248 and 
AAP247 as the basis for identifying children and adolescents at high-risk of CVD. 
A report from Morrison 303 called for the NCEP cut-points to account for pubertal 
stage, age, sex, and race after demonstrating marked differences in the prevalence of NCEP 
defined borderline- and high-risk LDL cholesterol in these groups in cross-sectional LRC 
data. The report by Friedman et al. 226 highlighted in the previous section, showed that the 
utility of prediction of adult dyslipidemia using the NCEP cut-points differed according to 
baseline age. For example, the lowest sensitivity occurred at ages 11 to 16 years, while 
specificity was lowest at ages 11 and 13 years; the years that coincide with puberty. Analyses 
by sex- or race- were not possible due to low stratum size. Collectively, these data provided 
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the first diagnostic evidence of the limitations of fixed cut-points for all children and 
adolescents. 
In an attempt to account for age and sex in the interpretation of fasting lipid and 
lipoprotein profiles, Jolliffe and Janssen25 ' recently proposed new lipid and lipoprotein cut-
points for adolescents aged 12 to 19 years based on combined data from three National 
Health and Nutrition Examination Surveys (NHANES). These cut-points were derived using 
age- and sex- specific growth curves that were linked to adverse adult lipoprotein thresholds 
established by the NCEP adult treatment pane1. 304 This brought lipid and lipoprotein risk 
definitions in line with age- and sex-specific percentile distributions already established to 
define risk presence for both hypertension305 and overweight and obesity.306, 3o7  In an editorial 
to the Jolliffe and Janssen paper, Gidding252 outlined limitations of using NHANES data in 
defining cut-points that included: (1) a substantial proportion of the NHANES cohort was 
excluded from lipid and lipoprotein analysis because of non-fasting status at presentation; 
and (2) only single lipid and lipoprotein measurements were collected in the NHANES cohort 
thus the cut-points do not take into account measurement variability of lipid and lipoprotein 
levels that have been documented. 161,308-310  
As it is unknown whether the new cut-points provide an improved prediction of those 
adolescents most likely to develop CVD risk later in life, one of the primary aims of this 
thesis is to compare the utility of the fixed cut-points stipulated by NCEP and those based on 
distributions from NHANES suggested by Jolliffe and Janssen to predict both dyslipidemia in 
adulthood and markers of preclinical atherosclerosis in adulthood. 
It is also necessary to note that the 2008 update of lipid screening guidelines from the 
AAP also provided age- and sex-specific cut-points. However, the authors did not mention 
the work by Jolliffe and Janssen in their discussion and instead, proposed yet another, un-
tested, set of cut-points for classification based on percentiles from the LRC Prevalence 
Study.311 The proposed new cut-points had a number of limitations that were not properly 
considered and have been the subject of a letter to the editor by the author of this thesis 
(original contribution I). For example, the proposed lipid and lipoprotein distributions were 
derived from Caucasian children in the LRC study3 " and as such, should be applied to 
biracial populations with caution. Moreover, although the authors recommend lipid screening 
to commence from the age of two years, the proposed cut-points presented began from age 
five; hence, it was not clear how blood lipid and lipoprotein concentrations of children aged 
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from two to four years should be classified. Because of the recency of these revised cut-
points, they were not examined in this thesis. 
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1.7. AIMS OF THIS THESIS 
This thesis makes use of data from three population-based prospective cohort studies 
conducted in Australia (the Childhood Determinants of Adult Health, CDAH, Study), Finland 
(the Cardiovascular Risk in Young Finns Study), and the United States (the Bogalusa Heart 
Study). These studies collected baseline blood lipid and lipoprotein measures in children and 
adolescents in the 1980s, with follow-up measures collected 15-20 years later when 
participants were young adults. The specific aims examined for this thesis make use of these 
data, and are outlined below: 
I. To examine in the CDAH study: 
a. the long-term (20 year) tracking of blood lipid and lipoprotein levels from 
childhood and adolescence to young adulthood (Chapter 3); and 
b. factors that affect the tracking of blood lipid and lipoprotein levels from 
childhood to adulthood (Chapter 3). 
2. To determine the utility of two classifications (NCEP vs. NHANES) of paediatric 
dyslipidemia to predict dyslipidemia in adulthood (Chapter 4). 
3. To determine the utility of paediatric LDL cholesterol and HDL cholesterol dyslipidemia 
classifications (NCEP vs. NHANES) in predicting carotid artery IMT in adulthood 
(Chapter 5). 
4. To assess whether maintaining or changing LDL cholesterol and HDL cholesterol 
dyslipidemia status from adolescence to adulthood has an effect on carotid artery IMT 
measured in adulthood (Chapter 5). 
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1.8. SUMMARY 
The converged evidence from studies reviewed in the preceding text provides support for: the 
origin of atherosclerosis in early life; the association of risk factors in youth with early signs 
of atherosclerosis; and the prediction of adult risk status from childhood or adolescent risk 
factor levels. Because of this evidence, guidelines for the screening and management of lipid 
disorders in children and adolescents were established. In recent times, reports from the US 
Preventive Service Task Force, 25° the American Heart Association, 249 and others ,220, 251-253 
have outlined challenges with the existing guidelines and have called for their revision: 96 
One area of the existing guidelines outlined for revision includes the lipid and lipoprotein 
cut-points used to assign risk status. Two classifications of paediatric dyslipidemia have been 
circulated that attempt to define normal-, borderline-, and high-risk lipid blood levels. 
Nevertheless, no study has assessed which of these classifications is most effective for 
predicting those who will develop dyslipidemia or high preclinical atherosclerosis (carotid 
IMT) in adulthood. A comparison of the predictiveness of these classifications may provide a 
more accurate assessment of those children and adolescents at high-risk for CVD later in life 
and help identify those who may benefit most from intervention. The principal aim of this 
study was therefore to examine the utility of paediatric dyslipidemia classifications that 
define normal-, borderline-, and high-risk lipid and lipoprotein levels to predict dyslipidemia 
and high carotid IMT in adulthood. A number of related aims were to examine tracking of 
blood lipid levels from childhood to adulthood; factors that affect tracking of blood lipid 
levels from childhood to adulthood; and whether changes in blood lipid levels between 
adolescence and adulthood had an effect on the level of arterial thickening measured in 
adulthood. 
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2. METHODS 
2.1. INTRODUCTION 
This chapter describes the methods employed in this study. The primary data sources utilised 
to examine the aims of this study include: The Childhood Determinants of Adult Health 
(CDAH) Study, The Cardiovascular Risk in Young Finns Study, and the Bogalusa Heart 
Study. This Chapter provides an overview of the CDAH, Young Finns, and Bogalusa studies 
and describes in-depth, the methodological aspects central to this thesis. Extended methods of 
the CDAH study is included, as the follow-up has not previously been described in detail. 
Detailed descriptions of some measures that are not used in pooled analyses between the 
three cohort studies are described in the relevant results chapters where they are used. 
2.2. AUSTRALIAN DATA: THE CHILDHOOD DETERMINANTS OF 
ADULT HEALTH (CDAH) STUDY 
The 2004-2006 CDAH study is a population based, prospective follow-up of the 1985 
Australian Schools Health and Fitness Survey (ASHFS) that collected extensive lifestyle and 
biological measures on a representative sample of 8498 Australian school children aged 7 to 
15 years. The CDAH study was established to examine childhood predictors of adult CVD 
and diabetes with long-term follow-up of the cohort over the coming decades. 
2.2.1 SAMPLE SELECTION AND PARTICIPANTS 
The sampling procedures of the original ASHFS have been described in detail elsewhere, 149. 
312 but will be summarised here. The sampling frame was defined as all students aged 7 to 15 
years who were currently attending schools (primary or secondary, government, catholic, or 
independent) in Australia. Children were selected using a two-stage (school, then student) 
probability plan that was designed to yield a self-weighted sample (that is, the data do not 
need to be weighted since the sample design gives each individual an equal chance of being 
selected). The first stage of sampling selected schools with probability proportional to 
enrolment numbers. Of the 121 schools selected, 90.1% (N = 109) agreed to participate. The 
distribution of schools surveyed is displayed in Figure 11. The second stage utilised simple 
random sampling to ascertain children within each age and sex category from the selected 
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schools. Of the 12,578 students that were invited to participate in the study, 8498 participated 
representing an overall response proportion of 67.5%. 
Darwin (2) 
NORTHERN 
TERRITORY 
OUEENSLAND 
(C17  TASMANIA Hobart (1) 
Figure 11. Distribution of schools surveyed in 1985 ASHFS. 
Between 2001 and 2004, 6840 (81%) of the original participants were traced using 
the following methods: the Australian National Death Index, current and historical electoral 
rolls, telephone listings, and school and family networks. Eighty-six participants were 
deceased at the time of follow-up. The main causes of death were: injury and poisoning 
(includes suicide, 39 cases), accidents (8 cases), neoplasm (5 cases), heart and circulatory 
diseases (4 cases). Of the remainder of traced participants, 5170 (61% of the original cohort) 
contributed data to the follow-up with 2410 (28% of the original cohort) attending one of 34 
field-clinics held Australia wide between May 2004 to May 2006. Figure 12 displays 
participation, response proportions, and loss to follow-up in the ASHFS (1985) and CDAH 
(2004-2006) studies. 
At baseline, consent from both parent and child was required for inclusion in the 
study; at follow-up, all participants gave written informed consent. The baseline study was 
approved by the State Directors General of Education and the follow-up survey was approved 
by the Southern Tasmania Health and Medical Human Research Ethics Committee. 
86 deceased 
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Age (y) of Participants 
7-15 	 26 — 36 
1658 not 
traced 
6840 traced 
121 schools 
approached 
  
   
109 schools 
participated 
  
   
12,578 children 
invited 
  
 
	I 8498 children participated + 
i 
1584 did not 
participate 
+  
3328 lost to 
follow-up 
5170 
participated 	I 	I 
Year of measurement 
I 	 i 
1985 2004-2006 
ASHFS 	 CDAH 
Figure 12. Participants and response proportions in ASHFS; and participants, response proportions 
and loss to follow-up in the CDAH study. Note. Of the 1584 that did not participate, 817 of these did 
not respond to attempts to contact and 767 of these refused to participate in the study. 
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2.2.2 DATA COLLECTION 
Baseline (1985) 
A team consisting of 10 data colledtors and a supervisor were recruited in each state and 
territory to administer the questionnaire and physical examinations. Blood samples were 
collected by qualified nurses with experience in venipuncture. All personnel underwent a 
period of training in the method of standardised protocols prior to the commencement of data 
collection. Personnel were allocated specific tasks to ensure a minimum amount of people 
were involved in collecting specific measurements throughout the survey, thus limiting the 
potential of inter-measurer error. Registered site visits were undertaken by the principal 
investigators to maintain protocol standardisation throughout the survey. 
Field clinics were used as the primary source of data collection in 1985. Clinics were 
conducted at the participating school over consecutive school days. A range of measurements 
were collected during clinics, including: field tests (height, weight, girths, field-based 
fitness), technical tests (muscular strength, skin folds, blood pressure, lung function, sub-
maximal fitness), laboratory-based tests (maximal fitness, body density), fasting blood 
samples (lipids and lipoproteins), and questionnaire (diet, physical activity, smoking, alcohol 
and general health). Field tests were completed by all participants. Technical tests and blood 
samples were collected on those aged 9, 12, and 15 years. Of this sub-sample of 9, 12, and 15 
year olds, 1919 participants of the total eligible 2809 (68.3% response proportion) consented 
to provide blood samples. Laboratory-based tests were conducted on a sub-sample of those 
aged 9, 12, and 15 years (N=290). Participants aged 9 to 15 years completed questionnaires. 
The level of participation for each test category is displayed in Table 4. A strict testing order 
was adhered to, with anthropometric measures performed first, followed by fitness tests after 
a thorough warm-up. Questionnaires were then administered to children in groups of four 
with supervision provided by data collectors. Participants aged 9, 12, and 15 years attended 
the following day for the completion of technical tests. Fasting blood samples were collected 
at the school as soon as possible after the field and technical data collection had been 
completed. 
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Table 4. Response Proportions and Number of Participants in 1985 ASHFS* 
Sex & Age Field & Technicalt Questionnaire Blood Sample 
Response 
proportion 
(%) 
N % Response 
proportion 
(%) 
Response 
proportion 
(%) 
BOYS 
7 475 11.0 71.5 
8 490 11.4 75.0 
9 482 11.2 71.1 490 14.6 71.9 371 36.7 77.0 
10 492 11.4 77.0 493 14.7 75.7 
11 489 11.4 68.9 482 14.4 66.6 
12 494 11.5 66.0 486 14.5 63.4 349 34.5 70.6 
13 465 10.8 65.4 468 14.0 65.0 
14 467 10.9 65.5 472 14.1 66.5 
15 450 10.5 63.3 461 13.8 64.8 291 28.8 64.7 
Subtotal 4304 100 69.3 3352 100 67.7 1011 100 70.8 
GIRLS 
7 478 11.4 69.6 
8 496 11.9 73.2 
9 487 11.7 72.5 492 15.2 73.8 348 38.3 71.5 
10 497 11.9 75.2 496 15.3 73.7 
11 483 11.6 70.5 483 14.9 69.5 
12 489 11.7 65.7 488 15.1 64.7 307 33.8 78.9 
13 438 10.5 58.6 437 13.5 59.1 
14 405 9.7 53.6 417 12.9 55.3 
15 407 9.7 56.4 421 13.0 58.5 253 27.9 62.2 
Subtotal 4180 100 66.1 3234 100 65.0 908 100 70.9 
TOTAL 8484 67.5 6586 66.1 1919 68.3 1 
This table was reproduced from the original ASHFS report, 312 which included data for 8484 participants; however, data from a 
further 14 participants were identified in the dataset when follow-up was initiated and were included in the analyses. 
Field and technical tests included height, weight, girths, sit and reach, sit-ups, standing long jump, push-ups, 50m sprint, and 
1.6km sprint. 
The original published table had the incorrect response proportion for blood sample measures and has been rectified here 
(incorrect 70.8% vs. actual 68.3%). 
Follow-up (2004-2006) 
Field clinics were again established as the primary avenue for data collection at follow-up. 
Participants unable to attend a clinic were offered alternate options to provide data to the 
follow-up. Consequently, the levels of participation (in terms of data obtained) differed 
considerably for participants in the follow-up survey, and are displayed in Table 5. Measures 
collected at follow-up included: blood biochemistry, physical measurements (blood pressure, 
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anthropometry, lung function, cardiorespiratory fitness, muscular fitness, bone density, 
carotid and brachial artery ultrasound studies), and questionnaire data (diet, physical activity, 
smoking habits, alcohol use, general health, personal and family medical history, 
socioeconomic status, reproductive health, and mental health). Participants were mailed self-
complete questionnaires one to two weeks before their scheduled clinic visit and were asked 
to bring the completed forms with them to the clinic. 
Table 5. Levels of participation in the 2004-2006 CDAH study 
Males Females All 
N 	% N % N % 
Clinic 1150 47.2 1260 46.1 2410 46.6 
Enrolment data only* 620 25.4 604 22.1 1224 23.7 
Short questionnaire (no clinic attendance) t 445 18.3 464 17.0 909 17.6 
Full questionnaire (no clinic attendance)t 159 6.5 278 10.2 437 8.5 
Remote pathology (no clinic attendance) 62 2.5 122 4.5 184 3.6 
Other 2 0.1 4 0.1 6 0.1 
Total 2438 100 2732 100 5170 100 
*All participants completed the enrolment questionnaire; these values represent those participants from 
whom no other data were collected. The enrolment questionnaire was self-completed and returned by 
mail or completed by telephone interview when follow-up contact with participants was first made 
between 2001 and 2004. The short or long questionnaire was administered to those that indicated at 
time of enrolment (2001-2004) their willingness to participate but who were unable to attend clinics 
when re-contacted (2004-2006). The enrolment questionnaire is provided in Appendix 2. 
t The short questionnaire is provided in Appendix 3. 
The full questionnaire is provided in Appendix 4 
Percentages may not add to 100 because of rounding. 
Data collection teams for each state consisted of eight locally recruited staff and three 
core staff. The core staff (project manager, trained phlebotomist, ultrasound technician) was 
maintained throughout fieldwork clinics. Staff recruited locally were briefed on the 
background of the survey before undertaking training workshops to ensure measures were 
collected according to standard procedures of the survey. A central group of technicians 
travelled to each state from the Menzies Research Institute to conduct the training workshops. 
Personnel were trained to perform specific tasks, with compliance to standardised protocols 
monitored throughout data collection by the project manager. 
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Geographic Information Systems software was used to map participants' current 
postcode (Figure 13) to identify local clinic sites that would be accessible to as many 
participants as possible. Clinic locations were selected to maximise the proportion of enrolled 
participants living within a 10 kilometre radius (55% of participants residing within this 
10km radius of the site ultimately attended clinics). Clinic venues included community halls, 
sport halls, church halls, and schools. The field clinics were conducted between 7:00 am and 
2:00 pm on weekdays and weekend days. Approximately 15 to 30 participants attended daily. 
Participants moved through the clinic in a circuit-like manner that took 2.5 to 3 hours to 
complete. The order of measurements followed a strict protocol. Anthropometric, blood 
pressure, vascular ultrasound examinations, and blood samples were collected before 
participants were allowed breakfast. Following breakfast, participants completed a computer-
administered mental-health questionnaire, lung function test, cardiorespiratory fitness test, 
strength tests, ultrasound assessment of bone density, and were issued a pedometer. 
(41 
Figure 13. Distribution of CDAH participants according to postcode as of January 2004. 
Methods 	 85 
2.2.3 MEASURES 
The baseline and follow-up measures relevant to the aims of this thesis are described in detail 
below. A full description of other tests and protocols from the baseline survey can be found 
in the ASHFS handbook. 3I2 
2.2.3.1 Blood collection and biochemistry 
The LRC procedures3I3 were followed for blood sampling in 1985, with exceptions noted 
below. Approximately 10 ml of venous blood was drawn from the antecubital vein of seated 
participants after a 12-hour fast. Solid Ethyl Diamine Tetra-Acetic Acid was used as the 
anticoagulant. One minor departure from the LRC procedure concerned the initial cooling of 
blood samples before specimen processing. The LRC states that blood samples should be 
cooled immediately on wet ice, but in some centres this was done by placing them in a 
domestic refrigerator. Plasma was separated from blood cells by centrifugation and then 
stored at approximately zr .0 until transport to the Central Analytical Laboratory at the 
Flinders Medical Centre (Adelaide, South Australia). On a weekly basis, samples were flown 
from the nearest state capital in insulated containers and reached the central laboratory cold 
but not frozen on the day of dispatch. Throughout the baseline survey, the analytical 
laboratory met the criteria for precision accuracy as specified for standardisation by the WHO 
Collaborating Centre for Reference and Research in Blood Lipids (Centers for Disease 
Control and Prevention, Atlanta, Georgia). Samples with unknown assigned values from the 
Centre were incorporated into each run. Plasma total cholesterol and triglycerides were 
determined using a Technicon Auto Analyzer II (Technicon Instrument Corp, Tarrytown, 
New York, USA), HDL cholesterol was analysed following precipitation of apo-B containing 
lipoproteins with heparin manganese. The concentration of LDL cholesterol was determined 
indirectly using the Friedewald formula: 3 " LDL cholesterol = total cholesterol - 
(triglycerides/2.2 + HDL cholesterol) 
At follow-up, 30 mL of venous blood was drawn from the antecubital vein of 
reclined (seated or lying) participants after an overnight fast of at least eight hours. Samples 
for lipid assays were stored in white-top serum tubes and allowed to clot (coagulate) for 15 
minutes at room temperature prior to centrifugation. All samples were centrifuged within 
two-hours of venipuncture and then stored upright in a fridge or ice container and held at 
approximately 4 °C. At the completion of each clinic day, all samples were sealed in an 
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insulated container with cold packs, and dispatched via overnight courier to the central 
analysing laboratory (MedVet, Adelaide, South Australia) where assays were completed. For 
12 clinic days (once per clinic location in the states of New South Wales and Western 
Australia, as well as one clinic site in Victoria and Queensland), temperature data loggers 
where included in the insulated containers dispatched for overnight delivery. Temperature 
during transport ranged from 0.7° to 3.6°C (mean temperature, 2.6°C). Serum total 
cholesterol, triglyceride, and HDL cholesterol concentrations were determined enzymatically 
using an Olympus AU5400 automated analyser (Olympus Optical, Tokyo, Japan). LDL 
cholesterol was calculated using the Friedewald formula. 3l4 
Throughout both the baseline (1985) and follow-up (2004-2006) period, the 
analytical laboratory met the criteria for precision accuracy as specified for standardisation by 
the WHO Centre for Reference and Research in Blood Lipids (Centers for Disease Control 
and Prevention, Atlanta, Georgia). Samples with unknown assigned values were incorporated 
into each analytical run or immediately following calibration of the analyser. Over the course 
of the 2004-2006 study, inter-assay coefficient of variation ranged from 2.1 to 2.8% for total 
cholesterol, 4.2 to 5.4% for HDL cholesterol, and 3.0 to 4.6% for triglycerides. Also during 
follow-up, duplicate aliquots from a single blood draw were collected from the first 
participant scheduled for each clinic day (N=108) to examine measurement errors associated 
with collection, processing, and analysis of blood samples. All duplicate assays were 
conducted by technicians blinded to the first-run results. The coefficients of variation were 
1.6% for total cholesterol, 2.8% for HDL cholesterol, and 2.6% for triglycerides. 
2.2.3.2 Blood pressure 
Blood pressure measurements were obtained from the left brachial artery using a standard 
mercury sphygmomanometer at baseline, and from the right brachial artery using a digital 
automatic monitor (Omron HEM907, Omron Healthcare Inc, Kyoto, Japan) at follow-up. All 
measurements were taken after the participant had been seated with legs uncrossed for five 
minutes. The participant's upper arm girth was measured and an appropriate cuff size was 
selected. At baseline, systolic pressure was recorded at Korotokoff s first phase and diastolic 
pressure was recorded at both Korotokoff s fourth and fifth phases. Korotokoffs fifth phase 
was taken to represent diastolic pressure. This procedure was repeated after five minutes, and 
the mean of the two measurements was used in the analyses. At follow-up, three consecutive 
measurements of systolic and diastolic pressures were recorded. Each consecutive 
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measurement was separated by a one minute interval to avoid any spasms in the artery that 
could lead to erroneous measurements. The mean of these three measurements was used in 
the analyses. 
2.2.3.3 Anthropometry 
Anthropometric measurements of height and weight were collected at baseline and follow-up. 
Standing height was measured to the nearest 0.1 cm using a portable stadiometer, with the 
participant in bare feet and any obstructive headwear removed. Weight was measured with 
participants in light clothes without shoes using regularly calibrated bathroom scales that 
recorded to the nearest 0.5 kg at baseline, and with a digital Heine portable scale to the 
nearest 0.1 kg at follow-up. Body mass index at baseline and follow-up was calculated using 
the formula: BMI = weight (kg) / [height (m)] 2 . 
2.2.3.4 Smoking 
At baseline, participants aged 9 years and older completed a questionnaire that included the 
following question: 'How long have you been smoking regularly? (regularly means 1 or more 
times a week)'. Children and adolescents could respond: 'I don't smoke'; 'just started'; '1 to 
6 months'; '7 months to 1 year'; '1 to 2 years'; '2 to 4 years'; 'more than 4 years'. The 
responses were collapsed into a binomial categorical variable defining current smoking status 
as: 0=smoking less than once per week (<1/week), i.e. those that indicated 'I don't smoke', 
and 1=smoking at least once per week (>1/week), i.e. those that indicated any of options 2 to 
7. At follow-up, participants were asked: 'Over your lifetime, have you smoked at least 100 
cigarettes, or a similar amount of tobacco?' Those who indicated they had smoked at least 
100 cigarettes or equivalent tobacco over their lifetime were then asked the following 
question: 'How often do you now smoke cigarettes, cigars, pipes or any other tobacco 
products?': Participants could respond: 'Daily (>1/day)', 'At least once a week (but not daily) 
(?1/week)', 'Less often than weekly (<1/week)', 'Not at all (ex-smoker)'. At follow-up, 
participants were classified as current smokers if they indicated cigarette smoking on a 
weekly basis or more often, i.e. those who had smoked at least 100 cigarettes over their 
lifetime and indicated they were `Daily!, or 'At least once a week' smokers. Those that 
indicated they had not smoked at least 100 cigarettes in their lifetime, or indicated they 
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smoked less often than weekly or were ex-smokers were considered as not current smokers at 
follow-up. 
For the analyses, these baseline and follow-up definitions of current smoking status 
were used as they provided the most consistent definition across the three cohorts. A 
summary of the smoking information collected in each study and reasoning for the choice of 
the smoking definition is provided in Appendix 5. 
2.2.3.5 Carotid artery ultrasound studies 
Epidemiological studies that perform ultrasonography typically have participants attend 
specialist clinics for scans in addition to any clinic attendance that involves physical 
measurements. Because a number of the 34 field clinic locations in the CDAH study did not 
have access to all of the necessary resources to perform ultrasound scans (including specialist 
scanning facilities, equipment, or personnel); all ultrasound studies were performed at the 
field site. This had additional benefits that included reduced participant burden and the use of 
a single machine to perform all ultrasound studies. 
B-mode ultrasound studies of the carotid arteries were performed using a portable 
Acuson Cypress (Siemens Medical Solutions USA Inc., Mountainview, CA, USA) 
ultrasound machine with a 7.0-MHz linear-array transducer by a single technician who 
travelled to each of the field clinics. The Cypress is a miniaturised cardiac and vascular 
ultrasound system that is more portable than standard clinic-based machines owing to the 
incorporation of an in-built foldable monitor, removable transducers, the omission of a 
recording device, and the subsequent low weight (8 kg) of the complete system (Figure 14). 
Before its inclusion in CDAH, a study was conducted to determine if pre-clinical measures of 
vascular structure and function derived from the Cypress ultrasound machine were 
comparable to those from a clinic-based machine (Acuson Sequoia 512, Siemens Medical 
Solutions USA Inc., Mountainview, CA, USA) used routinely in clinical practice (original 
contribution II). This a-priori validation work was necessary to provide confidence in the 
measurements obtained from the machine (measures that have ultimately been used as 
outcomes in this thesis), and because data pooling with the Cardiovascular Risk in Young 
Finns Study, which had used the Acuson Sequoia 512 machine to perform carotid artery 
studies, was anticipated. Briefly, consecutive carotid and brachial artery images were 
recorded from a convenience sample of 23 apparently healthy young adults (mean age 31 
years) with the portable type and clinic type instruments. The analyses revealed a high level 
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of agreement between the two machines for measurements of maximum (mean difference = 
0.001 mm) and mean carotid IMT (mean difference = -0.025 mm), and brachial flow 
mediated dilatation (mean difference = 0.27 %). It was concluded that measurements of 
vascular structure and function derived from the portable machine compared  well with those 
from a clinic based machine. 31 5 
Figure 14. Acuson Cypress portable ultrasound machine 
Where facilities allowed, a room separated from other testing stations was used for 
ultrasound examinations at field-clinic sites. Difficulties in performing ultrasound 
examinations in a field-work setting were recorded by the technician and are listed in Table 
6. Temperature extremes (cold or heat) were identified as an issue for both participant and 
technician comfort during ultrasound examination at some clinics. Blankets as well as 
portable heaters and fans were used in an attempt to maximise participant comfort. Air 
temperature was recorded for each participant at the start of the ultrasound examination. 
Methods 
	
90 
Mean ± standard deviation (SD) temperature was 21.0±3.0°C when carotid artery 
examinations were performed. 
Table 6. Problems encountered in performing ultrasound examinations in a field-work setting 
Problem encountered 	 Frequency 	Approximate number of participants not 
measured as a consequence of problem 
encountered  
-Equipment did not arrive from 	 1 clinic 	 37* 
transport company in time for clinic 	(4 clinic days) 
-Excessive light that made 	 1 clinic 	 0 
visualisation of the digital monitor 	(3 clinic days) 
difficult 
-Excessive noise, affected 
concentration: 
-renovations and construction 	2 clinic days 	 0 
work to adjacent building 
-noise from other field-clinic 	2 occurrences 	 0 
stations 
-Power failures 	 3 occurrences 	 1 
-Participant and technician comfort 
cold (insufficient heating) 	 Several 	 0 
heat (insufficient cooling) Several 0 
-Probe error 	 3 occurrences 	 0 
-Software or technician error 
application error 	 6 occurrences 	 2 
transfer error 2 occurrences 2 
accidental eraser 	 2 occurrences 	 2 
*A total of 48 participants were affected by the failure of equipment to arrive in time for this clinic, 
however, 11 participants returned for measurement at a subsequent clinic. 
The ultrasound technician was trained in the carotid artery imaging protocols used in 
the Cardiovascular Risk in Young Finns study by one of their ultrasonographers. 41 During 
scanning, time-gain-compensation and depth settings were adjusted to optimise image 
quality. The left common carotid artery and left carotid bulb were traced using a transverse 
scan. Once the beginning of the flow divider was localised, the probe was rotated 90°. The 
longitudinal image was then focused on the posterior (far) wall of the vessel and the scanning 
angle adjusted so that the greatest distance between the lumen-intima interface and the 
media-adventitia interface was localised. Several 3-5 second real-time images were recorded 
that included the beginning of the carotid bulb and approximately 30 mm of the common 
carotid artery. All images were stored in digital format for off-line analysis in the analysis 
program Image Pro Plus version 5.02 (Media Cybernetics, Inc., Silver Spring, MD, USA). 
From the 3 to 5 second real-time images, the two highest-quality end-diastolic frames 
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(coinciding with the R-wave on a continuously recorded ECG) with the clearest vessel 
boundaries were selected by the reader for measurement. Each image selected for 
measurement was given a quality score (1 = excellent, 2 = average, 3 = unacceptable) based 
on the presence of clear vessel boundaries. 80 % of images were rated excellent, 18.9 % were 
rated average, and 1.1 % were rated as poor. From each of these images, six measurements of 
the common carotid far wall were taken approximately 10 mm before the border of the 
carotid bulb (Figure 15). Maximum carotid IMT was defined as the mean of the maximum 
IMT measurements from the two selected frames. Although carotid IMT measurements for 
the entire cohort were performed by two readers, all IMT measurements for participants aged 
9, 12, and 15 years who had complete measurements available from the 1985 survey were 
performed by one-reader (the author). This was done to eliminate inter-reader error in this 
sub-sample. Carotid measurements taken from this sub-sample are used in the present 
analyses. Intra-rater reproducibility for replicate max IMT measurements was assessed in a 
random sample of 30 participants. The average absolute difference and standard deviation 
was 0.02+0.04 mm. 
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Figure 15. B-mode ultrasound image of the left common carotid artery (CCA):  A) border of carotid 
bulb widening (0 mm), B) CCA far wall lumen-intima interface, C) media-adventitia interface. 
Definitions of the CCA segment in each cohort: CDAH and Young Finns, CCA  IMT is taken as the 
distance between B and C measured in the vicinity 10 mm proximal to the border  of the bulb widening 
(A); Bogalusa, CCA IMT is taken as the distance between B and C measured 0-10  mm proximal to the 
border of the bulb widening (measurement area highlighted by yellow box). 
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2.3. FINNISH DATA: THE CARDIOVASCULAR RISK IN YOUNG FINNS 
STUDY 
The Cardiovascular Risk in Young Finns Study is an on-going five-centre epidemiologic 
study of atherosclerosis risk factors and precursors from childhood to adulthood.316 The study 
was devised in the late 1970s as a collaborative effort between all university departments of 
paediatrics or medicine (i.e. in Helsinki, Kuopio, Oulu, Tampere, Turku) to study the levels 
of CVD risk factors and their determinants in children and adolescents of various ages in 
different parts of Finland (Figure 16). Two pilot studies in 1978 (N=264, age 8 years) 317 and 
1979 (N=634, aged 3, 12 and 17 years) 3I8 preceded the first main cross-sectional (baseline) 
study performed in 1980. Thereafter, follow-up studies were conducted at intervals of three 
years until 1992. The 21-year examination was performed in 2001 when participants were 
young adults aged 24 to 39 years. It is these data that have been used to study the aims of this 
thesis. The 27-year follow-up clinics were completed in the first half of 2008. 
Figure 16. The five centres where data collection for the Cardiovascular Risk in Young Finns Study 
was conducted. 
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2.3.1 SAMPLE SELECTION AND PARTICIPANTS 
The study was carried out in all five Finnish university cities with medical schools and their 
rural surroundings. In 1980, 4320 children and adolescents aged 3, 6, 9, 12, 15 and 18 years 
(including equal numbers of males and females) were randomly chosen from the Finnish 
Social Insurance Institution's national population register of these areas to produce a 
representative sample of Finnish children. The population register covers the entire 
population in Finland and is kept up-to-date. The sampling procedure involved assigning a 
unique personal identification number to girls and boys of each age cohort in each study area. 
The unique identifying numbers were placed in a random order and every km girl and every 
/eh boy in each study area was selected so that the sample consisted of the required number of 
girls and boys. The varying k factors were determined on the basis of sample size and the 
total number of girls and boys in the different age cohorts in each study area. Letters of 
invitation to participate were sent to the households of selected children and adolescents. Of 
those invited, 3596 children and adolescents (83.1% of those invited) participated in the first 
cross-sectional study in 1980. The 21-year follow-up was performed between September 
2001 and January 2002, when 2283 subjects from the original cohort (63 %) were re-
examined then aged 24, 27, 30, 33, 36 and 39 years. 316 Data from two time-points were used 
to examine the aims of this thesis: baseline (childhood and adolescence, 1980) and follow-up 
(young adulthood, 2001). 
The study was conducted according to the guidelines of the Declaration of Helsinki, 
and the study protocols were approved by local ethics committees. Written informed consent 
was obtained from all participants in 2001 and their parents in 1980. 
• 
2283 
participated 
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Age (y) of Participants 
3-18 	 24 — 39 
i I  
4320 children 1 
invited 
y 
3596 children 
participated 
        
        
       
•  
3456 invited 
to participate 
in follow-up 
       
  
140 not 
invited to 
participate in 
follow-up 
   
      
       
1173 did not 
participate 
	■••• 
•  
1313 lost to 
follow-up 	I 
Year of measurement 
1980 	 2001 -2002 
Figure 17. Participants and response proportions for the baseline study; and participants, response 
proportions and loss to follow-up for the 21-year follow-up to the Cardiovascular Risk  in Young Finns 
Study. 
2.3.2 DATA COLLECTION 
Baseline (1980) 
Prior to physical examination, families were mailed a questionnaire that collected data on 
socioeconomic status, living environment, health, physical activity, and parent and grand-
parent state of health. Physical measurements were performed by trained nurses supervised 
by a chief investigator of the study. City-dwelling participants were examined at  the clinics of 
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the departments of paediatrics. For rural-dwelling participants, examinations were held at a 
local health centre (there were 12 rural clinics in total). Participants were examined between 
8:00 am and 10:00 am after an overnight fast. A series of measurements were collected at the 
time of the physical examination, including: anthropometry (height, weight, skin folds, 
upper-arm girth), directly-measured (by a nurse) pubertal-stage according to the Tanner 
classification, 319 blood pressure, and venous blood samples (lipids and lipoprotein variables, 
insulin, glucose). Dietary data were collected on half of the study group (N=1780). 
Participants aged 12, 15, and 18 years completed a questionnaire on smoking and the use of 
alcohol. 
Follow-up (2001-2002) 
For the 21 year follow-up, a total of 3456 of the participants in the baseline survey were 
invited by letter to attend clinics that were scheduled in all five centres (Helsinki, Kuopio, 
Oulu, Tampere, Turku). Those who did not respond to the invitation letter were later 
contacted by telephone. Of the 140 not invited, 80 were living abroad, 20 had unknown 
addresses, 20 had forbidden to be contacted again, and 20 participants in the original cohort 
were no longer alive. Causes of death for these individuals were suicide (14 cases), motor 
vehicle crashes (3 cases), alcohol poisoning (1 case), subarachnoid haemorrhage (1 case), and 
pancreatitis (1 case). Lack of time (33%), absence from the place of residence at the time of 
examination (13%), and unwillingness to participate (13%) were the main reasons given for 
non-participation in the follow-up. 
Prior to physical examination, participants were mailed a questionnaire that collected 
data on socioeconomic status, living environment, health, physical activity, diet, smoking, 
use of alcohol, and parent state of health. Physical measurements were performed by trained 
nurses supervised by a chief investigator of the study. As per baseline data collection, city-
dwelling participants were examined at the clinics of the departments of paediatrics and rural-
dwelling participants were examined at one of 12 local health centres. Participants were 
examined between 8:00 am and 10:00 am after a 12 hour fast. A series of measurements were 
collected at the time of the physical examination, including: anthropometry, blood pressure, 
blood samples, and ultrasound studies of the brachial and carotid arteries. 
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2.3.3 MEASURES 
All measures from both baseline and follow-up surveys that are relevant to the aims of this 
thesis are described in detail below. A full description of other measures and protocols from 
the baseline and follow-up surveys of the Young Finns study can be found elsewhere. 320' 321 
2.3.3.1 Blood collection and biochemistry 
All serum lipid determinations were done on fasting samples in duplicate in the same 
laboratory. In 2001, serum cholesterol and triglyceride concentrations were determined 
enzymatically (Olympus System Reagent, Olympus Diagnostica, Hamburg, Germany) in a 
clinical chemistry analyser (AU400, Olympus Optical, Mishima, Japan). HDL cholesterol 
was analysed after precipitation of very low-density lipoprotein and LDL with dextrane 
sulphate 500 000. 322 The concentration of LDL cholesterol was calculated using the 
Friedewald-formula. 314 Details of the methods in earlier studies have been previously 
published.217' 323 Due to changes in determination methods and kits during study years, 
lipoprotein levels from 1980 were corrected to those in 2001 using correction factor 
equations (this information is detailed in Appendix 6). 218 
2.3.3.2 Blood pressure 
Blood pressure was measured using a standard mercury sphygmomanometer at baseline, and 
using a random zero sphygmomanometer (Hawksley & Sons Ltd, Lancin, UK) at follow-up. 
All measurements were taken on the right arm, before venipuncture and after the participant 
had been seated for five minutes. Cuff size was chosen according to arm circumference. 
Systolic blood pressure was recorded for Korotkoff s first phase. Diastolic blood pressure was 
recorded at both Korotkoff s fourth and fifth phases. Korotkoff s fifth phase results have been 
used in the analyses. Readings to the nearest even number of millimetres of mercury were 
performed three times on each participant. The mean of these three measurements was used 
in the analyses. 
2.3.3.3 Anthropometry 
Height and weight measures were taken at both time-points using the following protocols. 
Height was measured using a wall-mounted Seca stadiometer with 0.5 cm accuracy, and 
weight was measured in light clothing without shoes with a digital Seca scale to the nearest 
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0.1 kg. Baseline and follow-up BMI was determined from weight and height measurements 
recorded in 1980 and 2001 respectively. 
2.3.3.4 Smoking 
Smoking habits at baseline and follow-up were ascertained as part of a self-administered 
questionnaire. At baseline, information on smoking habits was collected in conjunction with 
the medical examination in an isolated room where the participants could respond 
confidentially and undisturbed. Current smoking habits at baseline and follow-up were 
indicated as 'once a day or more often', 'at least once a week but not daily', 'less than once a 
week', 'stopped smoking or do not smoke at present', and 'never smoked'. Participants were 
classified as smokers at baseline if they indicated regular cigarette smoking on a weekly basis 
or more often. At follow-up, participants were classified as smokers if they indicated 
cigarette smoking on a weekly basis or more often. This definition for current smoking was 
consistent with data available from the CDAH and Bogalusa studies (Appendix 5). 
2.3.3.5 Carotid artery ultrasound studies 
Ultrasound studies of the carotid arteries were introduced at the 2001 follow-up study and 
were performed using a Sequoia 512 ultrasound machine (Acuson, Mountain View, CA, 
USA) with 13.0 MHz linear array transducer. Studies were performed simultaneously 
between September 2001 and January 2002 at all five centres (Helsinki, Kuopio, Oulu, 
Tampere and Turku). The left common carotid artery was scanned by ultrasound technicians 
at each study centre following a standardised protocol. The image was focused on the 
posterior (far) wall and gain settings were used to optimise image quality. A resolution box 
function (zoom) was used to record an image of 25 mm in width and 15 mm height. A 
magnified image was recorded from the angle showing the greatest distance between the 
lumen-intima interface and the media-adventitia interface. A moving scan with duration of 
five seconds which included the beginning of the carotid bifurcation and the common carotid 
artery was recorded and stored in digital format for subsequent off-line analysis. 
The digitally stored scans were manually analysed by one reader blinded to the 
subjects' details. The measurements were performed using ultrasonic callipers. From the five 
second clip image, the best quality end-diastolic frame was selected (incident with the R-
wave on a continuously recorded electrocardiogram). To measure carotid IMT, the image 
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was focused on the posterior (far) wall of the left carotid artery. At least four measurements 
of the far wall were taken approximately 10 mm proximal to the bifurcation to derive mean 
and maximum carotid IMT (Figure 15). All images were given a quality score (1 = excellent, 
2 = average, 3 = poor) based on the presence of clear vessel boundaries. 97.4 % of images 
were rated excellent, 2.4 % were rated average, and 0.2% were rated as poor. To assess intra-
individual reproducibility of ultrasound measurements, 57 subjects were re-examined three 
months after the initial visit (2.5 % random sample). The average absolute difference and 
standard deviation between measurements was 0.05±0.04 mm. 
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2.4. UNITED STATES DATA: THE BOGALUSA HEART STUDY 
The Bogalusa Heart Study is a long-term community-based epidemiologic investigation of 
the early natural history of atherosclerosis and essential hypertension. Between 1973 and 
2001, seven cross-sectional surveys of children and adolescents aged 4 to  17 years and six 
surveys of young adults aged 18 to 43 years (including some who had previously been 
examined in earlier studies) were conducted in a biracial (65% European-American, 35% 
African-American) population living in Ward 4 of Washington Parish, Louisiana. 324 The 
1970 population of Ward 4 was 22,371, including approximately 5000 children and 
adolescents aged 5 to 17 years. Washington Parish includes the main semi-rural community 
of Bogalusa (Figure 18) situated 112 kilometres (70 miles) north of New Orleans. Bogalusa 
was chosen as the screening site as it has a stable, biracial paediatric population and is 
demographically comparable to many other small southern USA communities. 325 
A 
B 
Bogalusa, LA 
Figure 18. Location of sampling area for the Bogalusa Heart Study: (A) location of Louisiana in the 
USA, and (B) location of Washington Parish and Bogalusa, LA. 
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2.4.1 SAMPLE SELECTION AND PARTICIPANTS 
The eligible population for the initial cross-sectional study conducted during the 1973-1974 
school year was all children aged 5 to 14 years attending any of the 14 schools (12 public, 
one parochial, one private) within Ward 4. In subsequent follow-ups conducted in 1976-1977, 
1978-1979, 1981-1982, 1983-1984, 1987-1988, and 1992-1994, the age range was expanded 
to include all children aged 4 to 17 years attending any of the 14 schools within Ward 4. 
Participation proportions in the cross-sectional surveys ranged from 80% to 92% for 
children and 60% to 65% for young adults. Due to the nature of the panel design of the 
Bogalusa study, consisting of repeated cross-sectional examinations every two to three years, 
serial observations from childhood and adolescence to adulthood were available for only 
some participants. The study cohort for this thesis was derived from individuals who 
participated in the 1984-1985 cross-sectional survey of 2666 children (baseline) and in the 
2001-2002 cross-sectional survey of 1203 young adults (follow-up). This cohort was 
favoured as the baseline and follow-up measures were collected at approximately the same 
time-points as those in the CDAH and Young Finns studies. Of the children and adolescents 
that attended the 1984-1985 baseline survey, a subset of 379 participants (14% of those 
eligible from baseline) were also examined in the 2001-2002 follow-up as young adults. 
Figure 19 displays participation, response proportions, and the subset with measurements 
from the two time-points. 
The study design and procedure were approved by the Louisiana State University 
and Tulane University Medical Center ethics and research committees. At baseline, written 
informed consent was obtained from parents of students; at follow-up, all participants 
provided written informed consent. 
—3330* children & 
adolescents invited 
Repeat Participants 
379 1 
• 
2666 children & 
adolescents 
participated 
(-80% response 
proportion) 
—2000* young adults 
invited 
• 
1203 young adults 
participated 
(-60% response 
proportion) 
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Baseline 	 Follow-up 
1984 -1985 2001 -2002 
Figure 19. Participants, response proportions, and repeat participants in the 1984-1985 (baseline) and 
2001-2002 (follow-up) cross-sectional surveys in the Bogalusa Heart Study. *This is an estimate of the 
total eligible population of children in Ward 4 at the time that was based on school  lists. *The exact 
number is unknown. Invitations were sent to those known to still reside in the area;  some participants 
not contacted directly were advised through word-of-mouth and participated. 
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2.4.2 DATA COLLECTION 
Baseline (1984-1985) 
Field staff received extensive training before data collection began. Performance criteria were 
established and assessed for all field staff on an on-going basis throughout data collection. 
Field personnel included two or three physicians, five registered nurses, six licensed practical 
nurses, one physician's assistant, six other staff members (project coordinator, nutritionist, 
clerical assistant), and several local volunteers. 
A mobile research unit was converted from a three-bedroom house trailer (caravan) 
to aid examination of the children to be used in conjunction with facilities at each of the 
schools. In addition, an administrative office was established in Bogalusa with a laboratory 
area for preparing blood samples for shipment to the Louisiana State University Medical 
Centre laboratory in New Orleans for assaying. 
Two-months before anticipated screening dates in each school, the project manager 
contacted the school's principal to obtain class lists. Five to six weeks before screening in 
each school, a letter of invitation (addressed to the parent) as well as a consent form and a 
health history form were given to home room teachers to hand out in class. Each child was 
asked to return the completed form the next day. Four weeks before screening, a follow-up of 
unretumed parental consents was conducted. Three weeks before screening, letters and 
consent forms were given to non-responders for a third time. One week before screening, 
parents of non-respondents were contacted by telephone or by home visits, and another 
consent form with stamped return envelopes was mailed or given to parents. Throughout the 
school year, the project manager visited each school to identify new students and obtain new 
consents for participation. Since a 12-14 hour fast was required for the lipid determinations, 
fasting instructions were sent to the parents the day before the child's screening session. 
When possible, all examinations were conducted in school auditoria and in the 
mobile research unit. All children (approximately 30 to 40 per day) were examined between 
8:30am and 12:00 noon. Figure 20 shows the flow of children throughout the clinical 
examination. The order of measurements followed a strict protocol. Blood samples were 
collected before participants were allowed brunch. Following brunch, measures of 
anthropometry (height, weight, upper-arm length, upper-arm circumference, and triceps and 
subscapular skin fold thicknesses), pubertal (maturation) stage (assessed by a physician), and 
blood pressure were collected. 
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Follow-up (2001-2002) 
Field staff received extensive training before data collection began and were routinely 
assessed for adherence to protocols throughout data collection. Field personnel included one 
physician, one echocardiographer, two registered (or former registered) nurses, and four 
research assistants. Many of these staff had assisted in data collection of one or more 
previous examinations in the Bogalusa Heart Study. A permanent office was established in 
Bogalusa that was used for administrative and data collection purposes (this was formerly the 
administrative office in the baseline survey, which is equipped with a laboratory area for 
preparation of blood samples for shipment to the Tulane University School of Public Health 
and Tropical Medicine in New Orleans for assaying). 
Approximately one-month before anticipated screening dates, participants were sent 
a letter of invitation to participate. Participants contact details are updated on an on-going 
basis, with any change of address or contact details indicated directly by the participant to the 
administrative office or study staff contacting next of kin to obtain the participant's new 
address or contact details. 
All adults (approximately 6 to 7 per day) were examined between 7:30am and 12:00 
noon. The flow of participants through the clinic essentially follows that from childhood. For 
example, blood and urine samples were collected first followed by brunch, and then 
anthropometric, blood pressure, echocardiography and ultrasound measurements, electro-
cardiogram, and tonometry were obtained. Participants complete a questionnaire while at the 
clinic that enquires on demographic, health, family history, diet, and physical activity habits. 
10% Blind 
duplicates 
 
New Orleans 
laboratory 
  
Heiig ItlIt m 
I Mercury sphygmomanometer 
Morcu 
••■••■•■• 
Mercury rhygmomanometer 
10% Roixamimod 
Enter 
Blood sample 
Brunch 
Figure 20. Flow of participants through the baseline clinical examination of the Bogalusa Heart Study. 
Adapted from Berenson et al. 33 
2.4.3 MEASURES 
The baseline and follow-up measures relevant to the aims of this thesis are detailed below. 
Other measures and protocols from the cross-sectional and follow-up surveys of the Bogalusa 
study have been described in detail elsewhere.2°9 
2.4.3.1 Blood collection and biochemistry 
Standardised protocols were used by trained observers in all examinations. 209 Blood samples 
were centrifuged in Bogalusa and the samples sent in a cold pack box on the evening of each 
screening day by bus to the laboratory in New Orleans. In 1984 to 1985, cholesterol and 
triglyceride levels were measured with a Technicon Auto Analyzer II (Technicon Instrument 
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Corn, Tarrytown, NY), according to the laboratory manual of the LRC program.313 In 2001 to 
2002, cholesterol and triglycerides levels were determined by enzymatic procedures using an 
Hitachi 902 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN). Lipoprotein 
cholesterol levels were analysed using a combination of heparin-calcium precipitation and 
agar-agarose gel electrophoresis procedures. 326 
2.4.3.2 Blood pressure 
Blood pressure measurements at baseline and follow-up were obtained on the right arm, with 
participants in a relaxed, sitting position. Measurements of upper arm length and 
circumference were made to ensure selection of correct cuff size. Systolic and diastolic blood 
pressures were recorded at the first, fourth, and fifth Korotkoff phases using mercury 
sphygmomanometers. The phase five reading was used to denote diastolic pressure in the 
analyses. Three blood pressure readings were taken by each of two randomly assigned 
observers for a total of six measurements. The trained observers were blinded to each other's 
readings. The mean of the six replicate readings was used in the analyses. 
2.4.3.3 Anthropometry 
At both baseline and follow-up, replicate height and weight measurements were collected. 
Height was measured to the nearest 0.1 cm using a manual height board. Weight was 
recorded to the nearest 0.1 kg using a balance beam metric scale (Detecto Scales, Inc, Webb 
City, MO). The average of the replicate measurements was used as the scores. Height and 
weight scores at baseline and follow-up were used to calculate BMI for each time-point. 
2.4.3.4 Smoking 
Smoking behaviour at baseline and follow-up were ascertained from the Bogalusa 'Health 
Habits Questionnaire.' 327 Smoking behaviour was identified as: a child/adult who smokes at 
least one cigarette a week (current smoker); a child/adult who used to smoke at least one 
cigarette a week but no longer smokes cigarettes (former smoker); a child/adult who never 
experimented with cigarettes (never smoker); a child/adult who is currently experimenting 
with cigarettes (fewer than one cigarette per week, experimenter); a child/adult who at one 
time was experimenting (<1/week) with cigarettes but quit smoking (former experimenter). 
Participants were classified as smokers at baseline or follow-up if they currently smoked at 
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least one cigarette a week. This definition for current smoking was consistent with data 
available from the CDAH and Young Finns studies (Appendix 5). 
2.4.3.5 Carotid artery ultrasound studies 
Trained sonographers performed B-mode ultrasound examinations using a Toshiba 
SonoLayer SSH 160A ultrasound system (Toshiba Medical, Tokyo, Japan) with a 7.5 MHz 
linear-array transducer, on participants in the supine position with the head slightly extended 
and turned to the opposite direction of the carotid artery being studied. Images of the 
common carotid (0 to 10 mm proximal to the origin of the carotid bifurcation, Figure 15), 
carotid bifurcation (covering the extent of the origin of the carotid bifurcation to the tip of the 
flow divider), and internal carotid (0 to 10 mm distal to the origin of the flow divider) 
segments from both the left and right carotid artery were recorded according to protocols 
previously described for the Atherosclerosis Risk in Communities (ARIC) Study. 154, 328, 329 
Images were stored on VHS tapes and read by certified readers from the Division of Vascular 
Ultrasound Research using a semi-automated image processing program according to strict 
protocols. 329' 330 All readers were blinded to risk factor data. Maximum IMT measurements 
were taken from the far wall of both left and right common carotid, carotid bifurcation, and 
internal carotid segments. All measurements were recorded at 1 mm intervals along the 
segment of the imaged vessel at the time coinciding with the R wave of a continuously 
recorded electrocardiogram. Seventy-five participants underwent repeat ultrasound 
examinations 10 to 12 days after their initial visit to determine intra-individual 
reproducibility. The average absolute difference and standard deviation between 
measurements for all carotid IMT segments was 0.05±0.03 mm. 
2.5. STATISTICAL ANALYSES 
All statistical analyses were performed using STATA Versions 9.2 or 10 (STATA Corn, 
College Station, TX, USA), and statistical significance inferred at a 2-tailed P-value <0.05. 
The statistical methods employed to address the aims of this study are covered in detail in 
subsequent chapters. 
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KEY POINTS 
• This chapter described three population-based prospective cohort studies from 
Australia, Finland, and the United States - the primary data sources used in 
this thesis. 
• The Childhood Determinants of Adult Health (CDAH) Study began in 1985 
with baseline measures collected on a representative sample of 8498 
Australian school children aged 7 to 15 years as part of the Australian 
Schools Health and Fitness Survey (ASHFS). Between 2004-2006, 2410 
(28%) attended clinics held throughout Australia. 
• The Cardiovascular Risk in Young Finns Study is an on-going epidemiologic 
study of atherosclerosis risk factors and precursors from childhood to 
adulthood. In 1980, 3596 children and adolescents aged 3, 6, 9, 12, 15 and 18 
years participated in the first cross-sectional study. The 21-year follow-up 
was performed between September 2001 and January 2002, when 2283 
participants from the original cohort (63%) participated in the study. 
• The Bogalusa Heart Study is a biracial community-based investigation of the 
early natural history of CVD. The study cohort was derived from individuals 
who participated in the 1984-1985 cross-sectional survey of 2666 children 
and in the 2001-2002 cross-sectional survey of 1203 young adults. A total of 
379 participants (14%) attended both surveys. 
• Diverse biological and lifestyle measurements were collected at baseline and 
follow-up in each cohort. The key exposure measures central to this thesis 
include fasting blood lipid and lipoprotein levels collected at baseline. 
• B-mode ultrasound was performed at follow-up in each cohort on the left 
common carotid artery to ascertain carotid IMT, a measure of preclinical 
atherosclerosis. 
Box 1. Summary of key points from Chapter 2: Methods 
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3. FACTORS AFFECTING THE TRACKING OF BLOOD 
LIPID AND LIPOPROTEIN LEVELS FROM CHILDHOOD 
TO ADULTHOOD: THE CHILDHOOD DETERMINANTS 
OF ADULT HEALTH (CDAH) STUDY 
3.1. INTRODUCTION 
As outlined in section 1.5.6, the term tracking is used in epidemiological studies to describe 
the degree of consistency over time of an attribute, and is used to evaluate the longitudinal 
development of risk factors for chronic diseases. 246 From a paediatric perspective, tracking 
analyses are useful as they determine the ability to predict future values from measurements 
taken earlier in life, and to determine what risk factors, if any, should be the target of early 
treatment or prevention. Tracking is generally examined by the correlation between repeated 
measurements of the same attribute at two points in time, and the proportion of participants 
who remain within a specific group (dichotomies based on quantiles of the variable's 
distribution or clinically-defined cut-points) over time. 
Because of their causal relationship with CVD in adulthood, blood lipid and 
lipoprotein levels have been investigated for tracking in the paediatric setting. In the past 25 
years, 10 prospective studies have reported tracking of lipid and lipoprotein levels from 
childhood or adolescence into adulthood. These studies drew from five US cohorts, and a 
single cohort from each of Finland, Denmark, the Netherlands, Canada, and Australia. The 
- data from these studies were provided in 20 publications. 160162, 223, 224, 231-245 Appendix 7 
provides an overview of the studies in terms of the sample size, observed population, length 
of follow-up, age at baseline and follow-up measurements, fasting status, statistical analyses, 
and summarises the main correlation findings from these studies. Appendix 8 provides a 
summary of studies that reported stability tracking by risk-group status. The studies showed 
considerable variation in terms of: sample size, ranging from 48 to 2446 participants; length 
of follow-up, which ranged from 3 to 27 years; age at baseline, with a range from 5 to 19 
years; and the type of correlations and definition of risk-groups used in the statistical 
analyses. The Amsterdam Growth and Health StUdy239-24I did not use fasting lipid samples in 
their analyses, and most studies measured only total cholesterol levels at both time-points. 
The Bogalusa Heart Study 162, 231, 233 and Cardiovascular Risk in Young Finns Study 161, 223 
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reported tracking for LDL cholesterol, HDL cholesterol, and triglycerides in addition to total 
cholesterol. 
While these studies found that youth levels correlate well with adult levels, they have 
shown that a substantial proportion of youth with high-risk levels will not have high-risk 
levels in adulthood and that a substantial proportion of those adults with high-risk levels had 
normal levels as children or adolescents. 245 ' 331 That is, there exists a reasonable amount of 
instability in the maintenance of abnormal blood lipid and lipoprotein levels from youth to 
adulthood. As such, these findings have called into question both the approach to, and utility 
of, screening for paediatric lipid disorders. 196, 220, 332 This has led to the study of factors that 
influence tracking in some of these studies. 
Except for the period of infancy, 333 tracking of lipids and lipoproteins does not 
appear to be largely dependent on age at baseline measurement. However, the Bogalusa Heart 
study noted that tracking of HDL cholesterol improves after the age of eight years most likely 
due to the puberty-related decrease in HDL cholestero1. 162 Studies with multiple intervals 
between baseline and subsequent follow-up measurements show that tracking is time 
dependent. 161, 244 That is, the degree of tracking decreased as the time interval between 
measurements becomes longer. Using data from the studies detailed in Appendices 7 and 8, 
Figure 21 was constructed to show the weighted-mean Spearman's correlation coefficients 
160-162, 223, 224, 232, 235-238, 243, 244 . y from tracking studies 	 D length of follow-up for total cholesterol 
levels measured during childhood or adolescence and adulthood, and the weighted-mean 
percent remaining in the extreme fifth of the population distribution from tracking studies' 61 ' 
223, 224, 235, 237 for total cholesterol between childhood or adolescence and adulthood by length 
of follow-up. This graphical representation supports the conclusions of previous studies that 
suggest time between measurements has an effect on tracking of total cholesterol levels. Of 
the studies that reported tracking separately for males and females, males tend to track 
slightly better than females for total cholesterol, LDL cholesterol and triglycerides. The 
Bogalusa Heart study is the only study identified that examined the effect of race on 
tracking. 162, 231  While there was some modest evidence of better tracking of total cholesterol 
and LDL cholesterol levels in African-Americans compared with Caucasians, the authors 
noted that race did not appreciably affect the magnitude of the correlation coefficients or the 
proportions that were at risk at both time-points.I62 
••■•■• 
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Figure 21. Weighted-mean Spearman's correlation coefficients from tracking studies 160-162, 223. 224, 232,  
235-238. 243, 244 by length of follow-up for total cholesterol levels measured during childhood or 
adolescence and adulthood (upper figure portion); and weighted-mean percent remaining in the 
extreme fifth of the population distribution from tracking studies 161, 223, 224. 235. 237 for total cholesterol 
between childhood or adolescence and adulthood by length of follow-up (lower figure portion). Error 
bars represent 95% confidence intervals. Correlation coefficients and proportions  from each study 
were weighted as N(study)/N(total) for each length of follow-up group. Sample sizes  for each length of 
follow-up group were: <5 years (correlation N=240, percent N=238); 5-9 years (correlation N=3002, 
percent N=3000); 10-14 years (correlation N=5677, percent N=883); 15-19 years (correlation N=705, 
percent N=299). Only studies with fasting lipid measures were considered for this figure. 
Two studies of those detailed in Appendices 7 and 8 examined the  role of lifestyle-
related factors in relation to tracking of lipid and lipoprotein levels between baseline and 
follow-up. 223, 224, 235 Their analyses compared participants with different tracking patterns. For 
example, participants who had high-risk levels at both baseline and follow-up were 
considered true positives; those who had high-risk levels at baseline but  not at follow-up 
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were considered false-positives; those who acquired hypercholesterolemia as adults were 
considered as false-negatives; and those who did not have high-risk levels at both baseline 
and follow-up were considered as true negatives. For example, Stuhldreher et al.224 and 
Orchard et al. 235 found in the Beaver County Lipid Study that those who had high-risk levels 
at baseline but not at follow-up had gained less weight, were less frequent smokers, and 
adhered to a diet low in saturated fat and cholesterol compared with those who acquired 
hypercholesterolemia in adulthood. In the six-year follow-up of the Young Finns Study, 
Porldca et al. 223 found that those who did not have high-risk levels at either time-point tended 
to gain less adiposity and were less likely to begin smoking compared with those who 
acquired a high-risk status. While those in the high-risk group at both time points gained 
more adiposity and were more likely to have begun smoking compared with those who were 
initially at high-risk. Collectively, these studies suggest some of the instability of blood lipid 
and lipoprotein tracking is the result of some participants adopting a healthier lifestyle, and 
others a less healthy lifestyle. Several studies have also reported that oral contraceptive use 
affects lipid levels, 334 ' 335 which may lead to poorer tracking in females who were not using 
oral contraceptives at the baseline examination. 160, 161,336 
Lipid and lipoprotein levels are known to be subject to significant measurement 
variabil ity.308-310  Consistent with this knowledge, current and previous paediatric guidelines 
have recommended multiple measures before risk classification. 196, 220, 247 Most tracking 
studies used single lipid and lipoprotein measurements in their analyses and in doing so, may 
have underestimated the strength of relationship between child or adolescent levels and adult 
levels. 337 Those studies that had two measurements available during childhood or adolescence 
examined the effect of multiple measures on their tracking analyses. Use of two separate 
childhood measurements increased the amount of adult lipid variability explained in the 
Cardiovascular Risk in Young Finns Study by up to 50 percent, 16I while the prediction of 
adult dyslipidemia was markedly enhanced by multiple observations of LDL cholesterol in 
the Bogalusa Heart Study (Figure 22). These data suggest that studies that have used a single 
measurement at baseline may have substantially underestimated the strength of the 
relationship between childhood or adolescent levels and adult levels. This is underscored by 
data presented by Porkka et al., 16I which show that regression toward the mean was the most 
important determinant of change in levels between childhood and adulthood, accounting for 
up to half of the variability. Although tracking would likely be improved by multiple child or 
adolescent measures, Lauer et al. 245 still noted that 25% to 45% of children with total 
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cholesterol levels greater than the 90 th percentile on two successive occasions did not meet 
the criteria for intervention suggested by NCEP ATPII1 338 when they became adults. 
Although this study did not examine what impact the adoption of cholesterol-altering health 
behaviours might have had on misclassification, the findings further emphasise the point 
made earlier that while children with high lipid and lipoprotein levels have a greater risk of 
having elevated adult levels than their peers with lower levels, a substantial proportion of 
these children will not have adult levels that meet intervention criteria. 
1 
	 2 
	 3 
Number of elevated LDL cholesterol (>90th percentile) measurements in childhood 
Figure 22. Prevalence of adulthood dyslipidemia by the number of elevated childhood LDL 
cholesterol measurements (adapted from Bao et al.). 23I Adult participants were classified as having 
dyslipidemia if their level of total cholesterol was 26.21 mmol/L, or LDL cholesterol 24.14 mmol/L, 
or HDL cholesterol <0.91 mmol/L, or triglyceride level was 24.52 mmol/L. 
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KEY POINTS: What the literature tells us about the tracking of blood lipid 
and lipoprotein levels between childhood or adolescence and adulthood 
• Tracking is a term used to express the degree of consistency over time of an 
attribute, and is used to describe the ability to predict future values from early 
measurements. 
• 10 prospective cohort studies have examined tracking of blood lipid and 
lipoprotein levels between childhood or adolescence and adulthood. 
• These studies suggest moderate to strong tracking of total cholesterol, LDL 
cholesterol, and HDL cholesterol levels, and low to moderate tracking of 
triglyceride levels between childhood or adolescence and adulthood. 
• Children with high lipid and lipoprotein levels have a greater risk of having 
elevated adult levels than their peers with lower levels, but a substantial 
proportion of these children will have adult levels that will not require 
intervention. 
• Tracking appears to be only modestly influenced by age, sex, and race. 
However, tracking tends to diminish as length of time between baseline and 
follow-up measures increases. 
• Changes in lifestyle factors (adiposity and smoking) that occur between youth 
and adulthood have an impact on whether an individual maintains, loses, or 
develops high-risk blood lipid and lipoprotein levels in adulthood. 
• Single lipid or lipoprotein measurements increase the likelihood of 
misclassification and in turn, can decrease the strength of tracking. 
• Key limitations of the tracking literature includes use of only one 
measurement to assign risk status at both baseline and follow-up in most 
studies, non-standardised definitions of the at-risk group, limited data 
available for LDL cholesterol, HDL cholesterol, and triglycerides, and the 
paucity of data examining lifestyle factors that may have contributed to 
individuals changing their risk status between childhood or adolescence and 
adulthood. 
Box 2. Summary of literature that has examined tracking of blood lipid and lipoprotein levels from 
childhood or adolescence to adulthood. 
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3.2. 	AIMS 
While the above literature demonstrates that tracking of total cholesterol levels from 
childhood or adolescence into adulthood has been examined in 10 studies, only two studies 
(the Bogalusa Heart Study 162, 231  and the Cardiovascular Risk in Young Finns Study 161, 223) 
have examined tracking of fasting LDL cholesterol, HDL cholesterol and triglycerides levels 
from large population-based samples. In addition, only two studies 223, 224, 235 have examined 
some lifestyle factors of interest (adiposity, smoking, diet) that contribute to misclassification 
of adult lipid levels from child levels; one of these had data on total cholesterol levels 
only.224 ' 235 Moreover, only two234, 244 studies have examined tracking over a period of 20 
years or more and only one of these studies has examined tracking of total cholesterol levels 
in an Australian population. 244 The aims were: 
1. To study the tracking of total cholesterol, LDL cholesterol, HDL cholesterol, and 
triglyceride levels over a 20-year period from childhood to adulthood in the Australian 
Childhood Determinants of Adult Health (CDAH) study, and 
2. To examine the effect of lifestyle changes on the tracking of these blood lipid and 
lipoprotein levels from childhood to adulthood. 
Factors affecting blood lipid and lipoprotein tracking 
	
116 
3.3. METHODS 
3.3.1 PARTICIPANTS 
In this chapter, 539 participants with baseline (1985) and follow-up (2004-2006) blood 
samples from the CDAH study were examined. These participants were from the 9, 12, and 
15 year old sub-sample that provided additional measures including bloods at the baseline 
survey (as detailed in section 2.3.1). 
3.3.2 MEASURES 
Blood lipid and lipoprotein measurements: Fasting blood lipids were measured at baseline 
and follow-up according to the protocols detailed in section 2.3.1.1. 
Adiposity: Anthropometric measurements of height and weight at both time points were 
determined according to protocols outlined in section 2.3.1.3 and BMI calculated. Waist 
circumference was measured to the nearest 0.1 cm at both time-points but was taken at the 
level of the umbilicus during baseline examination and at the narrowest point between the 
lower costal border and iliac crest at follow-up. In 1985, skin fold thickness of the tricep, 
bicep, subscapular, and suprailiac was recorded to the nearest 0.1 mm on the right-side of the 
body using Holtain Callipers. Three readings were taken from each site, and the readings 
were then averaged. At follow-up, tricep, bicep, subscapular, and iliac crest skin folds were 
measured to the nearest 0.5 mm on the right-side of the body using Slim Guide callipers. 
Measurements were repeated a maximum of three times, or discontinued if the first two 
readings were unchanged. The average of the two closest readings was used as the location 
specific score. At follow-up, skin fold measures were truncated at 40mm, as this was the 
maximum limit of the callipers. For the truncated skin fold measures, skin fold values were 
imputed from BMI and waist circumference using Tobit Regression 339 • 34° 
Smoking status: As described in section 2.3.1.4, participants were classified as smokers at 
baseline and follow-up if they indicated cigarette smoking on a weekly basis or more often. 
This was the most consistent indicator of smoking available at both time-points. 
Cardiorespiratory fitness: Cardiorespiratory fitness was estimated at baseline and follow-up 
as physical working capacity at a heart rate of 170 beats per minute on a friction-braked 
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bicycle ergometer (Monark Exercise AB, Sweden) according to standard protocols. 341 The 
test protocol comprised three successive sub-maximal workloads of three minutes at baseline, 
and four minutes at follow-up. The workloads were selected by the technicians on an 
individual basis to induce steady-state heart rate responses from the participant during the 
first, second and third workloads within the ranges of 115-130, 130-145, and 145-160 beats 
per minute respectively. Physical work capacity at 170 beats per minute was estimated by 
extrapolating the line of best fit from the heart rates recorded at each sub-maximal 
workload. 342 The measure of baseline and follow-up cardiorespiratory fitness used in this 
study was expressed in relative terms as watts per kg (W/kg) of lean body mass. Relative 
cardiorespiratory fitness is preferred because the absolute workload (watts) achieved is a 
function of muscle mass — best estimated by inclusion of lean body mass. 343 Body density 
was estimated from the log of the sum of four skin folds using the regression equations of 
Durnin and Rahaman for 12 and 15 year old children, 344 and Brook for 9 year old children348 
at baseline, and Dumin and Womersley346 for adults at follow-up. Calculations of body fat 
were made using the equation specified by Siri. 347 Lean body mass was then estimated by 
subtracting fat mass from total body mass. 
Socioeconomic position: Data on parental education (low = school only, medium = 
trade/vocational, and high = university) collected retrospectively at follow-up was used as an 
indicator of individual-level socioeconomic position (SEP) at baseline. 348 At follow-up self-
reported highest level of education (low = school only, medium = trade/vocational, and high 
= university) was used as the indicator of SEP. 
Dietary data: Participants aged 12 and 15 years at baseline recorded their food consumption 
over a 24-hour period. 349 The students, in groups of four or five, were given a record diary by 
a data collector and shown how to record their food intake with practical examples of food 
measurement. As a practice exercise, they recorded the breakfast they had eaten that morning. 
This recording was then checked for the detail necessary to allow coding and conversion into 
nutrient intake and the participants given feedback. The 24-hour recording period began at 
the end of the briefing session. Once the 24-hour recoding period had elapsed, each student 
was interviewed individually and their record diary checked to clarify missing or illegible 
information. A number of dietary variables were calculated from this record that included the 
proportion of dietary energy from saturated fat. 
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At follow-up, food habits and food frequency questionnaires were completed. 35° 
Questions on fat intake included: the type of milk usually consumed (1 = skimmed milk, 2 = 
low/reduced fat milk, 3 = whole milk); the frequency of trimming fat from meat (1 = I don't 
eat meat, 2 = usually, 3 = sometimes, 4 = never/rarely); and the type of spread usually used 
on bread (1 = I do not use any spread, 2 = spread other than butter or margarine, 3 = 
margarine, 4 = butter). The food frequency questionnaire does not allow the proportion of 
dietary energy from saturated fat to be derived (that was available from the baseline survey), 
however, these variables have been shown to provide reliable and valid estimates"' that are 
positively correlated with higher saturated fat intake. 352' 353 Scores from these three questions 
linked to fat intake were summed to derive a single variable of dietary behaviour relating to 
fat intake at follow-up. 340 
Use of hormonal contraceptives in females: Use of hormonal contraception (HC) was not 
ascertained in adolescent females at baseline. At follow-up, females were asked if they were 
currently using any of the following hormonal contraceptives: combined oral contraceptives, 
minipill, weekly contraceptive patch, progestagen, progestagen injection, progestin releasing 
intrauterine device, progestin releasing implant, or other. 
3.3.3 STATISTICAL ANALYSES 
Loss to follow-up 
Comparisons between baseline characteristics of participants and non-participants at follow-
up were performed using logistic regression. Participation (yes/no) was used as the binary 
dependent variable in these analyses. Both age and sex were included in models to account 
for differences in these variables between participants and non-participants. 
Tracking of blood lipids from childhood to adulthood 
Tracking was estimated in two ways: (1) Spearman's rank-order correlation coefficients; and 
(2) the proportion of participants who remained in high-risk categories in childhood and 
adulthood. Two approached were used to classify child and adolescent levels. First, paediatric 
NCEP or NHANES cut-points (Table 7) 196' 251 that were shown to be the best predictors of 
adult dyslipidemia in data from three cohorts 331 (see results detailed in chapter 4), and the 
adult cut-points stipulated in the third report of the National Cholesterol Education Program's 
Adult Treatment Panel (NCEP ATPIII). 304 Second, the upper fifth of the population 
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distribution in childhood and adulthood (lower fifth in the case of HDL cholesterol). The first 
approach provides clinically relevant information, while the second approach is most often 
used in the existing literature, which allows for comparison. 
Table 7. Paediatric 196' 251 and adult304 blood lipid and lipoprotein cut-points (mmol/L) used in the analyses 
Paediatric Adult 
NcEp 196 NHANES25I NCEP3°4 
12y 15y 
Total cholesterol 
Normal <4.40 <5.18 
Borderline high 4.40-5.17 5.18-6.21 
High 25.18 26.22 
LDL cholesterol 
Normal <2.85 <3.37 
Borderline high 2.85-3.36 3.37-4.13 
High 23.37 24.14 
HDL cholesterol* 
Normal >1.56 21.70 >1.48 21.55 21.49 21.55 
Borderline low 1.56-0.91 1.69-1.14 1.47-1.04 1.54-1.05 1.48-1.04 1.54-1.036 
Low <0.91 <1.13 <1.03 <1.04 <1.03 <1.036 
Triglycerides 
Normal <1.02 <1.70 
Borderline high 1.02-1.46 1.70-2.25 
High 21.47 22.26 
Abbreviations: y, age in years; M, males; F, females 
*As per recommendations from Magnussen et al., 33I (see chapter 4) NHANES cut-points25I for HDL cholesterol were used for those aged 12 or 15 years at baseline. 
NCEP cut-points were used for those aged 9 years because NHANES cut-points were not available for those aged <12 years. 
To convert total cholesterol, LDL cholesterol and HDL cholesterol to mg/di, multiply values by 38.67; to convert triglyceride values to mg/di, multiply values by 88.5. 
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Factors affecting tracking of blood lipid levels from childhood to adulthood 
In order to determine the factors that might impact on the tracking of childhood lipid and 
lipoprotein levels, participants were divided into four tracking groups depending on their 
status (using the clinical cut-points displayed in Table 7) in childhood and adulthood. 
Participants who remained in high-risk categories at both time-points were considered as true 
positives; those who were high-risk in childhood but not at follow-up were considered as 
false positives; those who were not high-risk in childhood but were in adulthood were 
considered as false negatives; and those that did not have high-risk levels at both time-points 
were considered true negatives (Figure 23). This is the approach that has been adopted in 
other studies that have examined factors that influence tracking (and thus prediction) of lipid 
and other risk factor levels between two time-points. 223-225, 235 In separate analyses for each 
lipid or lipoprotein, logistic regression was applied to examine the effect of changes in 
lifestyle-related variables (adiposity measures, cardiorespiratory fitness, social mobility, 
smoking, and saturated fat intake) between childhood and adulthood that increased the 
likelihood of being false positives (unstable tracking) as opposed to true positives (stable 
tracking) amongst those who were high-risk in childhood, and to identify the factors that 
increased the odds of being false negatives (unstable tracking) as opposed to true negatives 
(stable tracking) amongst those who were low-risk in childhood. The logistic regression 
models were adjusted for age and sex. If multiple lifestyle variables were found to be 
associated with tracking of a single lipid or lipoprotein variable, a model that included all 
significant lifestyle variables in addition to age and sex were fit to examine for independent 
effects. To examine if sex modified the relationships between lifestyle change and tracking, 
sex by lifestyle change interaction terms were fitted to each model. There were no significant 
interactions. 
Changes 	in continuous lifestyle-related variables (adiposity measures, 
cardiorespiratory fitness, and saturated fat intake) were analysed using the difference (adult 
minus child) of age- and sex-specific z-scores at each time-point. This approach was 
favoured as it accounts for any differences in measurement protocols between surveys and 
allows the full spectrum of change to be examined (small and large). For change in SEP, a 
social mobility variable was created,348 using highest level of parental education at baseline 
and highest level of own education at follow-up to derive change or stability in SEP as 
follows: persistently low (low at baseline and follow-up), persistently medium (medium at 
baseline and follow-up), persistently high (high at baseline and follow-up), upwardly mobile 
Childhood 
lligh risk 
 
Adulthood 
True Positives 11 High risk 
False Negatives 
.....False Positives 
Borderline 
or low risk 
  
Borderline 
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(moving from low at baseline to medium or high at follow-up, or medium at baseline to high 
at follow-up), and downwardly mobile (moving from high at baseline to medium or low at 
follow-up, or from medium at baseline to low at follow-up). 
Because the baseline level of the lifestyle risk factor may have an effect on the 
magnitude of change, models that included the baseline variable as a coyariate, that examined 
for interactions between the baseline variable and change were also fitted. There were no 
significant interactions. Examining the data either with or without the baseline variable in the 
model produced essentially similar results and did not change the conclusions. Because of 
this, the results are presented for the more parsimonious model (without the baseline variable 
as a covariate) because power was a consideration in some of the analyses. 
Figure 23. Schematic representation of blood lipid and lipoprotein categorical tracking possibilities 
from childhood to adulthood in the CDAH study. 
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3.4. RESULTS 
Comparison of baseline characteristics of participants and non-participants 
Participants (30.5% of those eligible from baseline) were older (mean 11.9 vs. 11.7 years, 
P=0.03), were more likely to be female (50.1 vs. 45.4%, P=0.07), had lower adiposity (mean 
BMI, 18.5 vs. 18.7 kg/m2 , P<0.01; waist, 65.2 vs. 65.5 cm, P=0.02; sum of skin folds, 36.0 
vs. 37.6 mm, P<0.01), were less likely to be smokers (10.8 vs. 14.2%, P<0.01), and were 
more likely to be of high SEP in childhood (28.2 vs. 21.0%, P<0.01) compared with non-
participants. Participants were however similar to non-participants with respect to childhood 
lipid and lipoprotein levels, cardiorespiratory fitness, and saturated fat intake as a percentage 
of total daily intake. 
Participant characteristics 
Key child and adult characteristics of male and female participants are summarised in Table 
8. With the exception of HDL cholesterol, females tended to have a more adverse lipid and 
lipoprotein profile in childhood than males, but this trend was reversed in adulthood. Males 
had higher fitness levels and lower sum of skin folds at baseline than females. At follow-up, 
males had higher BMI and waist circumference but lower sum of skin fold thickness 
compared with females. A higher proportion of adult males were smokers, used whole fat 
milk, and more seldom trimmed fat from meat compared with adult females. Mean length of 
follow-up between the two surveys was 20.0±0.5 years. 
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Table 8. Characteristics of 539 CDAH participants* who had blood lipid and lipoprotein 
measurements at baseline and follow-up 
Characteristic N Males N Females 
Childhood 
Age, y 269 11.9+2.5 270 11.9±2.5 
Total cholesterol, mmol/L 269 4.41±0.73 270 4.61+0.78 
LDL cholesterol, mmol/L 266 2.65+0.65 267 2.81±0.75 
HDL cholesterol, mmol/L 267 1.43±0.29 267 1.48±0.29 
Triglycerides, mmol/L 269 0.65(0.50,0.84) 270 0.66(0.54,0.85) 
BMI, kg/m 2 269 18.4±2.8 270 18.6±2.9 
Waist circumference, cm 269 66.7±8.6 270 63.7+7.8 
Skin folds (sum of 4), mm 266 31.0±15.3 269 41.0+17.6 
Fitness, W/kg 255 3.09±0.60 250 2.50±0.57 
Energy intake, k.It 165 10429±3451 169 7742±2294 
% kJ fatt 165 36.7+6.4 169 36.9±6.8 
% kJ saturated fart 165 16.1±3.8 169 15.8±3.7 
Current smokers, % 263 10.7 263 11.0 
Hormonal contraceptive users, % NA NA 
Parental education 
School only 102 41.8 94 36.7 
Trade/vocational certificate 74 30.3 73 28.5 
University 68 27.9 89 34.8 
Adulthood 
Age, y 269 32.4±2.6 270 32.4±2.5 
Total cholesterol, mmol/L 269 5.03±0.96 270 4.83±1.04 
LDL cholesterol, mmol/L 264 3.16+0.81 270 2.86±0.92 
HDL cholesterol, mmol/L 269 1.29±0.28 270 1.54±0.33 
Triglycerides, mmol/L 269 1.10(0.70,1.60) 270 0.80(0.60,1.10) 
BM1, kg/m 2 254 26.7±3.9 235 25.0±5.6 
Waist circumference, cm 254 90.5+9.7 236 78.5±11.6 
Skin folds (sum of 4), mm 254 66.0±24.7 236 78.7±32.1 
Fitness, W/kg 232 3.07±0.61 197 3.02+0.70 
Whole milk, % 250 47.6 246 31.3 
Usually use butter on bread, % 251 22.7 250 24.4 
Never or rarely trim fat from meat, 250 16.4 251 7.2 
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Characteristic N Males N Females 
% 
Current smokers, % 254 20.1 253 14.2 
Hormonal contraceptive users, % 270 33.7 
Education 
School only 100 40.2 129 48.9 
Trade/vocational certificate 83 33.3 53 20.1 
University 66 26.5 82 31.1 
*Changing Ns are the result of missing data for some participants. 
t Baseline dietary variables not measured for those aged 9 years. 
Statistics are means ± SD or median (interquartile range) for continuous variables or percent for 
dichotomous variables. 
To convert total cholesterol, LDL cholesterol and HDL cholesterol to mg/dl, multiply values by 38.67; 
to convert triglyceride values to mg/dl, multiply values by 88.5. 
Factors affecting blood lipid and lipoprotein tracking 
	
126 
Tracking of blood lipids and lipoproteins from childhood to adulthood 
Correlation coefficients 
Spearman's correlation coefficients for tracking of blood lipid and lipoproteins from 
childhood to adulthood are presented in Table 9. Overall, rank-order tracking was strongest 
for LDL cholesterol in both males and females, followed by total cholesterol and HDL 
cholesterol with triglycerides displaying the lowest rank-order tracking. Tracking of blood 
lipid and lipoprotein levels was generally consistent for males and females with the exception 
of triglycerides, where baseline levels in males tended to track more strongly into adulthood 
than baseline levels in females. No clear age differences were observed in correlation 
coefficients, although for triglycerides, the lowest values were seen in males and females 
aged 9 years at baseline. 
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Table 9. Spearman rank correlation coefficients for tracking of blood lipid and lipoprotein measures 
from childhood (1985) to adulthood (2004-2006) (N in parentheses) 
Age (y) in 1985 
Variable 9 12 15 All 
Total cholesterol 
Males 0.58 1 (95) 0.58 1 (86) 0.45 1 (88) 0.541 (269) 
Females 0.55 1 (95) 0.49 1 (85) 0.561 (90) 0.54 1 (270) 
LDL cholesterol 
Males 0.59 1 (92) 0.65 1 (85) 0.501 (85) 0.58 1 (262) 
Females 0.63 1 (94) 0.561 (83) 0.60 1 (90) 0.601 (267) 
HDL cholesterol 
Males 0.50 1 (94) 0.55 1 (86) 0.361 (87) 0.47 1 (267) 
Females 0.56 1 (95) 0.26* (84) 0.51 1 (90) 0.47 1 (269) 
Triglycerides 
Males 0.33 1 (95) 0.44 1 (86) 0.48 1 (88) 0.41 1 (269) 
Females 0.16 (95) 0.38 1 (85) 0.28 1 (90) 0.26 1 (270) 
*P<0.05,13<0.01. 
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Stability 
Figure 24 shows the proportions of males and females who had high-risk (using clinically-
defined cut-points) blood lipid and lipoprotein levels at both time-points. Tracking within the 
high-risk categories was generally low for all lipids and lipoproteins with the exception of 
HDL cholesterol in males. Males showed greater stability in high-risk categories compared 
with females. Among males and females classified as having high triglyceride levels in 
childhood, most (79% and 98% respectively) had normal levels in adulthood. For 
comparison, Table 10 shows the distribution of childhood risk categories by adult risk 
categories. Approximately 40-70% of participants who had high-risk total and LDL 
cholesterol levels as adults also had high risk levels in childhood. The majority of males and 
females with high-risk adult HDL cholesterol or triglyceride levels had normal levels as 
children. 
In addition to tracking by paediatric risk categories, Table 11 shows the probability 
of remaining in the extreme fifth of each blood lipid distribution from childhood to 
adulthood. Of the participants in the extreme fifth of the distribution at childhood, 40 to 50% 
were also in the extreme fifth in adulthood for most blood lipids and lipoproteins. The one 
exception being HDL cholesterol for females, with only 25% having extreme (low) levels at 
both time-points. 
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Figure 24. Proportions of males and females who had high-risk levels in childhood and adulthood for 
total cholesterol (TCH), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), and triglycerides (TG). Error bars represent 95% confidence intervals. High-risk 
defined according to paediatric NCEP or NHANES cut-points, 196. 251 and adult NCEP ATPIII cut-
points as detailed in Table 7•304 
Table 10. Tracking of blood lipids from childhood to adulthood expressed as proportions in pediatric 196' 251 levels by adult levels 304 . 
Males Females 
I 
Normal 
Child classification 
Borderline-high (low) High (low) 
I 	I 
Normal 
Child classification 
Borderline-high (low) 
I 
High (low) 
Adult classification N % N % N % N % N % N % 
Total cholesterol 
Normal 106 68.0 41 26.3 9 5.8 99 54.1 60 32.8 24 13.1 
Borderline-high 28 33.3 44 52.4 12 14.3 12 16.7 31 43.1 29 40.3 
High 5 17.2 12 41.4 12 41.4 1 6.7 7 46.7 7 46.7 
LDL cholesterol 
Normal 131 78.9 26 15.7 9 5.4 134 67.0 41 20.5 25 12.5 
Borderline-high 32 45.1 24 33.8 15 21.1 12 22.2 20 37.0 22 40.7 
High 8 32.0 7 28.0 10 40.0 3 23.1 1 7.7 9 69.2 
HDL cholesterol 
Normal 17 41.5 24 58.5 0 0.0 67 53.2 59 46.8 0 0.0 
Borderline-low 39 23.1 119 70.4 11 6.5 30 23.1 94 72.3 6 4.6 
Low 3 5.3 38 66.7 16 28.1 2 15.4 9 69.2 2 15.4 
Triglycerides 
Normal 126 58.9 11 5.1 77 36.0 133 53.6 17 6.9 98 39.5 
Borderline-high 9 36.0 7 28.0 9 36.0 9 69.2 3 23.1 1 7.7 
High 18 60.0 1 3.3 11 36.7 7 77.8 0 0.0 2 22.2 
Row totals for percentages may not add to 100 because of rounding. 
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Table 11. Proportions (%) remaining in the extreme fifth* of each blood lipid distribution from 
childhood to adulthood 
Males Females All 
Total cholesterol 46.3 38.9 42.6 
LDL cholesterol 40.4 50.0 45.2 
HDL cholesterol 52.0 25.0 38.2 
Triglycerides 44.6 42.6 43.6 
*Highest fifth for total cholesterol, LDL cholesterol, and triglycerides; lowest fifth for HDL 
cholesterol. 
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Factors affecting tracking of blood lipid and lipoprotein levels from childhood to adulthood 
The effects of changes in lifestyle-related variables on tracking patterns of total cholesterol, 
LDL cholesterol, HDL cholesterol, and triglycerides are displayed in Table 12. For LDL 
cholesterol, HDL cholesterol and triglycerides, participants who acquired high-risk levels in 
adulthood (false negatives) had significantly increased BMI, waist circumference, and sum of 
skin fold thickness between surveys relative to their peers compared with those who 
maintained normal-risk levels (true negatives). 
Of the remaining risk factors examined, false negative HDL cholesterol participants 
significantly decreased cardiorespiratory fitness between survey intervals compared with true 
negatives. Higher proportions of true positives were persistent smokers or had begun 
smoking compared with false positives for total cholesterol and HDL cholesterol 
respectively. False negative participants for HDL cholesterol were less likely to have moved 
upward in SEP status from childhood to adulthood compared with true negatives. Table 12 
shows that females who did not have adverse total cholesterol and triglyceride levels at 
baseline but did at follow-up (false negatives) were more likely to be current HC users than 
those who did not have adverse levels at both time-points (true negatives). In addition, 
females with adverse total cholesterol levels at both time-points (true positives) were more 
likely to be current HC users than those who had adverse levels in childhood but not in 
adulthood (false positives). 
In multivariable models that compared total cholesterol in participants classified as 
true positive or false positive, both change in waist circumference (P=0.05) and persistent 
smoking (P<0.01) remained significant (model R2=7.7%). For HDL cholesterol, 
multivariable models comparing true positives with false positives showed that the 
differences in change in waist circumference (P<0.01) and the proportion of participants that 
had begun smoking (P<0.01) remained statistically significant (model R2=10.8%). In 
multivariable models for HDL cholesterol that compared false negatives and true negatives, 
change in waist circumference (P<0.01) remained significant whereas the effects for change 
in cardiorespiratory fitness (P=0.10) and upward social mobility (P=0.07) were attenuated 
marginally (model R2=13.9%). 
Table 12. Factors affecting the tracking of blood lipid and lipoprotein levels from childhood to adulthood 
Blood lipid or lipoprotein variable 
Lifestyle variable 
True Positives 
N 	mean (SD) or 
False positives 
N 	mean (SD) or 
False negatives 
N 	mean (SD) or 
True negatives 
N 	mean (SD) or 
OA 
Total cholesterol 
A BMI 19 0.26 (0.85) 158 0.07 (0.91) 55 0.31 (0.73) 257 0.11 (0.85) 
A waist circumference 19 0.43 (0.97) 159 0.01 (0.85)* 55 0.18 (0.77) 257 0.07 (0.93) 
A skin folds (sum of 4) 19 0.23 (0.86) 159 -0.03 (1.03) 54 0.37 (0.86) 254 0.13 (1.00) 
A cardiorespiratory fitness 12 0.07 (1.47) 129 0.11 (1.14) 40 0.03 (1.12) 219 -0.05 (1.23) 
A saturated fat intake 9 -0.03 (1.52) 84 -0.06 (1.30) 48 0.19 (1.50) 166 -0.03 (1.42) 
Smoking status 
Never smoker 10 53 127 80 39 68 204 79 
Stopped smoking 1 5 7 4 5 9 19 7 
Began smoking 5 26 22 14 9 16 28 11 
Smoker at both time-points 3 16 3 2* 4 7 8 3 
Social mobility 
Persistently low 3 17 23 15 7 12 33 13 
Persistently moderate 3 17 18 12 7 13 24 10 
Persistently high 0 0 4 3 1 2 15 6 
Downwardly mobile 7 39 57 37 24 43 88 36 
Upwardly mobile 5 28 51 33 17 30 88 36 
Female participants currently using HC 12 57 10 30* 13 52 56 29t 
LDL cholesterol 
A BMI 18 0.39 (0.67) 127 0.02 (0.88) 56 0.47 (0.81) 279 
Ø•08(084)t 
A waist circumference 18 0.55 (0.83) 127 -0.03 (0.84)* 56 0.38 (0.92) 280 0.05 (0•89)1 
A skin folds (sum of 4) 18 0.34 (0.74) 127 -0.03 (0.97) 55 0.49 (0.91) 277 0.11 (0.98)1 
A cardiorespiratory fitness 10 0.01 (1.12) 101 0.21 (1.06) 41 -0.10(1.24) 241 -0.03 (1.25) 
A saturated fat intaket 7 0.03 (0.88) 65 0.00 (1.35) 45 0.20 (1.5) 185 -0.04(1.4) 
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Blood lipid or lipoprotein variable 
Lifestyle variable 
True Positives 
N 	mean (SD) or 
% 
False positives 
N 	mean (SD) or 
% 
False negatives 
N 	mean (SD) or 
% 
True negatives 
N 	mean (SD) or 
% 
Smoking status 
Never smoker 
Stopped smoking 
Began smoking 
Smoker at both time-points 
10 
2 
4 
1 
59 
12 
24 
6 
99 
6 
20 
4 
77 
5 
16 
3 
42 
4 
7 
5 
72 
7 
12 
9 
222 
20 
31 
7 
79 
7 
11 
3 
Social mobility 
Persistently low 3 17 16 13 6 II 40 15 
Persistently moderate 3 17 11 9 7 13 30 I I 
Persistently high 0 0 3 2 4 7 13 5 
Downwardly mobile 7 39 51 41 26 48 85 32 
Upwardly mobile 5 28 44 35 11 20 100 37 
Female participants currently using HC 12 46 8 31 12 39 59 32 
HDL 
cholesterol 
A BMI 18 0.09 (1.28) 81 -0.17(0.82) 118 0.45 (0.74) 270 Ø08(084)t 
A waist circumference 18 0.08 (1.14) 81 -0.26 (0.69)* 118 0.49 (0.75) 271 0.01 (0.92)' 
A skin folds (sum of 4) 18 -0.05 (1.87) 80 -0.24 (0.89) 118 0.51 (0.81) 268 0.05 (0.97)1 
A cardiorespiratory fitness 13 0.06 (1.27) 66 0.19 (1.30) 95 -0.22 (1.27) 224 0.08(1.13)' 
A saturated fat intake 15 -0.29 (1.92) 61 0.03 (1.42) 64 0.14 (1.42) 166 -0.01 	(1.33) 
Smoking status 
Never smoker 7 41 68 74 86 80 215 79 
Stopped smoking 0 0 9 10 8 7 15 6 
Began smoking 7 41 10 11* 13 12 34 12 
Smoker at both time-points 3 18 5 5 1 1 9 3 
Social mobility 
Persistently low 1 6 I I 12 18 18 36 14 
Persistently moderate 2 12 7 8 13 13 31 12 
Persistently high 1 6 1 1 6 6 12 5 
Downwardly mobile 10 59 31 35 43 42 88 33 
Upwardly mobile 3 18 39 44 23 22 96 371 
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Blood lipid or lipoprotein variable 
Lifestyle variable 
True Positives 
N 	mean (SD) or 
% 
N 
False positives 
mean (SD) or 
oA, 
False negatives 
N 	mean (SD) or 
% 
True negatives 
N 	mean (SD) or 
% 
Female participants currently using HC 6 46 10 26 3 21 73 36 
Triglycerides 
A BM1 12 0.32 (1.17) 188 0.07 (0.81) 37 0.53 (0.65) 252 0.10 (0.89)* 
A waist circumference 12 0.38 (1.28) 188 0.02 (0.84) 37 0.55 (0.67) 253 0.04 (0•91)t  
A skin folds (sum of 4) 12 -0.15 (1.89) 187 0.09 (0.99) 36 0.56 (0.87) 251 0•07(Ø•94)t 
A cardiorespiratory fitness 10 -0.21 (1.10) 147 -0.02(1.12) 32 0.25 (1.09) 211 0.02 (1.27) 
A saturated fat intake* 8 0.79 (1.23) 155 0.03 (1.41) 20 0.41 (1.71) 124 -0.16 (1.34) 
Smoking status 6 55 134 69 32 76 208 84 
Never smoker 0 0 23 12 1 2 8 3 
Stopped smoking 3 27 24 12 9 21 28 11 
Began smoking 2 18 12 6 0 0 4 2 
Smoker at both time-points 
Social mobility 
Persistently low 1 10 28 15 6 15 31 13 
Persistently moderate 0 0 20 11 5 13 27 11 
Persistently high 0 0 6 3 2 5 12 5 
Downwardly mobile 7 70 80 42 15 39 74 31 
Upwardly mobile 2 20 55 29 11 28 93 39 
Female participants currently using HC 7 30 7 23 25 61 52 301 
*P<0.05 for comparisons between true positives (reference group) and false positives using logistic regression 
t P<0.05 for comparisons between false negatives and true negatives (reference group) using logistic regression 
Totals for percentages may not add to 100 because of rounding. 
Abbreviations: HC = hormonal contraception, SD = standard deviation, A = denotes change in z-score (follow-up minus baseline) 
Note. 	True positives = those in the high-risk cluster at both childhood and adulthood 
False positives = those in the high-risk cluster at childhood, but not at follow-up 
False negatives = those not in the high-risk cluster at childhood, but were in adulthood 
True negatives = those not in the high-risk cluster at both childhood and adulthood 
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Additional analyses 
Because evidence remained in the adjusted models for effects of waist circumference, 
cardiorespiratory fitness, beginning smoking, and upward social mobility, a score was created 
using these variables to examine the effect of the number of improved lifestyle changes on 
the prevalence of low HDL cholesterol in adulthood (Figure 25). The group who did not 
improve any lifestyle factor between childhood and adulthood had more than double the 
prevalence of low HDL cholesterol levels in adulthood compared with the study sample mean 
(26.2% vs. 11.9%). The prevalence of low HDL cholesterol in those who had improved two 
lifestyle factors was less than one quarter (2.6% vs. 11.9%) of the study sample prevalence. 
The mean change in the number of positive lifestyle changes for this score was 1.4 ± 0.8. 
Ptrend<0 . 01 
I 	, 	I  
0 	 1 	 2 a.3 
No. of improved lifestyle changes 
Figure 25. Proportion of participants (least squared means) with high-risk (low) HDL cholesterol in 
adulthood according to the number of positive lifestyle changes from childhood. Positive lifestyle 
changes included: a 21 SD decrease in waist circumference z-score, a 21 SD increase in 
cardiorespiratory fitness z-score, upwardly mobile SEP (as described in methods), and not beginning 
smoking or not being a persistent smoker. Proportions are adjusted for age and sex. Dashed line 
indicates population mean of low HDL cholesterol in adulthood. Error bars represent 95% confidence 
intervals. Number of participants for each group was: 0 changes, N=32; 1 change, N=179; 2 changes, 
N=120; 23 changes, N=39. Ptrend from logistic model. 
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3.5. DISCUSSION 
Previous studies have shown that while tracking of lipid and lipoprotein levels is good, it is 
not entirely stable. The present study showed that despite rank-order tracking, a substantial 
proportion of high-risk youth did not have high-risk levels in adulthood, while the majority 
proportion of those with high-risk levels in adulthood did not have high-risk levels as 
children or adolescents. These data demonstrated that some of this instability was likely the 
result of participants adopting changes in lifestyle habits that a screening and intervention 
program would be designed to promote, such as weight control, physical activity, non-
smoking and improvements in socioeconomic circumstance. These findings are important for 
two reasons. First, they suggest that beneficial changes in potentially modifiable risk factors 
(smoking and adiposity) in the time between youth and adulthood has the potential to shift 
those with high-risk blood lipid and lipoprotein levels in childhood or adolescence to not 
have high-risk levels in adulthood. Second, they emphasise that preventive programs aimed 
at those who do not have high-risk blood lipid and lipoprotein levels in youth are equally 
important if the proportion of adults with high-risk levels is to be reduced. 
The effects of increased adiposity and beginning smoking on tracking of blood lipid 
and lipoprotein levels have been suggested in two previous studies. In the six year follow-up 
of 2236 participants in the Cardiovascular Risk in Young Finns Study, PorIcka et al.223 found 
that true positives for HDL cholesterol and triglycerides were more likely to increase relative 
BMI and sum of skin fold measures (bicep, tricep, and subscapular), and to have begun 
smoking compared with false positives. The reciprocal was also true in comparisons of false 
negatives and true negatives. Data from 611 and 295 participants from the Beaver County 
Lipid Study showed that tracking of total cholesterol levels was affected by changes in BMI 
over 9 year and later 16 year periods. 224. 235 Associations, however, over a longer follow-up 
period, and with LDL cholesterol reported in this study are novel. Also new are the findings 
concerning change in cardiorespiratory fitness and social mobility. 
These data showed that change in cardiorespiratory fitness was associated with 
tracking of HDL cholesterol from childhood to adulthood. The beneficial effect of short- to 
medium-term aerobic exercise training in raising HDL cholesterol levels is well 
established,354 with possible underlying mechanisms related to increased lipoprotein lipase 
activity in adipose tissue and muscle, reductions in the levels of cholesterol ester transfer 
protein, or a decrease in hepatic lipase activity. 355 The effects of exercise training on HDL 
cholesterol are thought to be both direct and mediated through exercise-induced reductions in 
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adiposity. 354  Although not a randomised controlled trial, these data provide observational 
epidemiological evidence that a long-term increase in cardiorespiratory fitness, and by 
association, physical activity, is associated with an improved HDL cholesterol profile. The 
effect was diluted with the inclusion of waist circumference in the multivariable model but 
remained marginally statistically significant, which provides some support for direct and 
indirect effects of increased physical activity in raising HDL cholesterol levels. 
Although both the Young Finns223 and Beaver County 224, 235 cohorts examined 
changes in indices of physical activity collected from questionnaire measurements, neither 
study found that physical activity significantly affected tracking of the studied blood lipid and 
lipoprotein variables. The discrepancy between the findings in this study with 
cardiorespiratory fitness and those from the Young Finns and Beaver County studies that 
used self-reported physical activity may be a result of reduced measurement error in the 
objective estimates of cardiorespiratory fitness at both time-points. That is, it would seem 
possible that self-report physical activity data collected at two time points, using (in some 
instances) non-validated questions, and delivered to individuals of vastly different ages, 
would not accurately quantify changes. Because change in cardiorespiratory fitness in an 
individual is strongly correlated with a change in energy expenditure and measurements are 
less subject to measurement error, Jackson et al. 356 have previously argued that change in 
objectively-measured cardiorespiratory fitness from one time-point to another might be a 
better indicator of change in physical activity than questionnaire measures of physical 
activity at each time point. 
For HDL cholesterol, upward social mobility from childhood to adulthood was 
associated with improvements in HDL risk status. This finding-is consistent with a Scottish 
study which found that those who moved from a lower SEP in childhood to a higher SEP in 
adulthood had higher adult HDL cholesterol levels."' The mechanisms through which 
improvements in SEP are related to decreases in HDL cholesterol risk are uncertain. 
Plausibly, this relationship could be mediated through changes in saturated fat intake, 
physical activity, smoking or adiposity, but upward social mobility remained independently 
associated with HDL cholesterol risk status in the multivariable model, which accounted for 
these and other factors. Possibly, changes in unmeasured variables, such as dietary 
components other than saturated fat, alcohol consumption, depression, stress or health service 
utilisation, could explain the observed association. 
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No association between change in saturated fat intake and blood lipid or lipoprotein 
tracking was observed. The Beaver County Study found that false positive participants for 
total cholesterol levels had significantly improved their nutrition score (adherence to a diet 
low in saturated fat and cholesterol) compared with their false negative counterparts. 224 One 
other study reporting on cluster tracking of a number of risk factors (total cholesterol, HDL 
cholesterol, and diastolic blood pressure) has previously reported that false positives 
significantly decreased their consumption of dietary fat compared with false negatives that 
increased consumption. Measurement inconsistency in the diet variables used to derive 
change in saturated fat intake in this study may have contributed to the lack of any 
association observed between this variable and tracking of the blood lipid and lipoprotein 
levels. Although related, comparing a direct assessment of saturated fat intake as a percentage 
of total daily caloric intake in childhood to a measure relating to saturated fat intake 
behaviour in adulthood is, at best, only a proxy for actual changes in either variable. The data 
collected at both time points did not allow either fat intake behaviour or saturated fat intake 
as a percentage of total daily caloric intake to be directly assessed. The resultant 
measurement error from comparing these related but different indicators of saturated fat 
intake would likely shift any true effect toward the null. 
In the absence of long-term clinical trials, analyses of the type employed in this study 
are important as they offer insight into the likely effects of changes in modifiable risk factors 
on whether an individual remains at, or changes risk status between childhood and adulthood. 
The findings that health promoting lifestyle changes that occur for adiposity, physical 
activity, smoking, and socioeconomic circumstance between childhood and adulthood have 
an impact on tracking of blood lipid and lipoprotein levels provides direction for prevention 
and intervention programs that may have an impact on adult blood lipid and lipoprotein 
levels and possibly, future CVD risk. While there is a paucity of evidence from clinical trials 
supporting prevention programs commencing in childhood or adolescence, these data go 
someway to supporting the recently revised American Academy of Pediatrics 220 statement for 
the management of hypercholesterolemia in children that endorsed population-wide 
preventive measures encouraging physical activity and following dietary guidelines both for 
the reduction in dyslipidemia and for overweight or obesity. 
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3.5.1 LIMITATIONS 
Potential bias due to loss to follow-up of almost 70% of the original eligible cohort needs to 
be considered. Participants at follow-up differed from non-participants with respect to 
baseline smoking, SEP, and adiposity. The differences in adiposity, although statistically 
significant, were relatively small in absolute terms. With respect to SEP, sensitivity analyses 
that stratified tracking by a measure of area-level SEP collected at baseline 348 showed that 
tracking for those of high SEP at baseline was consistent or lower than that in participants of 
low, low-medium, or medium-high SEP at baseline (LDL cholesterol: r = 0.57 [high SEP] vs. 
0.61 [low, low-medium, or medium-high]; HDL cholesterol: 0.45 vs. 0.47; and triglycerides: 
0.31 vs. 0.34 respectively). It is therefore unlikely that the differences in baseline SEP would 
have biased these results. With respect to smoking, sensitivity analyses that stratified tracking 
by baseline smoking status showed that tracking correlations were stronger for smokers at 
baseline compared with non-smokers (LDL cholesterol: r = 0.64 vs. 0.59; HDL cholesterol: 
0.56 vs. 0.45; and triglycerides: 0.40 vs. 0.32), suggesting that the tracking estimates 
presented were likely an underestimate of the true effect. 
Several potential sources of measurement error were also evident. First, only single 
measurements of lipid and lipoprotein levels were recorded at both time points. This was one 
of the major limitations of most previous studies that have examined tracking of blood lipid 
and lipoprotein levels from childhood to adulthood that unfortunately remains so for this 
study. There are considerable data that suggest short- to long-term within-person variability 
in the measurement of lipids and lipoproteins. 308-31° The variability in blood lipid measures 
from one time-point to another within the same person is a combination of what Davis et 
al. 337 defined as preanalytic factors (method of specimen collection), analytic factors 
(variability of reagents and instrument function), and biological factors (age, pubertal status, 
diet, season of year, and recency of acute infection). Knowledge of two separate childhood 
blood lipid values reduces what is known as the regression-toward-the-mean (or regression 
dilution) effect. I61 Regression toward the mean is a statistical principle that states that persons 
with low or high measures (e.g. blood lipid) on a first measure will tend to have values closer 
to the mean of the population distribution (of the blood lipid) on a second measure and will 
lead to an underestimate of the true effect. 358-36° Davis et al. empirically confirmed this 
relationship for total cholesterol measurements in predicting CVD risk, showing that a single 
measure underestimates the true tracking correlation coefficient by —15% when compared 
with the average of two measurements and by —23% when compared with a theoretical error- 
Factors affecting blood lipid and lipoprotein tracking 
	 141 
free measure. 332 Data from the Bogalusa Heart Study (reproduced in Figure 22) showed that 
stability tracking for LDL cholesterol increased by 15 percentage points (from 10 to 25%) 
when two measurements were used to classify levels in youth. What this means for this study 
is that the degree of tracking would be higher than these results suggested. Several methods 
to adjust for regression to the mean have been proposed in the literature. 360 However, these 
methods can not be applied in clinical settings for the prediction of adult blood lipid levels on 
the basis of childhood levels, 161 which is why the results for this study are not adjusted for 
regression to the mean. The above however emphasises the importance, from a clinical 
perspective, of repeat lipid and lipoprotein measurements to decrease the regression to the 
mean effect and thus assign risk more accurately. Both the current22° and previous 196' 247 
paediatric guidelines for blood lipid screening stipulate multiple measurements before lipid 
levels are classified. 
Second, because data were only available from two time points, only a single measure 
of change was available that did not allow the timing, duration, or frequency of changes to be 
examined. Third, measurement inconsistency in the diet variables may have contributed to 
the lack of any observable association in these data. Other important dietary variables that 
were unable to be examined include the intakes of cholesterol, polyunsaturated fatty acids, 
and fibre. It is apparent that other studies are required to answer the question of changes in 
diet with tracking of blood lipid and lipoprotein levels. Fourth, it was not possible to consider 
the potential role of pubertal status in these analyses because these data were not collected at 
baseline. Age was considered in the analyses as a proxy for pubertal status given the 
relationship between sexual maturation and lipids, and age and lipids have been shown to be 
similar in adolescents. 30° Fifth, childhood SEP was retrospectively recalled, although this is a 
commonly Used357' 361 and valid method that does not differ according to SEP. 362 Sixth, the 
measure of SEP was limited to education; findings may have differed had an alternate 
indicator been used. Finally, although adverse blood lipid and lipoprotein levels in adulthood 
are a risk factor for CVD, they do not provide evidence of the outcomes of most interest — 
CVD and mortality. 
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3.6. CONCLUSIONS 
Unhealthy lifestyle changes that occur between childhood or adolescence and adulthood have 
an impact on whether an individual maintains, loses, or develops high-risk blood lipid and 
lipoprotein levels in adulthood. These data suggest that prevention and intervention programs 
designed to promote weight control in the first instance, but also physical activity, non-
smoking and improvements in socioeconomic circumstances in the time between youth and 
adulthood are important for both those with and without high-risk levels in childhood or 
adolescence. 
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KEY POINTS 
• This chapter studied the tracking of total cholesterol, LDL cholesterol, HDL 
cholesterol, and triglyceride levels over a 20-year period from childhood to 
adulthood in the Australian Childhood Determinants of Adult Health (CDAH) 
study, and examined factors that affect the tracking of these blood lipid and 
lipoprotein levels. 
• Tracking (Spearman's rank-order correlations) was observed for total 
cholesterol (i-0.54), low-density lipoprotein cholesterol (r-0.59), high-
density lipoprotein (HDL) cholesterol (r-0.47), and triglycerides (r-0.34) (all 
P<0.01). 
• Between 40 and 98% of individuals with baseline high-risk blood lipid and 
lipoprotein levels according to the National Cholesterol Education Program 
cut-points no longer had high-risk levels at follow-up. 
• Participants who acquired high-risk levels in adulthood had significantly 
greater adiposity gains between surveys compared with those who lost their 
high-risk status and those who maintained normal-risk levels (All P<0.05). 
• Changes in cardiorespiratory fitness, smoking status and socioeconomic 
position in addition to waist circumference were also associated with HDL 
cholesterol tracking (P-0.10). 
• These data suggest that prevention and intervention programs designed to 
promote weight control in the first instance, but also physical activity, non-
smoking and improvements in socioeconomic circumstances in the time 
between youth and adulthood are important for both those with or without 
high-risk levels in childhood or adolescence. 
Box 3. Summary of key points from Chapter 3: factors affecting blood lipid and lipoprotein tracking 
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4. UTILITY OF TWO CLASSIFICATIONS OF PAEDIATRIC 
DYSLIPIDEMIA TO PREDICT DYSLIPIDEMIA IN 
ADULTHOOD 
4.1. INTRODUCTION 
As outlined in section 1.6, interest in screening children and adolescents for lipid disorders 
has gained momentum in recent times, with reports from the US Preventive Service Task 
Force,25° the AHA, 249 and others ,220, 251-253 outlining challenges with the existing guidelines 
issued by NCEP and calling for its revision. 196 One area of the existing guidelines outlined 
for revision included the lipid and lipoprotein cut-points used to assign risk status. Two 
classifications have been circulated that provide paediatric cut-points for what constitutes 
normal-, borderline-, and high-risk levels of total cholesterol, LDL cholesterol, HDL 
cholesterol, and triglycerides. The first was a single set of cut-points issued by NCEP, 196 that 
defined borderline-, and high-risk cut-points at values coinciding with the 75 th, and 95 th 
percentiles (25 °1, and 5 th for HDL cholesterol) of the entire population distribution from the 
LRC Prevalence Study. The NCEP cut-points apply to all children and adolescents aged 2 to 
19 years, hence do not account for changes in lipid distributions that occur with growth and 
maturation. The second classification derived age- and sex-specific cut-points for adolescents 
aged 12 to 19 years using data from three NHANES. 25I These cut-points were derived using 
growth curves that were linked to evidence-based dyslipidemia thresholds for adults. 
Although these two classifications of adolescent dyslipidemia have been circulated, no study 
has assessed which of these classifications is most effective for predicting those adolescents 
who will develop abnormal levels in adulthood. 
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4.2. 	AIMS 
The aims of this chapter were: 
1. To determine the utility of two classifications of paediatric dyslipidemia to predict 
dyslipidemia in adulthood. 
2. To evaluate the effect of different screening strategies on the ability to identify 
adolescents who would develop dyslipidemia as adults. 
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4.3. METHODS 
To address these aims, data from the three population-based, prospective cohort studies 
described in chapter 2 were used. 
4.3.1 STUDY SAMPLES AND MEASURES 
Australian Data (The Childhood Determinants of Adult Health [CDAH] Study) 
Study sample 
For these analyses, data from 365 participants (33 % of those eligible from baseline, 49 % 
male) aged 12 and 15 years at baseline who had lipoprotein data available at both baseline 
(1985) and follow-up (2004-2006) were used. 
Measures 
Protocols for baseline and follow-up measures of blood lipids and lipoproteins, and height 
and weight measures have been described in section 2.2.3. 
Finnish Data (The Cardiovascular Risk in Young Finns Study) 
Study sample 
For the present analyses, data on 1185 subjects (66 % of those eligible from baseline, 45 % 
male) with lipoprotein data available in 1980 and 2001 and who were aged 12, 15, and 18 
years at baseline (in 1980) were included. 
Measures 
Protocols for baseline and follow-up measures of blood lipids and lipoproteins, and height 
and weight measures have been described in section 2.3.3. 
Family History of Premature Coronary Heart Disease: Family history of premature 
coronary heart disease (CHD) was assessed by a questionnaire in 2001. Three different 
classifications, from stringent to broad, were established to assess family history. 83 Family 
history was considered positive only if each participant's father or mother had: (1) 
experienced myocardial infarction or had percutaneous coronary intervention or coronary 
bypass surgery at 55 years of age (N = 120); (2) been diagnosed with CHD, experienced 
myocardial infarction, or had percutaneous coronary intervention or coronary bypass surgery 
at 5_55 years of age (N = 176); or (3) been diagnosed with CHD, experienced myocardial 
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infarction, or had percutaneous coronary intervention or coronary bypass surgery at any age 
(N = 382). Results were essentially similar when using any of these three classifications. 
Results are expressed using classification two, as has been used to denote positive family 
history in previous work from the Young Finns study. 83 
United States Data (The Bogalusa Heart Study) 
Study sample 
For these analyses, 273 participants (18 % of those eligible from baseline, 44 % male, 29 % 
African American) aged 12 to 17 years at baseline who had fasting lipid and lipoprotein data 
available from both baseline (1984-1985) and follow-up (2001-2002) surveys were used. 
Measures 
Protocols for baseline and follow-up measures of blood lipids and lipoproteins, and height 
and weight measures have been described in section 2.4.3. 
4.3.2 CLASSIFICATION OF LIPOPROTEIN STATUS IN ADOLESCENCE 
AND ADULTHOOD 
Status of blood lipid and lipoprotein variables in adolescents was defined according to 
NCEP I96 and NHANES 2 " classifications (Table 13). In adulthood, NCEP ATPIII guidelines 
for total cholesterol (?6.22 mmol/L; >240 mg/dL), LDL cholesterol (?4.14 mmol/L; ?160 
mg/dL), HDL cholesterol (<1.036 mmol/L; <40 mg/dL), and triglycerides (?2.26 mmol/L; 
>200 mg/dL) were used to identify those at high risk (i.e. those with substantially increased 
risk of CVD).304 
Table 13. NCEP I96 and NHANES 2" adolescent lipoprotein cut-points (mmol/L) 
NCEP NHANES 
I 
12y 13y 14y 15y 16y 17y 
I 
18y 
M F M F M F M F M F M F M F 
Total 
cholesterol 
Normal <4.40 <5.18 <4.77 <4.99 <4.71 <4.86 <4.68 <4.84 <4.72 <4.88 <4.82 <4.95 <4.94 <5.05 <5.07 Borderline 4.40- 5.18- 4.77- 4.99- 4.71- 4.86- 4.68- 4.84- 4.72- 4.88- 4.82- 4.95- 4.94- 5.05- 5.07- high 5.17 6.02 5.46 5.82 5.40 5.69 5.37 5.69 5.45 5.76 5.61 5.87 5.81 6.01 6.02 High 25.18 26.03 25.47 25.83 25.41 25.70 25.38 25.70 25.46 >5.77 25.62 25.88 25.82 26.02 26.03 
LDL 
cholesterol 
Normal <2.85 <2.50 <2.38 <2.44 <2.41 <2.39 <2.41 <2.38 <2.43 <2.41 <2.45 <2.46 <2.47 <2.51 <2.52 Above 2.50- 2.38- 2.44- 2.41- 2.39- 2.41- 2.38- 2.43- 2.41- 2.45- 2.46- 2.47- 2.51- 2.52- normal 3.23 2.95 3.14 2.97 3.07 2.99 3.05 3.02 3.10 3.06 3.17 3.12 3.24 3.21 Borderline 2.85- 3.24- 2.96- 3.15- 2.98- 3.08- 3.00- 3.06- 3.03- 3.11- 3.07- 3.18- 3.13- 3.25- 3.22- high 3.36 3.97 3.51 3.85 3.54 3.75 3.56 3.73 3.60 3.80 3.67 3.90 3.76 3.99 3.89 High 23.37 23.98 23.52 23.86 23.55 23.76 23.57 23.74 23.61 23.81 23.68 23.91 23.77 24.00 23.90 
HDL 
cholesterol 
Normal >1.56 21.70 21.48 21.64 21.47 21.59 21.48 21.55 21.49 21.53 21.51 21.53 21.53 21.54 21.54 Borderline 1.56- 1.69- 1.47- 1.63- 1.46- 1.58- 1.47- 1.54- 1.48- 1.52- 1.50- 1.52- 1.52- 1.53- 1.53- low 0.91 1.14 1.04 1.11 1.05 1.08 1.05 1.05 1.04 1.04 1.04 1.04 1.04 1.04 1.04 Low <0.91 <1.13 <1.03 51.10 51.04 <1.07 <1.04 <1.04 <1.03 <1.03 <1.03 <1.03 <1.03 51.03 <1.03 
Triglycerides 
Normal <1.02 <1.44 <1.60 <1.48 <1.53 <1.52 <1.47 <1.56 <1.44 <1.59 <1.46 <1.62 <1.53 <1.65 <1.61 Borderline 1.02- 1.44- 1.60- 1.48- 1.53- 1.52- 1.47- 1.56- 1.44- 1.59- 1.46- 1.62- 1.53- 1.65- 1.61- high 1.46 1.83 2.02 1.92 1.92 2.01 1.81 2.09 1.78 2.15 1.82 2.19 1.93 2.23 2.08 High 21.47 21.84 22.03 21.93 21.93 22.02 21.82 22.10 21.79 22.16 21.83 22.20 21.94 22.24 22.09 
Abbreviations: y, age in years; M, males; F, females 
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4.3.3 STATISTICAL ANALYSES 
Two CDAH participants (one male), five Young Finn's participants (all male), and seven 
Bogalusa participants (three males) were currently taking lipid lowering medications at 
follow-up and were removed from the analyses. Including or excluding these participants in 
the analyses made no difference to the final results presented. 
Comparison of participants and non-participants 
Comparisons between baseline characteristics of participants and non-participants at follow-
up within each cohort were performed using logistic regression. Participation (yes/no) was 
used as the binary dependent variable in these analyses. 
Descriptive analyses 
Descriptive statistics were used to summarise participant characteristics at baseline and 
follow-up for each cohort. Continuous variables were expressed as means ± SD, while 
dichotomous variables were presented as proportions. 
Prediction of abnormal lipoprotein levels in adulthood 
Relative risks 
Log-binomial regression was used to examine associations between baseline lipid and 
lipoprotein classifications and the development of abnormal levels at follow-up. Relative 
risks and 95% confidence intervals were calculated for cohort-stratified and pooled data. 
Estimates were adjusted for age at baseline, sex, and change in BMI rank between 
adolescence and adulthood as it was associated with adulthood lipid and lipoprotein levels in 
all cohorts. This adjustment allowed the associations to be examined independent of any 
change in BMI, which would likely affect the prediction of adult status from adolescent 
classifications (as was shown in chapter 3). Analyses of Bogalusa data were also adjusted for 
race; pooled estimates were additionally adjusted for cohort and length of follow-up. The 
adjustment for cohort was to account for differences in lipid and lipoprotein determination 
methods between the three cohorts; the adjustment for length of follow-up was to account for 
any within-cohort differences between length of follow-up and risk of high-risk lipid or 
lipoprotein levels adulthood. Interactions between cohort and adolescent lipid and lipoprotein 
classifications were added to each pooled model and examined for significance. There were 
significant interactions between cohort and NCEP HDL cholesterol cut-points, and cohort 
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and NHANES HDL cholesterol cut-points. These data are considered in the results. BMI data 
were not available for 44 Australian, eight Finns, and two US participants at follow-up. 
Hence, log-binomial analyses were performed on reduced sample sizes of up to 319 CDAH, 
1172 Young Finns, and 264 Bogalusa participants. 
Direct comparisons of NCEP vs. NHANES classifications 
The ability of each adolescent classification to predict abnormal adult levels was assessed 
using diagnostic performance statistics, including: sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), and area under receiver-operating 
characteristic curves (AUC). Sensitivity was calculated as true positives/(true positives + 
false negatives), specificity as true negatives/(true negatives + false positives), PPV as true 
positives/(true positives + false positives), and NPV as true negatives/(true negatives + false 
negatives). Tests for significant differences of sensitivity and specificity between NCEP and 
NI-LANES adolescent cut-points were performed using McNemar's test. 363 Confidence 
intervals for sensitivity and specificity were calculated using the binomial distribution. The 
AUC has a range of 0 to 1, where a value of 0.5 represents no discrimination, and a value of 1 
would indicate perfect discrimination. Tests for significant differences between AUC for 
each adolescent classification were calculated using the DeLong algorithm. 364 This method 
assumes the correct null distribution when there are only three classification levels as is the 
case here (confirmed through simulation). 
Point estimates for pooled data are presented in the results, with cohort-stratified data 
presented graphically. Log binomial regression analyses and diagnostic performance statistics 
were calculated twice for each data set: the first using NCEP cut-points, and the second using 
NHANES cut-points. 
Evaluation of different screening strategies 
To evaluate whether different screening strategies had an effect on the ability to identify 
adolescents who would develop associated dyslipidemia as adults, the existing NCEP 
paediatric screening algorithm was considered that uses positive family history as a criterion 
before children and adolescents are subject to lipid and lipoprotein analysis. I96 The efficacy 
of lipid screening in adolescents who were overweight or obese in accordance with recent 
recommendations by the AHA and the AAP was also examined. 226 ' 249 The Young Finns 
cohort was chosen for these analyses to maximise sample numbers and take advantage of 
comprehensive data on family history of premature CHD available from the 2001 follow-up 
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survey. To identify adolescent Finns who may develop high-risk levels as adults, the 
following screening strategies were employed: (a) universal (whole- or random-population) 
screening employing the best performing high-risk cut-points from earlier analyses, (b) 
positive family history of CHD and lipid or lipoprotein levels exceeding best-performing 
high-risk cut-points, (c) overweight or obesity according to International Obesity Task Force 
criteria306 and lipid or lipoprotein levels exceeding best-performing high-risk cut-points, and 
(d) positive family history of CHD or overweight or obesity and lipid or lipoprotein levels 
exceeding best-performing high-risk cut-points. Sensitivity, specificity, PPV, NPV, and AUC 
were calculated for each screening strategy. 
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4.4. RESULTS 
To determine if the participants at follow-up were representative of the original eligible 
cohorts, baseline characteristics between participants and those lost to follow-up were 
compared (Table 14). Those lost to follow-up (67 % CDAH, 34 % Young Finns, 82 % 
Bogalusa) were more likely to be younger and male in all cohorts, and African American in 
the Bogalusa cohort (all P<0.05), but there were no statistically or clinically significant 
differences at baseline between participants and non-participants in any of the three cohorts 
in total cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride levels in age- and sex-
adjusted analyses. 
Participants 
365 
  
Age at baseline, y* 
Males, %t 
African Ameni 
 
49.0 
 
  
Total cholesterol, mmol/L: 
	
4.44 
LDL cholesterol, mmol/L: 
	
2.68 
HDL cholesterol, mmol/L: 
	
1.43 
Triglycerides. mmol/L: 0.76 
Table 14. Characteristics at baseline of participants and non-participants at follow-up 
CDAH Young Finns 	 Bogalusa 
U
tility
 o
f tw
o classification
s o
f paediatric d yslipidem
ia
 to
 predict dysli pidem
ia
 in
 ad ulthood 
Non-participants Participants Non-participants Participants Non-participants 
744 1185 601 273 1239 
1 .6 14.6!! 
56.6 44.6 55.0 44.0 52.1 
29.3 36410111 
4.44 5.18 5.17 4.16 4.15 
2.68 3.30 3.30 2.46 2.42 
1.41 1.55 1.54 1.49 1.57 
0.79 0.73 0.72 0.88 0.81 
Statistics are means for continuous variables and percentages for dichotomous variables 
*Differences between participants and non-participants examined using logistic regression adjusted for sex (additionally adjusted for race in Bogalusa 
analyses). 
Inifferences between participants and non-participants examined using logistic regression adjusted for age (additionally adjusted for race in Bogalusa 
analyses). 
:Differences between participants and non-participants examined using logistic regression adjusted for sex and age (additionally adjusted for race in 
Bogalusa analyses). 
P<0.05 
■-• 
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4.4.1 ADOLESCENT AND ADULT LIPID AND LIPOPROTEIN LEVELS 
Adolescent and adult lipid and lipoprotein levels, and the proportion of adults classified with 
lipid disorders in each study cohort are displayed in Table 15. With the exception of HDL 
cholesterol, females tended to have a worse lipid and lipoprotein profile in adolescence 
compared with their male counterparts, but this trend was reversed in adulthood. Compared 
with adult females, a higher proportion of adult males were classified as having abnormal 
levels of LDL cholesterol, HDL cholesterol, and triglycerides across all cohorts. 
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Table 15. Levels of lipid and lipoprotein variables in adolescence and adulthood in cohorts from 
Australia, Finland, and the United States 
Males Females 
I 
Adolescence 
I 	I 
Adulthood Adolescence 
I 
Adulthood 
CDAH (N=363) 
N 178 185 
Age, y 13.511.5 33.411.7 13.511.5 33.411.6 
Total cholesterol, mmoUL 4.3310.68 5.1110.95 4.5210.71 4.8510.95 
LDL cholesterol, mmol/L 2.6110.60 3.2310.78 2.7110.66 2.8410.79 
HDL cholesterol, mmol/L 1.3910.28 1.3010.29 1.4710.27 1.5610.35 
Triglycerides, mmol/L 0.7510.34 1.3010.81 0.7610.34 0.9710.58 
High total cholesterol* 13.5 6.5 
High LDL cholesterol* 11.4 4.3 
Low HDL cholesterol* 22.5 7.0 
High triglycerides* 10.1 4.9 
Young Finns (N=1180) 
N 523 657 
Age, y 14.9-12.4 35.912.4 14.812.4 35.812.4 
Total cholesterol, mmol/L 5.0710.87 5.5211.01 5.2710.87 5.1810.95 
LDL cholesterol, mmol/L 3.2410.79 3.6510.91 3.3510.79 3.2710.79 
HDL cholesterol, mmol/L 1.5010.31 1.1810.29 1.5810.29 1.4010.30 
Triglycerides, mmol/L 0.7010.33 1.6211.09 0.7510.34 1.1710.75 
High total cholesterol* 21.4 12.9 
High LDL cholesterol* 27.0 12.2 
Low HDL cholesterol* 33.9 11.1 
High triglycerides* 17.6 5.6 
Bogalusa (N=266) 
N 117 149 
Age, y 15.311.6 32.411.4 15.311.5 32.311.5 
Total cholesterol, mmol/L 4.0510.88 4.8910.94 4.2010.77 4.7410.99 
LDL cholesterol, mmol/L 2.3810.71 3.2410.79 2.4710.59 3.0310.87 
HDL cholesterol, mmol/L 1.4310.53 1.1010.29 1.5510.47 1.2910.37 
Triglycerides, mmol/L 0.9010.48 1.6611.46 0.8210.37 1.1610.57 
High total cholesterol* 6.8 8.7 
High LDL cholesterol* 15.4 12.1 
Low HDL cholesterol* 53.0 24.2 
High triglycerides* 12.8 4.7 
Data are means ± SD for continuous variables or percent for dichotomous variables. 
* Criteria for each adult lipoprotein cut-point are described in Methods. 
To convert total cholesterol, LDL cholesterol and HDL cholesterol to mg/di, multiply values by 38.67; 
to convert triglyceride values to mg/di, multiply values by 88.5. 
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Table 16 shows differences in lipid and lipoprotein levels between 15 year old male 
and female participants from each cohort. Observations were restricted to those aged 15 years 
for these analyses because lipid and lipoprotein levels differ by age in adolescence, and the 
15 year age group was represented in each cohort and provided adequate numbers for 
comparison (participants aged 12 years were also represented in each cohort but the sample 
size in these strata for the Bogalusa study was low). Young Finns participants had higher 
total and LDL cholesterol concentrations compared with CDAH or Bogalusa participants. 
CDAH participants had the lowest HDL cholesterol concentrations, while Bogalusa 
participants had the highest triglyceride levels across the three study sites. These findings 
need to be considered in terms of differences in lipid and lipoprotein measurement methods 
between each of the cohorts and is considered in the discussion. 
Table 16. Levels of lipid and lipoprotein variables in 15 year old male and female adolescents in cohorts from Australia, Finland, and the United States 
Males 	 Females 
I 	I 
Total 
	
LDL 
	
HDL 
	
Triglycerides, Total 
	
LDL 	HDL 	Triglycerides, 
cholesterol, 	cholesterol, 	cholesterol, cholesterol, 	cholesterol, 	cholesterol, 
mmol/L mmol/L mmol/L 	mmol/L 	 mmol/L mmola, mmol/L 	mmol/L 
CDAH 89 4.13/0.62 2.47/0.57 1.31/0.26 0.79/0.35 92 4.40/0.67 2.57/0.61 1.47/0.28 0.79/0.39 
Young 182 4.87/0.81* 3.11/0.72* 1.431-0.72* 0.72/-0.34 218 5.19/0.85* 3.26/0.81* 1.60/0.31* 0.72/0.30 
Finns 
Bogalusa 25 3.83/0.781 2.17±0.660 1.48/0.40* 0.86/0.51 36 4.04±0.76*t 2.43/0.61t 1.56/0.54 0.82/0.34 
* Differences between Young Finns or Bogalusa participants and CDAH participants (linear regression, P<0.05). 
1Differences between Bogalusa and Young Finns participants (linear regression, P<0.05). 
Note. Triglycerides were log transformed before linear regression was conducted owing to a right-skewed distribution. 
To convert total cholesterol, LDL cholesterol and HDL cholesterol to mg/di, multiply values by 38.67; to convert triglyceride values to mg/di, multiply 
values by 88.5. 
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The proportions of adolescents within normal-, borderline-, and high-risk categories 
according to NCEP and NHANES classifications are provided in Table 17. The proportions 
of adolescents with high-risk levels who had dyslipidemia in adulthood were higher for the 
NCEP cut-point compared with NHANES for total cholesterol, LDL cholesterol, and 
triglycerides. Whereas, the proportions of participants who had low HDL at both time points 
was higher when adolescent HDL cholesterol levels were classified using the NI-LANES cut-
point when compared with the NCEP cut-point. While these trends are consistent within the 
cohorts, the proportions of participants who were stable in the high-risk category varied 
substantially between cohorts. For example, the proportions of males and females who had 
high-risk LDL cholesterol levels (according to the NCEP adolescent classification) at both 
time points ranged from 8.6 to 19.0% for the CDAH and Bogalusa studies, while the 
proportions who were stable in these groups were 38.5% for male Finns and 43.8% for 
female Finns. 
The analyses presented in Table 17 are analogous to stability tracking. The results 
show that total cholesterol dyslipidemia persisted into adulthood for 11 to 49% of adolescents 
using the NCEP classification, and 2 to 31% of adolescents using the NI-LANES 
classification. LDL cholesterol dyslipidemia persisted into adulthood for 11 to 44% of 
adolescents using the NCEP classification, and 2 to 31% of adolescents using the NHANES 
classification. HDL cholesterol dyslipidemia persisted into adulthood for 0.5 to 15% of 
adolescents using the NCEP classification, and 2 to 21% of adolescents using the NHANES 
classification. Triglyceride dyslipidemia persisted into adulthood for 4 to 11% of adolescents 
using the NCEP classification, and 0.2 to 3% of adolescents using the NHANES 
classification. 
Table 17. Proportions of Australian, Finnish, and US adolescents within normal-, borderline-, and high-risk categories according to NCEP and NHANES 
cut-points for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides 
CDAH 	 Young Finns  
I 	I I 	I 
NCEP 	 NHANES 	 NCEP 	 NHANES 	 NCEP 
Bogalusa 
 
 
NHANES 
Males 	Females 	Males 	Females 	Males 	Females 	Males 	Females 	Males 	Females 	Males 	Females 
Total cholesterol 
Normal 	 53.6 	46.2 	85.5 	64.5 	23.1 	15.4 	52.3 	35.6 	71.7 	66.7 	85.8 	78.4 
Borderline-high 	35.2 34.4 12.9 25.8 35.4 35.3 32.4 33.2 15.8 20.3 9.2 13.7 
High 	 11.2 	19.4 	1.7 	- 	9.7 	41.5 	49.3 	15.3 	31.2 	12.5 	13.1 	5.0 	7.8 
LDL cholesterol 
Normal 	 66.9 	61.4 	41.0 	38.6 	33.0 	29.4 	14.0 	12.2 	79.7 	79.6 	59.3 	47.4 
Above normal 	- - 41.0 29.9 - - 36.9 27.9 24.6 38.2 
Borderline-high 	21.9 	19.6 	16.3 	19.6 	28.6 	26.8 	29.7 	29.1 	9.3 	11.8 	11.0 	7.9 
High 	 11.2 19.0 1.7 12.0 38.5 43.8 19.3 30.9 11.0 8.6 5.1 6.6 
HDL cholesterol 
Normal 	 25.8 	32.1 	18.0 	42.4 	38.3 	50.7 	33.0 	60.0 	30.0 	45.1 	32.5 	53.6 
Borderline-low 	72.5 66.9 68.0 53.3 60.2 48.9 61.9 38.4 55.0 47.7 46.7 32.7 
Low 	 1.7 	1.1 	14.0 	4.4 	1.5 	0.5 	5.1 	1.8 	15.0 	7.2 	20.8 	13.7 
Triglycerides 
Normal 	 86.6 	83.9 	95.5 	96.2 	84.3 	84.5 	97.5 	96.4 	68.3 	73.9 	90.8 	92.8 
Borderline-high 	8.9 11.3 3.9 2.2 11.9 11.6 2.3 2.9 20.8 17.7 5.8 4.6 
High 	 4.5 	4.8 	0.6 	1.6 	3.8 	4.0 	0.2 	0.8 	10.8 	8.5 	3.3 	2.6 
Data presented as percentages, totals may not add to 100 because of rounding. 
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4.4.2 PREDICTION OF ABNORMAL LEVELS OF LIPOPROTEIN 
VARIABLES IN ADULTHOOD 
Relative risks 
Adjusted relative risks for developing abnormal lipoprotein levels in adulthood across NCEP 
and NI-LANES total cholesterol (Figure 26), LDL cholesterol (Figure 27), FIDL cholesterol 
(Figure 28), and triglycerides (Figure 29) cut-points are displayed, along with point-estimates 
from pooled data in Table 18. The pooled data showed that the risk of developing an 
abnormal condition in adulthood was significantly higher in those adolescents with 
borderline- and high-risk levels compared with those with normal levels for all lipoprotein 
variables. Moreover, a graded increase in the risk of developing abnormal levels in adulthood 
was observed when moving from the normal, to borderline-risk, to high-risk groups. With the 
exception of the NHANES high triglyceride threshold in the CDAH cohort (that had no 
adolescent cases develop the risk factor in adulthood, Figure 29), stratified analyses indicated 
similar relative risk patterns for borderline- and high-risk classified adolescents in each 
cohort. Interaction terms between cohort and both NCEP and NHANES HDL cholesterol cut-
points were significant, suggesting that the relationship between adolescent risk-status and 
the development of abnormal HDL cholesterol levels as adults, differed between cohorts. The 
pooled estimates for HDL cholesterol are included for completeness, however in light of the 
significant interaction; the pooled estimates should be interpreted with caution. Instead, 
interpretations are best made using the relative risks stratified by cohort (Figure 28). In 
cohort stratified analyses, it is evident that the relative risks for HDL cholesterol in the 
Bogalusa data were substantially lower compared with estimates from CDAH and Young 
Finns data (Figure 28); race stratified data indicated that the HDL cholesterol classifications 
predicted abnormal levels in adulthood for African Americans but not Caucasian Americans 
(Figure 30). 
• 	High-risk High-risk 
CDAH Young Finns Bogalusa Pooled 
TOTAL CHOLESTEROL 
1 
CDAH 	Young Finns 	Bogalusa 	Pooled 
Figure 26. Relative risks and 95% confidence intervals of developing abnormal total cholesterol levels in adulthood according to borderline- and high-risk 
total cholesterol status in adolescence using NCEP and NHANES classifications. Estimates were adjusted for age at baseline, sex, change in BMI rank 
between adolescence and adulthood; Bogalusa analyses were additionally adjusted for race; estimates from Pooled data were additionally adjusted for 
cohort and length of follow-up. Normal classified adolescents were used as the referent group. All P<0.01 (analysis for trend) unless otherwise noted. 
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Figure 27. Relative risks and 95% confidence intervals of developing abnormal LDL cholesterol levels in adulthood according to borderline- and high-risk 
LDL cholesterol status in adolescence using NCEP and NHANES classifications. Estimates were adjusted for age at baseline, sex, change in BMI rank 
between adolescence and adulthood; Bogalusa analyses were additionally adjusted for race; estimates from Pooled data were additionally adjusted for 
cohort and length of follow-up. Normal classified adolescents were used as the referent group. All P<0.01 (analysis for trend) unless otherwise noted. 
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Figure 28. Relative risks and 95% confidence intervals of developing abnormal HDL cholesterol levels in adulthood according to borderline- and high- 
risk HDL cholesterol status in adolescence using NCEP and NHANES classifications. Estimates were adjusted for age at baseline, sex, change in BMI 
rank between adolescence and adulthood; Bogalusa analyses were additionally adjusted for race; estimates from Pooled data were additionally adjusted for 
cohort and length of follow-up. Normal classified adolescents were used as the referent group. All P<0.01 (analysis for trend) unless otherwise noted. 
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TRIGLYCERIDES 
Figure 29. Relative risks and 95% confidence intervals of developing abnormal triglyceride levels in adulthood according to borderline- and high-risk 
triglyceride status in adolescence using NCEP and NHANES classifications. Estimates were adjusted for age at baseline, sex, change in BMI rank between 
adolescence and adulthood; Bogalusa analyses were additionally adjusted for race; estimates from Pooled data were additionally adjusted for cohort and 
length of follow-up. Normal classified adolescents were used as the referent group. All P<0.01 (analysis for trend) unless otherwise noted. 
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Figure 30. Race-stratified US and pooled relative risks and 95% confidence intervals for the development of abnormal HDL cholesterol levels in 
adulthood according to borderline- and high-risk lipoprotein status in adolescence using NCEP and NHANES classifications. Normal classified 
adolescents were used as the referent group. All P<0.01 (analysis for trend) unless otherwise noted. 
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Table 18. Relative risks from pooled data for the development of abnormal lipoprotein variable levels in adulthood for those exceeding NCEP and 
NHANES adolescent lipoprotein cut-points* 
Adolescent cut-points 
NCEP NHANES 
n/N RR 95%C1 n/N RR 95%Cl 
Total cholesterol 
Normal 17/565 1.0 ref 53/966 1.0 ref 
Borderline-high 57/578 3.6 2.1-6.2 91/471 3.9 2.8-5.4 
High 169/612 10.4 6.3-17.1 99/318 7.1 5.2-9.6 
LDL cholesterol 
Normal 45/774 1.0 ref 15/414 1.0 ref 
Above normal 50/566 2.7 1.6-4.8 
Borderline-high 49/407 2.3 1.6-3.4 84/415 7.0 4.1-12.0 
High 179/544 6.5 4.8-8.9 124/330 14.8 8.6-25.2 
HDL cholesterolt 
Normal 79/732 1.0 ref 77/783 1.0 ref 
Borderline-low 293/979 2.9 2.3-3.6 255/859 2.9 2.3-3.6 
Low 27/40 5.5 4.3-7.2 67/109 5.6 3.9-8.1 
Triglycerides 
Normal 109/1457 1.0 ref 151/1689 1.0 ref 
Borderline-high 38/219 2.4 1.8-3.2 16/52 4.0 2.7-5.9 
High 24/79 4.8 3.4-6.7 4/14 4.4 2.0-9.8 
* Adjusted for age at baseline, sex, change in BMI rank between adolescence and adulthood, cohort, and length of follow-up. t Interpretation of the pooled 
relative risks for HDL cholesterol are to be treated with caution as the relative risks significantly differ between cohorts (see Figure 28). 
Abbreviations: RR, relative risk; CI, confidence interval 
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Direct comparisons of NCEP vs. NHANES classifications 
Diagnostic performance statistics of NCEP and NHANES adolescent cut-points in the pooled 
data are presented in Table 19. Cohort-stratified and pooled data for sensitivity and 
specificity of high-risk cut-points are presented for total cholesterol (Figure 31), LDL 
cholesterol (Figure 32), HDL cholesterol (Figure 33), and triglycerides (Figure 34). Where 
sample sizes permitted, sex-, age-, or race- (Bogalusa) stratified analyses were comparable 
with the results presented. Borderline- and high-risk NCEP cut-points for total cholesterol 
were considerably more sensitive than the corresponding NHANES cut-points, with modest 
to high tradeoffs in specificity. Although this trend was consistent across each cohort, there 
was substantial heterogeneity in the sensitivity point estimates and confidence intervals 
between studies (Figure 31). Of those adults with abnormal total cholesterol levels, 32.3% 
would not be identified in adolescence using the high-risk NCEP cut-point and 60.6% would 
not be identified in adolescence using the equivalent NI-LANES cut-point. The proportion 
classified as high-risk during adolescence that did not develop the risk factor in adulthood 
(false positives) was 72.4% for NCEP and 68.7% for NHANES classifications. 
The NCEP borderline- and high-risk LDL cholesterol cut-points were more sensitive 
and less specific than the NHANES cut-points (Table 19, Figure 32). The trade-off in 
sensitivity-gain and specificity-loss between both classifications was particularly noticeable 
at the high-risk cut-point. The NI-LANES high-risk cut-point did not identify 55.4% of those 
adults with an abnormal LDL cholesterol concentration, as opposed to the NCEP cut-point 
that did not identify 35.0%. A small improvement in PPV was observed when NHANES vs. 
NCEP high-risk cut-points were compared. Considerable heterogeneity was observed in 
sensitivities when cohort-stratified plots were compared. 
For HDL cholesterol, the best combination of diagnostic performance statistics was 
produced when concentrations were classified by the NI-LANES borderline- and high-risk cut-
points (Table 19, Figure 33). Even though sensitivity of the NI-LANES high-risk cut-point was 
higher than the corresponding NCEP cut-point, both classifications performed relatively 
poorly. That is, 83.3% and 93.3% of the adults with low HDL cholesterol would not be 
identified using the NHANES and NCEP high-risk cut-point respectively. The PPV for the 
high-risk NCEP cut-point was higher than the NHANES cut-point. Evaluation of AUC 
indicated that NHANES cut-points were significantly better at predicting low HDL in 
adulthood compared with NCEP cut-points. Increased sensitivity of the high-risk cut-point 
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and gains in specificity at the borderline-risk cut-point for NHANES compared with NCEP 
classifications is likely to explain these differences. 
The NCEP classification for triglycerides was a better predictor of high triglyceride 
levels in adulthood compared with the NHANES classification. For both borderline- and 
high-risk cut-points, gains in sensitivity were relatively large compared to modest trade-offs 
in specificity (Table 19, Figure 34). In practical terms however, the sensitivities of both 
classifications were poor. The classifications did not identify 86.0% (NCEP) and 97.7% 
(NHANES) of adults with a high triglyceride level. Significantly higher AUC is a reflection 
of increased sensitivity across all NCEP cut-points. 
Table 19. Diagnostic performance statistics from pooled data of adolescent borderline- and high-risk lipoprotein variable cut-points, determined using 
NCEP and NHANES classifications, to predict dyslipidemia in adulthood 
Lipoprotein variable Classification 
Dyslipidemia status in adolescence 
AUC 
Borderline risk High risk 
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
Total cholesterol 
NCEP 92.1* 36.8 19.2 96.6 67.7* 71.0 27.6 93.1 0.73 
NHANES 76.4 60.6* 24.1 94.0 39.4 85.9* 31.3 89.7 0.71 
LDL cholesterol 
NCEP 82.9* 50.5 23.8 94.0 65.0* 75.2 32.9 92.0 0.73 
NI-LANES 75.7 63.2* 27.8 93.3 44.6 86.0* 37.3 89.3 0.74 
HDL cholesterol 
NCEP 80.3 47.4 30.3 89.4 6.7 99•0* 65.9 78.8 0.65 
NHANES 80.8 51.3* 32.1 90.3 16.7* 96.7 59.3 80.3 0.69 1 
Triglycerides 
NCEP 35•4* 84.9 20.4 92.3 14.0* 96.5 30.5 91.1 0.61 1 
NHANES 11.2 97.1* 29.4 90.9 2.3 99•3* 26.7 90.3 0.54 
* P<0.05, McNemar's test for difference between sensitivities/specificities; t P<0.05, test for difference between AUCs. 
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver-operating characteristic curve. 
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Figure 31. Sensitivity, specificity and 95% confidence intervals for predicting abnormal total cholesterol levels in adulthood for adolescents classified as 
high-risk using NCEP and NHANES cut-points. 
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Figure 32. Sensitivity, specificity and 95% confidence intervals for predicting abnormal LDL cholesterol levels in adulthood for adolescents classified as 
high-risk using NCEP and NHANES cut-points. 
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Figure 33. Sensitivity, specificity and 95% confidence intervals for predicting abnormal HDL cholesterol levels in adulthood for adolescents classified as 
high-risk using NCEP and NHANES cut-points. 
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Figure 34. Sensitivity, specificity and 95% confidence intervals for predicting abnormal triglyceride levels in adulthood for adolescents classified as high- 
risk using NCEP and NHANES cut-points. 
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4.4.3 EVALUATION OF DIFFERENT SCREENING STRATEGIES 
Sensitivity, specificity, PPV, NPV, and AUC for different screening strategies in the Young 
Finns cohort are presented in Table 20 using NCEP cut-points for total cholesterol, LDL 
cholesterol, and triglycerides and NHANES cut-points for HDL cholesterol. 
Additional illustrations and data comparing false positive and false negative rates (Figure 35), 
and the proportion identified/not identified and degree of overlap between screening 
strategies (Figure 36, Figure 37) are also presented. Because results for total cholesterol and 
LDL cholesterol, and results for HDL cholesterol and triglycerides were similar, the focus 
herein pertains to LDL cholesterol and HDL cholesterol only. 
Adding positive family history and/or overweight-obesity status to the NCEP high-
risk cut-point only marginally improved the identification of adolescent Young Finns who 
would develop abnormal LDL cholesterol levels as adults compared with universal screening. 
Forty-three participants (20%) with high LDL cholesterol levels at follow-up were not 
identified by any of the screening strategies (Figure 36). Universal screening identified 75% 
of participants with high LDL cholesterol levels at follow-up, but at a high trade-off in false 
positives (66.2%). The absolute numbers of participants identified using family history, 
overweight-obese, or family history and/or overweight-obese were considerably lower than 
universal screening, but false positive proportions remained high (58.5%, 66.7%, 62.6% 
respectively; Figure 35). Improvements in sensitivity, specificity, and PPV where observed 
when NHANES HDL cholesterol high-risk cut-points were combined with family history, 
overweight-obese status, or family history/overweight-obese compared with universal 
screening. Regardless of the adolescent screening strategy employed, most adults (71%) with 
low HDL cholesterol levels were not identified at baseline (Figure 37). Selective screening of 
HDL cholesterol in those with family history, overweight-obese, or family 
history/overweight-obese identified less total cases but at a considerably lower proportion of 
false positives compared with universal screening (Figure 35). Interestingly, screening 
adolescents using positive family history or overweight-obese status, without HDL 
cholesterol analysis, independently identified more total and unique at-risk individuals 
compared with universal HDL cholesterol screening (Figure 37). 
Table 20. Capacity of different screening strategies to identify adolescent Young Finns who developed dyslipidemia in adulthood 
Lipoprotein variable Screening strategy 	 N . 	Sensitivity Specificity PPV NPV AUC 
Total cholesterol 
Universal 	 1180 	77.8 	60.7 	28.4 	93.1 	0.70 
Positive family history' + cut-points 	 174 	80.5 60.2 	38.4 	90.9 	0.71 
Overweight: + cut-points 	 87 	100.0 	58.3 	33.3 	100.0 0.79 
Positive family history" OR Overweight: + cut-points 	 241 	84.0 58.6 	34.7 	93.3 	0.72 
LDL cholesterol 
Universal 	 1158 	74.4 	66.4 	33.8 	91.9 	0.73 
Positive family historyt + cut-points 	 173 	77.3 62.8 	41.5 	89.0 	0.73 
Overweight: + cut-points 	 85 	78.9 	54.6 	33.3 	90.0 	0.67 
Positive family historyt OR Overweight: + cut-points 	 239 	76.8 60.7 	37.4 	89.5 	0.72 
HDL cholesterol 
Universal 	 1179 	10.8 	98.7 	69.2 	80.4 	0.72 
Positive family historyt + cut-points 	 174 	15.6 99.3 	83.3 	83.9 	0.72 
Overweight: + cut-points 	 87 	29.0 	100.0 	100.0 71.4 	0.71 
Positive family historyt OR Overweight: + cut-points 	 241 	20.7 99.5 	92.3 	79.8 	0.73 
Triglycerides 
Universal 	 1180 	12.5 	97.2 	35.6 	90.0 	0.61 
Positive family historyt + cut-points 	 174 	19.1 94.1 	30.8 	89.4 	0.64 
Overweight: + cut-points 	 87 	29.2 	90.5 	53.8 	76.7 	0.65 
Positive family historyt OR Overweight: + cut-points 	 241 	23.1 93.6 	40.9 	86.3 	0.66 
* Refers to the total number of participants that would be screened; t family history was considered positive if a participant's father or mother had been 
diagnosed with CUD, experienced myocardial infarction, or had percutaneous coronary intervention or coronary bypass surgery at <55 years of age at 
follow-up (2001); overweight or obese according to International Obesity Task Force BMI cut-points. Abbreviations: PPV, positive predictive value; 
NPV, negative predictive value; AUC, area under the receiver-operating characteristic curve. 
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Figure 35. Proportions of adolescents identified for treatment that did not maintain high-risk levels at 
follow-up (false positives) and adolescents not identified for treatment that developed high-risk levels 
at follow-up (false negatives) according to different screening strategies for A) LDL cholesterol and B) 
HDL cholesterol levels in the Young Finns cohort. 
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Figure 36. The number of Young Finns participants with high LDL cholesterol levels as adults 
(N=216) identified and not identified using different adolescent screening strategies. Abbreviations: 
N10, 1 , the total number of participants identified in adolescence by separate screening strategies who 
developed high LDL cholesterol levels as adults; Nu„,,„„ the number of participants identified by 
unique combinations of screening criteria. The size of each ellipse is based on the proportion of total 
adult cases identified by childhood screening and is approximately to scale. 
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Figure 37. The number of Young Finns participants with low HDL cholesterol levels as adults 
(N=250) identified and not identified using different adolescent screening strategies. Mow, the total 
number of participants identified in adolescence by separate screening strategies who developed high 
LDL cholesterol levels as adults; N uniq , the number of participants identified by unique combinations 
of screening criteria. The size of each ellipse is based on the proportion of total adult cases identified 
by childhood screening and is approximately to scale. 
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4.5. DISCUSSION 
Age- and sex-specific lipid and lipoprotein cut-points developed from NHANES data have 
been proposed to provide a more accurate classification of adolescents with lipid disorders 
compared with the NCEP classification. However, there have been no studies to assess 
whether the NHANES cut-points improve the prediction of those individuals that will 
develop associated dyslipidemia in adulthood. In this study, data from 1809 participants in 
three prospective cohort studies who had lipoprotein variables collected during adolescence 
and again in adulthood with a mean follow-up of 20.2 years were examined. After adjusting 
for potential confounding variables, pooled and cohort-stratified data showed that there is a 
progressive and substantial increase in the relative risk of adolescents with borderline- or 
high-risk lipoprotein levels, whether defined according to NCEP or NHANES cut-points, to 
develop associated dyslipidemia 15 to 20 years later. These findings are consistent with 
reports that have shown lipoprotein levels track from adolescence to adulthood, 161, 162 and 
underline the usefulness of evaluating lipoprotein variables to identify adolescents who may 
benefit from intervention. The present study directly compared differences in the predictive 
capacity of the NCEP and NHANES lipoprotein variable cut-points. The recently proposed 
NHANES cut-points for HDL cholesterol offered a better prediction of those adolescents 
most likely to develop abnormal levels in adulthood, while the predictions for total 
cholesterol, LDL cholesterol, and triglycerides were poorer than those achieved with the 
NCEP classification. It was evident though, that neither classification proved clearly better 
for prediction. These results are surprising given that the new NHANES cut-points recognise 
age and sex shifts during adolescence, and are linked to evidence- and health-based adult 
NCEP ATPIII thresholds. In interpreting these data, it is necessary to take into account the 
populations examined in this study, as well as consider the practical implementation of these 
findings to revision of paediatric cut-points in a likely update to the guidelines by the NHLBI 
Pediatric Cardiovascular Risk Reduction Initiative. 
Because the cohorts used in this study collected baseline data in the early to mid 
1980s, it is necessary to consider secular trends in lipid and lipoprotein data over this time in 
consideration of the performance of both NCEP and NI-LANES cut-points. Secular trend data 
from the Young Finns cohort have showed modest decreases in total cholesterol, and LDL 
cholesterol, with more substantial decreases for HDL cholesterol, and increases in 
triglyceride levels in both adolescents 217 and young adults2I8 since 1980. Moreover, when the 
source populations for each adolescent classifications are examined, it is evident that levels 
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of total cholesterol, LDL cholesterol, HDL cholesterol were lower and triglycerides levels 
higher in the NHANES studies by comparison with the LRC Prevalence Study, 196 from which 
the NCEP cut-points were derived. This trend is consistent when adolescent lipid and 
lipoprotein variable levels in CDAH, 365 Young Finns,366 and Bogalusa cohorts are compared 
with levels from NHANES. This is not surprising given that baseline data were collected 
prior to the more recent obesity epidemic; whereas the NT-LANES data were collected during 
this period. It is possible then, that the observed gains in predictive power of the NCEP cut-
points in these data could be attributed to the period when the cut-points were developed 
(reflecting the population distribution at the time). It can not be discounted that the NHANES 
cut-points may provide a more accurate classification of today's adolescents. Prospective 
studies of the type used in this study, with periods of follow-up that span adolescence and 
early adulthood, will always be subject to this limitation. 
Heterogeneity between cohort data was apparent. Although comparisons of NCEP 
vs. NT-LANES cut-points showed similar patterns within cohorts, the relative value of the cut-
points in each population differed considerably. Discrepancies in the sensitivity and 
specificity of high-risk cut-points were evident between studies when each classification was 
considered separately (Figure 2), particularly for total cholesterol and LDL cholesterol. For 
example, in adults with abnormal total cholesterol levels, 27.8 % of Australian, 77.8 % of 
Finn, and 42.9 % of US participants would have been identified in childhood using the NCEP 
high-risk cut-point. The value of these cut-points for screening should be considered in 
different population settings. For example, the efficacy of universal screening using the 
NCEP total cholesterol cut-points in a Finnish population would be different from that in an 
Australian population. Selection bias is unlikely to explain these differences, since baseline 
lipoprotein variables for participants and non-participants at follow-up were similar in each 
cohort. 
Noticeable differences in lipid and lipoprotein levels were apparent between 
countries in these data, which may partly explain the degree of heterogeneity observed. 
Because different methods were used for lipid and lipoprotein determination it would be 
erroneous to conclude that these necessarily reflect population differences. For example, 
several studies have shown that HDL cholesterol levels vary depending on the method of 
determination. 367-369 Using standardised methods for lipid determination, Knuiman et al 
demonstrated between country differences in total cholesterol and HDL cholesterol 
concentrations in 7 to 8 year old boys from 16 countries; 211 and differences in HDL 
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cholesterol concentrations in 33 to 48 year old males from 13 countries. 3" The heterogeneity 
observed in this study is likely a function of both actual differences and methodological 
differences. It is reassuring that the best performing classifications for each lipoprotein 
variable were consistent between cohorts despite differences in laboratory methodology for 
lipoprotein variable determination. 
The existing paediatric guidelines recommend targeted lipoprotein screening in 
children and adolescents with a positive family history of premature CHD or high total 
cholesterol levels (>6.2 mmol/L; 240 mg/dL), with a recent update recommending screening 
children who are overweight or obese. 220, 249 The screening data in the Young Finns cohort 
did not provide a clear indication on the best screening approach (universal vs. selective) for 
use in adolescents. For example, universal screening and selective screening for total 
cholesterol and LDL cholesterol are not acceptable with rates of false positives that suggest 
approximately 60% of adolescents identified as having high-risk levels would not have 
abnormal levels in early adulthood, which is strikingly consistent with the study from 
Friedman et al. that showed false positive rates of 61% and 69% respectively in data from the 
25 year follow-up of the Princeton LRC Prevalence Program. 276 However, universal 
screening comes with the benefit of identifying 75% of those affected in adulthood. Neither 
universal nor selective screening for HDL cholesterol or triglycerides was efficient in 
identifying those adolescents that developed abnormal levels as adults. Although selective 
HDL cholesterol screening reduced the false positive rate compared with universal screening, 
the strategies were inefficient at identifying adolescents who developed low HDL cholesterol 
levels as adults. This is highlighted by the fact that using overweight or obesity status, or 
positive family history alone to indicate an adolescent's risk identified more total cases than 
any form of HDL cholesterol screening. In consideration of these findings with current 
paediatric recommendations that endorse a selective screening approach, clinicians need to 
observe that a substantial number of adolescents with LDL cholesterol abnormalities may not 
have high-risk levels in early adulthood, and that most individuals that develop low HDL 
cholesterol levels as adults may not be identified in adolescence. 
4.5.1 LIMITATIONS 
Several limitations were evident. First, due to the recognised within-person variability of 
lipid and lipoprotein levels, 308-3 " misclassification of lipoprotein status may have occurred by 
using a single lipoprotein measurement at baseline and follow-up. In sensitivity analyses, the 
Utility of two classifications of paediatric dyslipidemia to predict dyslipidemia in adulthood 
	
182 
possible effect of misclassification was examined by comparing AUC of single and repeated 
adolescent measurements for Young Finns who had data collected in 1980 and 1983 and who 
remained adolescents. Consistent with the literature, 337 a single lipid or lipoprotein 
measurement underestimated the strength of association with the outcome when compared 
with repeated measures. Increases in AUC were in the order of 3 to 7% for total cholesterol, 
LDL cholesterol and HDL cholesterol, but was considerably higher for repeated triglyceride 
measurements (7% and 13% for NI-LANES and NCEP respectively) (see Appendix 9 for 
complete data). While these findings, based on a single lipid or lipoprotein measurement in 
adolescence, likely underestimate the ability of both paediatric classifications to predict 
associated adult dyslipidemia, it was reassuring that the best performing classification for 
each lipid and lipoprotein variable was consistent with the primary analyses and conclusions 
presented. Second, data from the Bogalusa Heart Study have not only shown differences in 
the distribution of lipid and lipoprotein levels by race, but that dynamic changes in blood 
lipid and lipoprotein levels that occur at the onset of puberty are differentially influenced by 
race. For example, HDL cholesterol levels decline rapidly in Caucasian boys at the onset of 
• puberty, whereas LDL cholesterol levels fall in African-American boys. 209' 300 Consequently, 
owing to the low number of African Americans in this study, these findings should be applied 
with caution to bi-racial populations until more data are available. Third, this study used lipid 
and lipoprotein risk status in adulthood as the outcome of interest and did not establish 
whether the two adolescent classifications predict clinically relevant end-points such as the 
presence and progression of atherosclerosis, or CVD events. Fourth, cut-points derived from, 
and intended for, US populations to Australian and Finnish data were used. Although these 
data suggest the adolescent cut-points could be generalised to other populations of European 
ancestry, applying them without consideration of possible country or region specific 
differences may not be optimal. Finally, the measure of family history of premature CHD in 
the Young Finns cohort was acquired at follow-up from self-report, and not during baseline 
examination or from hospital records or death certificates."' It is likely that the definition 
used here (pertaining to parental history) would have indicated several less children if it were 
collected in childhood. Moreover, research examining the net bias in both selection and recall 
for self-report measures of family history has shown a shifting of the true effect toward the 
nu11,371 ' 372 suggesting the estimates of prediction for family history in this study were likely 
conservative. 
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4.6. CONCLUSIONS 
Although neither classification proved clearly better for prediction of dyslipidemia in 
adulthood, the data suggest that the separate use of NHANES cut-points for HDL cholesterol 
and NCEP cut-points for total cholesterol, LDL cholesterol, and triglycerides may provide 
the most accurate classification of what constitutes normal-, borderline-, and high-risk lipid 
and lipoprotein levels in adolescents. In addition, the data highlighted substantial limitations, 
from an epidemiological perspective, to universal and targeted screening approaches to 
identifying youth with high-risk blood lipid and lipoprotein levels in young adulthood. 
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KEY POINTS 
• Two groups (the National Cholesterol Education Program, NCEP; 2 and 
Jolliffe & Janssen, 3 NHANES) have circulated paediatric cut-points of what 
constitutes normal-, borderline-, and high-risk lipoprotein variable levels. 
• No study has assessed which of these classifications are most effective at 
predicting those adolescents who will develop abnormal levels in adulthood. 
• Using pooled data from three prospective cohort studies from Australia, 
Finland, and the United States, the results suggest that clinicians wishing to 
identify lipid disorders in adolescents may improve risk stratification by the 
separate adoption of cut-points for HDL cholesterol stipulated by Jolliffe and 
Janssen, and NCEP stipulated cut-points for total cholesterol, LDL 
cholesterol, and triglycerides. 
• The data also suggest that clinicians employing current paediatric guidelines 
for targeted lipoprotein screening in children and adolescents with a positive 
family history of premature CHD or who are overweight or obese, need to 
consider that a substantial number of those adolescents identified with high 
total cholesterol or LDL cholesterol levels may not have high-risk levels in 
early adulthood, and that most individuals that develop abnormal HDL 
cholesterol or triglyceride levels as adults may not be identified in 
adolescence. 
Box 4. Summary of key points from Chapter 4: utility of two currently recommended North American 
paediatric dyslipidemia classifications to predict dyslipidemia in adulthood 
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5. THE ASSOCIATION OF PAEDIATRIC LOW- AND HIGH-
DENSITY LIPOPROTEIN CHOLESTEROL 
DYSLIPIDEMIA CLASSIFICATIONS AND CHANGE IN 
DYSLIPIDEMIA STATUS WITH CAROTID INTI1VIA-
MEDIA THICKNESS IN ADULTHOOD 
5.1. INTRODUCTION 
The previous chapter evaluated the ability of two classifications of paediatric dyslipidemia to 
predict dyslipidemia in adulthood using data from three prospective cohort studies. Both 
borderline- and high-risk cut-points stipulated by NCEP, I96 or age- and sex-specific cut-
points based on distributions from NHANES proposed by Jolliffe and Janssen 25I were shown 
to predict a progressive and substantial increase in the relative risk of dyslipidemia in 
adulthood. Although the data suggested that prediction of adult dyslipidemia may be 
improved by the separate adoption of the NCEP cut-points for total cholesterol, LDL 
cholesterol, and triglycerides, and NHANES cut-points for HDL cholesterol, it was evident 
• that neither classification proved substantially better. The data also suggested that while 
adolescent dyslipidemia status predicted adult dyslipidemia, most of those with paediatric 
high-risk levels did not have high-risk levels as adults, and, that the use of multiple potential 
screening strategies did not substantially improve this statistic. While these data are 
important, they do not provide evidence of the utility of paediatric dyslipidemia 
classifications to predict CVD or markers of atherosclerosis. While each of these (still young) 
cohorts will have to wait for clinical events to amass to a point that analyses using clinical 
outcomes can be performed, non-invasive assessments of preclinical markers of 
atherosclerosis (such as carotid intima-media thickness, IMT) that reflect change in the 
vasculature provide useful intermediary phenotypes of the disease process. That is, they 
allow the assessment of early atheroscleroses long before clinical manifestations become 
apparent. 
As outlined briefly in section 1.3, the ultrasonic assessment of carotid IMT provides 
a non-invasive, safe, quick, relatively inexpensive, and reproducible measurement of vascular 
structure that correlates with CVD risk factors, 373 coronary artery disease, 374 and is a predictor 
of future vascular events."' An overview of population-based cohort studies that have 
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examined the ability of carotid intima-media thickness to predict clinical cardiovascular 
events is presented in Appendix 10. Because of these features, carotid IMT is suitable for 
large epidemiological studies. As outlined in the Methods chapter, each of the three cohorts 
(CDAH, Young Finns, and Bogalusa) used in this study conducted B-mode ultrasound scans 
of the carotid artery. A useful addition to the data presented in the previous chapter would 
therefore be to examine the utility of the paediatric cut-points to predict carotid IMT. 
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5.2. 	AIMS 
The aims were: 
1. To determine which of the NCEP or NI-LANES adolescent LDL cholesterol and HDL 
cholesterol dyslipidemia classifications best predict high common carotid IMT in 
adulthood; and 
2. To assess whether maintaining or changing dyslipidemia status from adolescence to 
adulthood has an effect on carotid IMT measured in adulthood. 
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5.3. METHODS 
To address the aims, data from the three population-based, prospective cohort studies 
outlined in chapter 2 were used. 
Australian Data: The Childhood Determinants of Adult Health (CDAH) Study 
Study sample 
The CDAH sample has been described in section 2.2. For these analyses, data from 286 
participants (26% of those eligible from baseline, 50% male) aged 12 and 15 years at baseline 
who had LDL cholesterol and HDL cholesterol data from 1985 and carotid artery ultrasound 
measures at follow-up (2004-2006) were included. 
Clinic measurements 
Baseline and follow-up measurements of blood lipid and lipoproteins, blood pressure, BMI, 
and smoking habits were collected according to protocols described in section 2.2.3. 
Carotid artery ultrasound studies 
B-mode ultrasound studies of the left carotid artery were performed according to the 
protocols outlined in section 2.2.3.5. 
Finnish Data: The Cardiovascular Risk in Young Finns Study 
Study sample 
The Young Finns sample is described in section 2.3. For these analyses, 1171 subjects (66% 
of those eligible, 45 %male) who were aged 12, 15, and 18 years at baseline and who had 
LDL cholesterol and HDL cholesterol data from 1980 and carotid artery ultrasonography data 
in 2001 were included. 
Clinic measurements 
Protocols for baseline and follow-up measures of blood lipids and lipoproteins, blood 
pressure, BMI, and cigarette smoking have been described in section 2.3.3. 
Carotid artery ultrasound studies 
B-mode ultrasound studies of the left carotid artery were performed at follow-up using 
standardised protocols that were described in section 2.3.3.5. 
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United States Data: The Bogalusa Heart Study 
Study sample 
The Bogalusa Heart study sample has been described in section 2.4. For these analyses, 254 
participants (17% of those eligible from the 1984-1985 survey, 44% male, 30% African 
American) aged 12 to 17 years at baseline who had LDL cholesterol and HDL cholesterol 
measures from baseline (1984-1985) and carotid artery ultrasound at follow-up (2001-2002) 
were included. 
Clinic measurements 
Baseline and follow-up measures of blood lipid and lipoproteins, blood pressure, BMI, and 
cigarette smoking have been described in section 2.4.3. 
Carotid artery ultrasound studies 
B-mode ultrasound examinations of the left and right carotid artery were performed 
according to protocols described in section 2.4.3.5. 
5.3.1 CLASSIFICATION OF LDL CHOLESTEROL STATUS IN 
ADOLESCENCE AND ADULTHOOD 
NCEP I96 and NHANES25I paediatric cut-points were used to assign adolescent LDL 
cholesterol and HDL cholesterol status (see Table 13, chapter 4). At follow-up, NCEP adult 
treatment panel guidelines were used to classify participants as non-dyslipidemic (<4.14 
mmol/L; <160 mg/dL), or dyslipidemic (?4.14 mmol/L; ?_160 mg/dL) LDL cholesterol 
status, and non-dyslipidemic (>1.036 mmol/L; >40 mg/dL) or dyslipidemic (<1.036 mmol/L; 
<40 mg/dL) HDL cholesterol status."4 
5.3.2 CLASSIFICATION OF BLOOD PRESSURE STATUS IN 
ADOLESCENCE AND ADULTHOOD 
Participants aged < 17 years of age at baseline were classified according to age, sex, and 
height percentiles for blood pressure issued by the National High Blood Pressure Education 
Program.305 Blood pressure status in adolescence was classified as normal if systolic and 
diastolic blood pressures were <90 th percentile, prehypertensive if systolic or diastolic blood 
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pressure were ?90th,  but <95 th percentile, and hypertensive if systolic or diastolic blood 
pressure was >95 th percentile. For participants aged 18 years at baseline, blood pressure was 
classified as normal if systolic was <120 mm/Hg and diastolic <90 mm/Hg, prehypertensive 
if systolic was 120-139 mm/Hg or diastolic blood pressure was 80-89 mm/Hg, and 
hypertensive if systolic ?.140 mm/Hg or diastolic blood pressure was >90 mm/Hg according 
to the Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure. 376 
5.3.3 CLASSIFICATION OF OVERWEIGHT AND OBESITY STATUS IN 
ADOLESCENCE AND ADULTHOOD 
Adolescents aged < 17 years of age at baseline were classified as normal weight, overweight, 
or obese according to age- and sex-specific BMI cut-points endorsed by the International 
Obesity Task Force.306 Participants aged 18 years at baseline were classified as normal 
weight (BM1 <25kg/ m2), overweight (BMI ?_25 to <30kg/m 2), or obese (BMI >30kg/m2) as 
per classifications outlined by the WHO. 28° 
5.3.4 CAROTID IMT MEASUREMENTS AND CLASSIFICATION OF HIGH 
CAROTID IMT IN ADULTHOOD 
For the analyses, the most consistent IMT measurement across the three study sites was 
selected. This incorporated the maximum measurement at the far wall of the left common 
carotid artery (see Table 21 and Figure 38). While no consensus clinical definition of high 
carotid IMT currently exist for young adults, high IMT in adulthood was defined as a 
maximum IMT >90th percentile for age, sex, race (Bogalusa), and cohort specific values. The 
specific values used to denote high IMT are provided in Table 22. 
Cohort N Mean age at 
baseline, y 
Mean 
length of 
follow-up, 
y 
Young 1171 14.9 21.0 
Finns 
Bogalusa 254 15.3 17.1 
CDAH 286 13.4 20.0 
I 
Table 21. Comparison of common carotid IMT definitions obtained in Young Finns, Bogalusa, and CDAH populations. 
IMT definition 
I 
Carotid Wall 	Segment/s Measurements Mean Average absolute 
artery maximal 
IMT, mm 
difference of 
replicate measures ± 
SD, mm 
Left Far 	CCA Mean & Max 0.65±0.10 0.05±0.04 
IMT 
Left & 
right 
Far 	ICA, BIF, 
CCA 
Max IMT 0.73±0.14 0.05±0.03 
Left Far 	CCA Mean & Max 0.62±0.10 0.021-0.04 
IMT 
P
aediatric dysli p
idem
ia
 classificatio n
s &
 carotid IM
T
 in
 ad ulthood 
Abbreviations: CCA, common carotid artery; BIF, carotid bifurcation; ICA, internal carotid artery. 
Paediatric dyslipidemia classifications & carotid IMT in adulthood 
	
192 
IIIIIIIIIII111111111111111111111 	101' 
Omm 	 10nun 	 20mm 	 30mm 
Figure 38. B-mode ultrasound image of the left common carotid artery: A) border of carotid bulb 
widening (0 mm), B) common carotid artery far wall lumen-intima interface, C) media-adventitia 
interface. Definitions of the common carotid artery segment in each cohort: Young Finns and CDAH, 
common carotid artery IMT is taken as the distance between B and C measured in the vicinity 10 mm 
proximal to the border of the bulb widening (A); Bogalusa, common carotid artery IMT is taken as the 
distance between B and C measured 0-10 mm proximal to the border of the bulb widening 
(measurement area highlighted in yellow). 
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Table 22. Age, sex, race (Bogalusa only), and cohort specific 90 th percentile cut-points of maximum 
common carotid IMT (mm) used in each study to denote high IMT 
Young Finns 	 Bogalusa 	CDAH  
I 	II II I 
Age M F 
Caucasian African Americans 
M F M F M F 
29 0.925 0.805 0.983 0.898 0.715 0.660 
30 0.934 0.813 0.993 0.908 0.776 0.704 
31 0.942 0.821 0.993 0.908 0.770 0.715 
32 0.951 0.829 1.013 0.929 0.770 0.682 
33 0.770 0.720 0.960 0.837 1.023 0.940 0.770 0.715 
34 0.969 0.845 1.033 0.950 0.825 0.748 
35 0.978 0.853 1.043 0.960 0.770 0.693 
36 0.790 0.770 
39 0.864 0.770 
M = males; F = females 
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5.3.5 STATISTICAL ANALYSES 
Comparisons between baseline characteristics of participants and non-participants at follow-
up within each cohort were performed using logistic regression. Participation (yes/no) was 
used as the binary dependent variable in these analyses. 
Comparison of NCEP vs. NHANES adolescent dyslipidemia classifications 
Log-binomial regression was used to estimate the relative risk of high IMT at follow-up, for 
various baseline lipoprotein classifications. 377 Estimates were adjusted for age at baseline, 
sex, race (for the Bogalusa data only), and length of follow-up. The adjustment for length of 
follow-up was to account for within-cohort differences observed between length of follow-up 
and risk of high IMT in both the CDAH and Bogalusa studies. For pooled estimates, a term 
for cohort was included in the models to account for differences in lipoprotein determination 
methods between the three cohorts. Baseline BMI status (normal weight vs. overweight/obese 
in adolescence)306 was also considered as a potential confounding variable in these analyses. 
The analyses for NCEP and NHANES HDL cholesterol classifications were stratified by 
BMI status due to effect modification. 
The ability of each adolescent LDL cholesterol and HDL cholesterol classification to 
predict high carotid IMT in adulthood was assessed using sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), and area under receiver-operating 
characteristic curves (AUC). Tests for significant differences of sensitivity and specificity 
between NCEP and NHANES adolescent cut-points were performed using McNemar's 
test. 363 Confidence intervals for sensitivity and specificity were calculated using the binomial 
distribution. Tests for significant differences between AUC were calculated using the 
DeLong algorithm.364 This method assumes the correct null distribution when there are only 
three classification levels (i.e. normal-, borderline, and high-risk groups), as is the case here. 
Analyses for HDL cholesterol classifications were stratified by BMI status owing to effect 
modification. 
Change in dyslipidemia status and high IM7' in adulthood 
A change variable was created that divided participants into four categories depending on 
their lipoprotein status at both time-points. Participants were classified as persistent non-
dyslipidemia, non-dyslipidemia to dyslipidemia, dyslipidemia to non-dyslipidemia and 
persistent dyslipidemia. Their adolescent lipoprotein status was determined using what was 
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judged to be the best performing LDL cholesterol and HDL cholesterol paediatric 
dyslipidemia classifications for predicting adult IMT, ascertained from the above mentioned 
comparison analyses. Log binomial regression was used to estimate the relative risk of high 
carotid IMT in adulthood depending on the change variable. These analyses were performed 
for pooled data only and are presented adjusted for age at baseline, sex, cohort and length of 
follow-up in model 1, and with additional adjustments for BMI at baseline, systolic blood 
pressure at baseline, and smoking status at baseline in model 2. Interaction between the 
model variables was tested; no significant interactions were found. 
To compliment the analysis of categorical variables, the effect of change in the 
continuous lipoprotein levels on the continuous outcome measure of IMT using linear 
regression was also examined. The life-course analysis approach described by De Stavola et 
al. was adopted,378 with the adolescent lipoprotein variable and change in the lipoprotein 
variable (derived as the difference between adult and adolescent lipoprotein levels) used as 
predictor variables. The regression coefficient for the adolescent lipoprotein variable 
quantifies the total effect, i.e. the sum of direct and indirect (mediated via adult lipoprotein 
levels due to tracking) 161, 162 effects of adolescent LDL cholesterol or HDL cholesterol on 
IMT, whereas the regression coefficient for change in lipoprotein levels quantifies the 
additional gain from increasing or decreasing lipoprotein levels by 1 mmol/L between 
adolescence and adulthood relative to participants with the same adolescent lipoprotein level, 
but whose lipoprotein level was unchanged. Multivariable models were specified, including 
adolescent LDL cholesterol and change in LDL cholesterol; and adolescent HDL cholesterol 
and change in HDL cholesterol. All models were adjusted for age at baseline, sex, cohort, 
length of follow-up, baseline BMI, baseline systolic blood pressure, and baseline smoking 
status. The assumption of linearity in the regression models of the continuous predictor 
variables was checked using the method of fractional polynomials. 379 The analyses are 
presented stratified by adolescent BMI status due to effect modification. The distribution of 
IMT values were somewhat right-skewed, however for ease of interpretation and 
comparability with previous studies in young adults, non-transformed IMT values were used. 
Using log-transformed IMT values made little difference to the results presented. 
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5.4. RESULTS 
5.4.1 CHARACTERISTICS OF PARTICIPANTS AND NON-PARTICIPANTS 
Non-participation in those eligible for follow-up measures (34% Young Finns, 82% 
Bogalusa, 67% CDAH) was more likely in males and those of younger age in each cohort, 
and more likely in African-Americans in the Bogalusa cohort (Table 23). There were no 
statistically or clinically significant differences in LDL cholesterol or HDL cholesterol levels, 
or LDL cholesterol or HDL cholesterol dyslipidemia status between participants and non-
participants in any of the three cohorts (Table 23). 
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Table 23. Baseline characteristics of participants and non-participants in follow-up surveys of each study. 
Young Finns Bogalusa CDAH 
Participants Non- 
participants 
Participants Non- 
participants 
Participants Non- 
participants 
1171 615 254 1256 286 817 
Age at baseline, y* 14.9±2.4 14.7±2.4 14.8±1.5 14.1±1.6* 13.4±1.5 13.4±1.5 
Males, % .1. 44.7 55.5* 43.7 52.0* 50.0 55.3 
African American, %I . 29.9 36.5* 
1.1)1. cholesterol, mino1/1. 3.300.79 3.310.86 2 47±066 2.420.58 2.6910.69 2.6710.67 
HDL cholesterol, mmol/L 1.550.30 1.530.32 1.48±0.51 1.570.53 1.440.29 1.400.30 
NHANES LDL cholesterol, % Normal 13.2 15.0 52.6 53.9 38.5 37.9 
Above-normal 31.7 30.9 31.9 33.8 37.8 35.4 
Borderline-high 29.6 28.1 9.6 9.6 16.8 19.6 
High 25.5 26.0 6.0 2.7 7.0 7.1 
NCEP LDL cholesterol, % Normal 31.0 31.1 79.7 79.8 64.3 64.3 
Borderline-high 27.7 26.5 10.4 13.7 21.0 20.3 
High 41.3 42.4 10.0 6.6 14.7 15.3 
NHANES HDL cholesterol, % Normal 48.0 41.6 44.5 51.4 31.8 29.3 
Borderline-low 48.8 55.3 38.6 35.0 59.8 59.7 
Low 3.3 3.1 16.9 13.7 8.4 11.0 
NCEP HDL cholesterol, % Normal 45.4 42.3 38.6 49.6 31.8 27.3 
Borderline-low 53.6 56.1 50.4 41.1 66.8 69.7 
Low 0.9 1.6 11.0 9.3 1.4 3.1 
Statistics are means ± SD for continuous variables and percentages for dichotomous variables. Differences between participants and non-participants 
examined using logistic regression. Analyses comparing differences in lipoprotein levels/proportions are adjusted for age and sex, with Bogalusa analyses 
additionally adjusted for race. *P<0.05 
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5.4.2 ADOLESCENT AND ADULT CHARACTERISTICS BY CAROTID IMT 
STATUS 
Mean values for key baseline and follow-up variables are displayed in Table 24 for males and 
females in each cohort who had IMT >90 th percentile and IMT <90 th percentile. Across each 
sex and cohort, those with high IMT at follow-up tended to have higher LDL cholesterol 
levels during adolescence and adulthood. Bogalusa participants and females in the CDAH 
study with high IMT had lower HDL cholesterol levels during adolescence but not at follow-
up. 
Table 24. Mean values for adolescent and adult characteristics in those with and without IMT ?90 th percentile in adulthood in cohorts from Finland, the 
United States, and Australia 
Males 	 Females 	 All 
N 469 54 566 82 1171 
age, y 15.0±2.4 14.8±2.4 14.8±2.4 15.0±2.5 14.9±2.4 
LDL-C, mmol/L 3.220.78 3.49±0.84 3.340.79 3.390.79 3.300.79 
HDL-C, mmol/L 1.500.31 1.490.33 1.590.29 1.570.29 1.550.30 
age, y 36.0±2.4 35.8±2.4 35.8±2.4 36.0±2.5 35.9±2.4 
LDL-C, mmol/L 3.630.92 3.84±0.83 3.250.78 3.350.80 3.43±0.87 
HDL-C, mmol/L 1.180.28 1.150.31 1.400.30 1.370.31 1.300.31 
IMT, mm 0.640.08 0.870.11 0.610.07 0.790.06 0.65±0.10 
N 98 13 128 15 254 
age, y 14.8±1.6 14.9±1.9 14.8±1.5 14.7±1.3 15.3±1.5 
LDL-C, mmol/L 2.390.72 2.620.67 2.480.61 2.760.67 2.47±0.66 
HDL-C, mmol/L 1.440.52 1.170.54 1.560.49 1.320.39 1.480.51 
age, y 31.8±1.5 32.2±1.6 31.9±1.5 31.9±1.2 32.4±1.4 
LDL-C, mmol/L 3.210.81 3.500.66 3.030.89 3.390.83 3.15±0.85 
HDL-C, mmol/L 1.090.27 1.150.37 1.280.35 1.220.49 1.200.34 
IMT, mm 0.730.11 1.060.11 0.670.09 0.920.08 0.73±0.14 
N 119 24 131 12 286 
age, y 13.4±1.5 13.1±1.5 13.4±1.5 13.3±1.5 13.4±1.5 
LDL-C, mmol/L 2.610.56 2.730.67 2.670.63 3.58±1.58 2.69±0.69 
HDL-C, mmol/L 1.380.26 1.450.35 1.500.28 1.36±0.38 1.440.29 
age, y 33.4±1.7 32.9±1.6 33.4±1.6 32.9±1.8 33.3±1.7 
LDL-C, mmol/L 3.210.71 3.260.75 2.790.80 3.96±2.17 3.05±0.90 
HDL-C, mmol/L 1.270.29 1.330.30 1.570.36 1.570.33 1.430.36 
1MT, mm 0.600.08 0.80±0.08 0.590.07 0.78±0.05 0.62±0.10 
Statistics are means ± SD. 
1 	 1 	I 	 I 
Cohort 	 IMT <90th % 	IMT >90 th % IMT <90th % 	IMT >90th % 
Young Finns 
Adolescence 
Adulthood 
Bogalusa 
Adolescence 
Adulthood 
CDAH 
Adolescence 
Adulthood 
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To convert LDL-C and HDL-C to mg/di, multiply values by 38.67. 
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5.4.3 COMPARISON OF NCEP VS. NHANES CUT-POINTS 
The prevalence of adolescent LDL cholesterol dyslipidemia was 32.3% for NCEP or 19.6% 
for NHANES cut-points. RDL cholesterol dyslipidemia was prevalent in 2.5% adolescents 
using NCEP cut-points or 6.1% adolescents using NT-LANES cut-points. Pooled data showed 
that the risk of having high IMT in adulthood was significantly higher in those with 
borderline- and high-risk LDL cholesterol levels in adolescence compared with those with 
normal levels using NHANES cut-points (Figure 39A). Use of the NCEP LDL cholesterol 
cut-points showed only those with high-risk levels in adolescence had significantly increased 
risk of high IMT in adulthood compared with those classified as normal, although the 
borderline-risk group showed a non-significant trend toward increased risk (Figure 39A). A 
graded increase in the risk of having high IMT in adulthood was observed when moving from 
the normal, to borderline-risk, to high-risk groups for both NCEP and NHANES LDL 
cholesterol cut-points (Figure 39A). 
Normal weight adolescents with NCEP classified high-risk (low) HDL cholesterol 
were at significantly increased risk of having IMT at or above the 90 th percentile at follow-up 
(Figure 39B). There was no increased risk of having high IMT at follow-up for normal 
weight adolescents classified as borderline-risk HDL cholesterol levels using either 
classification or for those with high-risk HDL cholesterol levels according to NHANES cut-
points (Figure 39B). For overweight or obese adolescents, the risk of high IMT in adulthood 
was significantly increased in those with borderline- or high-risk HDL cholesterol levels 
compared with those who had normal levels using either paediatric classification (Figure 
39C). The relative risks were similar for overweight or obese adolescents with borderline- or 
high-risk HDL cholesterol levels. When data where not stratified by BMI status, only those 
with high-risk HDL cholesterol were at significantly increased risk of having high IMT- at 
follow-up (NCEP, relative risk= 2.5, 95%C1 1.4-4.6; NHANES, relative risk = 1.6, 95%CI 
1.0-2.7). 
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NCEP 	 NHANES 
LDL cholesterol pediatric classification 
NCEP 	 NHANES 
HDL cholesterol pediatric classification 
Figure 39. Adjusted (age, sex, cohort, length of follow-up) relative risks and 95% confidence intervals 
for having high intima-media thickness (>90 th percentile) in adulthood according to NCEP and 
NHANES cut-points for: A) LDL cholesterol dyslipidemia status, B) HDL cholesterol dyslipidemia 
status in normal weight adolescents, and C) HDL cholesterol dyslipidemia status in overweight/obese 
adolescents. 
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NCEP 	 NHANES 
HDL cholesterol pediatric classification 
Figure 39 (con't). Adjusted (age, sex, cohort, length of follow-up) relative risks and 95% confidence 
intervals for having high intima-media thickness (?90 th percentile) in adulthood according to NCEP 
and NIL-LANES cut-points for: A) LDL cholesterol dyslipidemia status, B) HDL cholesterol 
dyslipidemia status in normal weight adolescents, and C) HDL cholesterol dyslipidemia status in 
overweight/obese adolescents. 
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Diagnostic performance statistics comparing NCEP and NI-LANES classifications in 
normal weight and overweight or obese adolescents are presented in Table 25. The NCEP 
high-risk LDL cholesterol cut-points were more sensitive but less specific than the NHANES 
cut-points. Although this trend in sensitivity and specificity was consistent across cohorts, 
heterogeneity in the point estimates between cohorts was observed (Appendix 11). False 
positives were high for both LDL cholesterol classifications with 85.1% of those with high 
levels using the NCEP cut-points not developing high IMT in young adulthood, and 84.7% 
with high levels using the NT-LANES cut-points not having high IMT in young adulthood. 
Sensitivity, positive predictive value, and AUC values increased when borderline- and high-
risk HDL cholesterol cut-points were applied to overweight or obese adolescents (Table 25), 
but remained low overall. The diagnostic performance characteristics were similar for both 
classifications of adolescent HDL cholesterol. Area under the receiver operating 
characteristic curve using other age-, sex-, and cohort-specific cut-points of IMT (70 th, 75 th , 
80th, 85 th, 90 th, 95 th percentiles) in these data did not appreciably modify the results presented 
(Figure 40). Diagnostic statistics of adolescents with other risk factors including hypertension 
and cigarette smoking in addition to the NCEP dyslipidemia cut-points are displayed in Table 
26. The addition of hypertension to the LDL cholesterol cut-points improved the prediction 
of those with high IMT in adulthood. The prediction was comparable to those who were 
overweight and did not improve further when either hypertension or overweight status was 
combined with the LDL cholesterol cut-points. 
Table 25. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) data of NCEP and 
NHANES classifications for adolescent borderline risk and high risk lipoprotein variable cut-points to predict high carotid IMT in adulthood 
Lipoprotein 
variable 
Classification 
Dyslipidemia status in adolescence 
Borderline risk 	 High risk 
AUC* p_ 
value 
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
Normal weight 
LDL 
cholesterol 
NCEP 64.8: 44.0 12.2 91.3 38.9: 68.7 12.9 90.4 0.55 
NHANES 50.6 56.6: 12.2 90.6 23.5 80.71 12.7 89.8 0.55 0.73 
HDL 
cholesterol 
NCEP 53.7 43.9 10.3 88.8 3.1 98.8: 22.7 89.5 0.49 
NHANES 52.5 47.0: 10.6 89.2 4.9 95.4 11.4 89.4 0.49 0.69 
Overweight/obese 
LDL 
cholesterol 
NCEP 63.2: 52.0 24.7 84.9 50.0: 70.4 29.7 84.9 0.60 
NHANES 55.3 59.2: 25.3 84.1 34.2 85.5 1 37.1 83.4 0.63 0.33 
HDL 
cholesterol 
NCEP 92.1 30.5 24.6 94.0 15.8 90.3: 28.6 81.3 0.62 
NHANES 89.5 30.5 24.1 92.2 26.3 83.8 28.6 82.2 0.62 0.88 
Sensitivity = true positives/(true positives + false negatives) X 100. Specificity = true negatives/(true negatives + false positives) X 100. PPV = true 
positives/(true positives + false positives) X 100. NPV = true negatives/(true negatives + false negatives) X 100. 
*Normal-, borderline-, and high-risk included in AUC analyses as three groups. 
1Test for difference between AUCs 
I McNemar's test for difference between sensitivities and specificities 
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Figure 40. Comparison of AUC for the ability of NCEP and NHANES LDL cholesterol (A) and HDL 
cholesterol (B) dyslipidemia classifications to predict high adult carotid IMT using different percentile 
cut-points. 
Table 26. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) data for combining 
NCEP high risk lipoprotein variable cut-points to other risk factors present in adolescence to predict high carotid IMT in adulthood 
Lipoprotein variable Screening strategy N * Sensitivity Specificity PPV NPV AUC 
LDL cholesterol 
Universal 1707 41.0 68.9 14.9 89.8 0.56 
Overweightt + NCEP cut-points 190 50.0 70.4 29.7 84.9 0.60 
Hypertension* + NCEP cut-points 355 45.3 71.2 21.6 88.1 0.61 
Smoking + NCEP cut-points 218 30.3 79.5 20.8 86.5 0.54 
Hypertensiont OR Overweight* + NCEP cut-points 491 43.4 71.6 21.9 87.4 0.60 
HDL cholesterol 
Universal 1710 5.5 97.8 25.6 88.7 0.53 
Overweightt + NCEP cut-points 192 15.8 90.3 28.6 81.3 0.62 
Hypertension* + NCEP cut-points 355 7.6 99.3 66.7 86.0 0.54 
Smokine + NCEP cut-points 218 9.1 96.8 33.3 85.6 0.52 
*Refers to the total number of participants that would be screened; toverweight or obese according to International Obesity Task Force BMI cut-points; 
*hypertension defined according to the National High Blood Pressure Education Program, 305 43articipants were classified as smokers at baseline if they 
indicated regular cigarette smoking on a weekly basis or more often. Family history was considered but not included in these analyses owing to divergence 
in the definitions of positive history between the three cohorts. 
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5.4.4 EFFECT OF CHANGE IN DYSLIPIDEMIA STATUS ON HIGH IMT 
For the analyses of change in lipoprotein status between adolescence and adulthood, the 
NHANES classification was used to assign adolescent LDL cholesterol dyslipidemia status 
and the NCEP classification was used to assign adolescent HDL cholesterol dyslipidemia 
status. In Table 27 pooled relative risks of having a high IMT in young adulthood according 
to LDL cholesterol and HDL cholesterol dyslipidemia status during adolescence and 
adulthood are presented. A change in LDL cholesterol status from non-dyslipidemia to 
dyslipidemia or dyslipidemia to non-dyslipidemia did not significantly increase the risk of 
high IMT compared with those who remained normal at both times. Those with LDL 
cholesterol dyslipidemia at both times had significantly increased risk of high IMT in 
adulthood than those with persistently normal levels. Analysis of continuous data showed that 
participants with higher baseline levels of LDL cholesterol had higher carotid IMT as adults 
(regression coefficient for a one SD increase = 0.014, P<0.001). There was some evidence 
that those who increased LDL cholesterol levels between adolescence and adulthood had 
higher carotid IMT at follow-up but this effect was not significant (regression coefficient for 
a one SD increase = 0.005, P=0.08). 
For HDL cholesterol, the relative risk of having a high IMT in adulthood was 
significantly increased for participants who had low (dyslipidemic) levels in adolescence 
irrespective of their adult levels (Table 27). The relative risk of high IMT in the non-
dyslipidemia to dyslipidemia group was similar to that of the persistent non-dyslipidemia 
group. Only a small number of participants moved from dyslipidemia to non-dyslipidemia, so 
the data for this group should be interpreted with caution. Analyses of continuous data 
showed evidence that higher HDL cholesterol levels in overweight or obese adolescents were 
associated with lower IMT in adulthood (regression coefficient for a one SD increase = - 
0.011, P=0.01), whereas change in HDL cholesterol between adolescence and adulthood was 
not. In normal weight adolescents, analyses of continuous data showed no association 
between baseline or change in HDL cholesterol levels and carotid IMT in adulthood. In 
multivariable analyses that included adolescent and change variables for LDL cholesterol and 
HDL cholesterol in the model, baseline lipoprotein levels were generally stronger predictors 
of IMT than changes in levels between adolescence and adulthood (Figure 41). 
Table 27. Relative risks (RR) from pooled data for the effect of change in LDL cholesterol and change in HDL cholesterol status between adolescence and 
adulthood on carotid artery intima-media thickness >90 th  percentile. 
Model 1 Model 2 
Lipoprotein status in adolescence and adulthood n/N* % RR 95%CI n/N*t % RR 95%CI 
LDL cholesterol 
Persistent non-dyslipidemia 127/1206 10.5 1.0 ref 121/1148 10.5 1.0 ref 
Non-dyslipidemia to dyslipidemia 19/143 13.3 1.3 0.8-2.1 16/136 11.8 1.2 0.8-1.9 
Dyslipidemia to non-dyslipidemia 25/205 12.2 1.2 0.8-1.9 23/191 12.0 1.2 0.7-1.9 
Persistent dyslipidemia 25/124 20.2 2.1 1.4-3.1 24/117 20.5 2.0 1.4-3.0 
HDL cholesterol 
Persistent non-dyslipidemia 143/1303 11.0 1.0 ref 135/1234 10.9 1.0 ref 
Non-dyslipidemia to dyslipidemia 45/358 12.6 1.2 0.9-1.7 41/338 12.1 1.2 0.8-1.6 
Dyslipidemia to non-dyslipidemia 4/16 25.0 2.6 1.0-6.5 4/15 26.7 2.8 1.1-6.9 
Persistent dyslipidemia 7/27 25.9 2.6 1.3-5.2 7/27 25.9 2.1 1.1-4.3 
Model 1: adjusted for age at baseline, sex, cohort, and length of follow-up 
Model 2: additionally adjusted for baseline BMI, baseline smoking status, and baseline systolic blood pressure 
* Number of participants with high IMT/all participants. 
t Sample sizes differ between models 1 and 2 owing to missing baseline data on smoking and/or systolic blood pressure in some participants. 
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Figure 41. Regression coefficients (adjusted for age at baseline, sex, cohort, length of follow-up, systolic blood pressure at baseline, and smoking status at 
baseline) and their 95% confidence intervals for associations of adolescent LDL-C, change in LDL-C between adolescence and adulthood, adolescent 
HDL-C, and change in HDL-C with carotid IMT in adulthood for (A) normal weight and (B) overweight or obese adolescents. Regression coefficients 
expressed in millimetres for a one SD change in the continuous variables. 
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Based on this model, the level of IMT at 35 years of age for normal weight and 
overweight or obese adolescents, with normal and dyslipidemic levels of LDL cholesterol 
and HDL cholesterol at age 15 years was predicted (Figure 42). The difference in IMT at age 
35 years for normal-weight adolescents with and without dyslipidemia was minimal. IMT at 
age 35 years for those who were overweight or obese as adolescents and did not have 
dyslipidemia were comparable with normal weight adolescents. Those who were overweight 
or obese and had dyslipidemia as adolescents had markedly higher carotid IMT values at age 
35 years than the other groups (Figure 42). 
1.00 - 
0.90- 
• Overweight/obese & dyslipidemia 
O Overweight/obese & no dyslipidemia 
• Normal weight & dyslipidemia 
o Normal weight & no dyslipidemia 
0.50 - 
Males 	 Females 
Figure 42. Least square means and 95% confidence intervals of carotid IMT at age 35 years for males 
and females by BMI status and dyslipidemia status at age 15 years, adjusted for length of follow-up, 
cohort, change in LDL-C, change in HDL-C, baseline smoking status, and baseline systolic blood 
pressure. 
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5.5. DISCUSSION 
The aim of this study was to determine whether two classifications of paediatric dyslipidemia 
(NCEP vs. NHANES) predicted carotid IMT in adulthood and which of these would be most 
effective in identifying adolescents at high risk of increased IMT as adults. While these data 
suggest that both dyslipidemia cut-points were able to predict those with high IMT in 
adulthood, they do not provide a clear indication of which LDL cholesterol and I-IDL 
cholesterol cut-points should be preferred by those who wish to identify adolescents with 
lipid disorders. Given that there were no substantial differences in the diagnostic performance 
of the classifications, the simplicity in applying the fixed NCEP cut-points may offer an 
advantage over the age- and sex-specific NHANES cut-points in a clinical or research setting. 
Importantly, users of either classification need to be mindful that most adolescents identified 
with dyslipidemic LDL cholesterol and HDL cholesterol levels will not be at or above the 
90°' percentile for carotid IMT in early adulthood and most individuals with high IMT will 
not be identified by using lipoprotein levels in adolescence. Discrimination was considerably 
better for overweight or obese adolescents compared with their normal-weight peers, which 
does support targeted, rather than universal (whole- or random-population), screening 
strategies endorsed in current guidelines. 196, 220, 249 
Single adolescent measures of LDL cholesterol and HDL cholesterol in this study 
were stronger predictors of adult IMT than change between adolescence and adulthood. 
While a beneficial change in lipoprotein levels did show trends towards lower IMT in 
adulthood, particularly for those who were overweight or obese as adolescents, the magnitude 
of this effect was smaller than for the baseline measure. Moreover, based on predictive 
modelling (Figure 3), the degree of IMT difference at age 35 years between overweight or 
obese 15 year olds with LDL cholesterol dyslipidemia and HDL cholesterol dyslipidemia 
compared with normal-weight 15 year olds with normal LDL cholesterol and FIDL 
cholesterol levels was clinically significant ." (males, 0.11 mm; females, 0.08 mm) and more 
than would be expected from measurement error alone. 
Taken together, these data and others35 ' 37 ' 41 clearly show the importance of 
adolescent lipid levels as a predictor of preclinical atherosclerosis and provide some 
epidemiological rationale for recent recommendations for paediatric lipid screening released 
in July 2008.220 However, the efficacy of screening for dyslipidemia in a general population 
using NCEP or NHANES classifications as a way to identify adolescents at-risk of CVD has 
considerable limitations (as indicated above), particularly for clinic use. For normal weight 
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adolescents, population-wide primary prevention programs that target LDL cholesterol levels, 
such as those used in the Dietary Intervention Study in Children (DISC) and STRIP 
studies, 163 ' 164 and maintenance of healthy weight may be the most practical. Lipid screening 
in the general paediatric population could be limited to adolescents who have other CVD risk 
factors such as obesity or hypertension to further stratify the risk of this group. 
5.5.1 	LIMITATIONS 
This study has a number of potential limitations. First, although the most similar carotid IMT 
definition was selected, there was heterogeneity in the IMT location and ultrasound protocols 
between cohorts. While an attempt was made to take this heterogeneity into account by 
defining high IMT according to age, sex, race (Bogalusa), and cohort specific values, it is 
noted that attempts by future investigators to merge imaging studies for statistical power will 
have this limitation unless calls for standardisation of these methods are heeded. 375 Second, 
one explanation for the poor diagnostic performance of the dyslipidemia classifications in 
this study may have been due to differing methods of lipoprotein determination between 
NCEP/NHANES samples and the cohorts used in this study. Lipoprotein levels, particularly 
HDL cholesterol, have been shown to differ depending on the methodology used. 369 Third, 
change in dyslipidemia status or change in continuous lipoprotein levels had small, non-
significant effects on carotid IMT in adulthood. Because data were only available from two 
time-points separated by 15 to 20 years, multiple changes that may have occurred in the 
intervening period or the timing of these changes could not be accounted for. Moreover, 
multiple lipoprotein measurements were not collected on participants at baseline or follow-
up. Use of only one lipoprotein measurement at each time point may have contributed to 
misclassification of some participants, 161, 308 which would likely lead to an underestimate of 
the prediction estimates in this study.337 To improve accuracy, current paediatric guidelines 
require multiple measurements before lipid levels are classified. 196, 220  Fourth, the potential 
role of pubertal status as a confounding variable was unable to be accounted for because data 
were not available for all cohorts. Age was included in these analyses as a proxy for pubertal 
status given the relationship between sexual maturation and lipids, and age and lipids have 
been shown to be similar in adolescents. 30° In sensitivity analyses performed using Young 
Finns data that adjusted for pubertal status, the coefficients were generally unchanged from 
those analyses where age adjustment was used. Fifth, poorer image quality in ultrasound 
scans (assessed subjectively by image readers in the Young Finns and CDAH studies) was 
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associated with BMI (Young Finns, r = 0.12; CDAH, r = 0.18) and had the potential to bias 
carotid IMT measurements in overweight or obese individuals. Sensitivity analyses adjusting 
for image quality in the Young Finns and CDAH cohorts yielded similar results to those 
presented. This issue is covered in detail for the Young Finns and CDAH cohorts in original 
contribution VI. Briefly, no differences (bias) in the association between BMI and carotid 
IMT by image quality was observed. Finally, these data are from population-based cohorts 
and may not be generalised to other higher-risk patients, such as those with diabetes mellitus 
or a strong family history of premature CVD. 
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5.6. CONCLUSIONS 
The data presented in this study indicate that dyslipidemic lipoprotein levels in adolescence 
are associated with an increased risk of high IMT in young adulthood; that the predictive 
capacity of both NCEP and Nil-LANES cut-points are similar and could be applied for lipid 
screening with equal success; that adolescent lipid levels are more strongly associated with 
high IMT in adulthood than change in lipid levels; and that dyslipidemia in the presence of 
overweight or obesity, places affected adolescents at substantially higher risk of increased 
IMT as adults compared with those who do not have both risk factors. These data underscore 
the importance of both population-wide and individualised prevention programs to improve 
paediatric dyslipidemia related causes of early atherosclerosis. 
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KEY POINTS 
• The aims of this chapter were to determine which of the NCEP or NI-LANES 
LDL cholesterol and HDL cholesterol classifications of dyslipidemia status in 
adolescents is most effective at predicting high common carotid IMT in 
adulthood; and to assess whether maintaining or changing dyslipidemia status 
from adolescence to adulthood has an effect on carotid IMT measured in 
adulthood. 
• The findings indicated that paediatric dyslipidemia classifications predict 
adolescents at increased risk of high IMT in young adulthood; that these 
classifications perform with equal success; that adolescent lipid levels are 
more strongly associated with high IMT in adulthood than change in lipid 
levels; and that dyslipidemia in the presence of overweight or obesity, places 
affected adolescents at substantially higher risk of increased IMT as adults 
compared with those who do not have both risk factors. 
• The findings underscore the importance of both population-wide and 
individualised prevention programs to improve paediatric dyslipidemia 
related causes of early atherosclerosis. 
Box 5. Summary of key points from Chapter 5: Association of paediatric dyslipidemia classifications 
and change in dyslipidemia status with carotid IMT in adulthood 
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6. SUMMARY, RECOMMENDATIONS, AND 
CONCLUSIONS 
6.1. INTRODUCTION 
In this thesis, previous evidence demonstrating the origin of atherosclerosis to childhood and 
the role of adverse blood lipid and lipoprotein levels in the development of atherosclerosis 
have been presented. As a result of this evidence, blood lipid and lipoprotein levels have been 
the target of consensus statements for paediatric screening and treatment issued by the 
NCEP, I96 the AAP ,220, 247 and the  AHA249 since 1992 (the most recent update being July 2008 
from the AAP 220) and will be an important component in the yet to be released Pediatric 
Cardiovascular Risk Reduction Initiative by the NHLBI. 38° The basis of these documents is 
that treatment of lipid disorders beginning in childhood or adolescence may reduce the 
lifetime risk of CVD. Since the initial publication of the 1992 consensus document, a number 
of studies have supported and challenged several aspects of the guidelines, while new 
findings have revealed important gaps in the guidelines. Although interest and concern for 
the identification and treatment of lipid and lipoprotein abnormalities in the paediatric setting 
has been intense since the NCEP guidelines were issued, there has been a recent and 
noticeable gain in momentum towards recognising the limitations of these guidelines and the 
re-issue of them based on data that have become available in the past 15 years. The rapid gain 
in adiposity in the paediatric setting since the 1980s is also likely to have contributed to the 
increased momentum. While a number of areas for revision have been suggested, 249-252 
Daniels outlined some of the most important questions concerning the identification of youth 
with elevated lipid or lipoprotein levels that included: (1) the utility of paediatric lipid and 
lipoprotein levels for the prediction of important adult outcomes; (2) the best approach 
(universal vs. targeted) to screening; and (3) the acceptability of using a single set of cut-
points for lipids and lipoproteins across all ages aS. 38I The aims examined and the data 
presented in this report make significant progress toward addressing these concerns and as 
such, progresses the evidence base needed for recommendations on lipid and lipoprotein 
screening in the paediatric setting. The following sections provide a summary of the key 
findings from this report, the clinical and public health implications of the findings, and areas 
for future research. 
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6.2. SUMMARY OF RESULTS 
The key findings from this report are listed below, with the novelty of the findings indicated 
in parentheses: 
1. Paediatric classifications for dyslipidemia predict dyslipidemia and arterial thickening in 
young adulthood 15 to 20 years later (strengthening evidence); that the classifications 
examined differ somewhat in how strongly they predict adult dyslipidemia but perform 
with equal success in the prediction of arterial thickening in adulthood (research firsts); 
2. Universal (population-wide) or selective screening approaches that use paediatric 
dyslipidemia classifications to predict adult dyslipidemia (strengthening evidence) and 
high carotid LMT (research first) appear to be limited by either high rates of false 
positives or high rates of false negatives; 
3. Adolescent lipid and lipoprotein levels are more strongly associated with arterial 
thickening in adulthood than levels measured at the time of the ultrasound examination or 
change in levels between childhood and adulthood (strengthening evidence); 
4. Dyslipidemia in the presence of overweight or obesity places affected adolescents at 
substantially higher risk of increased arterial thickening as adults (research first); 
5. Unhealthy lifestyle changes that occur between childhood or adolescence and adulthood 
have an impact on whether an individual maintains, loses, or develops high-risk blood 
lipid and lipoprotein levels in adulthood (strengthening evidence). 
6.3. CLINICAL AND PUBLIC HEALTH IMPLICATIONS 
The findings from this study indicate that there is a progressive and substantial increased risk 
of adult dyslipidemia and arterial thickening associated with borderline-, and high-risk blood 
lipid and lipoprotein levels defined according to either of the paediatric dyslipidemia 
classifications (NCEP or NT-LANES) examined. The importance of paediatric dyslipidemia in 
the development of atherosclerosis was further emphasised by data indicating that elevated 
LDL cholesterol and HDL cholesterol in adolescence were stronger predictors of adult 
carotid artery thickening than contemporary levels or the change in levels between childhood 
and adulthood. While the presence of a statistical association between paediatric dyslipidemia 
and adult outcomes is an important pre-condition of risk factor screening, it is only one 
component in effective clinical prediction. The diagnostic data presented in this study 
highlighted possible limitations to strategies for screening in the paediatric setting. First, 
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while the statistical association was mostly similar across cohorts, there were important 
differences between cohorts. For example, sensitivity and positive predictive values using 
LDL cholesterol cut-points were considerably higher in the Young Finns cohort in predicting 
adult outcomes (dyslipidemia and high IMT) compared with the CDAH and Bogalusa 
cohorts. For HDL cholesterol, a higher proportion of Bogalusa adults with low HDL 
cholesterol levels or high IMT would have been identified in childhood compared with the 
proportions of CDAH or Young Finns adults. These findings suggest that the relative value 
(prediction, benefits, and adverse effects such as labelling and associated monetary costs) of 
screening using either paediatric classifications of dyslipidemia may differ by population. 
Second, the findings did not provide a clear indication as to whether a universal or 
targeted approach to screening would optimise the identification of adults with dyslipidemia 
or high carotid IMT. In these data, both screening approaches were undermined by either 
unacceptably high rates of false positives or high rates of false negatives. Most individuals 
that develop low HDL cholesterol levels as adults or high carotid IMT would not be 
identified in adolescence using either approach, with selective screening further limited by a 
substantial number of adults with total or LDL cholesterol dyslipidemia not being identified 
for lipid or lipoprotein screening as adolescents. The inclusion of family history, overweight 
and obesity, hypertension, smoking, or combinations of these only modestly improved the 
prediction of dyslipidemia or high IMT in adulthood. This means that clinicians employing 
current paediatric guidelines for targeted lipoprotein screening in children and adolescents 
with a positive family history of premature CHD or who are overweight or obese, need to 
consider that a substantial number of those adolescents identified with high total cholesterol 
or LDL cholesterol levels will not have high-risk levels or high carotid IMT in early 
adulthood, that most individuals that develop abnormal HDL cholesterol or triglyceride levels 
as adults will not be identified in adolescence. 
While it is evident that additional data are needed on how to best develop screening 
strategies for lipid and lipoprotein levels, the inclusion of additional risk factors such as 
overweight and obesity, hypertension, and smoking did improve, albeit modestly, the 
performance of targeted lipid and lipoprotein screening. Moreover, it appears that the single 
set of cut-points issued in the original NCEP guidelines work as well overall as an approach 
based on age- and sex-distributions, with the simplicity in applying the fixed NCEP cut-
points offering a distinct advantage over percentile-based cut-points in a clinical or research 
setting. 
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In the debate of routine screening for lipid and lipoprotein disorders to identify youth 
at substantially increased risk of future CVD, it is important to consider the relationship 
between lipid and lipoprotein levels in atherosclerosis and the total burden of the disease. For 
example, because CVD is a disease of mass occurrence, effective programs and interventions 
implemented at the population level would serve to reduce CVD burden in its entirety. 
Evidence for effective population-based programs and interventions delivered in the 
paediatric setting is growing yet not well established. Theoretically however, even small 
changes in the distribution of lipid and lipoprotein levels and other CVD risk factors at the 
population level would likely have a large public health impact. 382 Put into context, while the 
debate of routine screening to identify only those youth at highest risk of subsequent CVD 
remains an important concern; it is only one component in an effective strategy toward 
reducing the overall burden of CVD. Admittedly, both population-wide and individualised 
approaches have been central components of the initial and updated guidelines, but lacking 
are cost-benefit analyses concerning screening approaches as well as individualised and 
population-wide intervention programs. This is especially important as new guidelines are 
developed. 
Findings from this study confirmed the importance of adiposity changes on tracking 
of blood lipid and lipoprotein levels found in the Beaver County and Cardiovascular Risk in 
Young Finns studies ,223, 224, 235 but also suggested for the first time that changing fitness and 
socioeconomic circumstance in the time between youth and adulthood may also affect 
tracking independent of adiposity. Findings for both these factors were limited to HDL 
cholesterol, which supports the need for other studies to replicate these findings. Importantly 
though, these data suggest that effective programs and policies that aim to first limit adiposity 
gains (beyond what is associated with normal growth and development) as well as increase 
physical activity or cardiorespiratory fitness and socioeconomic conditions may improve 
adult levels of blood lipid and lipoprotein irrespective of baseline levels. Population-based 
programs may be best to achieve these aims, but the efficacy of such interventions in the 
paediatric setting to limit or prevent obesity has not been convincing. For example, a 
Cochrane review of school-, community-, and family-based interventions on this subject 
concluded that diet and/or physical activity approaches did not significantly improve BMI 
levels, despite observed improvements in diet and/or physical activity levels. 383 A more 
recent review from the same authors on school-based interventions concluded that despite 
inconsistent trends across studies, the data suggested that combined physical activity-diet 
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interventions may help prevent children becoming overweight in the long term. 384 While 
these data underscore the need for more research into effective, population-wide 
interventions for the prevention and reduction of paediatric obesity, the point made above 
remains, that even small changes to the population distribution may have a large public health 
impact. 382 Whether this effect would be large enough to affect lipid and lipoprotein tracking 
remains untested. Data on the effectiveness of population-based interventions to improve 
physical activity and fitness in the paediatric setting have been more forthcoming; 385,386 while 
interventions to improve socioeconomic circumstance are more difficult. Because the 
indicator of SEP used in this study was based on education, interventions that seek 
improvements in education represent one potential strategy through which improvements in 
SEP may be achieved. 348 Again, the effectiveness of such interventions to achieve the 
necessary effect on tracking of lipid and lipoprotein levels is not known. 
Taken together, the findings highlight that youth lipid and lipoprotein levels are 
important in predicting adult outcomes, that they are subject to modification, and while there 
are potential limitations to lipid and lipoprotein screening in the paediatric setting, the data 
underscore the importance of both population-wide and individualised prevention programs 
to reduce the early development of atherosclerosis associated with paediatric dyslipidemia. 
6.4. FUTURE RESEARCH NEEDS 
In compiling this work, a number of areas for future research direction and consideration 
have become evident. A number of these areas have been highlighted in the previous section, 
but other priority areas include: 
• Factors that affect tracking of blood lipid and lipoprotein levels: A substantial 
limitation in this study was the lack of consistent dietary information at both time points 
to provide meaningful data on the effect of change in a number of important dietary 
variables (including saturated fat, poly and mono unsaturated fats, cholesterol, and fibre) 
on lipid and lipoprotein tracking. Thus, this represents one area for future examination. 
Further, the effect of accelerated adiposity gain during childhood and adolescence on 
blood lipid and lipoprotein tracking needs to be examined. Because this study only had 
data available from a single time-point in youth, it was not possible to determine the 
rapidity of adiposity gain and the subsequent short- and long-term effects on lipid and 
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lipoprotein tracking. Low birth weight has been associated with more adverse lipid 
profiles in childhood and adulthood and with a faster yearly rate of LDL change 
(increase) in the Bogalusa Heart Study suggesting that there may be early programming 
of lipid and lipoprotein levels. 387 The effect of birth weight on lipid and lipoprotein 
tracking has not been examined however. 
• Systematic review and meta-analysis of studies that have examined tracking of 
blood lipid and lipoprotein levels between youth and adulthood: Although over 20 
publications from 10 studies have provided data on lipid and lipoprotein tracking from 
youth into adulthood, only few systematic reviews are available and no meta-analysis has 
been conducted. Data are available for a good number of participants, over varying 
lengths of follow-up, from different industrialised populations worldwide, on both males 
and females, and beginning at a wide range of ages during youth. A meta-analysis of 
these data would be useful both to summarise findings from these studies that have 
accumulated over a period of 25 years, and to determine what characteristics may 
influence tracking. Additionally, it would serve to identify additional areas for future 
research and to stimulate a new wave of research within the area of lipid and lipoprotein 
tracking. 
• Multiple blood lipid and lipoprotein measures at baseline and follow -up 
examinations: A well known yet woefully unaccounted for fact in study designs, is the 
measurement variability of lipids and lipoproteins. All guidelines issued on paediatric 
lipid screening have recognised, and advocated for, multiple measures before risk 
classification. While this has a considerable cost limitation, studies specifically designed 
to assess either the efficacy of lipid screening or interventions to improve lipid levels in 
paediatric populations that do not collect multiple measures at baseline and follow-up 
could be underestimating the predictiveness of the screening program or missing effects 
of interventions due to misclassification. This is particularly important for studies with 
short follow-up periods, where meaningful but small changes may not be able to be 
detected because they are obscured by measurement error. 
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• Cut-points or screening that observe race and maturation differences: None of the 
paediatric lipid cut-points examined in this thesis, nor the ones advocated in the July 
2008 update of the guidelines for paediatric lipid screening, 22° take account for variations 
in lipid and lipoprotein levels due to race or pubertal status. Evidence has shown that 
both race and pubertal status have a substantial influence on blood lipid and lipoprotein 
levels. 300' 388-391 One wonders given the limitations observed in this study concerning high 
rates of false-positives and false-negatives whether the prediction of adult CVD risk, 
subclinical-, or clinical disease may improve if cut-points observed stage of sexual 
maturation, race, and sex. Another consideration may be to avoid lipid and lipoprotein 
screening altogether during the pubertal years. The LRC data provided in the Friedman 276 
paper showed that prediction of adult total and LDL cholesterol levels from levels 
measured in youth was poorest during the years of puberty. An approach that 
incorporates screening before and after puberty may reduce the proportions of false 
positive and false negative individuals. 
• Utility of non -HDL cholesterol levels for paediatric screening: Non-HDL cholesterol, 
obtained directly by subtracting HDL cholesterol levels from total cholesterol levels, is 
considered by some groups as a simpler and more effective screening tool for the 
assessment of CVD risk compared with LDL cholesterol. Non-HDL measurements avert 
certain limitations of LDL cholesterol measurements estimated using the Friedewald 
equation.314 For example, estimated LDL cholesterol does not include all classes of 
atherogenic lipoproteins, and the measurement does not require overnight fasting. 392 
Consequently, non-HDL cholesterol is increasingly being used in clinical research 
involving adult populations,392 ' 393 and has also been specified as a secondary target for 
therapy among patients with the metabolic syndrome or diabetes mellitus in the NCEP 
ATPIII recommendations. 304 For paediatric populations, past and current screening 
guidelines have not advocated for the measurement of non-HDL cholesterol. This is 
puzzling considering available data that have shown: child non-HDL cholesterol to be a 
better predictor of adult dyslipidemia and non-lipid CVD risk factors in adulthood such 
as hyperinsulinemia, and hyperglycaemia compared with LDL cholestero1; 234 non-HDL 
to be strongly predictive of metabolic related risk factors such as triglycerides, EIDL 
cholesterol, adiposity, and HBA lc in childhood;394' 395 youth with type 1 and type 2 
diabetes to commonly have elevated non-HDL cholestero1, 396' 397 and that the prevalence 
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of high non-HDL cholesterol levels in youth with type I diabetes increases with poor 
glycaemic control and duration of diabetes. 395 Non-HDL cholesterol is also included in 
the calculation of the PDAY risk score. 47 These and other available evidence suggest that 
childhood non-HDL cholesterol levels have a place in the prediction of dyslipidemia and 
nonlipid CVD risk factors (particularly metabolic-related abnormalities) in adulthood. 
Future research should aim to establish paediatric cut-points for non-HDL cholesterol; or 
should cut-points for non-HDL cholesterol be included in the upcoming release from the 
NHLBI's Expert Panel for the Pediatric Cardiovascular Risk Reduction Initiative, the 
cut-points and associated screening procedures should be subject to similar predictive 
testing that other lipid and lipoproteins have been submitted to. 
• Utility of paediatric blood lipid and lipoprotein levels to predict CVD morbidity and 
mortality: Data linking childhood and adolescent blood lipid and lipoprotein levels to 
clinically important CVD outcomes is currently lacking. The cohorts used in this study 
will likely be the first to be able to provide these data, but with the oldest participants in 
each of these samples still only in their fifth decade of life, a time when CVD is only just 
beginning to present, it appears these important analyses are still some time off. The 
collaboration between the three cohorts used in this thesis may provide an avenue for 
performing these analyses sooner by pooling event data, which was the main goal 
underlying the partnership between the groups. Funding to determine the feasibility of 
such analyses using these three cohorts has recently been granted (Magnussen CG, from 
the Finnish Foundation for Cardiovascular Research, May 2009). These data will be 
important to determine the causal role of blood lipid and lipoprotein levels in youth in the 
development of clinically significant disease. 
• Dichotomous vs. weighted scoring systems for lipid and CVD risk assessment: An 
ongoing concern surrounding dichotomous definitions for CVD risk factors (both in adult 
and paediatric settings) is that lipid and lipoprotein levels span a continuum of risk, 
where specific inflection points may not exist and the interplay of them with other CVD 
risk factors such as obesity, blood pressure, and smoking are not taken into consideration. 
This may be particularly important if an interaction between lipid and lipoprotein levels 
and other related risk factors may lead to exponential rather than additive increases in 
risk. An example from this study is evident in the data presented in Chapter 5, where the 
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presence of overweight and obesity status in addition to high-risk LDL and HDL 
cholesterol levels in adolescence substantially increased adult IMT levels. It is also 
possible that different thresholds exist where more aggressive treatment or intervention 
may be required. These problems have also been outlined as distinct limitations of the 
dichotomous definition of the metabolic syndrome, with calls from a recent Scientific 
Statement from the Al-IA calling for the development of a weighted scoring system that 
takes into account each risk factor, their interaction, and important patient 
characteristics. 127 In line with such an approach for paediatric metabolic syndrome, a 
weighted scoring system that takes into account the full spectrum of risk associated with 
increasing lipid and lipoprotein levels, and indeed other CVD risk indicators, may also 
prove useful toward improved identification and risk stratification of youth with elevated 
lipid and lipoprotein levels or elevated CVD risk. 
• Tools for estimating absolute CVD risk and the possibility of risk assessment 
without laboratory analysis in the paediatric setting: While lipid and lipoprotein 
levels are an important contributor to CVD, they are not the only contributor. Multiple, 
mostly preventable, causal factors contribute to CVD. 398 The probability that an 
individual will develop CVD within a given period depends more closely on the presence 
of a number of risk factors rather than any single risk factor. 399 That is, the screening for 
and possible modification of, multiple CVD risk factors may be more effective in 
reducing CVD risk than a major reduction of a single risk factor. 40° Because of the 
available evidence, a number of countries now adopt adult guidelines based on the 
assessment and treatment of absolute CVD risk rather than separate guidelines that focus 
on individual risk factors.401403 Given the evidence available in the paediatric setting 
suggesting the importance of a number of risk factors in the prediction of atherosclerosis 
in pathological and imaging studies, a risk approach that considers the assessment of 
multiple risk factors appears pertinent. The development, validation, and calibration of 
such risk scores in the paediatric setting are therefore required. Because data on clinical 
outcomes are not available, preclinical markers may be a useful alternative as an 
intermediary outcome in the development and testing of these scores. Should such a tool 
be developed for use in the paediatric setting, approaches that simplify risk assessment 
but maintain adequate risk prediction should be examined. In the adult setting, a recent 
paper by Gaziano et al.404 demonstrated that non-laboratory-based measures (age, sex, 
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smoking, blood pressure, adiposity) included in a risk score that omitted a blood draw 
(and subsequent lipid and lipoprotein analysis) performed equally in the prediction of 
CVD events compared with non-laboratory- plus laboratory-based measures. It has also 
been shown that a simple lifestyle score derived from eight factors (normal BMI, non-
smoking, low alcohol, salt and meat consumption and regular fish consumption, leisure 
time physical activity and skim milk use) predicts mortality in elderly men405, 406 and 
cardiometabolic risk factors in young adult males and females aged 25 to 36 years. 407 A 
simplified risk assessment or score that could omit a blood draw and provide reasonable 
discrimination has obvious advantages in the paediatric setting. 
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6.5. CONCLUSIONS 
The findings from this study suggest that paediatric dyslipidemia classifications are useful in 
predicting adolescents who are at increased risk of having dyslipidemia or preclinical 
atherosclerosis in young adulthood. While the findings highlight potential limitations to lipid 
and lipoprotein screening in the paediatric setting, they underscore the importance of both 
population-wide and individualised prevention programs to reduce the early development of 
atherosclerosis associated with paediatric dyslipidemia. 
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Table. Summary of non-invasive imaging techniques used to assess preclinical atherosclerosis 
Arterial Phenotype 
Premise 
Technique 
Wall thickness 
(structural)606 '  
-Diffuse intimal 
thickening occurs 
early in 
atherosclerosis, prior 
to lesion 
development. 
-High-resolution B-
mode 
ultrasonography of 
large (carotid, aorta, 
femoral) and conduit 
(brachial) arteries to 
assess the intima-
media thickness 
(distance between the 
lumen-intima 
interface and the 
media-adventitia 
interface). 
-IMT measurements 
can be quantified as 
the average of 
arterial wall 
thickness (excluding 
segments involved 
with plaque), the 
maximal measured 
value, and as the 
average of multiple 
values measured at 
different 
sites/segments. 
Endothelial function 
(functional)Oz ° 
-The endothelium is 
the key regulator of 
vascular homeostasis 
and has 
antithrombotic and 
antiproliferative 
properties. The 
presence of nitric 
oxide (NO) in the 
endothelium plays a 
major role in both 
actions. 
-Alteration in 
endothelial function 
precedes structural 
atherosclerotic 
changes. 
-High-resolution B-
mode 
ultrasonography to 
measure diameter of 
artery before and in 
response to shear 
stress (increased 
blood flow) during 
reactive hyperaemia 
(induced by inflation 
and then deflation of 
a blood pressure cuff 
around the forearm). 
This technique is 
known as brachial 
artery flow-mediated 
dilatation (FMD). 
-The degree of FMD 
occurs mainly due to 
NO release from the 
endothelium. 
-Decreased FMD or 
the absence of a 
response is 
suggestive of 
endothelial 
dysfunction. 
Calcification 
(structural) 
-Coronary artery 
calcification is 
part of the 
pathogenesis of 
atherosclerosis. 
-It occurs almost 
exclusively in 
atherosclerotic 
arteries. 
-Is absent in the 
normal vessel 
wall. 
-Detected by 
cardiac computed 
tomography: 
electron-beam CT 
(EBCT) & multi-
detector CT 
(MDCT). 
- Both 
technologies 
employ thin-slice 
CT imaging (1.5- 
6 mm slice 
thickness), using 
fast scan speeds 
to reduce motion 
artefact. 
-Scans are 
obtained with 
participants in a 
supine position 
during I or 2 
breath-holding 
sequences and are 
triggered by 
continuously 
measured ECG at 
40% to 80% of 
the R-R interval 
(near end-diastole 
before atrial 
contraction), to 
minimise the 
effect of cardiac 
motion.4u 
-Presence and 
degree of calcium 
is scored 
according to 2 
methods (Agatson 
and volume), with 
the summed 
(total) score for 
the entire 
coronary arteries 
typically used. 
-The amount of 
calcium detected 
Elasticity/stiffness/distensibility 
(mechanical)64 . 65 
-Proximal large arteries have 
high elastic properties that are a 
result of high elastin to 
collagen ratio in their walls. 
The gradual loss of elastic 
properties of these variables 
with aging is a result of 
progressive elastic fibre 
degeneration. 
-Decreased elasticity is thought 
to represent an early risk 
marker for CVD. 
Various indices and techniques 
used. These include: 
-Arterial wave propagation  
(Pulse-wave velocity, PWV 
between two points, e.g. 
carotid-femoral). 
-Carotid & aortic pressure  
waves (central pulse & systolic 
blood pressures, augmentation 
index). 
-Change in vessel diameter to 
distending pressure 
(compliance, distensibility) 
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Arterial Phenotype 
    
       
 
Wall thickness 
(structurar " 
Endothelial function 	Elasticity/stiffness/distensibility 
(functional)" " (mechanical)64 : 
Calcification 
(structural)  
indicates the 
amount of 
underlying 
coronary 
atherosclerosis. 
  
       
Limitations 
Predictive value 
-Imaging equipment 
is not currently able 
to differentiate 
between the intima 
and media, so both 
are measured. 
Variation in IMT 
measurements may 
be due to 
hypertrophy of media 
not thickening of 
intima. 
-Internal carotid and 
near walls cannot be 
measured precisely 
in a large number of 
subjects. 
-Heterogeneity in 
protocols (imaging, 
measurements, 
arterial segment) 
used introduce 
difficulties in pooling 
data from multiple 
studies and for meta-
analysis. 
-Imperfect 
correlation with 
coronary 
atherosclerosis. 
-Largest amount of 
evidence available 
for common carotid 
IMT. 
-A recent systematic 
review and meta-
analysis 
demonstrated that for 
each 0.1mm increase 
in common carotid 
IMT, the risk of MI 
increased by 15% 
and the risk of stroke 
by 18%.° ' 
-Requires skilled 
sonographer and 
appropriate training 
period. 
-High biological 
variability (reflected 
by wide normal-
range of dilatation 
response). 
-Not high test-retest 
repeatability (product 
of high biological 
variability and 
within- and between-
measurer 
differences). 
-Degree of dilatation 
can be effected by: 
recent smoking, 
recent food/beverage 
intake (high fat meal, 
alcohol, vitamin C), 
recent exercise, 
circadian pattern, 
viral illness, and 
phase of the 
menstrual cycle for 
females. 
-Imperfect 
correlation to 
coronary circulation. 
-Vasodilatory 
response is related to 
vessel size, 
suggestions that those 
with brachial arteries 
>4.7-mm should have 
FMD of radial artery 
examined. 
-Attenuated FMD has 
been shown to be an 
independent predictor 
of CVD events in 
those with 
established 
atherosclerosis. More 
recently, Yeboah et 
al. demonstrated the 
prognostic utility of 
FMD in a large 
prospective study of 
older adults without 
established CVD.'" 
pwv 
-Does not provide information 
on arterial geometry. 
-Inaccuracy of distance 
measurement. 
Central pulse-waves  
-Indirect measure of arterial 
stiffness. 
Change in vessel diameter to 
distending pressure  
-Requires skilled technician 
-Requires measurement of 
central pulse pressure. 
E_Na 
-Gold-standard measure of 
arterial stiffness. 
-Largest amount of evidence 
available. 
-Has independent predictive 
value for CVD morbidity and 
mortality. 
Central pulse-waves 
-Independent predictors of all-
cause mortality and CVD 
events persons with established 
CVD. 
-No data available from 
disease-free populations. 
Change in vessel diameter to 
distending pressure 
-Radiation 
exposure 
-High rates of 
zero scores before 
5d' decade of life. 
-'Noise' can be 
mistaken for 
calcium on CT 
images leading to 
higher calcium 
scores, 
particularly in 
those with large 
chest size or those 
with high body 
mass index. 
-Cost 
-More recent 
technologies 
(smaller slice 
thicknesses, 
higher speed, 
prospective 
cardiac gating) 
have been found 
to have high 
reproducibility, 
but earlier 
technologies were 
shown to have 
poor short-term 
test-retest 
reproducibility. 66 
-Vulnerable 
plaque may not 
exhibit significant 
calcification. 
-No meta-analysis 
available, but 
there is a high 
level of evidence 
demonstrating the 
presence and 
extent of coronary 
calcium to predict 
cardiac events in 
both symptomatic 
and asymptomatic 
-Effect tends to 
remain after 
adjustment for 
other (more 
conventional) risk 
factors and there 
are data to 
suggest the 
addition of 
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Arterial Phenotype  
I 	 I 
Wall thickness 	Endothelial function 	Elasticity/stiffness/distensibility 	Calcification 
(struchfral)60' 61 (functional)64 63 (mechanical)64.65 	 (structural)  
-Evidence suggestive of coronary calcium 
independent association with 	to risk scores 
CVD events in those with improves CVD 
established CVD, although the 	event prediction, 
independent effect has been particularly in 
challenged. 	 those with 
intermediate 10- 
-No data available from 	 year risk.41 ' 
disease-free populations. 
Simplicity* ++ ++/++q+ 
Reproducibility* +-H- ++ 
Safety* +++ +++ + (radiation) 
Low cost* -I-f- ++ 1-W+++/++ 
* Ratings based on review articles of these measures. 6163-67 + = fair, ++ = good, ++F = excellent 
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ENROLMENT QUESTIONNAIRE 
Your completices of this Errol:nett Questionnaire Ma @Dow is to confirm your personal detwls and 
enrol you as a study partieipont in the ealdlusol Determinants of dirket Health (MAN) Stuck At 
each later stage of follaw-up, you au be prmidert with additional study information and green a 
further opportunity to consent or decline to participate in that stage. 
Instructions for completing cpuntinanaire: 
Plane write in BLOM' LETTERS ming a black pat (Irpacale). 
borwate yam revalue by fitting in the circle cents the most appropriate 
answer *a by taking clarity & the boxes or space. 
YOur Personal Details 
Name: 
First Name' 
Michige Name(s) 
Preferred Name 
or =Wee to 
Surname 
Slade circles like this 
Not hie this 
Home Address: 
Suburb 
Postcode 
id different) 
Postal Address: 
Suburb 
Postcode 
Telephone Numbers: 
Home 	 Work 
Mobile 
Emad 
Your Date of Birth: 
L 0914374851 
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Your Marital Status: 	Single 	0 	 Separated/Divorced 0 
Married 	0 	 Widowed 	0 
De facto 	0 	 Other 	0 
- Which school were you at in 1985? 
What is the highest level of formal 
What is your current employment 
How tall are you? 
How much do you weigh? 	" 
education 
Primary School 
Grade 7-9 
Grade 10 
Grade 11 
Grade 12 
Trade Certificate 
Technical College 
Undergraduate 
Postgraduate 
status? 
Employed full-time 
Employed part-time 
Unemployed 
Home duties 
Student 
Permanently 
that you have completed? 
0 
0 
0 
0 
0 
0 
0 
university studies 0 
university studies 	0 
0 
or casual 0 
0 
0 
0 
unable to work / Disabled 0 
011 	OR 
kg 	OR 
ft 
St 
In 
lb 
Have you ever been a regular smoker? 	 Yes 0 	No 0 
(A regular smoker is someone who has smoked at 
least 7 cigarettes, cigars or pipes every week for at 
least 3 months) 
Are you currently a regular smoker? 	 Yes 0 	No 0 
In general, would you say your health is: 	 Excellent 	0 Fair 
Very Good 0 	Poor 
Good 	0 
0 
0 
L 2160374856 
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r- The name and contact details of two people who will always know where you are if you move: "1 
CONTACT 1  
First Name: 
Surname: 
What is their relationship to you? 
Parent 0 Grandparent 0 Brother/Sister 0 Other relative 0 Friend 0 Other 0 
If other, please specify 
Address: 
Suburb 
Postcode 
Telephone Numbers: 
Home Work 
Mobile 
Email 
CONTACT 2 
First Name: 
Surname: 
 
What is their relationship to you? 
Parent 0 Grandparent 0 Brother/Sister 0 Other relative 0 
	
Friend 0 
	
Other 0 
If other, please specify 
Address: 
Suburb 
Postcode 
   
 
Telephone Numbers: 
Home 
Mobile 
Work 
    
 
Email 
       
L 9206374854 
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OFFICE USE ONLY 
SCAN VERIFY CHECK 
   
Participant ID 
CDAH SHORT QUESTIONNAIRE 
GENERAL INECIRMATIO 
in ft  cm OR 1. How tall are you? 
2. (Females only) Are you currently pregnant? 0 Yes 	Go to question 4 
0 No 
3. How much do you weigh? 
	
kg 	OR 	 st 
	
I lb 
4. Which of the following describes your current employment status? (You can pick more than one). 
O Working full-time 
O Working part-time 
O Not working (but not retired) 
O Home duties 
O Full-time student 
O Part-time student 
O Retired 
O Permanently unable to work / ill 
O Other 
(please specify) 
5. What is the highest level of education you have completed?  (Select only one answer) 
O Primary School 
O Year 7,8 or 9 or equivalent 
O Year 10 or equivalent 
O Year 11 or equivalent 
O Year 12 or equivalent 
O Trade/apprenticeship (e.g. hairdresser, chef) 
O Certificate/diploma (e.g. child care, technician) 
O University Degree 
O Higher University Degree (e.g. Grad Dip, Masters, PhD) 
O Other 
(please specify) 
6. What is your current marital status? 
O Single 
O Married 
O De facto 
O Separated/Divorced 
O Widowed 
O Other 
(please specify)) 
II Year 
(select one) 
0 
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HEALTH AND LIFESTYLE 
7. Has a doctor or nurse ever told you that you have diabetes? 	 No 	> Go to question 8 
Yes 0 
IF 'YES'  
7a) In what year were you first told that you had diabetes? 
7b) Were you told that you had: 
Type I diabetes 
(previously known as "insulin-dependent diabetes") 
Type 2 diabetes 	 0 
(previously known as "non insulin-dependent diabetes") 
Don't know which type 	 0 
What advice and/or treatment have you had for diabetes? (select all that apply) 
Diet advice 0 
Tablets 0 
Insulin injections 0 
Diet advice and tablets 0 
Diet advice and insulin injections 0 
8. Over your lifetime, have you smoked at least 100 cigarettes, or a similar amount of tobacco? 
No 0 > Go to question 10 
Yes 0 
IF 'YES'  
9. Have you ever been a daily smoker? 	 No 	0 ..41P Go to question 10 
Yes 0 
7c) 
9a) When did you start smoking daily? 
Years of Age 
OR 
	
Year 
9b) How often do you now smoke cigarettes, cigars, pipes or any other tobacco products? 
Daily 	 0 > Go to question 10 
At least once a week (but not daily) 0 
Less often than weekly 	0 
Notatali 	 0 
9c). When did you finally stop smoking daily? 
Years of Age 
OR 
	
Year 
I 	I 
I times 
Yes 0 
No 0...> Go to page 4 
Baby 
  
Month 
  
Year 
 
           
 
2 
4 
         
          
          
           
 
5 
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10. How often, on average, have you have consumed an alcoholic drink in the last 12 months? This includes 
light beer, medium strength beer, full strength beer, wine, champagne, sparkling wine, wine cooler, spirit-based 
mixed drinks like Lemon Ruski, sherry, port or fortified wines, spirits, liqueurs, and other alcoholic drinks like 
cider. Please choose from the following options: 
Never, or less than once a month 	0 
1-3 times per month 	 0 
Once per week 	 0 
2-4 times per week 0 
5-6 times per week 	 0 
Once per day 	 0 
2-3 times per day 	 0 
4-5 times per day 	 0 
6 or more times per day 	 0 
MALES: 	Go to page 4 
FEMALES ONLY:  
11. Have you ever been pregnant? 
11a).How many times have you been pregnant? 
11b).How many live births have you had? 
1k). When were these babies born? 
First baby 
Second baby 
Third baby 
Fourth baby 
Fifth baby 
(If more than 5 l've births, please record in empty space below) 
11d). Were you ever told that you had gestational diabetes or pregnancy related diabetes? 
Yes 0 
No 0 
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r 5481263368 	 1 1 1 	1 	1 	4 
PHYSICAL ACTIVITY 
We are interested in finding out about the kinds of physical activities that people do as part of their daily lives. 
The following questions will ask you about the time you spent being physically active in the last 7days. Please 
answer each question even if you do not consider yourself to be an active person. Please think about the activities 
you do at work, as part of your house and yard work, to get from place to place, and in your spare time for 
recreation, exercise or sport. 
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical activities refer to 
activities that take hard physical effort and make you breathe much harder than normal. Think only about 
those activities that you did for at least 10 minutes at a time. 
12. During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging 
aerobics or fast bicycling? 
El days per week 
0 No vigorous physical activities 	•-). Skip to question 13 
12a). How much time did you usually spend on one of those days doing vigorous physical activities? 
hours minutes Per day 0 Don't know/Not sure 
Think about all the moderate activities that you did in the last 7 days. Moderate physical activities refer to 
activities that take moderate physical effort and make you breathe somewhat harder than normal. Think only 
about those activities that you did for at least 10 minutes at a time. 
13. During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, 
bicycling at a -egular pace or doubles tennis? Do not include walking. 
days per week 
0 No moderate physical activities ...40 Skip to question 14 
13a). How much time did you usually spend on one of those days doing moderate physical activities? 
minutes Per day 	0 Don't know/Not sure 
Think about the time you spent walking in the last 7 days. This includes at work and at home, walking to travel from 
place to place and any other walking that you might do soley for recreation, sport, exercise or leisure. 
14. During the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
11 days per week 
0 No walking •-•41, Skip to question 15 
14a). How much time did you spend walking on one of those days walking? 
hours 
hours minutes Per day 	
0 Don't know/Not sure 
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Think about the time you spend sitting on weekdays during the last 7 days. Include time spent at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a desk, visiting friends, reading or 
sitting or lying down to watch television. 
15. During the last 7 days, how much time did you usually spend sitting on a weekday? 
  
hours II minutes 	Per day 0 Don't know/Not sure 
     
YOUR HEALTH 
16. In general would you say your health is now: 
0 Excellent 	0 Very Good 	0 Good 	0 Fair 	 0 Poor 
17. The following questions are about activities you might do during a typical day. Does your health now limit you in 
these activities? If so, how much? 
17a)Moderate activities, such as moving a 
table, pushing a vacuum cleaner, 
bowling or playing golf. 
YES, 
limited a lot 
YES, 
limited a little 
NO, 
not limited at all 
0 0 0 
17b)Climbing several flights of stairs. 
0 0 0 
18. During the past 4 weeks, how much of the time have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 
18a)Accomplished less than you would like 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
0 0 0 0 0 
18b)Were limited in the kind of work or other 
activities. 
0 0 0 0 0 
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19. During the past 4 weeks, how much of the time have you had any of the following problems with your work or 
other regular daily activities s 	at t o 	 b e .t (such as feeling depressed or anxious)? 
19a)Accomplished less than you would like 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
0 0 0 0 0 
19b)Did work or other activities less carefully 
0 0 0 0 0 than usual 
20.During the past 4 weeks how much did pain interfere with your normal work (including both work outside the 
home and housework)? 
Not at all 	A little bit 	Moderately 	Quite a bit 	Extremely 
0 0 0 	 0 0 
21.These questions are about how you feel and how things have been with you during the past 4 weeks. For each 
question, please give the mg answer that comes closest to the way you have been feeling. 
How much of the time during the oast 4 weeks: 
All of 
the time 
Much of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
21a)Have you felt calm and peaceful? 0 0 0 0 0 
21b) Did you have a lot of energy? 0 0 0 0 0 
21c) Have you felt downhearted and 
depressed? 
0 0 0 0 0 
22. During the past 4 weeks how much of the time has your physical health or emotional problems interfered with 
your social activities (like visiting with friends, relatives etc.)? 
All of the 	Most of 	Some of 	A little of the 	None of the 
time the time the time time 	 time 
0 	 0 	0 	 0 0 
This is the end of the questionnaire, thank you for participating. 
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CDAH General Questionnaire 
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1 
  
OFFICE USE ONLY 
 
OFFICE USE ONLY 
  
    
(Bar code Lb here) 
 
SCAN 	VERIFY 	!CHECK 
 
     
SECTION A: This section asks you some questions about yourself. You may feel you 
have already answered these questions in our enrolment questionnaire, however your 
circumstances may have changed since you completed our enrolment questionnaire. 
1 Todays date 
2. What sex are you? 
3. What is your date of birth?  
0 Male 0 Female 
4 What is your current marital status? 
O Single 
O Married 
O be facto 
O Separated/Divorced 
O Widowed 
O Other 
(please specify) 
5. What is the highest level of education you have completed? (Select only one answer) 
O Primary School 
O Year 7, 8 or 9 or equivalent 
O Year 10 or equivalent 
O Year 11 or equivalent 
O Year 12 or equivalent 
O Trade/apprenticeship (e.g. hairdresser, chef) 
O Certificate/diploma (e.g. child care, technician) 
O University Degree 
O Higher University Degree (e.g. Grad Dip, Masters, PhD) 
O Other 
(please specify) 
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6. What Is your main source of income? (Select only one answer) 
  
IMMO 2 
  
O Wages or salary 
O Own business or share in partnership 
O A government pension or cash benefit 
O Superannuation 
O Investment/ Interest 
O Other income 
(please specify) 
7. What is your main occupation NOW (Select only one answer) 
Manager or administrator (e.g. magistrate, farm manager, general manager, director of 
nursing, school principal) 	 0 
Professional (e.g. scientist, doctor, registered nurse, allied health professional, teacher, 
artist) 	 0 
Associate professional (e.g. technician, manager, youth worker, police officer) 	 
Tradesperson or related worker (e.g. hairdresser, gardener, florist) 	 0 
Advanced clerical or service worker (e.g. secretary, personal assistant, flight 
attendant, law clerk) 	 0 
Intermediate clerical, sales or service worker (e.g. typist, word processing/data entry 
operator, receptionist, child care worker, nursing assistant, hospitality worker) 	0 
Intermediate production or transport worker (e.g. sewing machinist, machine 
operator, bus driver) 	 0 
Elementary clerical, sales or service worker (e.g. filing/mail clerk, parking inspector, 
sales assistant, telernarketer, housekeeper) 	 0 
Labourer or related worker (e.g. cleaner, factory worker, general farm hand, kitchen 
hand) 	 0 
No paid job 	  0 
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111111111 3 
8. Which of the following describes your current employment status? You can pick more than 
one. 
O Working full-time 
O Working part-time 
O Not working (but not retired) 
O Home duties 
O Full-time student 
O Part-time student 
O Retired 
O Permanently unable to work / Ill 
O Other 
(please specify) 
SECTION B: This section is about your health and your medical history 
1. Have you ever been told that you have high blood pressure' 
0 No -- >Skip to Question 2 
0 Yes 
IF 'YES ,  
la) When were you first told this? 
    
(Year) 
      
lb) Was this during pregnancy? 0 Yes 	0 No 	0 Not applicable 
1c) Are you currently taking medication prescribed by a doctor to lower your blood pressure? 
0 Yes 0 No 
1d) Has a doctor in the past year recommended you change your way of life, in order 
to lower your blood pressure? 
0 Yes 0 No 
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r 5363007497 4 
2. Have you ever been told that you have angina? 
0 No -->Skip to Question 3 
0 Yes 
):F 'YES'  
2a) When were you first told this? 
      
     
(Year) 
       
2b) Are you currently on tablets or other treatment for angina? 
0 Yes 0 No 
3. Have you ever been told that you have had a heart attack (includes 'coronary', 
'coronary occlusion', 'coronary thrombosis, 'myocardial infarction')? 
0 No -->Skip to Question 4 
0 Yes 
IF 'YES' 
3a) When were you first told this? 
4. Have you ever been told that you have had a stroke? 
0 No - - >Skip to Question 5 
0 Yes 
IF 'YES'  
4a) When were you first told this? 
(Year) 
(Year) 
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5. Have you ever been told that you have high cholesterol? 
0 No - >Skip to Question 6 
0 Yes 
IF 'yes .  
5a) When were you first told this? 
     
    
(Year) 
      
      
5b) Are you currently taking medication prescribed by a doctor to lower your blood 
cholesterol? 
0 Yes 0 No 
5c) Has a doctor in the past year recommended that you change your way of 
life, in order to lower your blood cholesterol? 
0 Yes 0 No 
6. Have you ever been told that you have high triglycerides? 
0 No -- > Skip iv Question 7 
0 Yes 
IF 'YES' 
(Year) 6a) When were you first told this? 
7. Are you currently taking aspirin-containing medication to prevent or treat heart disease 
or stroke? 
0 No 
0 Yes 
267 
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8 Has a doctor or nurse ever told you that you have diabetes? 
0 No --, Skip to Question 9 
0 Yes 
IF 'YES'  
8a) In what year were you first told that you had diabetes? 
     
    
(Year) 
      
8b) Were you told that you had: 
Type 1 diabetes 
(select one) 
0 
(previously known as "insulin-dependant diabetes") 
Type 2 diabetes 	 0 
(previously known as "non insulin-dependant diabetes") 
Don't know which type 	 0 
8c) What advice and/or treatment have you had for diabetes? (select all that apply) 
0 Diet advice 
0 Tablets 
0 Insulin injections 
0 Diet advice and tablets 
0 Diet advice and insulin injections 
L 	 i 
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9. Are you currently taking any medication prescribed by a doctor? 
0 No -- > Skip to Question 9b 
  
I 	I 	I 	1 7 
  
0 Yes 
9a) In the table below please provide the name (or type of medication) and what it was 
prescribed for. Please continue at the bottom of page 28 if you need more space. 
Medication 	 Prescribed for 
1 
2 
3 
4 
5 
6 
7 
9b) Are you currently using any of the following hormonal medications? 
(If you are female using hormonal contraceptives please do not include them in the 
"Other" category. We ask about contraception in Section )) 
0 I do not use any hormone medications 
0 Hormone replacement therapy 
0 Testosterone treatment (e.g., Androderm) 
0 Anabolic steroids 
0 Other (please specify) 
10. Have you had any illness causing a high temperature during the last two weeks? 
0 No -->Sklp to SECTION C (Pogo 8) 
0 Yes 
IF 'YES'  
10a) What was the duration of the fever? 
10b) Was your temperature measured? 
0 No 
0 Yes, but temperature not known 
0 Yes, my temperature was 
10c) How many days ago did the fever stop? 
ac 
Days ago 
days 
L 	 i 
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SECTION C: The following questions ask for your views about your health. This 
information will help keep track of how you feel and how well you are able to do your usual 
activities. 
1 In general would you say your health is: 
0 Excellent 	0 Very Good 0 Good 
	
0 Fair 	0 Poor 
2 The following questions are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? 
2a) Moderate activities, such as 
YES, 
limited a lot 
YES, 
limited a little 
NO, 
not limited at all 
0 0 0 moving a table, pushing a vacuum 
cleaner, bowling or playing golf. 
2b) Climbing several flights of stairs. 0 0 0 
3 During the past 4 weeks how much of the time have you had any of the following problems 
with your work or other regular daily activities  as a result of your physical health?  
3a) Accomplished less than you 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
0 0 0 0 0 
would like 
3b)Were limited in the kind of work 
0 0 0 o o 
or other activities. 
4 During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious) 
4a) Accomplished less than you would 
like 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
Nona of 
the time 
0 0 0 0 0 
4b) Did work or other activities less 
0 0 0 0 0 carefully than usual 
SF-I 2v2nd Health Survey '3'3 1992 2003 by Health Assessment Lab Medrcal Outcomes Trutt and QualityMetnc Inccapotated 
All nghts reserved 
SF-121 n a regntered trademark of Medrcal 010comes Trust 
(1Q0LA SF-12v2 Standard. English (Austral's). 7 03) 1 
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5. During the past 4 weeks,  how much did  1, interfere with your normal work (including both 
work outside the home and housework)? 
Not at all 	A little bit 	Moderately 	Quite a bit 	Extremely 
6. These questions are about how you feel and how things have been with you during the past 4  
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. 
r- 
 
How much of the time during the Last 	All of 	Much of 	Some of 	A little of 	Nona of 
4 weeks: 	 the time 	the time 	the time 	+ha time 	the time 
6a)Have you felt calm and peaceful? 	o 	o 	o 	o 	o 
6b) bid you have a lot of energy? 	 o 	o 	o 	o 	o 
6c)Have you felt downhearted and 
depressed? o 	o 	o 	o 	o 
7. During the past 4 weeks.  how much of the time has your physical health or emotional problem  
Interfered with your social activities (like visiting with friends, relatives etc.)? 
All of the 	Most of 	Some of 	A little of 	None of 
time the time 	the time the time 	the time 
0 	 0 0 	 0 0 
SF-12v2rm Health Survey 0 1992,2003 by Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. 
All tights resaved. 
SF-120 is a registered trademark of Medical Outcomes That. 
(1Q0LA SF-I2v2 Standard, English (Australia), 7/03) 
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SECTION C): This section is for WOMEN ONLY. 
If you are MALE please skip to SECTION E (page 15). The answers to the following questions 
will help us investigate the influence of hormones on the cardiovascular system. 
1 Are you currently using any of the following hormonal contraceptives, even if you are 
using them for reasons other than contraception? 
0 Oral contraceptive pill 
0 Minipill (progesterone only pill) 
0 Weekly contraceptive patch 
0 Progestagen (e.g., Implanon) 
0 Progestagen injection (e.g., Depo Provera) 
0 Progestin injection ( e.g. , Noristerat) 
0 Progestin releasing intrauterine device ( e.g. , Mirena, Copper T380A) 
0 Progestin releasing implant  ( e.g. Norplant) 
0 Other (please specify) 
2 How old were you when you had your first menstrual period? 
Years Months 
3 Have you had a hysterectomy; that is, an operation to remove your uterus? 
0 No - - >Skip to Question 4 
0 Yes 
IF YES  
3a) What age were you when you had the hysterectomy? 
   
  
Years 
    
3b) Were your ovaries removed as well? 0 Yes, both ovaries removed 
0 Yes, only one ovary removed 
0 No 
0 Don't know 
SKIP TO Question 5 
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NEU 
4. The menstrual cycle is the time from the first dav of one period to the first day of the 
next. 
Mar Non- bleeding days  
	The Menstrual cycle 	 
4a) How long is your usual menstrual cycle? 
In other words, how many days are there from the FIRST DAY OF ONE PERIOD to 
the FIRST DAY OF THE NEXT? 
Days 
4b) What is the longest menstrual Cycle you have had in the last 12 months? Again count 
from the FIRST DAY OF ONE PERIOD to the FIRST DAY OF THE NEXT. 
Days 
4c) What is the shortest menstrual cycle you have had in the last 12 months? Again 
count from the FIRST DAY OF ONE PERIOD to the FIRST DAY OF THE NEXT. 
Days 
5. Thinking about the most recent time when you were having periods and were NOT using 
hormonal contraceptives (e.g., the pill) and were not pregnant or breastfeeding: 
5a) Would you describe your periods as: 0 Very regular 
0 Fairly regular 
0 Irregular 
0 Very irregular 
5b) How old were you at this time? 
That is, at the most recent time when you were having periods and were NOT using 
hormonal contraceptives (e.g., the pill) and were not pregnant or breastfeeding. 
Years 
Sc) During this time, approximately how many periods did you have in the space of 12 
months? 
0 More than 13 
011-13 
0 6-10 
01-5 
0 None 
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6. Have you ever seen a doctor because of irregular periods? 
0 No -->Skip to Question 7 
0 Yes 
  
IME• 12 
  
IF YES 
6a) How old were you when you first saw your doctor about irregular periods? 
Years 
6b) Have you ever taken prescribed hormone medications for irregular periods? 
0 Yes 0 No 
6c) Has a doctor ever told you that you have polycystic ovaries or polycystIc ovary 
syndrome? 
0 Yes 	0 No 
7. Have you ever seen a doctor because of concern about the amount of hair on your face? 
0 No -->Skip to Question 8 
0 Yes 
F YES  
7a) Were you prescribed any treatment for this? 
0 No 
0 Yes 
(please specify) 
8. Has a doctor ever told you that you have acne? 
0 No - - >Skip to Question 9 
0 Yes 
IF YES 
8a) Were you prescribed any treatment for this? 
0 No 
0 Yes 
(please specify) 
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9. Have you ever tried to become pregnant for 12 months or more without succeeding? 
0 Yes 0 No 
10. Have you ever seen a doctor because you were having trouble becoming pregnant? 
0 No - - >Skip to Question 11 
0 Yes 
IF YES 
10a) Did you have any of the following fertility investigations? 
0 Test of blood or urine hormone levels 
0 Laparoscopy (incision in your stomach to look at your reproductive organs) 
0 Your partner's semen analysed 
10b) Did a doctor ever tell you that you or your partner had: 
0 An ovulatory problem? 
0 A tubal problem? 
0 Any other female fertility problem? 
- please specify 
0 Semen abnormalities? 
0 An unexplained fertility problem? 
11. Have you ever been pregnant? 
0 No -- Skip to SECTION E (Page 15) 
0 Yes 
12. How many times have you been pregnant? 
  
times 
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13. How many live births have you had? 
13a) When were these babies born? 
Baby Month Year 
First baby 1 
Second baby 2 
Third baby 3 
Fourth baby 4 
Fifth baby 5 
If you have had more than 5 live births please continue at the end of this section. 
14. When you were pregnant were you ever tested for diabetes? 
That is, did you have a blood or urine sugar test? This may have involved drinking a very 
sugary drink. 
0 Yes 0 No 
15. Were you ever told that you had gestational diabetes or pregnancy related diabetes? 
0 Yes 0 No 
r-- 9309007491 
SECTION  E This section is about your family's medical history 
The following questions are about your BIOLOGICAL parents and siblings. Because heart disease 
in women under 50 is uncommon, some questions are only asked about your male relatives. 
Please do not include adoptive or step-parents or siblings here 
1. Was your biological mother diagnosed with diabetes when she was under the age of 50? 
0 Yes 0 No 0 Don't Know 
2. Is your biological mother alive now? 0 Yes 	0 No 	0 Don't Know 
If NO: 
276 
15 
Years 2a) How old was she when she died? 
2b) Was the cause of her death diabetes? 
0 Yes 0 No 0 Don't Know 
3 Was your biological father diagnosed with diabetes when he was under the age of 50? 
0 Yes 0 No 0 Don't Know 
4. Was your biological father diagnosed with heart disease when he was under the age of 50? 
0 Yes 0 No 0 Don't Know 
5. Is your biological father alive now? 0 Yes 	0 No 	0 Don't Know 
If NO:  
5a) How old was he when he died? 	 Years 
5b) Was the cause of his death: 
Heart dIsease? 	0 Yes 0 No 	0 Don't Know 
Dionetes) 	 0 Yes 	0 No 	0 Don't Know 
3 0 Yes 0 No 
1 
	
0 Yes 0 No 
    
    
2 
	
0 Yes 0 No 
3 0 Yes 0 No 
0 Yes 0 No 
0 Yes 0 No 
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6. Do you have any BIOLOGICAL brothers? 
0 Yes 
0 No 	- - >Skip to question 7 
0 Don't Know — >Skil+ to  quassia^ 7 
IF YES 
6a) Have any of your biological brothers been diagnosed with the following illnesses when under 
the <km of 50?  
Heart disease 0 Yes 0 No 0 Don't Know 
Diabetes 	0 Yes 0 No 0 Don't Know 
6b) If 'YES' to either of the above, please complete details below (space has been 
allowed for you to complete details for up to 3 brothers If necessary): 
Age at diagnosis 	Did this result in 
(if known) 	his death? 
HEART DISEASE 
Age at diagnosis 	Did this result in 
(if known) his death? 
DIABETES 
L 	 i 
0 Yes 0 No 
0 Yes 0 No 2 
0 Yes 0 No 3 
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7 Do you have any BIOLOGICAL sisters 
0 Yes 
0 No 
	-->Skip to SECTION F 
0 Don't know -->Skip to SECTION F 
IF YES  
7a) Have any of your biological sisters been diagnosed with diabetes when under the age of 
50? 
0 Yes 0 No 0 Don't Know 
7h) If 'YES  please complete details below (space has been allowed for you to 
complete details for up to 3 sisters if necessary): 
Age at diagnosis 	Did this result in 
(if known) 
	
her death? 
SECTION F: This section is about smoking tobacco 
1 Over your lifetime, have you smoked at least 100 cigarettes, or a similar amount of tobacco? 
0 No -- > SKIP TO SECTION 6 (Page 20) 
0 Yes 
2 How often do you now smoke cigarettes, cigars, pipes or any other tobacco products? 
0 Daily 
0 At least once a week (but not daily) 	-- >Skip to Question 7 
0 Less often than weekly 	 -- >Skip to Question 7 
0 Not at all 	 -- >Skip to Question 7 
3. When did you start smoking daily? 
Years of Age 
OR I I 
Year 
II 
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MIMI 
4. What do you currently smoke? 
(Please indicate types and enter how many you smoke) 
0 	Manufactured cigarettes Cigarettes per day 
0 Hand-rolled cigarettes Grams per week* 
I 	I 
0 	Cigars Cigars per week I I 
0 	Pipes full of tobacco Grams per week* I I 
* A ona and fltraa quar+ar ounce pouch of tobacco equals 50 grams 
5. When you smoke manufactured cigarettes, which brand do you usually smoke? 
I do not smoke manufactured cigarettes 0 
The brand I usually smoke is 
(Please give as much detail as possible, eg Marlboro Lights) 
6. Have there been any periods of time when you gave up daily smoking and then started smoking 
again? 
No 0 -- >Skip to SECTION 6 (Page 20) 
Yes 0 
IF YES 
6a) Were any of these periods greater than 3 months duration? 
No 0 -->Skip to SECTION 6 (Page 20) 
Yes 0 
IF YES 6b) What is the total amount of time that you stopped smoking for? 
(Please add together all the periods of time when you stopped smoking) 
Years Months 
4a) 
4b) 
4e) 
4d) 
Now skip to SECTION G (Page 20) 
L 	 I 
No 0 - - >Skip to SECTION G (Page 20) 
Yes 0 
Years of Age 	 Year 
II 
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7. In the past have you ever been a daily smoker? 
8. When did you start smoking daily? 
9. When did you finally stop smoking daily? 
10.When you smoked daily, how much did you usually smoke? 
(Please indicate types and enter the number smoked) 
0 	Manufactured cigarettes Cigarettes per day I 
o 	Hand-rolled cigarettes Grams per week* I 
0 	Cigars Cigars per week I 
I 
0 	Pipes full of tobacco Grams per week* 	I I 
a A one and three quarter ounce pouch of tobacco equals 50 91121115 
11 When you smoked manufactured cigarettes, which brand did you usually smoke? 
I did not smoke manufactured cigarettes 0 
The brand I usually smoked was 
(Please give as much detail as possible, eg Marlboro Lights) 
12 .Prior to the time when you finally stopped daily smoking, were there any periods of time when 
you gave up daily smoking and then started smoking again? 
No 0 - - >Skip to SECTION G (Page 20) 
Yes 0 
IF YES 
12a) Were any of these periods greater than 3 months duration? 
No 0 -->Skip to SECTION G (Page 20) 
Yes 0 
IF YES 12b) What is the total amount of time that you stopped smoking for? 
(Please add together all the periods of time when you stopped smoking) 
  
Years 
 
Months 
L 	 I 
    
    
10a) 
10b) 
10d) 
i 
281 
20 1 
SECTION 6: These questions are about your life when you were growing up 
until the age of 12. They are mostly about your parents or other adults who you lived with and 
who were responsible for you. 
1 This question is about only the people who lived in the some house as you and were like 
parents to you for most of the time until you turned 12. 
la) 	bid you live in the some house as your father or another male who was like a father to 
you? 
0 No - -> Skip to question lc 
0 Yc.r. 
IF YES 
1 b) What is the highest level of education completed by your father (or other male who 
lived with you and was like a father to you) 
0 No schooling 
0 Primary School only 
0 Year 7, 8 or 9 or equivalent 
0 Year 10 or equivalent 
0 Year 11 or equivalent 
0 Year 12 or equivalent 
0 Trade/apprenticeship (e.g. hairdresser, chef) 
0 Certificate/diploma (e.g. child care, technician) 
0 University Degree 
0 Higher University Degree (e.g. Grad Dip, Masters, PHD) 
0 Other (please specify) 
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1c) Did you live in the same house as your mother or another female who lived with you and 
was like a mother to you? 
0 No -->Skip to question 2 
0 Yes 
IF YES 
1d) What is the highest level of education completed by your mother (or other 
female who lived with you and was like a mother to you) 
0 No schooling 
0 Primary School only 
0 Year 7, 8 or 9 or equivalent 
0 Year 10 or equivalent 
0 Year 11 or equivalent 
0 Year 12 or equivalent 
0 Trade/apprenticeship (e.g. hairdresser, chef) 
0 Certificate/diploma (e.g. child care, technician) 
0 University Degree 
0 Higher University Degree (e.g. Grad Dip, Masters, PHD) 
0 Other (please specify) 
2 What was the MAIN occupation of your father (or other male who lived with you and was 
like a father to you), and your mother (or other female who lived with you and was like a 
mother to you) until you turned 12?  Please only select one answer for your father and one 
answer for your mother. 
Occupation 
Manager or administrator (e.g. magistrate, farm manager, general manager, 
Father Mother 
director of nursing, school principal 	  0 0 
Professional (e.g. scientist, doctor, registered nurse, allied health professional, 
teacher, artist) 	  0 0 
Associate professional (e.g. technician, manager, youth worker, police officer) 0 0 
Tradesperson or related worker (e.g. hairdresser, gardener, florist) 	 0 0 
Advanced clerical or service worker (e.g. secretary, personal assistant, flight 
attendant, law clerk) 	  0 0 
Intermediate clerical, sales or service worker (e.g. typist, word processing/ 
data entry operator, receptionist, child care worker, nursing assistant, 
hospitality worker) 	  0 
Intermediate production or transport worker (e.g. sewing machinist, machine 
operator, bus driver) 	  0 
Elementary clerical, sales or service worker (e.g. filing/mail clerk, 
parking inspector, sales assistant, telemarketer, housekeeper) 	  0 0 
Labourer or related worker (e.g. cleaner, factory worker, general farm hand, 
kitchenhand)    	 0 
No paid job 	  0 
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3. Thinking about until you were 12, how many rooms were there in the home where you lived the 
longest? 
Please include buildings on the property that were regularly used for living, such as bungalows. 
If your house had open plan areas, consider each area as a separate room (I. e. an open plan 
kitchen, dining and living area would count as three rooms). Do not include separate toilets. 
Rooms in house 
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4. Thinking about most of the years until you were 12 did your parents or the people who 
brought you up own the house you mostly lived in, or did they rent it? 
0 They owned or were paying off the house 
0 They rented the house 
0 Unsure 
5. Thinking about the years until you were 12, how many times did you move house? 
If you did not move house, please write "0" 
II Times 
 
6. All together, how many brothers and sisters did you have in your family until you were 12? 
Include adopted, step and half 'brothers and sisters. 
Please also include any brothers or sisters that may have died, but not those who died before 
you were born. 
I did not have any brothers or sisters 0 
n Older sisters 
n Younger brothers 
Younger sisters 
n Twin brother to you 
Twin sister to you 
7. About how much did you weigh when you were born? 
0 3 pounds or less (less than 1360g) 
0 More than 3 pounds and up to 5 pounds (1361-2270 grams) 
0 More than 5 pounds and up to 8 pounds (2271-3630 grams) 
0 More than 8 pounds (more than 3630 grams) 
0 Don't know 
Older brothers 
r- 0688007492 
SECTION H: The following statements have been used by many people to describe how I 
much support they get from other people. 
We would like to know whether you share any of these feelings and how strongly you feel 
about them, by filling in the circle according to whether you strongly agree, agree, disagree 
or strongly disagree with each one. If you are undecided, select the column with this heading. 
5114°1191Y 
Agree 
Agree Undecided Disarm: Str‘"91 Y 
Oisagrea 
1. People do not come and visit me as often as 
I would like. 
0 0 0 0 o 
2. I find it easy to make friends. o o 0 0 0 
3. I often need help from other people but 
can't get it. 
0 o o o 0 
4. I'm afraid of being left alone. 0 0 o 0 0 
5. I seem to have a lot of friends. o 0 0 0 o 
6. I don't have anyone that I can confide in. 0 0 0 0 0 
7. The person who means most to me takes an 
interest in my affairs. 
0 0 0 0 0 
8. There is someone who needs me as much as 
I need them. 
o o o 0 o 
9. I don't have a very close friend. 0 o o 0 o 
10. The person who means most to me does 
spend time with me. 
0 0 0 o 0 
11. I have no-one to lean on in times of trouble. o o o o 0 
12.1 have someone to share good news with. 0 0 0 0 0 
13. There is someone who can always cheer me 
up. 
o o o o o 
14. I often feel very lonely. o 0 o o o 
15.1 feel there is something missing from my 
life. 
0 0 0 0 0 
-)85 
24 
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SECTION I: This section contains 60 statements. Read each statement carefully. For 
each statement fill in the circle with the response that best represents your opinion. Make 
sure your answer is in the correct box. 
Fill in Strongly Disagree if you strongly disagree  or the statement is definitely false 
Fill in Disagree if you disagree or the statement is mostly false 
Fill in Neutral if you are neutral about the statement, you cannot decide, or the statement is 
about equally true and false 
Fill in Agree if you agree or the statement is mostly true 
Fill in Strongly Agree if you strongly agree or the statement is definitely true 
Strongly 
Disagree 
Disagree Net:fro! Agree 
Strongly 
Agree 
1. I am not a worrier. o o o o o 
2. I like to have a lot of people around me. o 0 o o o 
3. I do not like to waste my time. o o o o o 
4. I try to be courteous to everyone I meet. o o o o o 
5. I keep my belongings clean and neat. o o o o o 
6. I often feel inferior to others. o o o o o 
7. I laugh easily. o o o o o 
8. Once I find the right way to do something, 
I stick to it. 
o o o o o 
9. I often get into arguments with my family 
and co-workers. 0 o   o o o 
10. I am pretty good about pacing myself so 
as to get things done on time. o o o  o o 
11. When I am under a great deal of stress, 
sometimes I feel like I am going to pieces. 
0 0 0 o o 
12. I do not consider myself especially 
"light-hearted". o o o o o 
13. I am intrigued by the patterns I find in art 
and nature. 
0 0 o o 0 
14. Some people think I am selfish and 
egotistical. 
0 0 o o o 
15. I am not a very methodical person. o o o o o 
16. I rarely feel lonely or blue. o o o o o 
Reproduced by special permission of the Publisher, Psychological Assessment Resources, Inc., 16204 North Florida Avenue, Lutz, 
Florida 33549. from NE0 Five Factor Inventory, by Paul Costa and Robert McGnu, Copyright 1978, 1985, 1989 by PAR, Inc. L Further reproduction is prohibited without permission of PAR Inc. 
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Disagree 
Disagree Neutral Agree 
Strongly 
Agree 
17.1 really enjoy talking to people. o o o o o 
18. I believe letting students hear controversial 
speakers can only confuse and mislead them. 0 0 0 0 0 
19.1 would rather cooperate with others than 
compete with them. 
o o o o 0 
20. I try to perform all the tasks assigned to 
me conscientiously. 
0 0 0 0 0 
21.1 often feel tense and jittery. 0 0 o o 0 
22. I like to be where the action is. o o o o 0 
23. Poetry has little or no effect on me. 0 0 0 o 0 
24.1 tend to be cynical and sceptical of 
others' intentions. 
0 0 0 0 0 
25. I have a clear set of goals and work 
toward them in an orderly fashion. 
0 0 0 0 0 
26. Sometimes I feel completely worthless. o o o o 
27. I usually prefer to do things alone. 0 0 0 0 0 
28. I often try new and foreign foods. 0 o o o 0 
29. I believe that most people will take 
advantage of you if you let them. 
o o o o 0 
30. I waste a lot of time before settling down 
to work. 
0 o o o o 
31.I rarely feel fearful or anxious. 0 0 0 0 0 
32. I often feel as if I am bursting with 
energy. 0 0  0 0 0 
Reproduced by special permission of the Publisher, Psychological Assessment Resources, Inc., 16204 North Florida Avenue, Lutz, 
Florida 33549, from NE0 Five Factor Inventory, by Paul Costa and Robert AkcCnze, Copyright 1978,1985, 1989 by PAR, Inc. 
Further reproduction is prohibited without permission of PAR Inc. 
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StrenglY 
Disagree 
Disagree Undecided Agree Streng lY 
Agree 
33. I seldom notice the moods or feelings that 
different environments produce. 0 
0 0  
 0 0 
34. Most people I know like me. o o o o o 
35. I work hard to accomplish my goals. 0 o o o 0 
36. I often get angry at the way people 
treat me. 
0 0 0 0 0 
37. I am a cheerful, high-spirited person. 0 o o o 0 
38. I believe we should look to our religious 
authorities for decisions on moral issues. 
0 0 0 0 0 
39.Some people think of me as cold and 
calculating. 
0 o o o o 
40. When I make a commitment, I can always 
be counted on to follow through. 0 0 0  0 0 
41.Too often, when things go wrong, I get 
discouraged and feel like giving up. 
0 0 0 0 0 
42. I am not a cheerful optimist. 0 0 0 o o 
43. Sometimes when I am reading poetry or 
looking at a work of art, I feel a chill or 
wave of excitement. 
0 0 o o 0 
44. I am hard-headed and tough-minded in my 
attitudes. 
0 o o o 0 
45. Sometimes I am not as dependable or 
reliable as I should be. 
0 0 0 0 0 
46. I am seldom sad or depressed. 0 0 0 o 0 
47. My life is fast-paced. 0 0 0 0 0 
48. I have little interest in speculating on the 
nature of the universe or the human condition 0 
 o o o  o 
49. I generally try to be thoughtful and 
considerate. 
0 0 o o o 
Reproduced by special permission of the Publisher, Psychological Assessment Resources, Inc., 16204 North Florida Avenue, Lutz, 
Florida 33549, from NEO Five Factor Inventory, by Paul Costa and Robert McCrae, Copyright 1978,1985, 1989 by PAR, Inc. 
Further reproduction is prohibited without permission of PAR Inc. 
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Disagree 
Disagree Undecided Agree  
Agree 
50. I am a productive person who always gets 
the job done. 
0 0 0 0 0 
51.1 often feel helpless and want someone 
else to solve my problems. 
0 0 0 o o 
52. I am a very active person. 0 0 0 0 0 
53. I have a lot of intellectual curiosity. 0 0 o o o 
54. If I do not like people. I let them know it. o o o o , o 
55. I never seem to be able to get organised. 0 0 0 0 0 
56.At times I have been so ashamed I just 
wanted to hide. 0 0 0 0 
0 
57. I would rather go my own way than be a 
leader of others. 0 0 0 0 
0 
58. I often enjoy playing with theories or 
abstract ideas. 0 0 0 
0 
_ 
0 
59. If necessary, I am willing to manipulate 
people to get what I want. 
0 0 0 0 0 
60. I strive for excellence in everything I 
do. 
0 o o o o 
Reproduced by special permission of the Publisher, Psychological Assessment Resources, Inc., 16204 North Florida Avenue. Lutz, 
Florida 33549, from NE0 Five Factor Inventory, by Paul Costa and Robert McCrae, Copyright 1978,1985, 1989 by PAR, Inc. 
Further reproduction is prohibited without permission of PAR Inc. 
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APPENDIX 5 
Definition of smoking status for each cohort 
291 
Current smoking status: Toward a consistent definition between CDAH, Young Finns, 
and Bogalusa studies. 
Bogalusa:  
At baseline (ages 8 to 17y) and follow-up, participants were categorized as: 
1) currently smokes at least one cigarette a week (>1/week) 
2) currently experimenting with cigarettes (fewer than one cigarette per week) 
(<1/week) 
3) used to smoke at least one cigarette a week but no longer smokes cigarettes (former) 
4) at one time was experimenting (<1/week) with cigarettes but quit smoking (former 
experimenter) 
5) never experimented with cigarettes (never) 
Young Finns:  
At baseline (those aged 12 years or older) and follow-up, participants were categorized: 
I) once per day or more often (?1/day) 
2) at least once per week, but not daily (>1/week) 
3) less than once per week (<1/week) 
4) stopped smoking or do not smoke at present (former) 
5) never smoked (never) 
CDAH:  
At baseline, participants aged 9 years and older were asked a series of questions on smoking 
behaviour that included the following question: 
'How long have you been smoking regularly? (regularly means 1 or more times a week)'. 
1) 'I don't smoke% 
2) 'just started'; 
3) ' 1 to 6 months'; 
4) '7 months to 1 year'; 
5) ' 1 to 2 years'; 
6) '2 to 4 years'; 
7) 'more than 4 years'. 
These responses could be collapsed into a binomial categorical variable indicating: 
1) at least once per week (>1/week), i.e. those that indicated any of options 2-7. 
2) less than once per week (<1/week), i.e. those that indicated 'I don't smoke' 
292 
Never smokers at baseline could be ascertained from the question: 
'Have you ever smoked even part of a cigarette?'. Those responding 'No' could be classified 
as Never smokers at baseline. 
At follow-up, those that indicated they had smoked at least 100 cigarettes or equivalent 
tobacco over their lifetime were asked the following question: 
'How often do you now smoke cigarettes, etc': 
1) Daily 1/day) 
2) At least once a week (but not daily) 1/week) 
3) Less often than weekly (<1/week) 
4) Not at all (Ex-smoker) 
Considering the available data from the three cohorts, it appears the most consistent 
definition of current smoking status that could be applied at both baseline and follow-up 
would involve collapsing the responses into three categories: 
1) Currently smoking at least once per week (>1/week) 
2) Currently smoking less often than weekly (<1/week) 
3) Not currently smoking (includes never or former smokers) 
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APPENDIX 6 
Correction factors used in the Cardiovascular Risk in Young Finns Study to 
account for changes in lipid and lipoprotein determination kits between baseline 
and follow-up surveys 
294 
Lipid and lipoprotein correction factors used in the Cardiovascular Risk in Young 
Finns Study 
Due to changes in lipid and lipoprotein determination methods and kits during study years, 
levels from 1980 were corrected by using the following correction factor equations. These 
equations were determined by linear regression analysis utilizing standardized principal 
component adjustments. All equations were developed by the Young Finns research group 
previously. 218 
Total cholesterol = 1.091 * total cholesterol (1980) — 0.271 mmol/L 
HDL cholesterol = 1.068 * HDL cholesterol (1980) — 0.0277 mmol/L 
Triglycerides = 1.00758 * triglycerides (1980) + 0.0582 mmol/L 
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APPENDIX 7 
Overview of studies of blood lipid and lipoprotein tracking from childhood to 
adulthood: correlation data 
Table. Overview of studies that have examined tracking by correlation of blood lipid levels in childhood or adolescence and adulthood, sorted by date of 
first publication and study 
Study Publication N Population 
Duration 
of 
follow- 
up 
Age 
Fasting 
status 
Findings 
Baseline Follow- 
up 
Analyses 
(adjustments) TCH LDL-C HDL-C TO Comments 
Beaver County Orchard, 561 264 M; 9y 11-14 y 20-24 y 10 h Correlations — M: rA).57 NA NA NA 
Lipid Study, 
USA 
19832" 297 F type not specific 
(adjusted for 
age) 
F. rA:1.49 
Stuhldreher, 295 144M; 16y 11-14y 27-30y 10 h Correlations — M: r0.38 NA NA NA 
1991124 155 F type not specific F: r=0.51 
(no adjustments 
specified) 
Muscatine Lauer, 2446 1167M; 6-15 y 8-18 y 20-30y Yes Pearson's NA NA NA Only TCH collected 
Study, USA 1988/1989m 1279 f correlation 
coefficients 
stratified by 
age & sex 
at baseline. 
Correlations between 
TCH (baseline) and 
other lipids at follow- 
up are presented but 
not listed here. 
99 55 M; 54 15 y 7-8 y 20-25 y M r=0.56 
F F: r).64 
612 292M; 13y 9-10 y 20.25y M: r4.58 
311F F r).49 
1018 476M; 12 y 11-12 y 20.25y M: r3.51 
542 F F: r41.54 
1041 490M; 10 y l3-14y 20-25y M: r-41.51 
551F F: r- ).52 
339 155 M; 14 y 13-14 y 26-30 y M: r3.52 
184F F: r4.52 
767 352 M; 8y 15-16 y 20-25 y M: r=0.64 
415 F F: r).53 
568 263 M; 12 y 15-16 y 26-30 y M: 	.63 
305 F F: r4.55 
615 299M 6y l'7-18y 20-25y M: r0.72 
316F F: r:).54 
479 233M; II y 17-18y 26-30 y M . r-A3.64 
246 F F: r4.48 
Amsterdam Kemper, 200 93 M: 107 Sy 13.51-0.6 21.51-0.6 No Pearson's M. r0.70 NA M: r- 142 NA Examined tracking of 
Growth & 
Health Study, 
19902" F Y Y correlation 
coefficients (no 
F: r- 0.65 F: r- 0.52 TCH/HDL-C ratio 
(M: r-A3.62; F: 
the Netherlands adjustments 
specified) 
stratified by sex 
r. ).68). 
Blood lipids 
Age 	 Findings  
Duration 	Baseline 	Follow- 	Fasting 	Analyses 
Study 	 Publication 	N 	Population 	of up status 	(adjustments) 	TCH 	LDL-C 	HDL-C 	TG 	 Comments 
follow- 
up 
determined from 
non-fasting sample 
Twisk, 199624° 	181 	83 M; 98 	15y 	13.0±0.8y 27.11-0.8y 	No 	Tracking 	GEE.71 	NA 	M: 	NA 	Examined tracking of 
& 1997141 F coefficients TC.51 TCH/HDL-C ratio 
(TC) estimated 	 F: TC.).65 	 (TC.1.71; r0.49). 
using 
generalized 	r3.54 	 M: r-41.55 	 HDL-C stratified by 
estimating F: r-4).62 sex due to significant 
equations & 	 sex-HDL-C 
Pearson's interaction 
correlation 
coefficients 
(sex, age, time, 
change of 
behaviour — 
time-dependent 
Bogalusa Heart 	Webber, 	1586 	718 M; 	12 y 	2-14 y 	14-26 y 	12 h 	Spearman 	 Tracking of VLDL-C 
Study, USA 1991 1" 868 F correlation cholesterol also 
coefficients 	 examined. TCH & 
stratified by LDL-C track better 
age, race, MM, 	 in blacks, HDL-C & 
triglycerides track 
better in Whites 
669 	286 M; 	12 y 	9-14 y 	21-26 y 	 M(White): 	M(White): 	M(White): 	M(White): 
383 F r-41.45; rIl.50: 	r.43; 	rA.42; 
	
M(Black): 	M(Black): 	M(Black): 	M(Black): 
r'160; r0.69, rAT29; r-A1.22; 
F(White): 	F(White): 	F(White): 	F(White): 
r=0.42; r).44; 	r4.34; r325; 
F(Black): 	F(Black): 	F(Black): 	F(Iillack): 
r0.64 r=0 61 r=0.39 r=0.I I 
Bao, 1996" & 	1169 	Not 	15 y 	5-14y 	2O-29y 	12h 	Spearman 	r = 0.4-0.6 	r = 0.4-0.6 	r =0.2-0.4 	r = 0.2-0.4 
Nicklas, specified correlation 
2002 	 coefficients 	R2- 3.29 	122 3.30 	R2-40.27 	R2 3.19 
stratified by age, 
race, sex. 
Linear 
regression (age, 
race, sex, 
baseline BM!, 
change in BMI) 
Srinivasan, 	1163 	519 M; 	27 y 	5-14 y 	32-41 y 	12 h 	Linear 	NA 	R2 =0.23 	NA 	NA 	Also examined non- 
2006' 644 F regression (age, 	 HDL-C: R2=-0.26 
race, sex, 
Study Publication N Population 
Duration 
of 
follow- 
up 
Age 
Fasting 
status 
Analyses 
(adjustments) 
Findings 
Comments 
Baseline Follow- 
up TCH LDL-C HDL-C TG 
baseline BMI, 
change in BMI 
Cardiovascular 
Risk in Young 
Finns Study, 
Finland 
Porkka, 
19912u 
2236 1065 M; 
1171 F 
3-6 y 3-18 y 12 h Spearman's 
correlation 
coefficients 
stratified by 
age & sex 
238 104M; 3y 18 y 21 y M: r-A1.69 M: r3.69 M: r41.69 M: r=0.52 Also examined HDL- 
134 F F: rA).51 F: r=0.47 F: r-A171 F: r4).57 C /TCH ratio 
238 104M; fly 18 y 24y M: rt).68 M: r41.72 M: r3.58 M: r=0.49 
134 F F: r41.52 F:1=0.49 F: r-41.65 F: r0.34 
295 238M, 
295 F 
6y 15 y 21 y M: rA0.65 M: 
F: 
M: r-0.59 
F: r41.54 
M: r4.).45 
F: r0.31 
Porldut, 
1994m 
883 414 M; 
469 F 
12 y 3-18 y 15-30 y 12 h Spearman 
correlation 
coefficients 
stratified by 
age & sex 
Also examined LDL- 
C/HDL-C ratio 
156 77 M; 79 12y 9y 21 y M: 1- 3.63 M: rA.58 M: r41.56 M: r0.18 
F F r4).52 F: r:).53 F: r=0.60 F: r'0.22 
149 64 M; 85 12y 12 y 24y M: r4.57 M: r3.56 M: r0.69 M: r=0.45 
F F r=0.60 F: r4,11.59 F: rA0.52 F: r"0.21 
115 51 M; 64 12y 15 y 27 y M: r'0.40 M: r=0.44 M: r=0.48 M: M3.53 
F F: r-41.40 F:1=0.51 F: r0.57 F: r,1.58 
116 51 M; 65 12y 18 y 30 y M: r4,1.73 M: r=0.67 M: r=0.54 M: r=0.49 
F F: r4I.51 F: rA0.48 F r=0.56 F: rit.37 
Fels 
Longitudinal 
Study, USA 
Guo, 1993 236 96 Not 
specified 
12 y 9-11 y 19-21 y Yes Banded 
correlation 
model (none) 
1=0.65 r=0.46 NA 
Danish Youth 
& Sport Study, 
Denmark 
Anderson, 
l993 
200423i 
203 88 M; 115 
F 
8 y 15-19 y 23-27 y Yes Pearson's 
correlation 
coefficients 
M. r=0.39 
F: r4.5I 
NA M: r4.29 
F: r4.49 
M: r=0.32 
F: r4.33 
Also examined 
tracking of 
combined/clustered 
(none) CHD risk factors 
Quebec Family 
Study, Canada 
Katzmarzyk, 
200,242 
147 76 M; 71 12 y 8-18 y 20-30y 12-14 h Partial 
correlation 
coefficients 
stratified by sex 
NA NA M: 
F: rO.56 
M: r::0.37 
F: r.20 
Examined tracking of 
Metabolic syndrome 
(lipid) components 
only. 
(age at baseline, 
length of 
follow-up) 
Snub Publication N Population 
Duration 
of 
follow- 
up 
Age 
Fasting 
status 
Baseline Follow- 
up 
Aerobics 
Centre 
Longitudinal 
Study, USA 
Eiserunann, 
2004243  
48 36M; 12 
F 
10.9 y 12-18y 26.6±4.9 
Y 
Yes 
Busselton 
Study, 
Australia 
Adams, 
20051" 
1764 Not 
specified 
3-27y 
15-20 y 
>20 y 
10-15 y 
15-20 y 
>20 y 
3 y 
5-10 y 
l0-15 y 
15-20 y 
>20 y 
5-18 y 
5-9 y 
10-14 y 
15-18 y 
19-44 y 
20-36y 
20-41 y 
20-45y 
Not 
specified 
Findings 
Analyses 
(adjustments) 	TCH 	LDL-C 	HDL-C 	-IV, 	t. 'moment:, 
Partial 	r=0.62 	NA 	r=0.60 	r=0.54 	Length of follow-up 
correlation used as covariate 
coefficients 	 since the time 
(length of between visits varied 
follow-up; to 	 between participants 
account for age (range 5-24 y). 
& sex; baseline 	 Also examined 
and follow-up tracking of composite 
variables were 	 risk factor scores. 
regressed onto 
ace & sex and 
the residuals 
used for 
analyses) 
Pearson's 	 NA 
	
NA 	NA 	No adjustment for 
correlation sex, data were 
coefficient (age 	 combined for track 
& survey year) width analysis 
because variation 
was not sic different 
by sex. 
1-41.45 
r,3.44 
r).44 
rA3.39 
ro.43 
rA).48 
r3.40 
TCH = total cholesterol; LDL-C = low-density lipoprotein cholesterol; VLDL-C = very-low-density lipoprotein cholesterol; HDL-C = high-density 
lipoprotein cholesterol; TG = triglycerides; M = males; F = female; NA = not available; CHD = coronary heart disease; MetS = metabolic syndrome; BMI 
= body mass index; GEE = generalized estimating equations. 
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APPENDIX 8 
Overview of studies of blood lipid and lipoprotein tracking from childhood to 
adulthood: stability data 
Table. Overview of studies that have examined tracking of lipid and lipoprotein levels by risk-group from childhood and adolescence to adulthood, sorted 
by date of first publication and study 
Study Publication N Population 
Duration 
of follow- 
up 
Age 
Fasting 
status 
Risk group 
Proportion in same 
risk group at follow- 
up 
Comments 
Baseline Follow- 
up 
Baseline Follow-up 
Beaver County Orchard, 1983'35 561 264M; 9 y 11-14 y 20-24 y 10 h TCH >801 TCH >80" M-50.0%, 
Lipid Study, USA 297 F percentile percentile F=46.8% 
Stuhldreher, 295 144M; 16 y 11-14 y 27-30 y 10 h TCH >806 TCH >80" M=37.9%; 
1991 2" 155 F percentile percentile F=42.4% 
Muscatine Study, 
USA 
Latter, 
1988'"/1989m 
2446 1167M; 
1279 F 
6-15 y 8-18 y 20-30y 12h TaL>90" 
percentile 
TCH>90" 
percentile 
24-32% TCH only Single measurement at 
baseline considered for risk 
classification 
TCIL>90" 
percentile 
TC1t>.75" 
percentile 
50-87% 
TCH<90" 
percentile 
TCH<75" 
percentile 
78-84% 
I atler, 	1 990 : ' 2 -", o' II 3 ■ M. 
1214 f 
6-15 y 8-18 y 2040 y 12 h TCI-75* 
percentile 
TC 1-90" 
percentile 
TCH>6,20 
nnnol/L 
TCH>6.20 
mmol/L 
17% 
34% 
Baseline risk group defined from 
two consecutive TCH levels >75" 
percentile 
Follow-up risk groups defined 
using original NCEP adult 
guidelines." (equivalent to 
current) 
20-25 TCI-75" TC1-5.17 M=44.6% 
percentile mmol/L F=57.4% 
TCIL>90* TCI-5.17 M=75.0% 
percentile rnmol/L F=75.0% 
26-30 TCF75" TCI-5.17 M58.0% 
percentile mmol/L F=48.5% 
TCI-L>90" TCF5.17 M=77.8% 
percentile mmol/L F=55.6% 
Amsterdam Kemper, 19902' 200 93M; 107 Sy 13.5±0.6 21.51-0.6 No TCH >75* TCH >75* M=61% Blood lipids detennined from non- 
Growth & Health F Y y percentile percentile F=42% fasting sample. 
Study, the 
Netherlands 
HDL-C <25* HDL-C <25* M=53% Examined TCH/HDL-C ratio 
percentile percentile F=48% (M=54%; F3%). 
Twislc, 1997241 181 83 M; 98 F IS y 13.01-0.8y 27.1±0.8y No Not available - predictive values 
not calculated as all available 
longitudinal data (multiple follow- 
Study Publication N Population 
Duration 
of follow- 
up 
Age 
Fasting 
status 
Risk group 
Proportion in same 
risk group at follow- 
up 
Comments 
Baseline Follow- 
up 
Baseline Follow-up 
ups) used in analyses. 
Bogalusa Heart 
Study, USA 
Webber, 
1991 m 
1586 718 M; 
868 F 
12 y 2-14 y l4-26y 12b 
669 286M; 
383 F 
9-14 y 2l-26y TCI-75th 
percentile 
TCH>75th 
percentile 
M(white)=47%; 
M(b1ack),58%; 
Tracking of VLDL-C also 
examined: M(white)=50%; 
F(white)=40%; M(black)=36%; F(white-45%; 
F(black)=59% F(black)=30% 
LDL-C 275 th 
percentile 
LDL-C >75th 
percentile 
M(white)=53%; 
M(black)9%; 
F(white)=52%; 
F(black)=55% 
HDL-C <25 th 
percentile 
HDL-C <25 th 
percentile 
M(white)=42%; 
M(black)=53%; 
F(white)=46%; 
F(black)=38% 
TG>75 th  
percentile 
1G275 th 
percentile 
M(white)=57%; 
M(black)=33%; 
F(white)=38%, 
Fit:dad:I-24% 
Bao, 199e. & 
Nicldas, 2002 2" 
1169 Not 
specified 
15 y 5-14 y 2O-29y 12 h TCH, LDL-
C, HDL-C, 
TO >80 th 
percentile 
TCH, LDL-
C, HDL-C, 
TG >80 th 
percentile 
TCH & LDL-C >40%; 
HDL-C & 10 >30% 
Used pediatric 	& adult's' NCEP 
LDL-C cut-points to define risk 
groups. 
Examined effect of repeated 
measures on misclassification. 
LDL-C 
>3.36 
tmnol/L 
LDL-C 24.14 
nunoUL 
(2160 mg/dL 
28% 
(2130 
inedL) 
LDL-C  290th 
percentile 
LDL-C 24.14 
nunol/L 
(2160 
mg/dL) 
single LDL-C measure 
in childhood=26.9%; 
two LDL-C measures 
in childhood=52.3% 
Snnivasan, 
2006244 
1163 519 M, 
644F 
27 y 5-14 y 32.41 y 12 Ii LDL-C >80 th 
percentile 
LDL-C >80 th 
percentile 
-38% Also examined non-HDL-C 
LDL-C 
>3.36 
LDL-C 24.14 
mmol/L 
41.8% 
=ion 
(2130 
mg/dL) 
(2160 
otaldL) 
Cardiovascular 
Risk in Young 
Porkka, 1991 1u 2236 1065M; 
1171 F 
3-6 y 3-18 y 12 h TCH 280th 
percentile 
TCH >80th 
percentile 
3-year, M5.6%; 
F=55.3% 
Also examined HDL-C/TCH ratio 
(3-year, M=66.0%; 
Finns Study, 
Finland 
6-year, M=55.5%; 
F=50.4% 
F=61.9% 
6-year, M=54.0%; 
Study Publication N Population 
Duration 
of follow- 
up 
Age 
Fasting 
status 
Risk group 
Proportion in same 
risk group at follow- 
up 
Comments 
Baseline Follow- 
up 
Baseline Follow-up 
F=56.8%) 
LDL-C >80th 
percentile 
LDL-C >806 
percentile 
3-year, M=59.8%; 
F=56.3% 
6-year, M=58.9%; 
F=54.5% 
HDL-C <20 th 
percentile 
HDL-C <2(rh 
percentile 
3-year, M=60.6%; 
F=53.5% 
6-year, M=54.1%; 
F=49.0% 
TG ?80th 
percentile 
TG >80th 
percentile 
3-year, M=42.4%; 
F=41.8% 
6-year, M-394%, 
F=34 2°., ■■ 
Porkka, 1994'" 883 014 M; 
469 F 
12y 3-18y 15-30 y 12 h TCH, LDL- 
C, HDL-C, 
TG 280th 
percentile 
TCH, LDL- 
C, HDL-C, 
TO >80th 
percentile 
TCH, LDL-C, & 
HDL-C -50%; 
TG -30% 
Examined effects of repeated 
measurements & regression- 
toward-the-mean. Repeat 
measurements increased the amount 
of adult lipid variability explained 
by up to 50% in TCH, LDL-C & 
1-IDL-C models. 
Fels Longitudinal 
Study, USA 
Guo, 1993' 96 Not 
specified 
12 y 9-11 y 19-21 y Yes TCH 25.17 
nunol/L 
(2130 
TCH 25.17 
mmol/L 
(2160 
mg/dL) 
M=59% 
F=59% 
Cut-points used at baseline are to 
NCEP high-risk:' 96 cut-points used 
at follow-up are equivalent to 
borderline-risk (TCH & LDL-C), 
and high-risk (HDL-C) according 
to NCEP" 
LDL-C 
>3.36 
mmol/L 
(2130 
mg/dL) 
LDL-C 23.36 
nnnol/L 
(160 
ing/dL) 
M=46% 
F=46% 
HDL-C HDL-C M=30% 
<0.91 
mmol/L (<35 
1118/(11,) 
<1.03 
nurion (<40 
m8M1-) 
F=25% 
Danish Youth & Anderson, 203 88 NT 115 8 y 15-19 y 23-27 y Yes TCH >80 d' TCH 280 th M=26% Also examined TCH/HDL-C ratio: 
Sport Study, l993' F percentile percentile F52% M-47%; F=58% 
Denmark 
I/HDL-C I/HDL-C M=47% 
>80 th 
percentile 
>80th 
percentile 
F=58% 
TO ?80th 
percentile 
TG ?80th 
percentile 
M=50% 
F=29% 
Busselton Study, Adams, 20052" 1764 Not 3-27 y 5-18 y 19-44y Not TCH >75 th TCH >75 th 40-60% 15-18 y at first measurement 
Study 
Age 	 Risk group  
Duration 	Baseline 	Follow- 	Fasting 	Baseline 	Follow-up 	Proportion in same 
Publication 	N 	Population 	of follow- up status risk group at follow- 
up 	 up  
Comments 
Australia 	 specified 	 specified 	percentile 	percentile 	 maintained rank in extreme quarter 
more consistently than those <15 y  
TCH = total cholesterol; LDL-C = low-density lipoprotein cholesterol; VLDL-C = very-low-density lipoprotein cholesterol; HDL-C = high-density 
lipoprotein cholesterol; TO = triglycerides; M = males; F = female; NA = not available; NCEP = National Cholesterol Education Program 
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APPENDIX 9 
Area under ROC curve point estimates and 95% confidence intervals for 
prediction of abnormal lipid and lipoprotein levels in adults using NCEP and 
NHANES adolescent lipoprotein classifications for Young Finns with repeat 
lipid and lipoprotein measurements 
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Table. Area under ROC curve point estimates and 95% confidence intervals for prediction of 
abnormal lipid and lipoprotein levels in adults using NCEP and NHANES adolescent lipoprotein 
classifications for Young Finns with repeat lipid and lipoprotein measurements 
Lipoprotein n 
NCEP NFIANES 
AUC 
(95% Cl) 
P value . AUC 
(95% CI) 
P value .  
Total cholesterol 
Single measurement 682 0.71 0.71 
(0.67-0.75) (0.66-0.75) 
Repeat measurements t 682 0.76 <0.01 0.75 <0.01 
(0.72-0.80) (0.70-0.79) 
LDL cholesterol 
Single measurement 667 0.74 0.74 
(0.70-0.78) (0.70-0.78) 
Repeat measurements t 667 0.77 0.03 0.76 0.13 
(0.72-0.81) (0.71-0.80 
HDL cholesterol 
Single measurement 679 0.70 0.74 
(0.67-0.74) (0.70-0.78) 
Repeat measurements t 679 0.77 <0.01 0.80 <0.01 
(0.74-0.81) (0.76-0.84) 
Triglycerides 
Single measurement 682 0.59 0.54 
(0.54-0.65) (0.51-0.58) 
Repeat measurements t 682 0.72 <0.01 0.61 <0.01 
(0.66-0.78) (0.56-0.67) 
* Test for difference between AUCs of single and repeat measurements, t12 & 15 year old Finns at 
baseline (1980) who had repeat lipoprotein measurements as adolescents in 1983. 
Abbreviations: AUC, area under the receiver-operating characteristic curve; CI, confidence interval 
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APPENDIX 10 
Summary of studies showing the association between carotid IMT and clinical 
cardiovascular end points 
Table. Carotid IMT and clinical cardiovascular disease end points: Overview of population-based cohort studies, sorted by date of first publication and 
study 
IMT Definition 	 Analyses 
End 	Sample size at 
dic 	 Pi hl 	 n 	 P 	I 	 P 	/c rick/Fuent 
 
IMT 
Segments 	Measurements 	Modelled As 	Adjusted for 
 
Foil Fi ndings  
   
KIHD (Kuopio 	Salonen, 	Longitudinal Men 42 to 60 y Definite or 	1257/36 	1 mo-3 y 	Left & 	Mean, far wall 	Continuous; 	Unadjusted (effect 	Risk of MI 
Ischanic Heart 1993413 possible right CCA fixed cut- size for adjusted 	inaeased by 
Disease Risk 	 MI 	 point (IMT 	model not published) 	I I% (6%-16%) 
Factor Study), >1.0 mm); for each 0.1 mm 
Eastern Finland 	 Cox 	 of 1MT. 
	
proportional Those beyond 
hazards 	 cut-point: 
HR=2.1 (0.8-5.2) 
for MI 
ARIC 	 Chambless, Longitudinal 45-64 y free of 	MI 	10,841/290 or 	Median: 5.2y 	Left & 	Mean, far wall 	Continuous, 	Age, centre, race, 	For each SD 
(Atherosclerosis 	199741. 	 clinical CHD 13,204/626* 	or 10.6 y* right thirds, 95 th LDL & HDL (0.19 mm) 
Risk in 	 event 	 CCA, 	 percentile, 	cholesterol, BMI, 	increment of 
Communities 	 BIF, ICA, fixed cut- sports activity, 	mean combined 
Study), USA combined 	 points (1MT 	cigarette-years, 	IMT: 
>1.0 mm); hypertension, Male, HR=1.2 
Cox 	diabetes, ethanol, 	(1.0-1.3) 
proportional 	fibrinogen, stratified 	Female. HR=1.4 
hazards by sex 	(1.2-1.6). 
Upper vs. lower 
third: Male, 
HR=2.0 (1.3- 
3.1), Female, 
E1R=3.8 (1.7-8.4) 
Chambless, 	Longitudinal 	45-64 y 	Stroke 	14,214/199 or 	Median: 7.2 y 	Left & 	Mean, the wall 	Continuous, 	Age, centre, race, 	For each SD 
20004" without 14,165/371* 	or 10.7 y* right thirds, 956 LDL & HDL 	(0.18 mm) 
previous 	 CCA, 	 percentile, 	cholesterol, BM1, 	increment in 
stroke BIF, ICA, fixed cut- 	waist:hip ratio, sports 	mean combined 
combined 	 points; Cox 	activity, current 	IMT: 
proportional 	smoking, former 	Male, HR=1.2 
hazards smoking, 	(1.1-1.4) 
hypertension, 	Female, liR=1.4 
diabetes, left (1.2-1.6). 
ventricular 	Upper vs. lower 
hypertrophy, 	third: Male, 
fibrinogen, white 	HR=2.2 (1.3- 
blood cell count, 	4.0). Female, 
stratified by sex 	HR=2.3 (1.1-4.9) 
Rotterdam Study, 	Bots, 	Nested case- 	> 55 y 	MI, Stroke 	Cases: 98 (MI), 	Mean: 2.7 y 	Left & 	Mean, near + 	Continuous, 	Age, sex, BMI, 	For each SD 
the Netherlands 	1997416 control 95 (stroke); right CCA 	far wall fifths; smoking, systolic 	(0.16 mm) 
Controls: 1373 	 logistic 	blood pressure, 	increment of 
       
1MT Definition 
  
SCS 
 
            
 
End 	Sample size at 
Pithlicatinn 	!legion 	 Pnrmlatinn 	Pnint/c ricL/Fv.nrc 
 
IM'T 
Cpom,,Itc 	Monenrownpni, 	Mrs,IplIpti 
 
Shirk FnlInw-nn Ar1inct,e1 few 	Finelinoc 
	
regression 	hypertension, total & 	mean CCA 1MT: 
FIDL cholesterol, 	MI, OR=1.4 
diabetes, 	(1.2-1.8); stroke, 
inclusion/exclusion 	012=1.5 (1.2- 
previous MI & stroke 	1.8); 
Upper quintile 
vs. reference 
category: MI, 
OR=1.4 (0.7-
3.1), stroke, 
OR=2.8 (1.2-6.6) 
for MI 
Iglesias del 	Case-cohort 	2 55 y 	MI 	Cases: 194; 	Mean: 4.6 y 	Left & 	mean max, 	Continuous, 	Age, sex, BMI. 	For each SD 
Sol, Controls: 2073 right 	near + far wall quarters; Cox 	smoking, systolic & 	(NA) increment 
20024" 	 CCA, proportional diastolic blood 	in combined 
BIF, ICA, 	 hazards 	pressure, total & FIDL 	IMT: 
combined cholesterol, diabetes, 	MI, RR=I.4 
inclusion/exclusion 	(1.24.6); 
previous MI & stroke 	Upper vs. lower 
quarter: MI, 
RR=4.8 (2.5-9.4) 
Hollander, 	Longitudinal 	2 55 y 	Stroke 	5479/378 	Mean: 6.1 y 	Left & 	Mean, near + 	Continuous, 	Age, sex, smoking, 	For each SD 
20034I4 right CCA 	far wall 	thirds; Cox 	systolic & diastolic 	increment (NA) 
proportional 	blood pressure, total & in IMT: 
hazards HDL cholesterol, 	stroke, RR=1.2 
diabetes, history of 	(1.0-1.4); 
CVD 	Upper vs. lower 
third: stroke, 
RR=2.3 (1.3-3.9) 
CHS 	 Oleary, 	Longitudinal 	2 65 y without 	MI, stroke 	4476/267 (M1), 	Median: 6.2 y 	Left & 	Mean max, 	Continuous, 	Age, sex, systolic & 	For each SD 
(Cardiovascular 	1990 9 CVD 	 284 (stroke) right 	near 4- far wall 	fifths; Cox diastolic blood 	(NA) increment 
Health Study), CCA, proportional 	pressure, atrial 	in combined 
USA 	 ICA. 	 hazards 	fibrillation, pack-years IMT: 
combined of smoking, diabetes 	RR=1.4 (1.3- 
1.5); MI, 
RR=1.4 (1.3- 
1.5); stroke, 
RR=I.3 (1.2- 
1.5); 
Upper vs. lower 
fifth: combined 
end-point, 
RR=3.2 (2.2- 
4.5); MI, 
RR=3.6 (2.1- 
IMT Definition 	 Analyses 
End 	Sample size at 	 IMT 
Study 
	
Publication 	Design 	Population 	Point/s 	risk/Events 	Follow-up 	Segments 	Measurements 	Modelled As 	Adjusted for 	Findings  
6.1); stroke, 
RR=2.6 (1.6-4.0) 
Cao, 	Longitudinal 	? 65 y without 	MI, stroke, 	5020/593 (MI), 	Median: 11.0 	Left & 	Mean max, 	Thirds; Cox 	Age, sex, race. 	Upper vs. lower 
200742" CVD 	CVD 	613 (stroke), Y 	right 	near + far wall 	proportional 	systolic & diastolic 	third, MI: 
death, 696 (CVD 	 CCA, hazards 	blood pressure, BMI, 	HR=I.8 (1.4- 
combined, 	death), 1844 ICA, 	 smoking, amount 	2.4), stroke: 
All-cause 	(all-cause 	 combined smoked, HDL & LDL 	HR=I.8 (1.4- 
mortality death) cholesterol, diabetes, 	2.3), CVD death, 
CRP HR=2.2 (1.7- 
2.8), composite 
CVD: HR=I.8 
(1.5-2.2), all' 
cause mortality: 
HR=I.5 (1.3-1.8) 
No acronym, 	Kitamura, 	Longitudinal 	Men 60-74 y 	Stroke 	1289/34 	Mean: 4.5 y 	Left & 	Max, near +Qers; 
	
Age, systolic blood 	Upper vs. lower 
Japan 	 2004421 without right far wall 	uCanox pressure, BMI, 	quarter, stroke: 
previous 	 CCA, 	 proportional 	anfihypertensive 	RR=4.8 (1.9- 
stroke or CHD ICA (incl. hazards medication, ST-T 	12.0) 
BIF),  abnormalities, 
combined 	 community 
MDCS (Malmo 	Rosvall, 	Longitudinal 	46-68y 	MI or 	5163/113 	Median: 7 y 	Right 	Mean, far wall 	Continuous, 	Age, sex, low physical For each SD 
Diet and Cancer 	2005 ( a)an without cardiac CCA thirds, fixed 	activity, smoking 	(0.15 mm) 
Study), Sweden previous 	death 	 cut-points 	habits, hypertension, 	increment in 
stroke or (several); 	diabetes, LDL & HDL CCA IMT: 
cardiovascular 	 Cox cholesterol, waist 	MI/cardiac 
disease proportional 	circumference 	death, HR=1.2 
	
hazards (1.1-1.4); 
Upper vs. lower 
third: RR=1.5 
(0.8-2.6) 
Rosvall, 	Longitudinal 	46-68 y 	Stroke 	5163/86 	Median: 7 y 	Right 	Mean, far wall 	Continuous. 	Age, sex, low physical For each SD 
2005 (b)423 without CCA thirds, fixed 	activity, smoking 	(0.15 mm) 
previous 	 cut-points; 	habits, systolic blood 	increment in 
stroke or Cox pressure, 	CCA IMT: 
cardiovascular 	 proportional 	hypertension, stroke, HR=I.2 
disease hazards 	diabetes, LDL & HDL (1.0-1.4); 
cholesterol, 	Upper vs. lower 
triglyceridcs, waist 	third: RR=2.5 
circumference 	(1.2-5.4) 
LILAC 	 Murakami, 	Longitudinal 	>75 y 	All-cause 	298/30 (death), 	Mean: 3.2 y 	Left & 	Mean, near + 	Continuous; 	Age, Mini-Mental 	For each 0.1 nun 
(Longitudinal 	200542' and 9 	 right far wall t Cox 	State Examination 	increment in left 
Investigation for vascular 	(cardiovascular 	 CCA, 	 proportional Score 	CCA IMT, all- 
the Longevity 	 mortality death) 	 BIF, ICA hazards 	 cause mortality, 
     
IMT Definition 	Analyses 
   
         
End 	Sample size at 
Study 	 Puhli Atinn 	Decion 	Pnnulatinn 	Point!, rick/F 
 
IMT 
cPOMPtli 	 NAP2 nremente 	Mnflr.11&el A 
   
Fdt vun  Adimuedfnr 
 
FmAino , 
and Aging in 	 RR=1.2 (1.0- 
Hokkaido 1.4); 
County), Japan 	 cardiovascular 
mortality, 
RR=1.3 (1.0- 
1.8). 
For each 0.1 nun 
increment in 
right CCA 1MT, 
all-cause 
mortality, 
RR=1.5 (II-
2.0); 
cardiovascular 
mortality, 
RR=1.4 (1.0- 
2.0). 
CAPS (Carotid 	Lorenz, 	Longitudinal 	I9-90y 	MI,stroke 	5052/228 	Mean: 4.2 y 	Lefl & 	Mean, far wall 	Continuous, 	Age, sex, BMI, For each SD 
Atherosclerosis 	2006425 (myocardial right CCA quarters, Cox 	systolic & diastolic 	(0.16 mm) 
Progression event), 107 	 proportional blood pressure, 	increment in 
hazards Study), Germany 	 (stroke or TIA), antihypertensive 	CCA 1MT: 
50 (death) 	 medication, LDL 	combined end- 
cholesterol, lipid- 	point, HR=1.2 
lowering medication, 	(1.1-1.3); MI, 
nicotine consumption, 	RR
1.3): stroke, 
I.20(l 
diabetes 
RR=1.1 (1.0- 
1.3); 
Upper vs. lower 
quarter: 
combined end-
point, RR=1.9 
(1.1-3.2); MI, 
RR=1.8 (1.0- 
3.5); stroke, 
RR=1.8 (0.6-5.2) 
The Edinburgh 	Price, 	Longitudinal 	60-79 y fret of 	MI, stroke 	1007/78 (MI), 	12 y 	Left & 	Max, far wall 	fixed cut- 	Age, sex, diabetes, 	Above vs. below 
Artery Study, 2007426 MI or stroke 65 (stroke) 	(mean/median 	right CCA point (IMT 	smoking, systolic 	cut-point, OR 
UK 	 not specified) >0.9mm), blood pressure, 	(MI/stroke) = 1.6 
logistic 	total/HDL cholesterol 	(1.1 -2.4) 
regression 
The Tromso 	Johnsen, 	Longitudinal 	25-84 y with 	MI 	6226/295 	Median: 5.8 y 	Right 	Mean 1MT, 	Quarters, 	Total & HDL 	Upper vs. lower 
Study. Norway 2007427 no previous CCA, 	near + far wall 	Cox cholesterol, smoking, 	quarter, Male: 
MI 	 combined proportional 	systolic blood 	RR 1.7 (1.0- 
CCA, 	 hazards 	pressure, white blood 	3.1), 
IMT Definition 	 Analyses 
End 	Sample size at 	 1MT 
Study 
	
Publication 	Design 	Population 	Point/s risk/Events Follow-up 	Segments 	Measurements 	Modelled As 	Adjusted for 	Findings  
BIF, ICA cell count, monocyte 	Female: RR=2.9 
count, fibrinogen, 	(1.1-7.7) 
lipid-lowering & 
antihypertensive 
medication 
*Additional data incorporated in the Lorenz et al. systematic review and meta-analysis. 
IIMT definition not clearly described. 
MI = myocardial infarction; CVD = cardiovascular disease; CHD = coronary heart disease; CCA = common carotid artery; BIF = carotid bifurcation; ICA 
= internal carotid artery; HR = hazards ratio; RR = relative risk; OR = odds ratio; SD = standard deviation. Studies included in the Lorenz et al.375 
systematic review and meta-analysis are highlighted in blue. 
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Appendix 11 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV), and area under the curve (AUC) data of NCEP and NHANES 
classifications for adolescent borderline risk and high risk lipoprotein variable 
cut-points to predict high IMT in adulthood by cohort 
Table. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) data of NCEP and 
NHANES classifications for adolescent borderline risk and high risk lipoprotein variable cut-points to predict dyslipidemia in adulthood 
Dyslipidemia status in adolescence 
Borderline risk High risk 
AUC Sensitivity Specificity 	PPV NPV Sensitivity Specificity PPV NPV 
LDL cholesterol 
(Normal weight) Young Finns NCEP 74.8 32.1 11.9 91.2 45.4 60.0 12.3 89.9 0.54 
NHANES 59.7 46.1 12.0 90.3 27.7 75.0 12.0 89.4 0.54 
Bogalusa NCEP 9.1 85.1 3.8 93.5 0.0 94.1 0.0 93.5 0.47 
MANES 0.0 89.9 0.0 93.2 0.0 96.4 0.0 93.6 0.50 
CDAH NCEP 46.9 64.7 16.1 89.4 28.1 87.3 24.3 89.4 0.58 
NHANES 34.4 77.4 18.0 89.1 15.6 94.1 27.8 88.5 0.56 
Pooled NCEP 64.8 44.0 12.2 91.3 38.9 68.7 12.9 90.4 0.55 
NHANES 50.6 56.6 12.2 90.6 23.5 80.7 12.7 89.8 0.55 
LDL cholesterol 
(Overweight/obese) Young Finns NCEP 88.2 30.4 23.8 91.3 70.6 53.6 27.3 88.1 0.63 
NHANES 76.5 40.6 24.1 87.5 47.1 76.8 66.7 85.5 0.65 
Bogalusa NCEP 41.2 66.7 28.0 78.3 35.3 83.3 40.0 80.4 0.56 
NHANES 41.2 72.2 31.8 79.6 23.5 90.7 44.4 79.0 0.61 
CDAH NCEP 50.0 75.9 22.2 91.7 25.0 86.2 20.0 89.3 0.63 
NHANES 25.0 79.3 14.3 88.5 25.0 96.6 50.0 90.3 0.60 
Pooled NCEP 63.2 52.0 24.7 84.9 50.0 70.4 29.7 84.9 0.60 
NHANES 55.3 59.2 25.3 84.1 34.2 85.5 37.1 83.4 0.63 
Dyslipidemia status in adolescence 
Borderline risk High risk 
AUC Sensitivity Specificity 	PPV NPV Sensitivity Specificity PPV NPV 
HDL cholesterol 
(Normal weight) Young Finns NCEP 51.3 47.1 10.7 88.7 0.8 99.5 16.7 89.1 0.49 
NHANES 47.9 49.9 10.5 88.6 2.5 97.3 10.3 89.0 0.49 
Bogalusa NCEP 63.6 38.5 6.3 94.2 9.1 92.9 7.7 94.0 0.52 
NHANES 63.6 46.8 33.3 92.9 9.1 87.0 33.3 79.3 0.53 
CDAH NCEP 59.4 33.9 11.5 85.2 9.4 100.0 100.0 88.4 0.50 
NHANES 65.6 34.4 12.7 87.4 12.5 93.7 22.2 88.1 0.52 
Pooled NCEP 53.7 43.9 10.3 88.8 3.1 98.8 22.7 89.5 0.49 
NHANES 52.5 47.0 10.6 89.2 4.9 95.4 11.4 89.4 0.49 
HDL cholesterol 
(Overweight/obese) Young Finns NCEP 94.1 26.1 23.9 94.7 5.9 94.2 20.0 80.2 0.60 
NHANES 100.0 26.1 25.0 100.0 5.9 88.4 11.1 79.2 0.59 
Bogalusa NCEP 88.2 46.4 33.3 92.9 29.4 82.1 33.3 79.3 0.67 
NHANES 76.5 44.6 29.5 86.2 41.2 76.8 35.0 81.1 0.63 
CDAH NCEP 100.0 10.3 13.3 100.0 0.0 96.6 0.0 87.5 0.53 
NHANES 100.0 13.8 13.8 100.0 50.0 86.2 33.3 92.6 0.72 
Pooled NCEP 92.1 30.5 24.6 94.0 15.8 90.3 28.6 81.3 0.62 
NHANES 89.5 30.5 24.1 92.2 26.3 83.8 28.6 82.2 0.62 
Sensitivity = true positives/(true positives + false negatives) X 100. Specificity = true negatives/(true negatives + false positives) X 100. PPV = true 
positives/(true positives + false positives) X 100. NPV = true negatives/(true negatives + false negatives) X 100 
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